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ABSTRACT 
 
 
 
This thesis investigates the design, synthesis and biological assay of cysteine protease 
inhibitors within the papain superfamily of cysteine proteases.  This is achieved by 
examining the effect of inhibitor design, especially warheads, on IC50 values and structure-
activity relationships between cysteine protease inhibitors of the papain superfamily.  The 
representative proteases used are m-calpain, µ-calpain, cathepsin B and papain.  Chapter 
One is an introductory chapter; Chapters Two-Four describe the design and synthesis of 
cysteine protease inhibitors; Chapter Five discusses assay protocol; and Chapter Six 
contains the assay results and structure-activity relationships of the synthesised inhibitors. 
 
Chapter One introduces cysteine proteases of the papain family and examines the 
structure, physiology and role in disease of papain, cathepsin B, m-calpain and µ-calpain.  
The close structural homology that exists between these members of the papain 
superfamily is identified, as well characteristics unique to each protease.  Covalent 
reversible, covalent irreversible and non-covalent warheads are defined.  The generic 
inhibitor scaffold of address region, recognition and warhead, upon which the inhibitors 
synthesised in this thesis are based, is also introduced. 
 
Chapter Two introduces reversible cysteine protease inhibitors found in the literature and 
that little is known about the effect of inhibitor warhead on selectivity within the papain 
superfamily.  Oxidation of the dipeptidyl alcohols 2.6, 2.26, 2.29, 2.30, 2.35 and 2.36 
utilising the sulfur trioxide-pyridine complex gave the aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 
and 2.22.   Semicarbazones 2.37-2.40 were synthesised by a condensation reaction between 
the alcohol 2.3 and four available semicarbazides.  The amidoximes 2.48 and 2.49 
separately underwent thermal intramolecular cyclodehydration to give the 3-methyl-1,2,4-
oxadiazoles 2.41 and 2.50.  The aldehydes 2.3 and 2.27 were reacted with potassium 
cyanide to give the cyanohydrins 2.51 and 2.52.  The cyanohydrins 2.51 and 2.52 were 
separately reacted to give 1) the α-ketotetrazoles 2.43 and 2.55; 2) the α-ketooxazolines 
2.42 and 2.58; 3) the esterified cyanohydrins 2.60 and 2.61.  A two step SN2 displacement 
reaction of the alcohol 2.6 to give the azide 2.62, an example of a non-covalent cysteine 
protease inhibitor. 
 
Abstract  II 
       
                                                                                                                                                       
Chapter Three introduces inhibitors with irreversible warheads.  The well-known 
examples of epoxysuccinic acids 3.1 and 3.5 are discussed in detail, highlighting the lack 
of irreversible cysteine protease specific inhibitors.  The aldehydes 2.3 and 2.27 were 
reacted under Wittig conditions to give the α,β-unsaturated carbonyls 3.14-3.18.  Horner-
Emmons-Wadsworth methodology was utilised for the synthesis of the vinyl sulfones 3.20-
3.23. The dipeptidyl acids 2.24 and 2.28 were separately reacted with diazomethane to give 
the diazoketones 3.25 and 3.26.  The diazoketones 3.25 and 3.26 were separately reacted 
with hydrogen bromide in acetic acid (33%) to give the α-bromomethyl ketones 3.27 and 
3.28, which were subsequently reduced to give the α-bromomethyl alcohols 3.29-3.32.  
Under basic conditions the α-bromomethyl alcohols 3.29-3.32 ring-closed to form the 
peptidyl epoxides 3.33-3.36. 
 
Chapter Four introduces the disadvantages of peptide-based inhibitors.  A discussion is 
given on the benefits of constraining inhibitors into the extended bioactive conformation 
known as a β-strand.  Ring closing metathesis is utilised in the synthesis of the macrocyclic 
aldehyde 4.4, macrocyclic semicarbazone 4.15, the macrocyclic cyanohydrin 4.16, the 
macrocyclic α-ketotetrazole 4.18 and the macrocyclic azide 4.19.   
 
Chapter Five introduces enzyme inhibition studies.  The BODIPY-casein fluorogenic 
assay used for establishing inhibitor potency against m-calpain and µ-calpain is validated. 
Assay protocols are also established and validated for cathepsin B, papain, pepsin and α-
chymotrypsin.  A discussion of the effect of solvent on enzyme activity is also included as 
part of this study. 
 
Chapter Six presents the assay results for all the inhibitors synthesised throughout this 
thesis and an extensive structure-activity relationship study between inhibitors is included.  
The alcohols 2.26 and 2.30 are unprecedented examples of non-covalent, potent, cathepsin 
B inhibitors (IC50 = 0.075 µM selectivity 80-fold and 1.1 µM, selectivity 18-fold).  The 
macrocyclic semicarbazone 4.15 is an unprecedented example of a potent macrocyclic 
cysteine protease inhibitor (m-calpain: IC50 = 0.16 µM, selectivity 8-fold).  The 
cyanohydrin 2.51 contains an unprecedented cysteine protease warhead and is a potent and 
selective inhibitor of papain (IC50 = 0.030 µM, selectivity 3-fold).  The O-protected 
cyanohydrin 2.61 is a potent and selective inhibitor of pepsin (IC50 = 1.6 µM, selectivity 
1.5-fold).  The top ten warheads for potent, selective cathepsin B inhibition are: carboxylic 
Abstract  III 
       
                                                                                                                                                       
acid, methyl ester, diazoketone, esterified cyanohydrin, α-bromomethyl ketone, α,β-
unsaturated aldehyde, vinyl sulfones, α-bromomethyl-C3-S,R-alcohol, alcohol and α,β-
unsaturated ethyl ester.  The selectivity of these warheads was between 5- and 130-fold for 
cathepsin B.  The best inhibitors for cathepsin B were the α-bromomethyl ketone 3.26 
(IC50 = 0.075 µM, selectivity 16-fold), the α,β-unsaturated aldehyde 3.18 (IC50 = 0.13 µM, 
selectivity 13-fold)  and the esterified cyanohydrin 3.59 (IC50 = 0.35 µM, selectivity 22-
fold).   
 
Chapter Seven outlines the experimental details and synthesis of the compounds prepared 
in this thesis. 
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ABBREVIATIONS 
 
 
1,1,2-TCE 1,1,2-trichloroethane 
δ chemical shift (in NMR) 
Boc tert-butoxycarbonyl 
BODIPY 4,4-difluoro-5,7-dimethyl-4-bora-3a,4-diaza-s-indacene-3- 
 propionic acid (in assay) 
bs broad singlet (in NMR) 
Cbz benzyloxycarbonyl 
COSY correlation spectroscopy 
d doublet (in NMR) 
DCM dichloromethane 
dd doublet of doublets (in NMR) 
DIPEA N,N-diisopropylethylamine 
DMF N,N-dimethylformamide 
EtOAc ethyl acetate 
EDCI 1-[3-(dimethlamino)propyl]-3-carbodiimide hydrochloride 
EDTA  ethylenediaminetetraacetic acid (in assay) 
EGTA  ethylene glycol tetraacetic acid (in assay) 
DMSO dimethyl sulfoxide 
EI electron impact ionization (in mass spectrometry) 
equiv equivalent(s) 
ES electrospray ionization (in mass spectrometry) 
Et2O diethyl ether 
GB/SA generalised Born/surface area (in modeling) 
Grubbs 2nd   
generation catalyst  benzylidene[1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidiny 
  lidene]dichloro(tricyclohexylphosphine)ruthenium. 
      HATU N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium 
hexafluorophosphate 
HCl hydrochloric acid 
HOBt 1-hydroxybenzotriazole 
HRMS high resolution mass spectroscopy 
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hr hour(s) 
Hz hertz (in NMR) 
IR infrared 
J coupling constant (in NMR) 
KOH potassium hydroxide 
K2CO3 potassium carbonate 
LiAlH(OtBu)3 lithium tri-tert-butoxy aluminium hydride 
LiAlH4 lithium aluminium hydride 
LRMS low resolution mass spectrometry 
m multiplet (in NMR) 
MCMM Monte Carlo multiple minimum 
MeOH methanol 
min(s) minute(s) 
MgSO4 magnesium sulphate 
MOPS 3-(N-morpholino)propanesulfonic acid (in assay) 
mp melting point 
NaOH sodium hydroxide 
NH4Cl ammonium chloride 
NMR nuclear magnetic resonance 
Pet ether petroleum ether (50-70o C) 
Pd/C palladium on carbon catalyst 
ppm parts per million  
RCM  ring closing metathesis 
RMSD root mean square deviation (in modelling) 
rt room temperature 
SAR structure activity relationship 
s singlet (in NMR) 
SO2Cl thionyl chloride 
SO3.Pyr sulfur trioxide-pyridine complex 
t triplet (in NMR) 
TFA trifluoroacetic acid  
THF tetrahydrofuran 
TLC thin layer chromatography
 
Acknowledgments  VI 
       
                                                                                                                                                       
ACKNOWLEDGMENTS 
 
 
 
Firstly I would like to thank my supervisor Professor Andrew Abell for his guidance 
throughout my PhD and especially for his tireless reading and advice during the process of 
writing. 
 
Thank you to the many people who provided invaluable assistance throughout my PhD 
especially: Bruce Clark, Robert Stainthorpe and Marie Squire (mass spectrometry); Rewi 
Thompson and John Blunt (NMR); the Lincoln crew (Jim Morton, Matt Muir, Hannah Lee 
and Karl Gately); members of the Abell Group: Nathan and Matt for managing to read 
through the many drafts of my thesis without falling asleep; Steve and Wanting Jiao for 
modelling many of my compounds; and Kelly, Anna, Andrea and Shazia who helped keep 
things in perspective and were always ready for a coffee break! 
 
To my many friends, who thought I was going to be an eternal student…. I’m finally done; 
and especially for Jess, Tamati, Connie and Suzy, who were always willing to put up with 
me complaining that I’d never finish, thanks so much for your encouragement and 
distractions – I’ll finally be able to spend some time with you again. 
 
I would like to thank my parents, Chris and Jean, for their never-ending encouragement 
and love; also Trevor and Virgina, the ‘dreaded’ in-laws, for making me one of the family 
and looking after me so well. 
 
And finally, for Antony, thank you, thank you, thank you for your patience, love, support 
and encouragement.  Love you forever babe xx.  
 
 
 
  
CHAPTER ONE 
 
 
 
Introduction to Cysteine 
Proteases 
 
 
 
 
 
 
 
 
Chapter One – Introduction  2 
1.1 OVERVIEW OF PROTEASES 
 
Proteases account for approximately 2% of the genes in most organisms, second in number 
only to transcription factors.1  Because of this, proteases have long been the subject of 
intensive research.2  Proteases are involved in numerous physiological processes that 
include food digestion, cell maintenance, cell signalling, wound healing, cell 
differentiation and cell growth.3  Breakdown in the control of protease activity leads to 
undesired and unregulated proteolysis.  This is the cause of many diseases, such as 
Alzheimer’s disease, stroke, cancer, viral infections and cataracts,4 thus inhibitors of 
proteases have the potential to provide successful therapeutics for a wide range of diseases. 
 
The purpose of this chapter is to provide an overview of proteases (in particular the 
cysteine proteases); discussing roles in normal physiology and disease, the structure of 
active sites, and requirements for effective inhibition.  Attention is focused on the family of 
cysteine proteases, particularly the calpains, cathepsin B and papain (representative 
cysteine proteases, see Table 1.1).  This chapter will conclude with a section on the design 
of cysteine protease inhibitors. 
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Clan 
 
 
Family 
 
Proteases 
 
Occurrence 
 
CA 
 
C1A (CL-like) 
 
Papain 
 
Plant 
  Cathepsin L Mammals 
  Falcipains Plasmodium 
flaciparum 
  Rhodesian Trypanosoma brucei 
rhodesiense 
  Cruzain Trypanosoma cruzi 
 C1B (CB-like) Cathepsin B Mammals 
 C2 Calpains Mammals 
 
 
CD 
 
C14 
 
Caspases 
 
Mammals 
 
 
CL 
 
C60 
 
Sortases 
 
Staphlococcus 
aureus 
 
 
PA 
 
C3A-C3G 
 
Picornaviral proteases 
 
HRV, HAV 
 C30 Coronaviral main proteases TGEV, SARS-CoV 
 
  
Table 1.1 Classification of cysteine proteases.  HRV human rhinovirus, HAV hepatitis A virus, TGEV 
transmissible gastroenteritis virus, SARS-CoV sever acute respiratory syndrome coronavirus5 
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1.2 CLASSIFICATION OF PROTEASES 
 
There are currently six known classes of proteases: serine, threonine, cysteine, aspartic 
acid, glutamic acid and metallo- proteases (S, T, C, G, M, A).  The most widely recognised 
system of enzyme classification defines proteases by 1) catalytic mechanism, 2) structure 
(clans and families) and 3) individual protease.6,7 
 
Catalytic mechanism 
Proteases are primarily categorised according to catalytic centre composition, as the make-
up of the active site residues determines the mechanism of peptide bond hydrolysis.8  
There are two fundamentally different catalytic mechanisms for hydrolysis.  For serine, 
threonine and cysteine proteases, the key catalytic nucleophile is an intrinsic component of 
the active site (the residue being Ser, Thr or Cys respectively), while aspartic acid, 
glutamic acid and metallo proteases use an activated water molecule as the nucleophile.9,10 
 
Structure 
Clans are defined as groups of proteases that have arisen from a single origin and are based 
on the similarity of tertiary structures, with each clan representing an homologous set of 
proteases.11  Clans may be composed of more than one class of protease as illustrated by 
the clan PA which contains examples of both serine and cysteine proteases.  Within each 
clan, families are identified by a letter that represents the type of hydrolysis it catalyses 
followed by a unique number (1, 2, 3…).12,13  Table 1.1 above outlines the classification of 
cysteine proteases, the main topic of this thesis.   
 
Individual Protease 
Finally, proteases are defined to be individual and distinct if specificity and sensitivity to 
inhibitors is different, they are of different catalytic types or are encoded by different genes 
within the same organism.14  
 
These three guidelines provide a unique code for all known proteases that allows inter-
relationships to be studied. 
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1.3 CYSTEINE PROTEASES 
 
Cysteine proteases are widely distributed throughout nature, having been found in viruses, 
bacteria, protozoa, plants, mammals and fungi.8  There are three structurally distinct clans 
of cysteine proteases: the papain family, the caspases and the picornaviridae family.  The 
majority of cysteine proteases known to date are members of the papain family.15 
 
One of the biggest challenges faced in the design of specific cysteine protease inhibitors is 
the similarity in structure that exists within clans (for example clan CA, containing papain-
like proteases). Effort towards identifying inhibitors that are specific for individual 
cysteine proteases is essential for the design of effective therapeutic drugs.  
 
 
1.3.1 Cysteine Protease Active Sites 
 
The active site of cysteine proteases consists of a) a catalytic triad (Cys, His and Asn) that 
is responsible for hydrolysis of the peptide bond (Figure 1.1) and b) subsite binding 
pockets where orientation of the substrate for catalysis occurs via interaction between 
subsites of the enzyme and amino acid residues of the substrate (Figure 1.2). 
 
Mechanism of Proteolysis 
The cysteine and the histidine of the catalytic triad form a thiolate-imidazolium ion pair 
which confers high nucleophilicity upon the cysteine thiol.   Under these conditions the 
cysteine thiol acts as a nucleophile to hydrolyse the scissile bond of the substrate.  The 
overall mechanism of substrate hydrolysis shown in Figure 1.1 occurs in four steps. The 
initial tetrahedral intermediate (b) is stabilised by hydrogen bonding to Cys25 and Gly19 
which make up the oxyanion hole (a) followed by acylation of the enzyme and release of 
the C-terminal substrate fragment.  Hydrolysis of the acyl-enzyme forms a second 
tetrahedral intermediate (c).  Collapse of this intermediate regenerates the free enzyme and 
releases the N-terminal substrate fragment (d).15  
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d
HO
 
Figure 1.1 Proposed mechanism of hydrolysis by cysteine proteases (enzyme residues in blue) 
 
Binding pockets 
The nomenclature used for defining the binding pockets and selectivity of proteases is 
based on the notations of Schechter and Berger16 (Figure 1.2) and is relative to the site of 
cleavage (scissile bond).  Sn represents the enzyme subsites (pockets) and Pn the amino 
acid side chains bound in these positions.  The properties of Sn and Sn’ for a given protease 
govern the binding of Pn and Pn’ residues, thus the choice of amino acid residues is 
dependent upon the target protease. 
 
N
H
O
H
N
O
N
H
O
H
N
O
N
H
O
P3 P1 P2'
P2 P1' P3'
S3 S1 S2'
S2 S1' S3'
 
 
Figure 1.2 Standard Schechter and Berger nomenclature for substrate residues and corresponding binding 
sites.16  Red line denotes the scissile bond. 
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Peptidase Activity 
Proteases can show exopeptidase or endopeptidase activity towards substrates.  
Exopeptidases are proteases that hydrolyse an amino acid from the end of a polypeptide 
chain while endopeptidases hydrolyse a peptide bond within a polypeptide chain (see 
Figure 1.3).17  Some proteases (such as cathepsin B) exhibit both modes of cleavage. 
 
N
H
O
H
N
O
N
H
O
H
N
O
N
H
O
P3 P1 P2'
P2 P1' P3'
S3 S1 S2'
S2 S1' S3'
H
N
O
N
H
O
H
N
O
OH
O
P3 P1
P2
S3 S1
S2
 
                                            a                                                                    b 
Figure 1.3 a) endopeptidases cleave within a peptide chain and b) exopeptidases at the end of a peptide chain 
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1.4 THE PAPAIN SUPERFAMILY 
 
Papain-like cysteine proteases (henceforth referred to as the papain superfamily)18 belong 
to clan CA and include cathepsin B and calpains (refer to Table 1.1).19  Cysteine proteases 
of the papain superfamily have been implicated in numerous diseases and cellular 
processes and are thus attractive targets for therapeutic drugs.11  The high degree of 
conservation of structure within proteases of the papain superfamily (clan CA) means that 
the design of selective inhibitors has long proven a challenge for the synthetic chemist.11  
Better understanding of the differences between active site specificities of cysteine 
proteases will aid the development of therapeutic drugs for the diseases associated with 
specific cysteine proteases, thus cathepsin B (CA.C1B) and calpains (CA.C2) were chosen 
as representatives of each family within the clan CA for investigation. Papain, as the 
archetypal protease of the papain superfamily, was important for this investigation as all 
other members of the clan CA are closely related to it.  Cathepsin B and the calpains are 
involved in many diseases (specified in following sections) that currently have few 
therapeutic treatments, thus an increased understanding of selectivity within the papain 
superfamily will aid the treatment of diseases associated with these proteases.  Papain, 
cathepsin B and calpain will be discussed in turn in the following Sections 1.4.1-1.4.3 with 
regard to structure, function and role in disease (see Table 1.2). 
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Chapter 
 
 
Section 
 
Focus of discussion 
 
1 
 
1.4.1 
 
Papain:  structure, specificity, function and role in 
disease 
 
1 1.4.2 Cathepsin B: structure, specificity, function and 
role in disease 
 
1 1.4.3 Calpain (m- and µ-): structure, specificity, function 
and role in disease 
 
1 1.4.4 Structural homology between papain, cathepsin B 
and the calpains (m- and µ-) 
 
1          1.5     Design of cysteine protease inhibitors 
 
1          1.6 Contents of this thesis 
 
 
Table 1.2 Structure for the remainder of Chapter One. 
 
 
1.4.1 Papain  
 
Papain is a plant protease isolated from Carica papaya (papaya latex).8 It has a monomeric 
polypeptide structure6 with a molecular weight of around 23 kDa and consists of 212 
amino acid residues with three disulfide bridges (Cys22-Cys63, Cys56-Cys95 and Cys153-
Cys200).  The polypeptide chain is folded into two domains, the L-domain consisting of 
residues 10-11 and 207-212 while the R-domain is made up of the remaining residues.20  
The two domains (L and R) are separated by a cleft which contains the active site thiol 
(Cys25) positioned at the entrance of the α-helix (residues 24-42) on the L-domain.  On the 
opposite side of the cleft (R-domain) but still in close proximity is a His159 residue.  The 
His159 residue is positioned to act as the base catalyst for activation of the thiol group 
during peptide hydrolysis.  The last member of the catalytic triad (Asn175) is thought to 
orientate His159 for interaction with Cys25,15 resulting in the activation of both the His159 
and Cys25. The backbone NH group of Cys25 and the side chain NH2 group of Gln19 (both 
hydrogen bond donors) form the oxyanion hole (see Figure 1.4) for binding substrate and 
promoting reactivity for nucleophilic attack.21  The N-terminal domain (L) consists of a 
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bundle of α-helices while the C-terminal (R) domain contains a β-barrel.  A long helix runs 
through the middle of the molecule.  The catalytic cysteine is at the start of this helix (see 
Figure 1.5). 
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Figure 1.4 The oxyanion hole of papain 
 
Typically, papain is isolated in an inactive form (known as a zymogen or pro-enzyme)17 in 
which the active site is blocked by a disulfide bond between the active site Cys25 and Cys22 
(in the active form, this disulfide bond links the Cys22 and Cys63 residues).  This inactive 
form of papain is essential for forming the correct quaternary structure of the enzyme 
before it is activated. 8  Activation of papain occurs via either disulfide exchange with thiol 
reagents or reducing agents.8  
 
 
 
Figure 1.5 Crystal structure of papain showing secondary structure (α-helices in red and β-sheets in aqua).  
Catalytic residues are shown in ball-and-stick representation, Cys25 His159 and Asn175.  (PDB 1PPP) 
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Specificity 
Papain exhibits endopeptidase, amidase and esterase activities.  The active site of papain 
consists of the subsites S1-S4 and S1’-S3’ (seven in total).8  The S2 subsite of papain is the 
most important primary substrate recognition site of the protease and is defined by the 
residues Tyr69, Tyr67, Phe207, Pro68, Ala160 Val133 and Val157.  The other subsites of papain 
are not as well defined or as strict in amino acid preferences.22   
 
The preferred amino acids at the S2 subsite are those with bulky nonpolar side chains, such 
as Phe.  This was utilised by Menard23 who, with a fluorogenic peptide fixed at the P2 
position (with a Phe residue), varied the amino acid at the P1’ position and identified the 
specificity of S1’ subsite of papain. The results of Menard’s study23 have been graphed 
according to amino acid properties, namely hydrophobicity (non-polarity), polarity, acidity 
and basicity (see Figure 1.6). It is apparent that amino acids with large nonpolar side 
chains are the most readily hydrolysed (Leu, Ala and Phe).    
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Figure 1.6 Specificity of S1’ subsite of papain 
 
Hydrogen bonding of substrates to the active site cleft 
The active site cleft of papain runs along the interface of the two domains in a V-shaped 
valley (see Figure 1.7).  This cleft is broad but narrows around the active site.  A crystal 
structure of papain with leupeptin bound24 shows the critical hydrogen bonds that are 
formed.  The Gly66 residue on the L-domain forms two critical hydrogen bonds (A and B 
as shown in Figure 1.8) while the backbone carbonyl of Asp158 residue also participates by 
forming hydrogen bond C to the substrate. 
                     Non-polar                            Polar                  Acidic        Basic   
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Figure 1.7 Surface diagram of the active site cleft of papain.  The active site is a V-shaped valley where the 
L and R domains meet.  The active site cysteine is shown in yellow at the base of the cleft (PDB 1PPP) 
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Figure 1.8 Hydrogen bonding to the active site cleft of papain 
 
Function and disease states of papain 
The large quantities of papain found within Carica papaya and its general specificity 
toward substrates suggest it has a protective role, guarding the plant against pests.6  Papain 
is not thought to be involved in any human diseases as it is only expressed in plants.    
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1.4.2 Cathepsin B 
 
Cathepsin B is initially synthesised in an inactive form comprising 314 amino acid 
residues.  Amino acids 1-62 at the C-terminal end are essential for correct folding and 
stabilisation of the protease.  These 62 residues are subsequently cleaved to liberate the 
active enzyme.25  The mature, active cathepsin B enzyme is a polypeptide chain of 252 
residues26 (two chains consisting of 47 and 205 amino acid residues respectively27) 
showing close structural homology to papain.  About 166 amino acid residues of cathepsin 
B are equivalent to those in papain.  
 
Active cathepsin B is a 30 kDa bilobal protease that is disc shaped (diameter 50 Ǻ, 
thickness 30 Ǻ) with access to the active site via a large cleft on the top of the molecule.27  
The quaternary structure of cathepsin B is reminiscent of papain, being folded into two 
distinct domains.  The active site cleft is located at the interface of the two lobes 
(domains).  The left-hand (L) domain comprises the N-terminal half of the polypeptide 
chain (residues 11-148) while the R domain is made up of residues 1-10 and the C-terminal 
part (residues 149-252) of the chain (see Figure 1.9). 
 
 
Figure 1.9 Crystal structure of Cathepsin B showing secondary structure (α-helices in red and β-sheets in 
aqua).  Active site in ball-and-stick representation: Cys29, His199 and Asn219.  Occluding loop indicated by red 
box (PDB 1ITO) 
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The structure of the L-domain of cathepsin B is predominantly defined by three central α-
helices equivalent to those found in papain and other plant proteases.  The section of 
polypeptide chain from Ile105 to Pro126 represents a novel structural feature known as the 
occluding loop (see Figure 1.10).  This occluding loop is a covalently closed section of the 
polypeptide chain that partially blocks access to the active site; the boundary of the 
occluding loop is defined by a disulfide bridge between Cys108 and Cys119.   
 
It is this occluding loop that confers exopeptidase activity upon cathepsin B due to the 
presence of the positively charged histidine residues (His110 and His111) that can accept a 
negative charge at the C-terminus of the substrate.  The flexibility of the occluding loop 
allows it to adopt another conformation, in which it no longer blocks the binding cleft; in 
this conformation cathepsin B acts as an endopeptidase.25,28,29  The C-terminal half of the 
chain (R-domain) has a barrel-like structure formed by six extended strands aligned in a β-
sheet.  The residues Asn219 to Gly229 form the support for the occluding loop. 
 
 
Figure 1.10 Crystal structure of Cathepsin B showing the occluding loop (in red box).  The His110 and His110 
(green, left side of loop) and the disulfide bridge (green, right side of loop) of the occluding loop are also 
shown.  (PDB 1ITO) 
 
The active site of cathepsin B is much like that of papain, with the S2 subsite comprised of 
the residues Trp221, Gln23, His199, Ala200 and Ala173.  The active site residues Cys29 (Cys25 
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in papain) and His199 (His159) are on opposite sides of the cleft7 (as in papain) but close 
enough to interact, forming an ion-pair at a pH range of 4.0-8.5.  The pH within a 
biological system also has a determining role in whether cathepsin B displays 
endopeptidase or exopeptidase activity.  The stability of the occluding loop is pH 
dependent, giving rise to endopeptidase activity at neutral pH (membrane) and 
exopeptidase activity at acidic pH (lysosomes), thus the location of cathepsin B determines 
the substrate specificity.28 
 
Specificity 
Cathepsin B has broad substrate specificity, showing only a slight preference for basic 
residues and Phe at the P2 position, while bulky side chains are disfavoured at P1.30  
Menard’s study23 of the preferred residues for P1’ of papain (as previously described) also 
included a study of cathepsin B preferences.  These results (see Figure 1.11), graphed 
according to amino acid properties (hydrophobicity, polarity, acidity and basicity), indicate 
that cathepsin B prefers amino acids with large hydrophobic side chains, such as Trp, Tyr, 
Phe, Val and Leu, at the P1’ position.  The S1’ pocket of cathepsin B has a broader 
specificity than that of papain which preferentially accepts only Phe, Leu and Ala (refer to 
Figure 1.6).  This suggests that inhibitors with good binding affinity for papain will also 
bind well in the active site of cathepsin B, making the design of specific inhibitors a 
challenge.  
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Figure 1.11 Specificity of S1’ subsite of cathepsin B 
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Hydrogen bonding of substrates to the active site cleft 
The active site cleft of cathepsin B is slightly narrower than that of papain (see Figure 
1.12).  Jia et al31 published a crystal structure of cathepsin B* with a chloromethyl ketone 
inhibitor bound.  This crystal structure suggested that only the hydrogen bonds B and C (as 
denoted in Figure 1.13) were formed.31  Gly74 (topologically identical to Gly66 in papain) 
forms the hydrogen bond B and Gly198 the hydrogen bond C.  It is assumed that if a crystal 
structure of cathepsin B with leupeptin bound was available, hydrogen bond A would also 
be formed. 
 
 
 
Figure 1.12 Surface diagram of the active site cleft of cathepsin B.  The active site is a cleft between the L- 
and R-domains of cathepsin B.  The active site cysteine is shown in yellow at the base of the cleft (PDB 
1POP)   
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Figure 1.13 Hydrogen bonding to the active site cleft of cathepsin B 
                                                 
*
 22 crystal structures of cathepsin B, with and without inhibitors bound can be found on the protein data 
base: www.rcsb.org/pdb/home/home.do 
Chapter One – Introduction  17 
Role in Physiology and Disease 
Cathepsin B is found ubiquitously throughout tissues, suggesting it has an essential 
function.  Its presence in the lysosomes implies a role in protein degradation as the 
lysosomes are the organelles responsible for digesting waste and recycling products.26  
Other roles of cathepsin B are proposed to include remodelling of the extracellular matrix, 
wound healing, bone remodelling and apoptosis.28,32 
 
Cathepsin B is implicated in a number of pathological states, some of which include: 
inflammatory airways diseases, bone and joint disorders, acute pancreatitis, tumour 
metastasis, Alzheimer’s disease and ischemic neuronal death.11,25,33,34  The role cathepsin B 
plays in these diseases is summarised in Table 1.3.  The design of specific inhibitors for 
cathepsin B is considered important for chemotherapy and other cancer treatments. 
 
 
Disease 
 
 
Proposed Cathepsin B Disruption 
 
Ref 
 
Inflammatory Airways 
Disease 
 
Secretion of cathepsin B by bronchial epithelial 
cells and activated by Neutrophil Elastase 
 
25
 
 
 
Bone and Joint Disorders Breakdown of the cartilage extracellular matrix 
occurs via cathepsin B activated 
metalloproteinases 
25
 
 
 
 
Acute Pancreatitis Cathepsin B rapidly activates trypsin which can 
activate pancreatic enzymes that damage the 
pancreas 
25
 
 
 
 
Tumour Metastasis Increased expression and secretion of cathepsin 
B in tumours 
11,28,33,34
 
   
Alzheimer’s Disease Cathepsin B is associated with amyloid plaques 
in Alzheimer’s Disease brains.  Insufficient 
activity proposed to promote Alzheimer’s 
28,35
 
 
 
 
 
Table 1.3 Role of cathepsin B in some disease states 
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1.4.3 Calpains (m- and µ-) 
 
Calpains are calcium-activated neutral cysteine proteases that are ubiquitous and 
intracellular in distribution within biological systems.  Two major isoforms have been 
identified (m- and µ-) that differ in the requirements of calcium concentration for 
activation (mM and µM amounts respectively).  m-Calpain and µ-calpain are of interest in 
this thesis due to an important role in the development of cataract (this topic is discussed in 
detail below). 
 
The calpains (m- and µ-) are heterodimers comprising two distinct subunits: the large 
highly homologous 80 kDa subunit and the common small 30 kDa subunit.  The large 
subunit of µ-calpain is usually slightly heavier than the corresponding m-calpain large 
subunit (81.9 kDa compared with 79.9 kDa respectively),3 but in both calpains it consists 
of four domains (I-IV); domains V and VI make up the small subunit of m-calpain and µ-
calpain (see Figure 1.14).  Domain I is a single α-helix that plays a role in stabilising and 
activating the enzyme.  The amino acid sequence has no homology with any known 
polypeptide.3  Domain II contains the active site and is generally divided into two 
subdomains IIa and IIb.  The active site Cys105 resides on IIa, while the His262 and Asn286 
which complete the catalytic triad are on IIb (see Figure 1.15). 
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Figure 1.14 The structure of m-calpain.  Secondary structure is depicted: α-helices in red, β-sheets in aqua.  
The domains are annotated (PDB 1KFU) 
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Figure 1.15 Crystal structure of the domain IIa and IIb of µ-calpain (calcium bound).36  Active site in ball-
and-stick representation: Cys115, His272 and Asn296.  (PDB 1TLO) 
 
The calpains are unique among cysteine proteases in having an absolute requirement of 
calcium for activation.37  The importance of calcium binding for activation was highlighted 
by Moldoveanu et al,38,39 who established that the binding of calcium ions to calpain 
results in a conformational change to the active site of the enzyme.  The catalytic Cys105 is 
8.5 Ǻ removed from His262 in the absence of calcium, too great a distance for formation of 
the active catalytic triad.  Binding of calcium to calpain induces a conformational change 
that reduces the distance between the Cys105 and His262 to 3.7 Ǻ, a distance at which 
interactions are possible (see Figure 1.16). 
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Figure 1.16 Arrangement of the active site without calcium bound (left) and with calcium bound (right) 
 
The calcium binding sites are located on domains IV and VI in the form of EF-hand 
structures (see Figure 1.17).  EF-hand motifs are defined by a helix-loop-helix structure.  
A calcium ion binds in the loop region of the EF-hand as shown in the Figure 1.17.  
Domains IV and VI each have five EF-hand motifs, of which eight bind calcium.  One EF-
hand motif from each of domains IV and V interact, forming a link between the large and 
small subunits respectively.  Domain III comprises 8 β-strands that are shaped into a β-
sandwich structure.  This domain is most likely responsible for the translocation of calpain 
to the membrane (a process which is calcium dependent).  Domain V comprises one half of 
the S subunit and contains clusters of Gly residues which contributes to the overall 
hydrophobic nature of calpain.40 
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Figure 1.17 Domain IV of calpain with calcium ions bound (pink).  A single EF-hand is inset.  (PDB 1DVI) 
 
The overall topology of calpain is highly conserved relative to that of papain (and thus 
cathepsin B).  A loop containing four Tyr residues (Tyr297, Tyr304, Tyr325 and Tyr356), 
unique to calpains, is thought to be important for the formation and conformation of the 
calpain catalytic domain.  The N- and C- terminal portions of this loop are highly 
conserved among calpains and contain acidic residues.  The calcium requirement of 
calpain activation has been ascribed to this region.40   
 
Specificity 
Calpains m- and µ- have limited and specific subsite specificity.  This is supported by the 
finding that cleavage of proteins by calpain results in large polypeptide fragments rather 
than small peptides or amino acids thus suggesting that calpains only cleave at limited 
sites.3  The specificities of m- and µ-calpain are very similar if not identical. 
 
Several reviews41-43 on calpain inhibitors have shown 1) that bulky aromatic groups are 
most favoured at P3; 2) the P1 position favours Leu over other amino acids and 3) the P2 
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position requires an amino acid with a side chain able to form a hydrogen-bond. 36  A Leu 
or Val residue in the P2 position is favourable, but as a variety of amino acids are accepted, 
this is not a strict requirement.  Thus the S2 subsite of calpain has only a marginal effect on 
specifity.3  Cuerrier et al44 performed a subsite preference study using recombinant µ-
calpain (similar to Menard’s23 study of papain and cathepsin B).  This study indicated that 
µ-calpain has a preference for Ala and Met in the P1’ position (these results are assumed to 
hold true for both natural µ-calpain and m-calpain).   The results obtained are depicted in 
Figure 1.18 where it is apparent that calpain has a preference for large non-polar side 
chains, furthermore, the basic amino acids Lys and Arg are favoured, which is significantly 
different from papain and cathepsin B. 
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Figure 1.18 S1’ specificity of µ-calpain 
 
 
Hydrogen bonding of substrates to the active site cleft 
In the case of calpain, having the polypeptide substrate in a bioactive conformation that 
extends along the active site and forms hydrogen bonds with adjacent residues, appears to 
be more important than the exact amino acid sequence of the substrate.  It has been 
suggested that calpain has a much narrower active site cleft than papain and cathepsin B 
(see Figure 1.19), thus the three defined hydrogen bonds (A, B and C in Figure 1.20) are 
more important for the binding affinity of a substrate.45  
 
                         Non-polar                 Polar                   Acidic            Basic   
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Figure 1.19 Surface diagram of serine mutated µ-calpain active site cleft (1KXR PDB). 
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Figure 1.20 Critical sites involved in hydrogen-bonding at the calpain active site.   
 
Physiological Functions 
The ubiquitous nature of calpains is highly indicative of a fundamental role in nature.  The 
limited manner in which calpains degrade enzymes suggests that the normal function of 
calpains m- and µ- is a regulatory or signalling one rather than a digestive role.46 Calpains 
are involved in many other cellular functions including cell motility, proteolytic 
modification of molecules in signal transduction pathways, apoptosis and regulation of 
gene expression.   
 
The ratios of m- and µ -calpain within different cell types varies greatly.  The fact that m- 
and µ-calpain have similar subsite specificities and virtually identical structures suggests 
that the two isoforms can perform identical functions.  This assumption is strengthened by 
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the finding that human platelets contain exclusively µ-calpain while bovine platelets 
contain exclusively m-calpain; the function of the platelets is identical in both species.3 
 
Diseases associated with calpains 
Disruption to the calpain system is linked to number of degenerative conditions, which 
include cataract, myocardial infarction, neuronal ischemia, Alzheimer’s disease and gastric 
cancer.47-51  The role of calpain in these disease states is summarised in Table 1.4. The 
range of diseases with which calpain is associated make it a desirable therapeutic target. 
 
 
Disease 
 
 
Proposed Calpain Disruption 
 
Ref 
 
Cataracts 
 
Calcium influx activates m-calpain, cleaves 
crystallins into fragments that aggregate  
 
47,52
 
 
Myocardial Infarction 
 
Calcium homeostasis is lost in ischemic area 
which triggers calpain over-activation 
 
48,53,54
 
 
Neuronal Ischemia (Stroke) 
 
Calpains participate in apoptosis and necrosis 
which results in tissue damage in ischemic areas 
 
36,48
 
 
Alzheimer’s Disease 
 
Increased amount of m-calpain in the cytosolic 
part of brain 
 
48,49
 
 
Obsessive Compulsive 
Disorder 
 
Patients with obsessive compulsive disorder 
have significantly elevated calpain activity 
levels 
 
50
 
 
Gastric Cancer 
 
Associated with down regulation of µ-calpain 
 
 
51,55
   
 
Table 1.4 Some of the diseases associated with disruptions to the calpain system. 
 
One disease that has merited much attention over the past 10 years is that of cataract 
formation.56  The design of specific calpain inhibitors for the purpose of treating cataract is 
of special interest as there is currently no pharmaceutical treatment for cataract on the 
market; surgery is the only intervention available.  Research at the University of 
Canterbury, in collaboration with Lincoln University and Douglas Pharmaceuticals, is 
currently underway to develop a drug to slow the progression of cataracts to benefit the 
millions afflicted.   
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Cataract formation is a well defined example of protease over-activation leading to a 
pathological state.57  Defined by Webster as “a clouding of the lens of the eye…that 
obstructs the passage of light”, cataract is the leading cause of blindness in the world.58  
The World Health Organization estimates that of the 37 million people who are blind 
worldwide, about half are affected by cataract.59  Cataract surgery is the most frequent 
operation performed in the United States of America (20 million Americans over 40 years 
of age are affected; over 1.5 million cataract surgeries)60 and Australasia.61   Cataract 
surgery is successful, with over 80% of patients regaining at least 80% normal sight.  
There are two disadvantages of cataract surgery: the occurrence of a secondary cataract 
and the length of time that lapses before surgery.  Secondary cataracts arise from the 
outside layer of the lens, left in place to hold the artificial lens, becoming cloudy.  Patients 
that must wait for surgery often experience significant eyesight deterioration that affects 
everyday activities, thus a topical or oral treatment for cataract that can be applied while 
patients await surgery will greatly benefit their quality of life. 
 
There are three main types of cataract, all age-related: cortical, post sub-capsular and 
nuclear. 61  Cortical cataracts form in the periphery of the lens and account for 24% of all 
cataracts.  Post sub-capsular cataracts are the least common and develop at the back of the 
lens, affecting vision at a fast rate.  Nuclear cataracts, the most common type, develop 
from the centre of the lens and characteristically cause the lens to become brown in 
appearance.61  An inhibitor targeted for calpain should, in theory slow the progression of 
all three types of cataract.  The University of Canterbury, in collaboration with Lincoln 
University is currently involved in the elucidation of cortical cataract formation, a 
condition that has been observed naturally within a flock of Romney sheep.    
 
The lens of the human eye is located behind the cornea (Figure 1.21) and focuses light on 
to the retina, adjusting the focus to allow for depth perception.62  The main structural 
components of the lens are soluble crystallin proteins (three types: α, β and γ) that are 
arranged in a highly ordered matrix.  The ordered arrangement of crystallins in the lens is 
fundamental to transparency; fragmentation of the crystallins by calpain and subsequent 
aggregation and precipitation of insoluble protein fragments results in a change in the 
refractive properties of the lens. Under these conditions, light can no longer be transmitted 
through to the retina, but is scattered away from the eye, resulting in impaired vision (see 
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Figure 1.22).  The clouding of the lens (cataract) is the physical result of the proteolysis of 
the α, β and γ crystallins.52,63 
 
 
Figure 1.21 Structure of the eye showing the position of the lens within the eyeball58 
 
 
Figure 1.22 The difference in focusing of light between a normal and cataractous lens.   
 
The mechanism of cataract formation is thought to be triggered by injury to the lens, 
genetics or ageing.  Over the human lifetime eyes are exposed to UV light, toxins and free 
radicals, all of which damage the lens and compromise membrane integrity.  Any damage, 
whether environmental or genetic, allows increased passage of ions, such as calcium, into 
the lens.64  The resulting increase in calcium ion concentration leads to the over activation 
of calpain, which cause excess proteolysis of the crystallins within the lens.52 
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This thesis, through inhibitor design and biological assays, will investigate specificities 
between proteases of the papain superfamily.  The results obtained will aid the design of 
specific calpain inhibitors that could potentially be used for the treatment of cataract. 
 
 
1.4.4 Structural Homology of Clan CA Cysteine Proteases 
 
The Clan CA cysteine proteases papain, cathepsin B and calpain (m- and µ-) have some 
structural similarity, especially in and around the active sites.  Crystal structures of µ-
calpain, cathepsin B and papain available from the Protein Database were downloaded, the 
structures overlaid and the active sites isolated.  Figure 1.23 shows the resulting 
superposition of the active sites of papain, cathepsin B and calpain, clearly emphasising 
that the alignment of the catalytic triad Cys, His and Asn is almost identical in each 
protease.  The α-helix, to which the active site cysteine is attached, is also similarly 
positioned in both papain and cathepsin B (blue and red respectively); the corresponding α-
helix in calpain is tilted slightly as a result of overall enzyme structure.  This is a structure-
based difference that provides an opportunity for the design of specific cysteine protease 
inhibitors. 
 
 
Figure 1.23 Active site superposition of calpain (green) and papain (blue) and cathepsin B (red) show the 
structural conservation between these cysteine proteases.65  The active site cysteine in each case is situated at 
the end of the α-helix.  (PDB codes 1PPP, 1ITO and 1TLO) 
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Comparison of the amino acid sequences surrounding the active site residues also 
illustrates the structural similarities between papain, cathepsin B and µ-calpain (see Figure 
1.24).  The sequence alignments were created by downloading the amino acid sequences of 
papain, cathepsin B and µ-calpain from the Protein Data Base.  The amino acid sequences 
6-7 residues either side of each of the catalytic triad residues (Cys, His and Asn) were 
identified and selected for each protease (Cys25, His159, Asn175 in papain; Cys29, His199, 
Asn219 in cathepsin B; Cys105, His262, Asn286 in calpain).  A sequence alignment was 
prepared in the CLC workbench for each of the three residues Cys, His and Asn (annotated 
with an asterisk) as shown in Figure 1.24.  The consensus row (uncoloured) gives the 
residues most common to the three sequences and the conservation row provides a visual 
approximation of the similarity of the sequences between papain, cathepsin B and µ-
calpain (the higher the pink bar the more alike the amino acids).  This sequence 
comparison highlights the close structural homology that exists between cysteine proteases 
of the papain superfamily, as similar residues are found around each member of the 
catalytic triads for µ-calpain, cathepsin B and papain. 
 
These two visual aids (Figures 1.23 and 1.24), showing the closeness in structure between 
cysteine proteases within the papain superfamily help to illustrate the difficulties faced in 
the design and synthesis of selective inhibitors. 
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Figure 1.24 Partial sequence comparison around the active site residues of papain, cathepsin B, m-calpain 
and µ-calpain.  The asterisks denote the catalytic triad residues Cys (top), His (middle) and Asn (bottom) 
respectively.  The amino acids are coloured according to RasMol predefined colours, where polar amino 
acids are designated with bright colours and non-polar amino acids with darker colours. 
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1.5 DESIGN OF CYSTEINE PROTEASE INHIBITORS 
 
Many different types of inhibitors have found application with cysteine proteases, the 
modes of action of which are discussed below. 
 
Allosteric effectors 
Inhibitors of this type interact with a site other than the active site of the enzyme.17  A good 
example is the mercaptoacrylic acid PD15606 (Figure 1.25 below) which competes with 
calcium ions for the calcium binding sites of calpain.   This thesis does not consider 
inhibitors of this type. 
  
I
CO2H
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Figure 1.25 PD15606 an allosteric inhibitor of calpain 
 
Active site directed inhibitors 
These are defined as inhibitors that interact with the active site.17  Most inhibitors are in 
fact, active site directed and can be further divided according to the specific type of 
interaction that occurs between inhibitor and active site residues.  These sub-categories are 
listed in Table 1.5 and include substrate analogues, product analogues, affinity labels, 
transition-state analogues and enzyme-activated inhibitors.  The classification depends 
upon which catalytic step the inhibitor exhibits its inhibitory action. 
 
Non-covalent inhibitors 
The main interactions of non-covalent inhibitors with the enzyme active site are through 
hydrogen bonds and electrostatic interactions.  Non-covalent inhibitors are further 
subdivided into substrate analogues and transition state analogues according to similarity 
to catalytic pathway intermediates.8  Reversible inhibitors that bind to the enzyme with 
high affinity are called tightbinding inhibitors.  Transition state analogue multidomain 
inhibitors are generally tightbinding. 
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Covalent inhibitors 
Covalent inhibitors are subdivided according to whether reaction takes place via catalysis 
(mechanism based) or by an alternative chemical pathway (affinity labelling).8,10  
Mechanism-based inhibitors are further classified by the type of intermediate generated 
upon reaction with the active site.  These are as follows: 
 
• Transition state analogues.  Reaction of the inhibitor with the active site results in a 
product that is analogous to the transition state of the substrate but which cannot react 
further 
• Enzyme activated inhibitors.  The reactive intermediate is released upon reaction with 
the active site and goes on to react with the enzyme along a non-catalytic pathway 
• Dead end inhibitors.  Which react with the enzyme active site to form an irreversible 
enzyme-inhibitor adduct that cannot react any further 
• Alternate substrate inhibitors.  These react in the same manner as dead end inhibitors 
but can react further with the enzyme. 
 
Affinity label inhibitors have a warhead that reacts with the active site to form a permanent 
or irreversible enzyme-inhibitor complex.  If the inhibitor can react with other molecules 
that have similar functional groups to the active site it is called a chemically reactive 
affinity label.  On the other hand if the inhibitor is only reactive towards the enzyme’s 
active site it is called a quiescent affinity label.8 
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Active-site Directed Inhibitor Categories 
 
 
 Category Type Warhead example 
 
1. Non-covalent 
interactions 
  
substrate analogues 
  
 
 
   
 
tightbinding analogues transition state         
analogues 
 
 
 
   
2. Covalent 
interactions 
mechanism based transition state 
analogues 
 
enzyme activated 
inhibitors 
 
dead end inhibitors 
 
aldehydes 
 
 
esters, amides 
 
 
peptidyl nitriles 
 affinity labels  halomethyl ketones, 
epoxy derivatives 
 
Table 1.5 Different classes of active-site directed inhibitors8,10 
 
 
1.5.1 Inhibitors Synthesised in This Thesis 
 
The design of the inhibitors synthesised in this thesis is based on an address region, a 
recognition region and a warhead as outlined in Figure 1.26.  The recognition region is 
usually a di- or tripeptide with amino acids chosen to fit the target enzyme binding pockets.  
This may not be enough to confer specificity for a particular cysteine protease on the 
inhibitor, so additional recognition is often bestowed upon the inhibitor by the addition of 
an address region in the P3 position (often a large hydrophobic group).  The warhead is 
generally an electrophilic moiety that can react with the active site cysteine thiol.  
Warheads can interact covalently or non-covalently with the active site (see above Table 
1.5). 
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Figure 1.26 The three components of protease inhibitors 
 
The covalent reversible inhibitors synthesised in Chapter Two are transition state 
analogues; the irreversible inhibitors synthesised in Chapter Three are dead end inhibitors 
or affinity labels (as described in Table 1.5).   
 
There are abundant reviews on cysteine protease inhibitors† that focus on potency; 
however, there is a lack of information available about the selectivity of cysteine proteases 
within clans, especially within the papain superfamily.  One recent review66 highlights that 
target selectivity remains a major problem, even though potent inhibitors are available for 
most cysteine proteases.   
 
The purpose of this thesis is to provide insight into the selectivity that can be achieved 
between members of the papain superfamily, especially focussing on the nature of the 
inhibitor warhead.  This will be achieved through the design, synthesis and biological 
assay of cysteine protease inhibitors with a variety of warheads.  The warheads utilised 
were chosen on the basis of: previous successful use in the literature and in-house 
molecular modelling results that suggested the proposed target inhibitor would bind to the 
substrate in the extended β-sheet conformation that is favoured by cysteine proteases. 
 
                                                 
†
 The database Scifinder Scholar identifies 229 reviews about cysteine protease inhibitors as of March 2007 
 Warhead 
 
Address Region Recognition 
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1.6 OVERVIEW OF THIS THESIS 
 
Chapter Two discusses literature examples of inhibitors that bind reversibly to cysteine 
proteases and then details the synthesis of a range of dipeptidyl inhibitors as cysteine 
protease inhibitors.  Covalent reversible warhead examples synthesised include aldehydes, 
semicarbazones, oxadiazoles, α-ketotetrazoles, α-ketooxazolines and peptidyl nitriles.  An 
inhibitor with an azide ‘warhead’ was also synthesised as an example of a non-covalent 
reversible warhead. 
 
Chapter Three discusses irreversible cysteine protease inhibitors and includes the 
synthesis of cysteine protease inhibitors with Michael acceptor (α,β-unsaturated carbonyls 
and vinyl sulfones), α-bromomethyl ketones, α-bromomethyl alcohols and peptidyl 
epoxides as irreversible warheads for application as cysteine protease inhibitors. 
 
Chapter Four introduces the importance of having inhibitors constrained into a bioactive 
conformation and highlights macrocyclic compounds as a means of achieving this goal.  
Warheads previously investigated in Chapters Two and Three and found to be potent and 
selective against cysteine proteases are applied to the macrocyclic scaffold.  The warheads 
used include primary alcohols, aldehydes, semicarbazones, α-ketotetrazoles and azides. 
 
Chapter Five details the design and validation of the assay protocols utilised for the in 
vitro biological testing of the inhibitors synthesised in Chapters Two through Four.  The 
proteases the inhibitors were tested against were m-calpain, µ-calpain, cathepsin B, papain, 
pepsin and α-chymotrypsin. 
 
Chapter Six presents structure-activity relationships of the inhibitors synthesised and 
biologically evaluated against the cysteine proteases m-calpain, µ-calpain, cathepsin B and 
papain.  The relationships discussed are on the basis of the assay results in combination 
with molecular modelling and knowledge of protease active site structure.  Emphasis is 
placed on the selectivity achieved between cysteine proteases of the papain superfamily, 
although some points of interest are made about the inhibitory effects of selected inhibitors 
against α-chymotrypsin and pepsin. 
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2.1 INTRODUCTION TO REVERSIBLE INHIBITORS 
 
Covalent reversible inhibitors inactivate cysteine proteases by reacting with the active site 
cysteine thiol, resulting in the formation of a hemi-thioacetal, ketal or similar tetrahedral 
intermediate, the nature of which depends on the warhead.1  The general mechanism of this 
is shown in Figure 2.1 below.   
 
R1 R2
O
R1
-S-Cys
R2HO
His-ImH+
S-Cys
His-Im
 
 
Figure 2.1 General mechanism of inactivation of cysteine proteases by reversible inhibitors   
 
Several types of natural reversible cysteine protease inhibitors have been isolated from 
micro-organisms,2 with the most common being the peptidyl aldehydes.  Among those 
isolated from Streptomyces and Actinomycete are the leupeptins,3,4 chymostatins,1 antipain1 
and elastinal1 (see Figure 2.2).   These naturally occurring aldehydes are non-specific, 
inhibiting both cysteine and serine proteases (Table 2.1).1,5  Peptidyl aldehyde Leupeptin 
(Figure 2.2 and Table 2.1) for example, inhibits papain, cathepsin B and µ-calpain (IC50 
values of 0.50, 0.44 and 0.10 µM respectively), along with the serine proteases trypsin 
(IC50 = 5.0 µM).  Further, because of structural similarities within the papain superfamily 
(see Chapter One); leupeptin shows little selectivity between papain, cathepsin B and 
calpain.  This is typical of peptidyl aldehydes.   
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Figure 2.2 Peptidyl aldehydes isolated from natural sources 
 
  
IC50 (µM)1 
Enzyme Leupeptin* Antipain Chymostatin* 
 
 
Papain 0.50 0.16 7.5  
Cathepsin B 0.44 - 2.6  
µ-Calpain 0.10 - -  
Trypsin 2.00 0.26 >250  
Chymotrypsin >500 >250 0.15  
 
Table 2.1 Inhibitory potency of natural peptidyl aldehydes against a range of proteases.6  * Where leupeptin 
is defined as R1, R2 = i-butyl, R3 = Me; Chymostatin is defined as R = i-butyl  
 
The modification of the Arg, Ala and Asn residues in the P1 and P2 subsites (see Figure 
2.2) to Phe, Leu or Val residues which are favoured by cysteine proteases (refer to 
Chapter One) and the addition of an aryl protecting group on the N-terminus resulted in 
synthetic inhibitors that were selective for cysteine proteases over serine proteases (see 
Table 2.2); yet reported peptidyl aldehydes remain non-specific towards the cysteine 
protease family.  This is highlighted for peptidyl aldehydes 2.1 to 2.5 in Table 2.2.  
Aldehyde 2.1 shows 2-fold selectivity towards the calpains (0.040-0.050 µM) over papain 
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(0.14 µM) and cathepsin B (0.13 µM) but does not distinguish between papain and 
cathepsin B.  Aldehyde 2.2 has similar potency against the m- and µ-calpain and cathepsin 
B (0.060 µM, 0.027 µM and 0.027 µM respectively) and is at least 18-fold less active 
against papain (IC50 = 1.1 µM).  The aldehyde 2.3 is highly potent against all of the 
papain-like cysteine proteases tested (all IC50 values between 0.005-0.080 µM, see Table 
2.2).  Similarly, aldehyde 2.4 shows little specificity between the cysteine proteases m-
calpain, µ-calpain and cathepsin B (IC50 = 0.19 µM, 0.086 µM and 0.15 µM respectively); 
while aldehyde 2.5 shows little specificity between m-calpain and µ-calpain (Ki = 0.050 
µM and 0.036 µM respectively). 
 
  
IC50 (µM) 
Peptidyl Aldehyde m- 
calpain 
µ- 
calpain 
papain cathepsin 
B 
Ref 
 
 
 
2.1 O NH
O
H
N
O
O
H
 
 
 
0.040 
 
 
0.050 
 
 
0.14 
 
 
0.13 
 
 
1,2,7
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O N
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O
H
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O
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0.35 
 
 
0.056 
 
 
1.1 
 
 
0.027 
 
 
1,8,9
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0.005 
 
 
0.023 
 
 
0.016 
 
 
1, 10
 
 
 
2.4 O
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N
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0.19 
 
 
0.086 
 
 
- 
 
 
0.15 
 
 
1,9,11
 
 
2.5 N
H
O H
N
O
H
O
 
 
Ki = 
0.050* 
µM 
 
Ki = 
0.036* 
µM 
 
- 
 
- 
 
2
 
 
Table 2.2 Inhibitory potency of the synthetic peptidyl aldehydes 2.1 calpeptin; 2.2 MDL28170; 2.3 
SJA6017; 2.4 calpain inhibitor I.  These are broad spectrum cysteine protease inhibitors. * no reported IC50 
values  
 
Chapter Two – Reversible Inhibitors  44 
The dipeptidyl aldehyde 2.3 shows therapeutic potential against a rat selenite-induced 
cataract lens culture assay and more recently, in vivo in a sheep animal model.9  However, 
this aldehyde has limited aqueous solubility (0.1 mg/ml), a lack of metabolic stability 
(97.5% of sample metabolised after incubating for 1 h in human microsomes) and binds to 
proteins (95%); see Table 2.3.  These properties, along with its rapid metabolism into the 
alcohol 2.6 and acid 2.7 (Figure 2.3)12 suggest that the aldehyde reacts with biological 
proteins in vivo, limiting its membrane permeability and bioavailability.   
 
  
Table 2.3 Properties exhibited by aldehyde 2.3.9  *Toxicity tested against human neuroblastoma SY5Y cells 
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Figure 2.3 The aldehyde 2.3 is readily metabolised into the corresponding alcohol 2.6 and acid 2.7 
 
The above examples highlight the fact that aldehydes are potent inhibitors, but the 
reactivity of the aldehyde moiety under biological conditions results in non-specific 
inhibition of cysteine proteases.  As a result, a number of chemically less reactive 
 
O2S
N
H
H
N
O
O
F
H
 
2.3 
 
Toxicity  
  
LD50*  >1000 µM 
Permeability:  1.41 x 10-6 cm/s, 33% recovery 
Protein Binding  95% 
Metabolic Stability  97.5% metabolised (2.5%  recovery after 1 hr) 
Aqueous solubility   0.1 mg/ml 
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reversible warheads have been investigated as protease inhibitors.  A summary of some 
reversible warheads and their contribution to the inhibition of cysteine proteases follows. 
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2.2  REVERSIBLE WARHEADS UTILISED IN CYSTEINE 
PROTEASE INHIBITORS 
 
2.2.1 Semicarbazone Warheads 
 
Semicarbazones have long been established in synthetic chemistry as a means of purifying 
aldehydes.13  More recently, semicarbazones have been utilised as inhibitor warheads for 
the cysteine proteases cruzain,14 cathepsin K15 and calpain16 with moderate success.  While 
still being potent inhibitors, the semicarbazones are generally reported as being weaker 
than the corresponding parent aldehyde.15  The semicarbazones 2.9 to 2.11 illustrate this 
point (see Table 2.4), being 4- to 8-fold less potent than the parent aldehyde 2.8 (IC50 = 
0.051 µM). The loss of potency however, is offset by increased aqueous solubility and 
better pharmacokinetic profiles than the parent aldehyde 2.8 (data not given).15 
 
Peptidyl semicarbazones inhibit cysteine proteases by reversible attack of the thiolate on 
the protected carbonyl carbon to form a tetrahedral adduct as depicted in Figure 2.4.1,14  
The incorporation of a semicarbazone moiety is thought to be advantageous as it contains 
both hydrogen bond acceptors and donors.   
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Table 2.4 Semicarbazones are weaker inhibitors than the parent aldehyde15 
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Figure 2.4 Mechanism of inactivation by semicarbazones. 
 
 
2.2.2 Heterocyclic Warheads 
 
There are many examples of inhibitors of cysteine proteases bearing heterocyclic 
warheads,* for example see Figure 2.5, which includes the heterocycles: oxazole, 
oxazoline, oxatriazole, thiazole, thiazoline and imidazole that have been utilised in the 
literature.17-19 
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Figure 2.5 Some heterocyclic warheads used in protease inhibitors a) thiazole, b) oxazole, c) benzoxazole, d) 
benzothiazole e) tetrazole, f) oxazoline and g) pyridine  
 
The mechanism of heterocyclic inhibition is analogous to that of aldehydes and ketones, 
either through a hemi-thioacetal or ketal intermediate (refer to Figure 2.1).  The 
heterocyclic warhead can be considered a masked aldehyde or α-ketoamide as depicted in 
Figure 2.6.  Masking the reactivity of electrophilic groups such as aldehydes with a 
heterocycle increases the metabolic stability of the inhibitor and may aid localisation of the 
inhibitor to the target enzyme.2   
  
 
 
                                                 
*
 There have been over 300 patents filed regarding heterocyclic protease inhibitors filed. 
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Figure 2.6 The heterocyclic warhead as a) a masked aldehyde and b) a masked α-ketoamide 
 
Oxadiazoles 
Examples of 3,5 disubstituted 1,2,4-oxadiazoles are provided by Hamze20 and co-workers 
(see Figure 2.7), who synthesised a range of novel heterocyclic containing α- and β-amino 
acids for incorporation into peptides and protease inhibitors.  Condensation reactions 
between a carboxylic group with a range of substituted amidoximes and subsequent 
cyclisation resulted in substituted 1,2,4-oxadiazoles.  These oxadiazoles were substituted in 
the 5 position by the carboxylic acid moiety and in the 3 position by the amidoxime 
substituent. 
N
N
OR1
R2
 
 
Figure 2.7 Generic structure of 1,2,4-oxadiazoles substituted in the 3 position by R2 and in the 5 position by 
R1 
 
α-Ketoamides and α-ketoheterocycles 
The α-ketoamide inhibitors 2.12 and 2.13 shown in Figure 2.8 are potent µ-calpain 
inhibitors (IC50 values of 0.021 and 0.032 µM respectively). These examples are effective 
at protecting rats against ischemic brain damage.12  The α-ketoamide moiety is an isosteric 
replacement of aldehydes, with potency thought to arise from formation of a stabilised 
tetrahedral adduct due to hydrogen bonding between the electrophilic carbonyl of the α-
ketoamide and catalytic residues of the protease.21  There are over 40 patents associated 
with α-ketoamide inhibitors, only a few of which are specifically for cysteine proteases. 
Further, α-ketoheterocycles are isosteres of α-keto acids22,23 and can provide 
conformational restraint upon the inhibitor in which they are incorporated.24,25   
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Figure 2.8 Peptidyl α-ketoamides that are potent calpain inhibitors.16,26  2.12 IC50 = 0.021 µM and 2.13 IC50 
= 0.032 µM 
  
Edwards et al27 reported a series of peptidyl α-ketoheterocycles as potent inhibitors of 
Human Neutrophil Elastase (HNE) (see Table 2.5).  Both the α-ketooxazoline 2.16 and the 
α-ketobenzoxazole 2.15 were more potent than the analogous peptidyl aldehyde 2.14.  The 
increase in activity against Human Neutrophil Elastase is thought to partly arise from the 
heterocyclic ring possessing high electron withdrawing potential,28 denoted as σI.†  The 
more electron withdrawing the heterocycle, the more it can activate the adjacent ketone 
group towards nucleophilic addition by active site residues.  The electron withdrawing 
potentials
 
for a number of heterocycles are given in Table 2.6. Perusal of this data 
indicates that α-ketotetrazoles (σI = 0.49)29 are one of the most electron-withdrawing 
heterocycles, making this moiety a desirable warhead for cysteine protease inhibitors.  The 
electron-withdrawing ability of α-ketooxazolines (σI = 0.32)29 is less than that for α-
ketotetrazoles; however, the hydrogen bond accepting ability of the α-ketooxazoline ring is 
excellent.19,27  The combination of electron with-drawing ability and hydrogen bond 
acceptance make both α-ketotetrazoles and α-ketooxazolines desirable inhibitor warheads.  
 
 
 
 
 
 
 
 
 
 
 
                                                 
†
 The σ values are values that represent the electrical effects of the heterocycle as calculated by the Hammett 
Equation 
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Table 2.5 Potent α-ketoheterocyclic HNE protease inhibitors 
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Table 2.6 Electron withdrawing properties of heterocycles28,29 
 
 
2.2.3 Nitrile Warheads 
 
Peptidyl nitriles have been known as inhibitors of papain for over 30 years1 and more 
recently touted as potent, selective cathepsin B inhibitors.  Greenspan et al30 synthesised a 
range of peptidyl nitriles of cathepsin B. One of these, inhibitor 2.16, shown in Figure 2.9 
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was a potent inhibitor of cathepsin B (IC50 = 0.012 µM).  This peptidyl nitrile displayed 
greater than 100-fold selectivity for cathepsin B over other cathepsins. It also has a plasma 
concentration of 5.27 µM, corresponding to excellent bioavailability.30  X-ray crystal 
structure data (cathepsin B with a peptidyl nitrile inhibitor bound) helped to elucidate the 
mechanism of inhibition by peptidyl nitriles, showing the formation of a reversible 
thioimidate complex between the cysteine thiol of the enzyme and the nitrile moiety of the 
inhibitor (see Figure 2.10).30,31 
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Figure 2.9 A peptidyl nitrile protease inhibitor.  IC50 = 0.0012 µM; plasma concentration = 5.27 µM30 
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Figure 2.10 Mechanism of inhibition by peptidyl nitriles 
 
 
2.2.4 The Non-Covalent Azide ‘Warhead’ 
 
Fairlie32 and co-workers recently reported the first instance of the azide moiety being 
utilised as part of a cysteine protease inhibitor.  The inhibitors 2.19a-f (see Table 2.7), 
with an azidomethylene moiety acting as a non-covalent ‘warhead’, showed excellent 
inhibition of cysteine protease inhibitors (IC50 values in the sub µM region).  The azides 
2.19a-f were only tested for activity against caspases and cathepsins K, S and B; however, 
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it was suggested that the azide moiety would be useful for the inhibition of other cysteine 
proteases.    
 
     
2.19 
R
H
N
N3
XY
 
 
Y X R Enzyme IC50 (µM) 
 
2.19a    Biphenoyl-Val Ala CH2COOH   Casp-1 0.0045 
2.19b    Ac-Asp-Glu Leu CH2COOH   Casp-3 0.39 
2.19c    Cbz-Glu Leu CH2COOH   Casp-8 0.16 
2.19d    2-Naphthoyl Leu (CH2)3CH3       Cat K 0.0012 
2.19e    1-Naphthoyl Leu (CH2)3CH3 Cat S 0.018 
2.19f     Biphenoyl Phe      CH2CH(CH3)2 Cat B 0.058 
 
 
Table 2.7 Azidomethylene inhibitors of cysteine proteases32 
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2.3  DESIGN AND SYNTHESIS OF REVERSIBLE 
CYSTEINE PROTEASE INHIBITORS 
 
2.3.1 Design of Peptidyl Aldehydes  
 
This thesis focuses on the effect the inhibitor warhead has on selectivity between cysteine 
proteases of the papain superfamily.  Two general scaffolds were used; a Val-Leu and a 
Val-Phe dipeptide, all of which are preferred amino acids of cysteine proteases (see 
Chapter One for more detail).  Four aryl groups (4-fluorobenzenesulfonyl, 
benzyloxycarbonyl, 2-pyrrole carbonyl and 2-thiophene acetyl) were briefly investigated to 
determine the effect of the N-terminal group on selectivity between members of the papain 
superfamily.  Of the aldehydes synthesised, four were literature compounds.9,33,34  The 
purpose of synthesising the literature aldehydes was two-fold: firstly, to provide a measure 
of reproducibility and validation for assay results; and secondly, as will be discussed in this 
and subsequent chapters, the reactivity of the aldehyde moiety provides an excellent 
starting point for chemical modification of the warhead to produce less reactive, more 
selective inhibitors of cysteine proteases.  The synthesis of aldehydes 2.3 and 2.20 (see 
Figure 2.11) proved to be high yielding (this is discussed below); subsequent assay 
showed both of these aldehydes to be potent broad spectrum cysteine protease inhibitors 
(see Chapter Six for details), thus 2.3 and 2.20 were used as lead compounds for the 
design of specific cysteine protease inhibitors in this thesis.   
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Figure 2.11 The aldehydes 2.3 and 2.20 were the lead compounds for inhibitors synthesised in this thesis 
 
 
 
Molecular Modelling  
Using the general scaffolds as described above, moieties that had previously been utilised 
as cysteine protease inhibitor warheads were used to design the target compounds.  The 
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target compounds were docked into the molecular modelling program and the proposed 
binding modes resulting from this were used to determine the priority of synthesis.  
Cysteine proteases are known to bind substrates in an extended β-sheet conformation,35 
thus target compounds that exhibited an extended β-sheet conformation (as defined by 
three critical hydrogen bonds) were assumed to have good binding affinity to the protease 
and were subsequently synthesised and assayed for in vitro potency.   
 
Molecular modelling‡ was performed on target compounds using the following method:  a 
model of the active site of calpain was developed from the crystal structure of engineered 
µ-calpain published by Moldoveanu et al.36  The grid file was prepared from the crystal 
structure for these experiments by the mutation in silico of Ser115 to Cys115 to re-establish 
the natural amino acid composition of µ-calpain. A minimization of this structure, using 
the OPSL2001 force field and water as simulated solvent, resulted in a relaxed structure 
differing with an RMSD of the heavy atoms (C, N, O, S) of 0.96 Å from the reported 
crystal structure. Cys115 was deprotonated and His262 protonated to better mimic the amino 
acids in the active enzyme. A docking grid was generated, and inhibitor 2.3 was docked to 
the calpain model using GLIDE (Schrodinger)37 to establish the docking of this reference 
compound of known inhibitory activity. Figure 2.12 shows an overlay of the crystal 
structure of the Leupeptin-calpain co-crystal with the structure of each inhibitor docked to 
calpain. 
 
 
Figure 2.12 Overlay of 2.3 docked to the µ-calpain model (blue) and the leupeptin/engineered µ-calpain co-
crystal (orange). Hydrogen bonds to Gly208 and Gly271 are shown by the dotted lines 
  
                                                 
‡
 Molecular modelling was performed by Wanting Jiao of the University of Canterbury 
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Leupeptin and aldehyde 2.3 adopt the same overall orientation on binding where the 
aldehyde is located close to the active site cysteine. Importantly, both leupeptin and 2.3 
have their backbone conformations defined in the extended β-strand geometry with three 
hydrogen bonds to Gly208 and Gly271 (these will subsequently be referred to as hydrogen 
bonds A, B and C). Significantly, this binding motif is also apparent in published crystal 
structures. The β-strand motif is recognized by calpain on the carboxyl side of the scissile 
bond, the position in which most calpain inhibitors bind. However, while the crystal 
structure of the calpain-leupeptin complex suggests the existence of a covalent bond 
between protein and ligand, the docking experiments simply evaluate non-covalent 
interactions. The binding energy from the formation of a covalent bond is therefore not 
represented in the calculated docking scores.  All molecular modelling reported in this 
thesis follows the aforementioned protocol as developed at the University of Canterbury§ 
and will be referred to as the rigid µ-calpain model henceforth. 
 
The in-house heterocyclic aldehyde calpain inhibitor 2.20 was docked into the rigid µ-
calpain model and the best pose shown in Figure 2.13.  This suggests that the aldehyde 
2.20 forms the hydrogen bonds A, B and C (as defined above).  Additional hydrogen bonds 
are suggested to form between the sulfur atom of the heterocycle and Asn253, and the same 
sulfur atom and Lys347 (see Figure 2.13).  Heterocycles have previously been used to 
induce an extended conformation in peptide sequences, leading to the preparation and 
testing of calpain inhibitors that incorporated pyrrole and furan heterocyclic functionality 
within the University of Canterbury.38   
 
 
 
Figure 2.13 The in-house furan containing aldehyde inhibitor 2.20 and its molecular modelling results 
                                                 
§
 Molecular modelling protocol was established by Blair Stuart, Axel Neffe and Steven McNabb 
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The heterocyclic aldehydes 2.21 and 2.22 were docked into the rigid µ-calpain model and 
the best poses for each are shown in Figure 2.14.  This suggested that both aldehydes 2.21 
and 2.22 bind calpain in an extended bioactive conformation defined by hydrogen bonds 
A, B and C.  No additional hydrogen bonds were suggested to form, the NH group of the 
2-pyrrolecarbonyl 2.21 being a mismatch with the Asn253 which requires a donor atom; and 
the sulfur atom of the 2-thiophene acetyl 2.22 is not in close proximity to the Asn253 or 
Lys347 due to the methylene insertion. 
   
 
 
Figure 2.14 The heterocyclic aldehydes 2.21 and 2.22 synthesised for comparison to the heterocyclic 
aldehyde 2.20 and their molecular modelling results (low energy conformations) 
 
 
2.3.2 Synthesis of Peptidyl Aldehydes 
 
The synthesis of the aldehyde 2.3 was optimised from Inoue’s methodology10 as shown in 
Scheme 2.1.  Commercially available 4-fluorobenzenesulfonyl chloride 2.23 was coupled 
to L-valine under aqueous conditions to give the acid 2.24.  Reaction of this acid 2.24 with 
N-hydroxysuccinimide in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 
hydrochloride (EDCI) gave the activated ester 2.25 as a white solid in 95% yield. Samples 
of the ester 2.25 were separately reacted with L-leucinol or L-phenylalaninol to give the 
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dipeptides 2.6 or 2.26 respectively. The precursors 2.24, 2.25, 2.6 and 2.26 were purified 
by rinsing in a mixture of 5% ethyl acetate and 95% petroleum ether.  Subsequent 
oxidation of samples of the primary alcohols 2.6 and 2.26 using sulphur trioxide-pyridine 
complex and dimethylsulfoxide in the presence of DIPEA (Parikh-Doering Oxidation)39 
gave the aldehydes 2.3 and 2.27 as white solids in 89% and 77% yields respectively.  The 
oxidised products 2.3 and 2.27 were characterised by 1H NMR, which showed the absence 
of the alcohol methylene peaks at around 2.5 ppm; a singlet peak at around 9.0 ppm was 
observed; this is characteristic of an aldehyde peak.   
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Scheme 2.1 Reagents and Conditions: i) THF, H2O, L-valine, NaOH (75%); ii) N-hydroxysuccinimide, 
EDCI, DCM, THF (95%); iii) L-leucinol, DCM, DIPEA (87%); iv) SO3-pyr, DMSO, DIPEA, DCM (77-
89%) 
 
The sulfur trioxide-pyridine complex was used to oxidise the alcohols 2.6 and 2.26 to the 
aldehydes 2.3 and 2.27 because the reaction conditions are mild and isolation of the desired 
aldehyde is free from side products.40  This is highly beneficial as aldehydes are easily 
epimerised when undergoing chromatographic purification.  Examination of the 1H and 13C 
NMR spectra of aldehydes 2.6 and 2.27 for epimerization of the peptide aldehydes 
revealed only a single isomer was present in each case (see Figure 2.15). 
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Figure 2.15 1H NMR spectra (top) of aldehyde 2.27 showing the clearly single resonances for the CHO peak 
and the α-protons of the Leu and Val (circled); 13C NMR spectra (bottom) of aldehyde 2.27 showing the 
clearly single peaks of the Leu and Val sidechains (18-70 ppm) and the CHO peak (198 ppm) 
 
ppm 
ppm 
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In cases where epimerization has occurred, both isomers are clearly evident by 13C and 1H 
NMR. This is particularly true of the the P1 residue** (Leu in the case of both 2.6 and 2.27) 
and the aldehyde hydrogen and these signals are all clearly defined as single resonances for 
the aldehydes 2.6 and 2.27 (see example given in Figure 2.15).  The Parikh-Doering 
oxidation removed any need for purification of the aldehyde 2.3; however, purification of 
the aldehyde 2.27 was required.  This was achieved by recrystallisation of the crude 
material from a minimal amount of ethyl acetate.  The mechanism by which the sulfur 
trioxide-pyridine complex oxidises alcohols is shown in Figure 2.16.  The sulfur trioxide-
pyridine complex reacts with dimethylsulfoxide to give an activated sulfonium species.  
This reacts with the alcohol to yield the sulfonium intermediate which is deprotonated 
under basic conditions to generate the aldehyde and dimethylsulfide.41 
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Figure 2.16 Mechanism of oxidation by sulfur trioxide-pyridine41 
 
The aldehydes 2.19 and 2.2 were synthesised by the method outlined in Scheme 2.2.  
Samples of commercially available benzyloxycarbonyl-L-valine 2.28 were separately 
coupled to L-leucinol and L-phenylalaninol under standard N,N,N',N'-tetramethyl-O-(7-
azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) conditions to give the 
dipeptidyl alcohols 2.29 and 2.30 in 87% and 76% yields respectively.  Subsequent 
oxidation utilising the sulfur trioxide-pyridine complex gave the aldehydes 2.19 and 2.2 as 
white solids in 89% and 79% yields respectively.40  NMR analysis of the aldehydes 2.19 
and 2.2 showed an absence of the starting alcohol methylene peaks and there was no 
evidence of epimerisation (as previously described).   
                                                 
**
 The P1 residue is more susceptible to epimerization than the P2 residue because the P1 residue part of the 
aldehyde moiety whereas the P2 residue is a protected amino acid. 
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Scheme 2.2 Reagents and Conditions: i) HATU, DIPEA, L-leucinol or L-phenylalaninol (87%, 76%); ii) 
SO3-pyr, DMSO, DIPEA, DCM (89%, 79%) 
 
Syntheses of the aldehydes 2.21 and 2.22 are outlined in Scheme 2.3.  The N-protecting 
groups of the aldehydes 2.21 and 2.22 were 2-pyrrole carbonyl and 2-thiophene acetyl 
respectively.  Commercially available tert-butoxycarbonyl-L-valine 2.31 was coupled to L-
leucinol under standard HATU conditions to give the N-protected dipeptidyl alcohol 2.32.  
The tert-butoxycarbonyl protecting group of 2.32 was cleaved using trifluoroacetic acid to 
give the aminoalcohol 2.33 in excellent yield (>95%).  Coupling of the thiophene-2-acetyl 
chloride to the aminoalcohol 2.33 proved problematic.  The original solvent used was 
dichloromethane; however, analysis of the product by mass spectrometry established that 
both amide bond formation and esterification of the aminoalcohol 2.33 had occurred, 
giving the side product 2.34 as shown in Figure 2.17.   
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Figure 2.17 The product obtained from coupling amino-alcohol 2.34 with thiophene-2-acetyl chloride in a 
dichloromethane solvent system 
 
The formation of the side product 2.34 was overcome by adjusting the solvent system used.  
Tetrahydrofuran, dichloromethane:N,N-dimethylformamide (1:1) and N,N-dimethylform-
amide were used in separate reactions of the aminoalcohol 2.33  with thiophene-2-acetyl 
chloride, and the isolated products analysed by 1H NMR and mass spectrometry (see Table 
2.8).  N,N-Dimethylformamide was found to facilitate the coupling of 2-thiophene acetyl 
chloride to the aminoalcohol 2.33 to give the desired N-protected alcohol 2.35 with no 
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evidence of the side product 2.34 by mass spectrometry.  Under these new conditions, 
samples of the free amine 2.33 were separately coupled to 2-pyrrole carboxylic acid and 2-
thiophene acetyl chloride to give the dipeptidyl alcohols 2.35 and 2.36 in excellent yields 
of 78% and 83% respectively.  Oxidation of the alcohols 2.35 and 2.36 using the sulfur 
trioxide-pyridine complex gave the aldehydes 2.21 and 2.22 in 89% and 86% yield 
respectively. 
 
 
Solvent 
 
 
% Product 
2.35 
 
 
% Side product 
2.34 
 
Dichloromethane 
 
20% 
 
80% 
Tetrahydrofuran 50% 50% 
N,N-Dimethylformamide/Dichloromethane (1:1) 80% 20% 
N,N-Dimethylformamide 100% 0% 
 
 
Table 2.8 Solvent effects on formation of side product 
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Scheme 2.3 Reagents and Conditions: i) HATU, DIPEA, L-leucinol, DMF, (68%); ii) TFA, DCM (100%); 
iii) 2-pyrrole carboxylic acid or 2-thiophene acetyl chloride, DIPEA, DMF (2.35 78%, 2.36 83%); iv) SO3-
pyr, DMSO, DIPEA, DCM (2.21 89%, 2.22 86%) 
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2.3.3 Design and Synthesis of Semicarbazones  
 
The semicarbazone 2.37 was docked into the rigid µ-calpain model and the best pose is 
shown in Figure 2.18.  This suggested that the semicarbazone 2.37 adopts a β-sheet 
conformation†† as defined by hydrogen bonds A, B and C.  Two additional hydrogen bonds 
were observed between the sulfonamide oxygen groups and Asn253 or Lys347 and the 
semicarbazone NH group and Cys105.  It was hoped these extra hydrogen bonds will 
enhance the binding affinity of the semicarbazone 2.37 (see Chapter Six for more detail).  
The semicarbazone 2.37 was originally synthesised by Nakamura16 as a more water-
soluble alternative to the aldehyde 2.3,  showing that the semicarbazone 2.37 was 16-fold 
more water soluble than the aldehyde 2.3.  However, no other semicarbazone moieties 
were tested.  This provided impetus for the synthesis of novel semicarbazone containing 
inhibitors.  The readily available semicarbazides‡‡ 4-phenylsemicarbazone, 
thiosemicarbazone and the related phenylhydrazine hydrochloride were utilised to prepare 
semicarbazones as warheads for the exploration of P’ subsites of the cysteine proteases m-
calpain, µ-calpain, cathepsin B and papain.    
 
 
Figure 2.18 The semicarbazone 2.37 and molecular modelling results showing the hydrogen bonds formed to 
the enzyme 
 
The semicarbazone analogues were prepared as shown in Scheme 2.4 following the 
method described by Nakamura.16  The aldehyde 2.3 was reacted with the chosen 
                                                 
††
 The parameters that define a β-sheet conformation are described in detail in Chapter Four 
‡‡
 Note that phenylhydrazine hydrochloride is not a semicarbazide, but has been included in this section for 
discussion purposes 
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semicarbazide (semicarbazide hydrochloride, 4-phenylsemicarbazide hydrochloride, 
thiosemicarbazone, or the related phenylhydrazine hydrochloride) in a condensation 
reaction to give the desired semicarbazones 2.37-2.40 in high yields (90%, 83%, 85% and 
70% respectively) after recrystallisation from ethyl acetate. 
 
Neither the aldehyde 2.3 nor the four semicarbazides were sufficiently water-soluble for 
solely aqueous reaction conditions to be utilised, thus a suitable water miscible solvent was 
required.  Each semicarbazide was tested for solubility in water, tetrahydrofuran and 
methanol.    Semicarbazide hydrochloride and thiosemicarbazide hydrochloride were found 
to be soluble in a 1:1 mixture of tetrahydrofuran:water; aldehyde 2.3 was also soluble in 
this solvent system.  4-Phenylsemicarbazide hydrochloride and phenylhydrazine 
hydrochloride were found to be soluble in methanol; this too was a suitable solvent for the 
aldehyde 2.3 (see Table 2.9 for a summary of the solvent systems used).     
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Scheme 2.4 Reagents and Conditions: i) NaOAc, H2NNHR, solvent 
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Compound 
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Table 2.9 Solvent systems used for the semicarbazones 2.37-2.40 synthesised.  The percentage yields of the 
products are also given 
 
 
 
2.3.4 Design and Synthesis of Heterocycles 
 
The oxadiazole 2.41 and the α-ketooxazoline 2.42 were docked into the rigid µ-calpain 
model and the best poses shown in Figure 2.19.  This suggested that oxadiazole 2.41 
formed two critical hydrogen bonds between the sulfonamide NH group and Gly208 and the 
amide NH group and Gly271 (A and C); with additional hydrogen bonds suggested between 
the sulfonamide oxygen groups and Asn253 or Lys347.  α-Ketooxazoline 2.42 was suggested 
to adopt a β-sheet conformation as defined by hydrogen bonds A, B and C (see Figure 
2.19).   The α-ketotetrazole 2.43 (see Figure 2.20) was not modelled.  
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                  a)                                b) 
Figure 2.19 The heterocyclic warheads a) oxadiazole 2.41 and b) α-ketooxazoline 2.42 are suggested to form 
the hydrogen bonds as shown 
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Figure 2.20 The α-ketotetrazole 2.43 was not modelled; it was assumed to be able to form similar hydrogen 
bonds to the α-ketooxazoline 2.42 above. 
 
Samples of 4-fluorobenzenesulfonyl valine 2.24 and benzyloxycarbonyl valine 2.28 were 
separately reacted with to L-leucine methyl ester under standard HATU conditions to give 
the dipeptide methyl esters 2.44 and 2.45 in 96% and 95% yields respectively.  This 
reaction was optimised from the BOP methodology employed previously by Payne et al.42  
The methyl esters 2.44 and 2.45 were separately hydrolysed in the presence of lithium 
hydroxide to give the free acids 2.7 and 2.46.  N-Hydroxyethanimidamide (2.47) was 
prepared by the addition of hydroxylamine to acetonitrile and subsequently coupled to 
carboxylic acids 2.7 and 2.46 to yield the amidoximes 2.48 and 2.49 as colourless glassy 
solids in 79% and 82% yields respectively.  The 3-methyl-1,2,4-oxadiazoles 2.41 and 2.50 
were formed via thermal intramolecular cyclodehydration of the amidoximes 2.48 and 2.49 
in the presence of sodium acetate.  The crude products were separately recrystallised from 
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ethyl acetate/petroleum ether to give the pure oxadiazoles 2.41 and 2.50 as colourless 
glassy solids in 88% and 90% yields respectively. 
 
RHN
OH
O
2.24 R = Fps
2.28 R = Cbz
RHN
H
N
O
OMe
O
RHN
H
N
O
OH
O
RHN
H
N
O
O
O
N NH2RHN
H
N
O
O
N
N
2.44 R = Fps
2.45 R = Cbz
2.7 R = Fps
2.46 R = Cbz
2.48 R = Fps
2.49 R = Cbz
2.41 R = Fps
2.50 R = Cbz
i ii
iii
iv
 
 
Scheme 2.5 Reagents and Conditions: i) L-leucine methyl ester, DMF, HATU (96%, 92%); ii) LiOH, THF, 
H2O (94%, 98%); iii) N-hydroxyethanimidamide 2.47, DCM/DMF (9:1), HOBt.H2O, EDCI, -10°C (79%, 
82%); iv) NaOAc, EtOH, reflux (88%, 90%) 
 
The synthesis of the α-ketotetrazoles follows the method outlined in Scheme 2.6 (left hand 
side of diverging synthesis).  The aldehydes 2.3 or 2.19 were each reacted with sodium 
hydrogen sulfite and potassium cyanide to give the diastereomeric cyanohydrins 2.51 and 
2.52 respectively, in good yield (82% and 86%).  The cyanohydrins 2.51 and 2.52 were 
separately reacted with sodium azide and triethylamine hydrochloride22 to give the α-
hydroxytetrazoles 2.53 and 2.54 respectively.  Separate recrystallisation of the α-
hydroxytetrazoles 2.53 and 2.54 gave both of the pure products as pale yellow glassy solids 
(67% and 72% respectively).    
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Scheme 2.6 Reagents and Conditions: i) NaHSO3, MeOH, H2O, KCN, EtOAc; ii) NaN3, Et3N.HCl, toluene, 
reflux; iii) TEMPO, NaOCl, KBr, DCM/H2O; iv) Acetyl chloride, MeOH, CHCl3, ethanolamine, DIPEA; v)  
SO3-pyr, DMSO, DIPEA, DCM 
 
The tetrazole ring was indistinguishable by 1H NMR from the starting cyanohydrin.  Thus 
infrared spectroscopy and mass spectrometry were utilised to determine whether formation 
of the α-hydroxytetrazole had occurred.  Low resolution mass spectrometry was performed 
on separate samples of the α-hydroxytetrazoles 2.53 and 2.54, giving the required masses 
of 443.1 gmol-1 and 419.2 gmol-1 respectively; similarly, the infrared spectra of α-
hydroxytetrazoles 2.53 and 2.54 showed peaks around 1692 and 1649 cm-1, characteristic 
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of an N-N aromatic stretch and markedly different from the nitrile peak observed at 2220 
cm-1 for 2.52 (see Chapter Seven, Section 7.2.3).43  Use of these two spectroscopic 
methods provided evidence that the α-hydroxytetrazole was present.  Oxidation of the α-
hydroxytetrazole 2.53 to the α-ketotetrazole 2.43 using sulfur trioxide-pyridine complex 
returned starting material only, as evident from the 1H NMR of the isolated product.  The 
nitroxide 2,2,6,6-tetramethylpiperidinyl-1-oxyl (TEMPO) has been reported as a mild 
oxidant44 that maintains chiral integrity in oxidations of primary alcohols to aldehydes.  
TEMPO has also been used successfully in the oxidation of α-hydroxy amides to α-
ketoamides without evidence of epimerisation.45  Under these new conditions, 2.53 and 
2.54 were oxidised separately utilising TEMPO-NaOCl to give the α-ketotetrazoles 2.43 
and 2.55 successfully. 1H NMR was used to assess the formation of the ketone by 
observing the absence of the proton at the β-carbon.  The 1H spectra of the α-
hydroxytetrazoles 2.53 and 2.54 showed two distinct peaks for the hydrogen of the β-
carbon at around 4.5 ppm, due to the diastereomeric nature of the β-carbon (see Figure 
2.21, β-carbon hydrogen peaks circled).  Oxidation to the α-ketotetrazoles 2.43 and 2.55 
resulted in the loss of the hydrogen of the β-carbon.  Further evidence for successful 
oxidation was observed in the 1H and 13C NMR spectra, as the signals associated with the 
P1 residues were clearly defined as single resonances.  This indicated that the 
diastereomeric centre of the α-hydroxytetrazole had been oxidised.  Mass spectrometry and 
infrared analysis was again used to ensure that the tetrazole ring itself had remained intact 
during the oxidation and isolation of the product.  Once again, mass spectrometry gave the 
required masses (441.1 gmol-1 and 417.2 gmol-1), and peaks at 1946 and 1923 cm-1 
confirmed the conservation of the tetrazole ring.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.21 Partial 1H NMR spectrum of α-hydroxytetrazole 2.53 and α-ketotetrazole 2.42.  The methine 
hydrogen peaks are circled. 
 
The synthesis of the α-ketooxazolines46 2.42 and 2.58 on the right hand side of divergent 
synthesis is shown in Scheme 2.6.  Acetyl chloride was reacted with anhydrous methanol 
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to generate anhydrous hydrogen chloride in situ which was reacted with separate samples 
of the cyanohydrins 2.51 and 2.52 to give imidate intermediates that were immediately 
reacted with DIPEA and ethanolamine to give the α-hydroxyoxazolines 2.56 and 2.57.  
The mechanism of the oxazoline formation is as follows: the nitrogen of the nitrile of 2.51 
or 2.52 is protonated by the acid and subsequently reacts with excess methanol, forming 
the imidate shown in Figure 2.22 below (known as the Pinner reaction and the imidate a 
Pinner salt).47  Attack on the imidate by the oxygen and nitrogen atoms of ethanolamine 
constructs the α-hydroxyoxazolines (2.56 and 2.57).  The reaction is driven to completion 
by the loss of ammonia and the methoxy group.  Finally, the α-hydroxyoxazolines 2.56 and 
2.57 were oxidised with the sulfur trioxide-pyridine complex to give the α-ketooxazolines 
2.42 and 2.58 in reasonable yield (45% and 63% respectively).  
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Figure 2.22 Mechanism of formation of imidates 2.55 and 2.56 (Pinner salts)47 
 
 
2.3.4 Design and Synthesis of Peptidyl Nitriles 
 
The cyanohydrins 2.51 and 2.52 were initially synthesised as intermediates of the 
heterocyclic inhibitors; however, subsequent docking of 2.51 into the rigid µ-calpain 
model suggested that it was a potential cysteine protease inhibitor, with the best pose 
shown in Figure 2.23.§§  The warhead was purported to be in close contact with the active 
site cysteine thiol (comparable with parent aldehyde 2.3); the backbone of the inhibitor was 
suggested to bind in an extended bioactive conformation defined by hydrogen bonds A, B 
and C; and an additional hydrogen bond between the cyanohydrin R-OH group and Gly113 
or the cyanohydrin S-OH group and Cys115 was also suggested to occur.     
 
                                                 
§§
 The cyanohydrin could not be modeled as a diasteromeric mixture, hence the cyanohydrin was docked 
twice, once for each position of the secondary alcohol 
Chapter Two – Reversible Inhibitors  70 
 
 
Figure 2.23 Molecular modelling results of the cyanohydrin 2.51 
 
Two further peptidyl nitrile analogues 2.59 and 2.60, the protected esters of 2.51 and 2.52, 
were also synthesised on the basis of the molecular modelling results for the cyanohydrin 
2.51.  Further impetus was lent to this synthesis because the additional bulkiness provided 
by the benzyl protecting group might help identify differences in the P1’ subsites of m-
calpain, µ-calpain, cathepsin B and papain. 
 
Samples of the cyanohydrins 2.51 and 2.52 were separately reacted with N-
hydroxysuccinimide activated phenylacetic acid 2.59 to give the alcohol-protected nitriles 
2.60 and 2.61 as 1:1 diastereoisomers (see Scheme 2.7). 
 
 
 
 
 
 
 
O2
S
N
H
H
N
O
OH
F
CN
O2S
N
H
H
N
O
OH
F
CN
Gly113
Gly271
Gly208
Gly208
His272
Gly271
Chapter Two – Reversible Inhibitors  71 
 
RHN
H
N
O
CN
OH
RHN
H
N
O
CN
O
O
2.51 R = Fps
2.52 R = Cbz
2.60 R = Fps
2.61 R = Cbz
i
 
 
Scheme 2.7 Reagents and Conditions: i) Suc-phenylacetic acid 2.59, DIPEA, DCM 
 
 
2.3.5 Synthesis of the Azide Analogue  
 
The azide 2.62 was docked into the rigid µ-calpain model and the best pose shown in 
Figure 2.24.  This suggested that the azide 2.62 binds to calpain in an extended bioactive 
conformation defined by the hydrogen bonds A, B and C (see Figure 2.24).  This model 
also suggested that the azide moiety was in close contact with the active site cysteine thiol.  
These findings made the azide 2.62 a desirable target for cysteine protease inhibition. 
 
 
Figure 2.24 Molecular modelling of the azide 2.62 showing the three critical hydrogen bonds formed  
 
Commercially available 4-fluorobenzenesulfonyl chloride 2.23 was reacted with L-valine 
to give the N-protected carboxylic acid 2.24.  Subsequent reaction of the acid 2.24 with N-
hydroxysuccinimide gave the activated ester 2.25 in 95% yield. The ester 2.25 was reacted 
with L-leucinol to give the alcohol 2.6 as a white solid in 87% yield.  No purification was 
needed.  The azide 2.62 was formed in a two-step reaction. The alcohol 2.6 was reacted 
with mesyl chloride followed by sodium azide to give the azide 2.62. SN2 displacement of 
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the mesylate with sodium azide occurred without isolation of the intermediate mesylate 
(see Scheme 2.8).  Column chromatography on silica gave the pure azide 2.62 as a white 
solid in a 53% yield.  
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Scheme 2.8 Reagents and Conditions: i) THF, H2O, L-valine, NaOH (75%); ii) N-hydroxysuccinimide, 
EDCI, DCM, THF (95%); iii) L-leucinol, DCM, DIPEA (87%); iv) Et3N, MsCl, DCM (not isolated); v) 
DMF, NaN3 (53%) 
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2.4 CONCLUSION AND FUTURE WORK 
 
A series of dipeptidyl aldehydes were synthesised (2.3, 2.27, 2.19, 2.2, 2.21 and 2.22).  
Four of these aldehydes (2.3, 2.27, 2.19 and 2.2) were literature compounds synthesised to 
validate the in vitro assay protocols.  The aldehydes 2.21 and 2.22 were also broad 
spectrum cysteine protease inhibitors.  The high yielding reactions and ease of synthesis of 
2.3 and 2.19, as well as their potency (see Chapter Six) against cysteine proteases led to 
these being used as lead compounds for the design of novel, selective cysteine protease 
inhibitors.   
 
Subsequent replacement of the aldehyde moiety with warheads that were less chemically 
reactive resulted in the synthesis of novel cysteine protease inhibitors. These inhibitors 
included: semicarbazone warheads (2.37-2.40), oxadiazole warheads (2.41 and 2.50), α-
ketotetrazole warheads (2.43 and 2.55), α-ketooxazoline warheads (2.42 and 2.58) and 
nitrile warheads (2.51, 2.52, 2.60 and 2.61).  A non-covalent inhibitor with an azide moiety 
(2.62) in place of the warhead was also synthesised. 
 
Assay results of these inhibitors against the cysteine proteases m-calpain, µ-calpain, papain 
and cathepsin B and a structure-activity relationship discussion can be found in Chapter 
Six. 
 
Future work in the area of reversible cysteine protease inhibitors would involve further 
utilisation of non-covalent warheads.  Warheads that are non-covalent and non-reactive are 
of increasing interest as little or no interaction should occur between the warhead and in 
vivo nucleophiles.  Molecular modelling could be used to predict the hydrogen-bonding 
pattern of inhibitors and more importantly ensure the close proximity of the warhead to the 
active site cysteine. 
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Design and Synthesis of 
Irreversible Inhibitors of 
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3.1 INTRODUCTION TO IRREVERSIBLE INHIBITORS 
 
Many examples of irreversible warheads used in cysteine protease inhibitor design can be 
found in the literature.  Some important examples include diazoketones, halomethyl 
ketones, alkylating agents,1 acylating groups, phosphonylating groups and sulfonylating 
groups.2,3  Members of these irreversible groups are depicted in Figure 3.1 
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Figure 3.1 Irreversible inhibitor warheads include a) diazoketones, b) fluoromethyl ketones, c) chloromethyl 
ketones, d) sulfonium groups, e) acyl groups and f) phosphonium groups 
 
A number of naturally occurring irreversible inhibitors have been isolated, for example, the 
epoxysuccinic acid E-64 (3.1) (see Figure 3.2) has been isolated from Aspergillus 
japonicus.4,5  Epoxide 3.1 inhibits papain (IC50 = 0.29 µM), cathepsins B (IC50 = 0.24 µM) 
and L (IC50 = 0.11 µM), m-calpain (IC50 = 2.6 µM), µ-calpain (IC50 = 1.0 µM) and 
numerous other cysteine proteases, but is inactive against serine proteases.2,4,6  The 
derivatives 3.2 and 3.3 are also potent cysteine proteases inhibitors (IC50 values in sub µM 
range) see Table 3.1.  Extensive research has shown that active site thiol reacts with the C-
2 carbon (as labeled in Figure 3.2) of the oxirane ring in a suggested SN2 manner.7,8  
Crystal structures of 3.1 bound in the active site of papain show that it binds N-terminal to 
C-terminal relative to the scissile bond (see Figure 3.3) 9   
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Figure 3.2 Numbering of the oxirane ring carbons relative to attack by the active site cysteine thiol. 
Chapter Three – Irreversible Inhibitors  79 
 
 IC50 (µM) 
Compound  
Papain 
 
Cat B 
 
Cat L 
m-
calpain 
µ-
calpai
n 
 
 
3.1 HO
O
O
N
H
O
H
N
O
N
H
NH2
NH
 
 
 
0.29 
 
 
0.24 
 
 
0.11 
 
 
2.6 
 
 
1.0 
 
 
3.2 
 
HO
O
O
N
H
O
H
N
O
 
 
 
- 
 
 
0.24 
 
 
0.13 
 
 
- 
 
 
3.0 
 
 
3.3 
 
O
O
O
N
H
O
H
N
O
 
  
 
0.013 
 
 
0.0034 
 
 
- 
 
 
- 
 
 
- 
 
 
3.4 
O
O
O
N
H
O
N
CO2H
H
N
 
 
 
57 
 
 
0.0022 
 
 
17 
 
 
- 
 
 
200 
 
 
Table 3.1 Potency of epoxysuccinyl esters against cysteine proteases1 
 
Crystal structures of  3.1 bound in papain10 have been used to predict the mode of binding 
of 3.1 to the active site of cathepsin B.  Subsequent modifications to increase binding 
affinity of the inhibitor to the enzyme led to the development of the epoxide 3.4.  The 
synthetic peptidyl epoxysuccinate 3.4 (Figure 3.2), is a potent, selective irreversible 
inhibitor of cathepsin B (IC50 = 0.0022 µM, selectivity 8000-fold, see Table 3.1).7,11  
Yamamoto et al12 proved through use of an X-ray crystal of papain with 3.4 bound, that 
3.4 binds N-terminus to C-terminus in the active site (this opposite to 3.1, which binds C-
terminus to N-terminus) (see Figure 3.3).  Thus attack of the cysteinyl thiol occurs on the 
C-3 carbon of the epoxide rather than the C-2 as in the case of 3.1. 
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Figure 3.3 The binding modes of different epoxysuccinyl inhibitors.  The cysteinyl thiol can attack the C-2 
carbon of the epoxide as for 3.1 or can attack the C-3 carbon as for 3.4. 
 
Irreversible inhibitors have not found much therapeutic use due to problems associated 
with toxicity and side effects as the inhibitor accumulates within biological systems.  It has 
been suggested that long-term usage of irreversible inhibitors for the treatment of disease 
may lead to immune disorders.13  This is highlighted by the example of 3.3, 11 (Table 3.1)  
which was considered a promising pro-drug for the treatment of muscular dystrophy.   
However, clinical trials revealed that 3.3 caused hepatic injury in rats and teratogenic 
effects on rat embryogenesis.6,14  Irreversible inhibitors however, are still desirable for the 
treatment of disease as a short-term treatment, especially in the case of bacterial, viral or 
parasitic diseases.13  Furthermore, an inhibitor that is specific for and forms an irreversible 
covalent bond to its target enzyme is an excellent candidate for obtaining crystal structures 
of the enzyme with inhibitor bound, which will help elucidate the active site and binding 
clefts of enzymes that are not fully characterised.   
 
The inhibitors that are described in Chapter Three were designed to be specific, potent 
cysteine proteases.  All of the inhibitors in the following synthetic sections belong to the 
‘alkylating agents’ group of irreversible inhibitors.  
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3.2  IRREVERSIBLE WARHEADS UTILISED IN PROTEASE 
INHIBITORS 
 
3.2.1 Michael Acceptor Warheads 
 
Michael acceptor inhibitors have been reported as potent inhibitors of cysteine 
proteases.15,16  Kong17 and co-workers synthesised a series of potent Michael acceptor 
inhibitors for human rhinovirus (3.5a-c), with IC50 values less than 0.30 µM (see Table 
3.2).  The α,β-unsaturated acid 3.5d was 70-fold less potent than the α,β-unsaturated esters 
3.5a-c and the single amino acid α,β-unsaturated ester 3.5e was 50-fold less potent than the 
tripeptide analogue 3.5c. 
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                X R1 R2 R3 Y IC50 (µM) 
3.5a       Boc Val Leu Phe OMe 0.25 
3.5b       Boc Val Leu Phe OEt 0.13 
3.5c       Cbz Val Leu Phe OMe 0.17 
3.5d       Boc Val Leu Phe OH 18 
3.5e       Cbz Phe - - OMe 9.5 
 
Table 3.2 Michael acceptors showing inhibition of human rhinovirus17 
 
Michael acceptors such as vinyl sulfones and α,β-unsaturated carbonyls are proposed to 
inhibit cysteine proteases in a similar manner.  The active site cysteine undergoes a 1,4-
Michael addition reaction that results in the enzyme becoming permanently alkylated.  The 
oxygen atoms of the sulfone or the carbonyl are involved in hydrogen-bonding to the 
enzyme active site, thus helping to activate the β-carbon of the vinyl group for nucleophilic 
attack by the cysteine (Figure 3.4). 
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Figure 3.4 The proposed mechanism of inactivation of cysteine proteases by a) α,β-unsaturated carbonyl 
derivatives5 and b) by vinyl sulfones18 
 
 
3.2.2 Diazoketone Warheads  
 
Peptidyl diazomethyl ketones can act as cysteine protease inhibitors.  This was observed by 
Leary et al,19 who tested the diazoketones 3.6 and 3.7 inhibitory activity against papain. 
These assay results (measured as rates of inactivation) are shown in Table 3.3.  The 
dipeptidyl diazoketone 3.7 was found to be 200-fold more potent than diazoketone 3.6 
against papain.  Subsequently, Green et al20 tested the analogous dipeptidyl diazoketones 
3.6-3.9 against the cysteine protease cathepsin B and clostripain (a serine protease) in order 
to determine the selectivity of diazoketones for cysteine proteases.  The diazoketones 3.7 
and 3.9 were shown to be selective for cysteine proteases over the serine protease 
clostripain by 135- and 25000-fold respectively; however, there was no comparison within 
the cysteine protease family. 
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Inhibitor 
 
Rate of Inactivation (Ki/t) (M-1.s-1) 
 Papain19 Cathepsin B20 Clostripain20 
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2030 
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3.8 O NH
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O
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- 
 
 
302 
 
 
467 
 
 
3.9 
 
O N
H
O
O
H
N
O
N2
 
 
 
- 
 
 
1250 
 
 
0.05 
  
Table 3.3 The inactivation rate of papain by diazoketone inhibitors 
 
X-ray crystal structure analysis19 of papain treated with the diazoketone 3.6 showed that 
inhibition of the enzyme occurred via alkylation of the active site cysteine thiol.  The 
proposed mechanism of inactivation occurs via reaction of the carbonyl carbon with the 
active site thiolate to form a hemithioketal species. Proton transfer from the active site 
histidine to the methylene carbon occurs as in Figure 3.5.  The final step to give the 
thioether is proposed to occur via a three-membered transition state with simultaneous 
cleavage of nitrogen.1,6 
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Figure 3.5 Proposed mechanism of inactivation by diazoketones 
 
 
3.2.3 Halomethylketone Warheads 
 
Chloromethyl and fluoromethyl ketones have been reported as cysteine protease 
inhibitors.21-23  The fluoromethyl ketones 3.10a-e22 in Table 3.4 were tested against the 
cysteine proteases µ-calpain, cathepsin B and cathepsin L.  Inhibition was measured as a 
rate of inactivation (the faster the rate, the more potent the inhibitor).  The inhibitors 3.10a-
e are significantly more potent against µ-calpain than cathepsin B or L. The fluoromethyl 
ketones 3.10a and 3.10b show over 20-fold selectivity for µ-calpain than the other cysteine 
proteases tested.   
 
3.10 
 
R1HN N
H
O
O
F
R2
 
 
R1  R2 Rate of inactivation (M-1 s-1) 
   µ-calp cath B cath L 
 
3.10a   Cbz  benzyl 136300   300     5000 
3.10b   Morpholino- 4-sulfonyl  benzyl   67200   100     3200 
3.10c   (Benzylamino)carbonyl  benzyl   67000   275     9400 
3.10d   Cbz  CH2OTHP 100000 9000   22600 
3.10e   Cbz-Leu  benzyl 290000 4600 256000 
 
Table 3.4 Some potent fluoromethyl ketone calpain inhibitors.22 
 
A review by Donkor2 highlights that fluoromethyl ketones are usually more potent 
inhibitors than the corresponding chloromethyl ketones, as evidenced by the chloromethyl 
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ketone  3.11 (rate of inactivation 9500 M-1s-1) compared to the fluoromethyl ketone 3.12 
(rate of inactivation 290000 M-1s-1)2 in Figure 3.6.  Both fluoromethyl and chloromethyl 
ketones are indiscriminately reactive. This property is reflected by the ability to inhibit 
both cysteine and serine proteases, as well as glutathione and nonproteolytic enzymes.21   
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Cl
3.11
Rate of inactivation 9500 M-1s-1
3.12
Rate of inactivation 290000 M-1s-1
 
 
Figure 3.6 Comparison of rate of inactivation of a choromethyl ketone versus a fluoromethyl ketone against 
µ-calpain 
 
Two possible mechanisms have been postulated to explain the inactivation of cysteine 
proteases by halomethyl ketones (Figure 3.7).1  In mechanism A (red), the active site thiol 
reacts directly with the carbon of the halomethyl in a nucleophilic substitution reaction.  
Alternatively, in B (blue), the active site thiol reacts with the carbonyl carbon forming a 
covalent bond via a three-membered ring.  This second pathway is thought to be the most 
plausible since a tetrahedral intermediate is formed. 
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Figure 3.7 Proposed mechanisms for inactivation of cysteine proteases by halomethyl ketones.  X denotes 
the halogen: Cl, Br, F 
 
 
 
3.2.4 Peptidyl Epoxide Warheads 
 
Albeck and co-workers24 designed peptidyl epoxides 3.13a-d as selective inactivators of 
cysteine proteases (see Table 3.5), showing the epoxide moiety to be a weak electrophile 
that is stable under neutral or basic conditions but highly electrophilic upon protonation, 
such as would occur in the active site of an enzyme.  The epoxides 3.13a-d are weak 
inhibitors of papain and cathepsin B (Ki values >10 µM).  The epoxide 3.13d is the most 
potent inhibitor with Ki values of 30 µM and 10 µM against cathepsin B and papain 
respectively.  The selectivity observed between cathepsin B and papain ranges from 
between 2- and 6-fold in favour of papain, inclusive of the inhibitors 3.13a-d.  
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O N
H
O H
N
O
N
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O
R3
R2
R1
 
 
                  Ki (µM) 
                      R1-R2-R3 Cathepsin B Papain 
 3.13a                   Gly-Leu-Phe 640 - 
 3.13b                      -     -    Phe 570 370 
 3.13c                      -    Phe-Ala 320 60 
 3.13d                  Phe-OBn-Thr 30 10 
 
Table 3.5 Peptidyl epoxide inhibitors of cysteine proteases  
 
Peptidyl or amino epoxides interact directly with the cysteine of the active site (Figure 
3.8).  Epoxides are weak electrophiles that require activation by the catalytic histidine; 
upon protonation, epoxides become highly electrophilic.24   This protonation is thought to 
occur prior to, or simultaneously with, the nucleophilic attack of the thiolate.25 
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Figure 3.8 Proposed mechanism of inhibition of cysteine proteases by peptidyl epoxides. 
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3.3 DESIGN AND SYNTHESIS OF IRREVERSIBLE 
CYSTEINE PROTEASE INHIBITORS 
 
3.3.1 Design and Synthesis of Michael Acceptor Inhibitors 
 
Michael acceptors contain a double bond that is activated by the presence of an 
electrophilic group, such as an ester or sulfone (see Figure 3.9).16  This class of 
irreversible inhibitors require the catalytic cysteine residue for activation, being unreactive 
towards nucleophiles (including free thiols) under physiological conditions.26  Michael 
acceptor warheads are less reactive than aldehyde warheads, thus it is expected inhibitors 
with a Michael acceptor-type warhead will show increased selectivity between cysteine 
proteases of the papain superfamily. 
   
SO2RR''
R'
CO2RR''
R'
 
           a         b  
Figure 3.9 The general structure of a double bond activated by an adjacent a) sulfone group and b) ester 
group  
 
The target Michael acceptor 3.14 was docked in the rigid µ-calpain model and the best 
pose shown in Figure 3.10.  This suggests that the Michael acceptor 3.14 binds to calpain 
in a β-sheet, defined by hydrogen bonds A, B and C (as previously defined in Chapter 
Two).  The hydrogen bonds suggested to form to the Michael acceptor 3.14 are analogous 
to the hydrogen bonds purported to form to the aldehyde 2.3 (see Figure 3.9).  An 
additional hydrogen bond is suggested to exist between the methyl ester carbonyl oxygen 
group and His272 of 3.14. 
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          a)      b) 
Figure 3.10 Molecular modelling results of a) aldehyde 2.3 in comparison to b) Michael acceptor 3.14   
 
Synthesis of α,β-Unsaturated Carbonyls 
Samples of the aldehydes 2.3 and 2.19 were separately reacted with 
methyl(triphenylphosphoranylidene)acetate, ethyl(triphenylphosphoranylidene)acetate, or 
triphenylphosphoranylidene acetaldehyde to give the α,β-unsaturated carbonyls (3.14-
3.18).  Separate purification of each of the α,β-unsaturated carbonyls 3.14-3.18 by flash 
chromatography gave the pure α,β-unsaturated carbonyls as white solids in good yield 
(3.14, 93%; 3.15, 95%; 3.16, 89% and 3.17, 91%). 
 
 
R1HN
H
N
O
R1HN
H
N
O
i
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3.14 R = Fps, R2 = OMe
3.15 R = Fps, R2 = OEt
3.16 R = Cbz, R2 = OMe
3.17 R = Cbz, R2 = OEt
3.18 R = Fps, R2 = H
H
O
R2
O
 
 
Scheme 3.1 Reagents and Conditions: i) PPh3CHCO2Me, PPh3CHCO2Et or PPh3CHCHO, DCM 
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Utilisation of the Wittig reaction to yield the α,β-unsaturated aldehyde 3.18 proved 
problematic, as both the desired product 3.18, the diene 3.19 and the starting aldehyde 2.3 
(see Figure 3.11) were observed by mass spectrometry (being found as 399.1741, 
425.1329 and 373.1613 gmol-1 respectively 
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Figure 3.11 The starting material 2.3 and the two products 3.18 and 3.19 observed 
 
Each of these three products was distinguishable by its unique aldehyde peak observed as 
in the partial 1H spectra in Figure 3.12.  The starting material (aldehyde 2.3) has a 
characteristic singlet peak at 9.40 ppm; the product 3.18 and diene 3.19 both have 
characteristic multiplet peaks.  The use of 2D NMR techniques (COSY) allowed the 
unambiguous assignment of the multiplet at 9.65 ppm as the aldehyde peak of the desired 
α,β-unsaturated aldehyde 3.18 and the multiplet at 10.33 ppm as the aldehyde peak of the 
diene 3.19.* 
 
 
 
                                                 
*
 Note that the diene 3.19 was not isolated. 
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Figure 3.12 Partial 1H NMR showing the aldehyde peaks in a crude sample of α,β-unsaturated aldehyde 3.18 
that also contains a small amount of the side product 3.19 and starting material 2.3 
 
The reaction of the aldehyde 2.3 with triphenylphosphoranylidene acetaldehyde was 
optimised by investigating different ratios of triphenylphosphoranylidene acetaldehyde to 
aldehyde 2.3 and subsequent quantification of the products (see Table 3.6).  The 
conditions that gave the best yield of the desired product 3.18 were one equivalent of the 
aldehyde 2.3 and 0.9 equivalents of triphenylphosphoranylidene acetaldehyde.  The small 
amount of diene 3.19 formed was removed via column chromatography to give the desired 
α,β-unsaturated aldehyde 3.18 as a pale yellow solid in a 68% yield. 
 
 
Aldehyde 2.3  
(equiv) 
 
 
Ylide  
(equiv) 
 
% 3.18 
 
 
 
% 3.19  
diene 
 
% Starting 
material 
 
1.0 
 
1.1 
 
40 
 
60 
 
- 
1.0 1.0 70 30 - 
1.0 0.9 70 - 30 
1.0 0.8 50 - 50 
 
 
Table 3.6 Optimisation of experimental conditions for unsaturated aldehyde 3.18.   
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Synthesis of Dipeptidyl Vinyl Sulfones 
The vinyl sulfone moiety is more electron withdrawing than the α,β-unsaturated carbonyls 
of 3.14-3.18, so extension of the Michael acceptor series of cysteine protease inhibitors to 
include vinylogous sulfones will provide a direct comparison between the reactivity of the 
warhead and the selectivity shown between proteases of the papain superfamily. 
 
The formation of the vinyl sulfones 3.20-3.23 can be achieved in a number of ways. 
Olefination reactions such as Horner-Emmons-Wadsworth and Peterson can be used.27  
Peterson olefination occurs via the reaction of a trialkylsilane with an aldehyde or ketone 
to give a β-hydroxysilane which spontaneously eliminates water to give the desired alkene.  
Generally, the Peterson method leads to mixtures of geometric isomers.28 The synthesis of 
vinyl sulfones described in this section utilises Horner-Emmons-Wadsworth chemistry.29  
This methodology exclusively gives the trans product.27,30  Further, the phosphonate 
carbanions used in Horner-Emmons-Wadsworth reactions are more nucleophilic than the 
phosphonium ylides used in Wittig reactions, hence the phosphonate carbanions will react 
with a wide variety of aldehydes and ketones.29   
 
The vinyl sufones 3.20-3.23 were synthesised directly from the corresponding aldehydes 
2.3, 2.27, 2.19 and 2.2.  Commercially available diethyl(methylthiomethyl) phosphonate 
was oxidised in the presence of potassium permanganate to give 
diethyl(methylsulfonylmethyl) phosphonate 3.24 as a pale yellow glassy solid in excellent 
yield (89%).31  The phosphonium ylide 3.24 was subsequently reacted with separate 
samples of the aldehydes 2.3, 2.27, 2.19 and 2.2 using Horner-Emmons-Wadsworth 
methodology to give the vinyl sulfones 3.20-3.23 (see Scheme 3.2).  The vinyl sulfones 
3.20-3.23 were isolated and subsequently purified (3.20 and 3.22 by recrystallisation; 3.21 
and 3.23 by flash chromatography) to give the pure vinyl sulfones 3.20 and 3.22 as white 
solids  (89% and 78% yields respectively) and 3.22 and 3.23 as colourless oils (84% and 
66% yields respectively).   
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Scheme 3.2 Reagents and Conditions: i) (EtO)2P(O)CH2SO2CH3 3.24, n-butyllithium, -78°C, THF. 
 
Analysis of the products 3.20-3.23 by 1H and 13C NMR showed the presence of only one 
isomer, as determined by the clearly single resonances for P1 residues (for 3.20 and 3.22 
this was Leu; for 3.21 and 3.23, Phe) and the alkene.  The double bond of the vinyl 
sulfones was determined to be the trans isomer on the basis that the coupling constants 
observed for the vinyl sulfones 3.20-3.23 were 15.1 Hz, 15.2 Hz, 15.0 Hz and 15.0 Hz 
respectively. The coupling of protons across a trans alkene (13-18 Hz) is known to be 
larger than that for cis alkenes (8-12 Hz) as shown in Figure 3.13.32  The trans isomers 
formed are also consistent with the Horner-Emmons-Wadsworth methodology used. 
      
Hb
R2R1
Ha R2
HbR1
Ha
cis
J = 7-12 Hz
trans
J = 13-18 Hz
 
 
Figure 3.13 The size of the coupling constants (in Hz) observed for cis and trans alkenes.32  
 
3.3.2 Design and Synthesis of Diazoketones 
 
Leary19 and Green20 (detailed in Section 3.2.2 above) established diazoketones as specific 
cysteine proteases inhibitors, but did not effectively compare selectivity within the papain 
superfamily.  Thus the diazoketones 3.25 and 3.26 were synthesised (see Scheme 3.3).   
 
Samples of the dipeptidyl carboxylic acids 2.24 and 2.28 were separately reacted with 
ethyl chloroformate to form the corresponding mixed anhydrides, which were reacted 
immediately with diazomethane (prepared from Diazald and potassium hydroxide) to give 
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the diazoketones 3.25 and 3.26 as yellow oils.  Purification by flash chromatography on 
silica (1:4 ethyl acetate:petroleum ether) gave the pure diazoketones as pale yellow solids 
in 83% and 61% yields respectively.  
 
RHN
H
N
O
OH
O
RHN
H
N
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O
N2i
2.24 R = Fps
2.28 R = Cbz
3.25 R = Fps
3.26 R = Cbz
 
 
Scheme 3.3 Reagents and Conditions: i) Et3N, ClCO2Et, CH2N2, -15 °C to rt. 
 
 
3.3.3 Design and Synthesis of Peptidyl Epoxides 
 
An essential property of any protease inhibitor is that of stability, especially under 
physiological conditions.33  Peptidyl epoxides are stable under both neutral and basic 
conditions.25  Furthermore, the epoxide moiety shows little reactivity towards non-
proteolytic thiols, thus peptidyl epoxides are desirable targets for in vivo cysteine protease 
inhibition.33  The selectivity of inhibition by peptidyl epoxides within the papain 
superfamily of cysteine proteases has not been investigated; however, it has been shown 
that peptidyl epoxides do not inhibit serine proteases.24,25  
 
The 3R-epoxide† 3.27 was docked into the rigid µ-calpain model and the best pose shown 
in Figure 3.14.  This suggested that epoxide 3.27 would form only the hydrogen bonds A 
and C; however, an additional hydrogen bond was suggested between the oxirane oxygen 
group and His272.  Subsequent docking of the 3S-epoxide 3.27 into the rigid µ-calpain 
model suggested the hydrogen bonds A, B and C would all be formed.  These results 
would seem to indicate that the 3S-epoxide would have better binding affinity and thus be 
a more potent inhibitor if the three hydrogen bonds are important for good binding affinity 
to cysteine proteases (see Chapter Six for assay results and further discussion). 
 
                                                 
†
 Where 3R refers to the stereochemistry at the third stereocentre of the compound from left to right 
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Figure 3.14 Molecular modelling results of the 3R- and 3S- epoxide 3.27 
 
Synthesis of α-Bromomethyl Intermediates 
The diazoketones 3.25 and 3.26 were reacted with 33% hydrogen bromide in glacial acetic 
acid to give the α-bromomethyl ketones 3.28 and 3.29.  Care was needed in the formation 
of 3.29 as the benzyloxycarbonyl group is acid sensitive.  Thus, the hydrogen bromide 
solution was added dropwise until the yellow colour of the diazoketone disappeared then 
the solvent immediately removed from the reaction.  The residue was dissolved in 
dichloromethane and dried two or three more times to ensure excess acid was removed. 
 
Two methods of reduction were employed to give the α-bromomethyl alcohols 3.30-3.31 
(see Scheme 3.4).  Samples of the α-bromomethyl ketones 3.28 and 3.29 were 
stereospecifically reduced in the presence of lithium tri-t-butoxyaluminium hydride to give 
the α-bromomethyl alcohols 3.30 and 3.31 with the absolute configuration 1S, 2S, 3R (the 
alcohol moiety being anti with respect to the P1 sidechain).34  Further purification of the α-
bromomethyl alcohols 3.30 and 3.31 was not required.  Analysis of the α-bromomethyl 
alcohols 3.30 and 3.31 by 1H NMR showed the presence of only one diastereoisomer as 
determined by the clearly single resonances for the Leu (P1) residue.  The isolated products 
3.30 and 3.31 were assumed to be the anti isomers.  This assumption was based on the 
results of Hoffman34 and coworkers, who used lithium tri-tert-butoxyaluminium hydride 
for the reduction of α-bromomethyl ketones to α-bromomethyl alcohols; subsequent 
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reaction with base gave the corresponding epoxides, which were literature compounds of 
known stereochemistry.  Comparison of the 1H protons determined that the synthesised 
epoxides were of the same stereochemistry as the literature epoxides; both had anti 
orientation.      Lithium tri-tert-butoxyaluminium hydride was prepared from a solution of 
lithium aluminium hydride in diethyl ether, the product being precipitated by the addition 
of tert-butyl alcohol.35  The lithium tri-tert-butoxyaluminium hydride conferred 
stereospecifity upon the reduced products 3.30 and 3.31 by acting as a chelation-controlled 
reduction.34  Alternatively, samples of the bromomethyl ketones 3.28 and 3.29 were 
separately reduced in the presence of sodium borohydride to give the α-bromomethyl 
alcohols 3.32 and 3.33 as 1:1 racemic mixtures at the 3C position.  
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Scheme 3.4 Reagents and Conditions: i) 33% HBr in glacial acetic acid, DCM; ii) LiAlH(OtBu)3, EtOH, -
78°C; iii) NaBH4, EtOH, rt. 
 
The amino epoxides 3.27, 3.34-3.36 were synthesised from the α-bromomethyl alcohols 
3.30-3.33.  Samples of the 3R-alcohols 3.30 and 3.31 were separately reacted with 
potassium carbonate to give the 3R-epoxides 3.27 and 3.34 in yields of 82% and 89% 
respectively (see Scheme 3.5).   
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Scheme 3.5 Reagents and Conditions: i) K2CO3, MeOH 
 
In a similar manner, samples of the diastereomeric 3-S/R-alcohols 3.32 and 3.33 were 
separately reacted with potassium carbonate to give the 3-S/R-epoxides 3.35 and 3.36 as 
white solids in 74% and 83% respectively (see Scheme 3.6). 
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Scheme 3.6 Reagents and Conditions: i) K2CO3, MeOH 
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3.4 CONCLUSION AND FUTURE WORK 
 
The irreversible cysteine protease inhibitors synthesised included α,β-unsaturated 
carbonyls 3.14-3.18 and vinyl sulfones 3.20-3.23.  These were synthesised from the 
corresponding aldehydes (2.3, 2.27, 2.19 or 2.2 respectively) via Wittig or Horner-
Emmons-Wadsworth (modified Wittig) reactions.  Other irreversible inhibitors synthesised 
were based on the common diazoketone intermediates 3.25 and 3.26.  These were α-
bromomethyl ketones 3.28 and 3.29, α-bromomethyl alcohols 3.30-3.33 and amino 
epoxides 3.27, 3.34-3.36.   
 
It is envisaged that future work could include P’ extended vinyl sulfones of the nature 
shown in Figure 3.15, where R is an aryl N-protecting group and the X group includes 
large aryl groups, electron withdrawing groups and alkyl chains for exploration of the P’ 
subsites of cysteine proteases. Such irreversible inhibitors could be used to aid structural 
elucidation of the active site and active cleft residues of cysteine proteases of the papain 
superfamily.  
 
RHN
H
N
O
SO2X
 
Figure 3.15 Generic structure of vinyl sulfones that extend into the P1’ subsites. 
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4.1 INTRODUCTION TO PEPTIDOMIMETICS 
 
The inhibitors synthesised in Chapters Two and Three are peptide based; however, 
peptidic nature can be detrimental in terms of good drug character.  This observation has 
made the field of peptidomimetics* increasingly popular.  Effective drugs generally have 
the following characteristics: minimal peptide character, high metabolic stability, good 
membrane permeability, high selectivity for the target protease and good bioavailability.  
Qualitative analysis of inhibitors in terms of these criteria is described by Lipinski’s Rule 
of 5 (Table 4.1).1  Lipinski’s guidelines predict that better absorption or permeation of an 
orally administered compound are more likely if the compound meets two or more of these 
rules.   
 
 
Lipinski’s Rule of 5 
 
 
The compound should 
 
- not contain more than 5 hydrogen bond donors (OH, NH) 
 - not contain more than 10 hydrogen bond acceptors (N, O) 
 - have a molecular weight under 500 g mol-1 
 - have a partition coefficient logP < 5 
  
 
Table 4.1 Requirements for drug-like properties 
 
Chemical modifications to make peptide-like structures can enhance the stability or 
biological activity of a peptide structure. One important means by which the peptidic 
nature of a compound can be reduced is by incorporating a conformational restriction into 
the backbone.  Such macrocycles are increasingly being used as protease inhibitors.2  
Macrocyclic inhibitors are beneficial in two ways: 1) constraining the structure of an 
inhibitor into a bioactive conformation and 2) protecting the inhibitor against proteolytic 
cleavage, thus assisting stability of the inhibitor in vivo. 
 
 
 
                                                 
*
 For the purposes of this thesis peptidomimetics are defined as peptide-like structures derived from peptide 
chains by means of chemical modification. 
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Benefits of a bioactive conformation 
It is widely acknowledged that proteases (including serine, cysteine, aspartic and 
metalloproteases) bind inhibitors in an extended β-strand conformation.3  This was well 
illustrated in a recent review by Tyndall,4 in which the binding conformation of substrates, 
products and inhibitors bound in the active sites of serine, cysteine, aspartic, threonine and 
metalloproteases were analysed.  Out of the 1500 structures studied, 99.6% bound ligands 
in an extended β-strand conformation.   Thus compounds constrained in a β-strand 
conformation should exhibit improved binding affinity for the target protease relative to 
their conformationally flexible analogues.  A β-strand is a linear “saw-tooth” structure of 
amino acids as shown in Figure 4.1, where the side chains alternate above and below the 
plane of the peptide backbone.5  The bond angles that define a β-strand are Φ, ψ, and ω, 
(with optimum angles of -120°, 120° and 180° respectively). 
 
   
                 
N
N
H
P2
O
H
P1
O
φ
ψ
ω
 
 
Figure 4.1 “saw-tooth” nature of the β-strand and the angles denoted above (nomenclature according to 
Schechter and Berger)6 
 
The purpose of this chapter is to apply several warheads that have proven to be active 
against cysteine proteases to a β-sheet constrained backbone.  This will allow for 
comparison between the acyclic inhibitors (from Chapters Two and Three) and the 
constrained inhibitors (described below in Sections 4.2 and 4.3) to determine whether 
constraining the inhibitor into an extended β-sheet conformation does improve binding 
affinity.  The IC50 values for these inhibitors will be used as the basis for determining 
increased binding activity; assuming that an increased binding affinity will be reflected in 
an increase in potency against the cysteine proteases tested (results are presented and 
discussed in Chapter Six).   
 
Proteolytic protection via macrocycles 
The ease with which peptide inhibitors are metabolised in biological systems has resulted 
in the design of non-peptidic and peptidomimetic inhibitors.  Macrocyclic compounds have 
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been demonstrated to possess both higher resistance to proteolytic cleavage and improved 
cell permeability relative to their acyclic analogues.  Chen7 and co-workers compared  the 
acyclic HIV protease inhibitor 4.1 with its cyclic analogue 4.2  (see Figure 4.2).  The 
acyclic inhibitor 4.1 was 19-fold more potent than the macrocyclic analogue 4.2 in enzyme 
assays; however, under the conditions for cell assay the macrocycle 4.2 was 30-fold more 
potent to its acyclic counterpart 4.1.  This indicated that the macrocycle 4.2 had improved 
resistance to proteolytic degradation and improved cell permeability, which is reflected in 
the increased efficacy in cell assays. 
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4.1
HIV protease IC50 = 1.1 nM
HIV cell assay EC50 = 145 nM
4.2
HIV protease IC50 = 19 nM
HIV cell assay EC50 = 76 nM
 
 
Figure 4.2 Acyclic versus macrocyclic inhibitors of HIV protease7 
 
 
4.1.1 Ring-closing Metathesis 
 
Ring-closing metathesis is currently one of the most widely used methods for new carbon-
carbon bond formation and has found application in the design of conformationally 
constrained peptidomimetics.8  It is a powerful, reliable reaction that can tolerate a number 
of functional groups.9    For these reasons, ring-closing metathesis was deemed to be the 
most efficient way of synthesizing β-strand constrained inhibitors.  Further, ‘in house’ 
knowledge of this methodology for incorporation into protease inhibitors made ring-
closing metathesis a useful tool. 
 
The mechanism of ring-closing metathesis, in which a new carbon-carbon bond is formed, 
is outlined in Figure 4.2.10  The acyclic diene is reacted with the carbine catalyst [M] 
(often Grubbs’ second generation catalyst), forming the key metallacyclobutane 
intermediate, which undergoes cycloreversion towards the cycloalkene with release of 
         4.1           4.2 
HIV protease IC50    = 0.0011 µM  HIV protease IC50    = 0.019 µM 
HIV cell assay EC50 = 0.15     µ   HIV cell assay EC50 = 0.076 µM  
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ethene.  The forward reaction for ring-closing metathesis is driven by the production and 
removal of ethene. 
 
[M]
[M]
[M]
CH2
CH2
CH2[M]
 
 
Figure 4.2 Mechanism of ring-closing metathesis.  [M] is used to denote the carbine catalyst and attached 
ligands.10 
 
This chapter describes the synthesis of carbon to carbon macrocyclic inhibitors to 
conformationally constrain tripeptides into a β-strand conformation.  The generic structure 
of these compounds comprises three parts: an address region, the macrocyclic backbone 
and the warhead as shown in Figure 4.3.  Definitions of the address region and warhead 
moieties can be found in Chapter One.  The macrocyclic backbone has the same function 
as the recognition region of acyclic cysteine protease inhibitors (see Chapter One) and 
contains tripeptides with amino acids chosen to fit the target enzyme binding pockets. 
 
   
H
N
O
N
H
O
R H
N
 
 
Figure 4.3 Generic structure of macrocyclic β-strand inhibitors 
 
 
Address Region 
Warhead 
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4.2 DESIGN AND SYNTHESIS OF A MACROCYCLIC 
ALDEHYDE AS A CYSTEINE PROTEASE INHIBITOR 
 
 
4.2.1 Design of a Macrocyclic Cysteine Protease Inhibitors 
 
The macrocyclic compounds 4.3 and 4.4 (see Figure 4.4) were designed as cysteine 
protease inhibitors.  Subseqeunt docking of 4.3 and 4.4 into the rigid µ-calpain model and 
Boltzmann weighted conformational analysis was used to determine if the macrocycles 
could adopt a β-strand conformation in water.†  The structure of a specific conformer was 
determined using numerical methods to assign it as a β-strand or not.  The determining 
factor for each of these conformers was the distance between the NH group of the first 
amino acid and the carbonyl oxygen group of the central amino acid (shown in Figure 4.4) 
as previously published11 where an optimal β-strand is defined by a measured distance of 
approximately 2.5Ǻ.  Utilisation of these methods suggested the alcohol 4.3 existed as a β-
strand 67% of the time in water; similarly the aldehyde 4.4 existed as a β-strand 98% of the 
time.    
 
N
H
H
N
O
O
O
N
H
RO
O
4.3 R = CH2OH
4.4 R = CHO
 
Figure 4.4: Measurement used to define a β-sheet conformation 
 
The following sections outline the synthesis of the macrocyclic aldehyde 4.4 and the 
application of the semicarbazone, cyanohydrin, α-ketotetrazole and azide warheads to an 
analogous, available macrocyclic aldehyde.  The above mentioned warheads were selected 
on the basis of potency, observed selectivity and availability of materials.  
 
 
                                                 
†
 The Boltzmann distribution calculations were performed by Stephen McNabb of the University of 
Canterbury.  Conformational searches were conducted using the Monte Carlo multiple minimum (MCMM) 
method 
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4.2.2 Synthesis of a Macrocyclic Aldehyde 
 
The synthesis of the 17-membered ring macrocyclic aldehyde 4.4 is shown in Scheme 4.1.  
The methodology used for synthesizing the macrocyclic aldehyde 4.4 was developed and 
optimised by co-workers‡ at Canterbury University.  Commercial N-Boc-O-allyltyrosine 
4.5 was reacted with L-valine methyl ester using standard HATU methodology to give the 
dipeptide 4.6 in an 86% yield.  Hydrolysis of the ester 4.6 with lithium hydroxide and 
subsequent coupling to L-allylglycine methyl ester gave the diene 4.8, which was purified 
by flash chromatography on silica (1:4 ethyl acetate: pet ether to yield a white solid (83%).  
L-Allylglycine methyl ester 4.9 was prepared from acid-catalysed esterification of L-
allylglycine in the presence of methanol in quantitative yield.  Ring-closing metathesis was 
performed using Grubbs’ second generation catalyst under optimised conditions 
(microwave irradiation, 3 × 10 mol% Grubb’s second generation catalyst, 1,1,2-
trichloroethanol and chlorodicyclohexyl borane) to give the ring closed alkene 4.10 in the 
trans form§ as a brown solid (only one isomer was apparent by 1H NMR, see Chapter 7 
for more detail).  The brown colour was due to residual ruthenium from the Grubbs’ 
second generation catalyst; however, recrystallisation from methanol gave trans alkene 
macrocycle 4.10 as a white solid in 65% yield.  The cyclic olefin 4.10 was hydrogenated at 
atmospheric pressure and room temperature with palladium on carbon to give saturated 
macrocycle 4.11 in quantitative yield.  Cleavage of the N-Boc group of the macrocycle 
4.11 with trifluoroacetic acid gave the free amine 4.12, which was immediately reacted 
without purification with benzylchloroformate to give the benzyloxycarbonyl protected 
ester 4.13.  The crude ester 4.13 was recyrstallised from ethyl acetate to give the pure 4.13 
as a white solid in 86% yield.  The ester 4.13 was subsequently reduced in the presence of 
lithium aluminium hydride to give the crude alcohol 4.3.  Recrystallisation from methanol 
gave the pure alcohol 4.3 in 84% yield.  The primary alcohol 4.3 was oxidised utilising 
sulfur trioxide-pyridine12 to give the macrocyclic aldehyde 4.4 in good yield (79%).  No 
further purification was necessary.  
 
 
                                                 
‡
 Matthew Jones and Steve Aitken 
§
 Under the conditions used (microwave heating and the addition of chlorodicyclohexyl borane) only one 
isomer was apparent by 1H NMR.  This was assumed to be the trans form, based on the crystal structure of a 
similar macrocyclic diene synthesised under the same conditions by Andrew Muscroft-Taylor. 
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Scheme 4.1 Reagents and Conditions: i) HATU, DIPEA, L-Val-OMe, DMF, (86%); ii) LiOH, THF, H2O, 
(97%); iii) HATU, DIPEA, L-allyl-Gly-OMe, DMF, (83%); iv) 3 x 10 mol% Grubb’s second generation 
catalyst, 1,1,2-TCE, chlorodicyclohexyl borane, microwave (89%); v) H2, 20 mol% Pd/C, MeOH, EtOAc, 
(100%) vi) TFA, DCM; vii) CbzCl, DIPEA, H2O, THF (82%); viii) LiAlH4, THF, 0 °C (75%); ix) SO3-pyr, 
DMSO, DIPEA, DCM (79%) 
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4.3 SYNTHESIS OF MACROCYCLIC CYSTEINE 
PROTEASE INHIBITORS WITH ALTERNATIVE 
WARHEADS 
 
 
The macrocyclic aldehyde 4.14** was synthesised at Canterbury University. The aldehyde 
4.14 was chosen for further derivatisation as it is an excellent cysteine protease inhibitor 
(see Figure 4.5).  Docking of the aldehyde 4.14 into the µ-calpain model suggested that it 
binds to calpain in a β-strand conformation defined by the hydrogen bonds A, B and C; an 
additional hydrogen bond between the benzyloxycarbonyl carbonyl oxygen group and 
Lys347 was also suggested to occur.  The aldehyde 4.14 is currently being tested in vivo for 
the treatment of cataract in sheep as a topical ointment.  However due to the reactive nature 
of the aldehyde it is not an ideal drug candidate. 
 
 
 
Figure 4.5 The in-house macrocyclic inhibitor 4.14 
 
 
 
 
 
 
 
 
                                                 
**
 Matthew Jones and Andrew Muscroft-Taylor 
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4.14
IC50 =       30 nM (m-calpain) 
        =     220 nM (µ-calpain) 
        =       70 nM (cathepsin B) 
        > 50000 nM (papain) 
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4.3.1 Synthesis of a Macrocyclic Semicarbazone 
 
A sample of the macrocyclic aldehyde 4.14 was reacted with semicarbazone hydrochloride 
to give the macrocyclic semicarbazone 4.15 as outlined in Scheme 4.2.  Recrystallisation 
of crude 4.15 from ethyl acetate gave the purified product as a white solid in good yield 
(63%).   
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Scheme 4.2 Reagents and Conditions: i) semicarbazide hydrochloride, NaOAc, 1:1 THF:MeOH (87%) 
 
1H NMR analysis of the pure product showed the characteristic singlet peak at 9.3 ppm of 
the semicarbazone NH group and doublet peak at 7.5 ppm of the imine CH group (see 
Figure 4.6), which were unamibiguously assigned through 2D COSY NMR. 
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Figure 4.6 1H NMR of the macrocyclic semicarbazone 4.15 showing the characteristic peaks of the 
semicarbazone moiety 
 
4.3.2 Attempted Synthesis of a Macrocyclic α-Ketotetrazole 
 
The macrocyclic aldehyde 4.14 was reacted with sodium hydrogen sulfite and potassium 
cyanide at low temperatures to give the cyanohydrin 4.16 as a 1:1 mixture of 
diastereoisomers (see Scheme 4.3).  Recrystallisation from methanol gave the 1:1 mixture 
of diastereoisomers of 4.16 as a white solid in 81% yield.  1H NMR analysis confirmed the 
presence of two diastereoisomers, with the characteristic doublet peaks of the β carbon 
hydrogen atom of the cyanohydrin being observed at 6.5 and 6.6 ppm (see Figure 4.7)  
The fact that six doublet peaks were observed for the amide hydrogen atoms was further 
evidence that two diastereoisomers were present.  2D NMR (Cosy) was used to confirm 
these peaks as being the amide hydrogen and cyanohydrin β hydrogen. 
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Figure 4.7 1H NMR of the macrocylic cyanohydrin 4.16, isolated as a 1:1 mixture of diastereoisomers.  The 
β carbon hydrogen peaks of the two diastereoisomers are circled; the two NH peaks of each of the three 
amino acids in the backbone lie within the boxed area 
 
The cyanohydrin 4.16 was reacted with sodium azide and triethylamine hydrochloride 
applying the same methodology used for formation of the acyclic α-hydroxytetrazoles 2.43 
and 2.55 (see Scheme 4.3).  The cyanohydrin 4.16 and the reagents were suspended in 
toluene and heated at reflux for 24 h, after which an intractable dark orange solid was 
observed.  Analysis by thin layer chromatography showed trace amounts of the desired α-
hydroxytetrazole 4.17; however, the orange solid obtained was not suitable for column 
chromatography due to low solubility in organic solvent.  Recrystallisation from methanol 
was attempted, but returned a mixture of products by mass spectrometry.  The intractable 
orange solid was determined by mass spectrometry to contain a mixture of the starting 
cyanohydrin 4.16, triethylamine hydrochloride, the desired α-hydroxytetrazole product 
4.17 and unidentified side products. 
 
Due to the limited inhibition activity of the acyclic α-hydroxytetrazoles 2.43 and 2.55 (see 
Chapter Six) it was not expected that the macrocyclic α-hydroxytetrazole analogue would 
show much activity against the cysteine proteases tested.  Thus, the synthesis of the 
macrocylic α-hydroxytetrazole analogue 4.18 was abandoned.    
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Scheme 4.3 Reagents and Conditions: i) NaHSO3, KCN, MeOH, H2O, EtOAc (82%); ii) Et3N.HCl, NaN3, 
toluene, reflux 
 
 
4.3.3 Synthesis of a Macrocyclic Azide 
 
The analogous acyclic azide 2.62 was shown to be a weak inhibitor of cysteine proteases 
(see Chapter Six).  Incorporation of the azide moiety onto a macrocyclic scaffold will 
provide further opportunity to assess the effect of constraint of the inhibitor backbone on 
binding affinity.  
 
The macrocyclic alcohol 4.19 was reacted with mesyl chloride followed by sodium azide 
to give the macrocyclic azide 4.20.  SN2 displacement of the mesylate with sodium azide 
occurred without isolation of the intermediate mesylate (see Scheme 4.5).  
Recrystallisation of crude 4.20 from ethyl acetate gave the pure azide 4.20 as a white solid 
in 49% yield.  
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Scheme 4.5 Reagents and Conditions: i) Et3N, mesyl chloride, DCM; ii) DMF, NaN3 (53%) 
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4.4 CONCLUSION AND FUTURE WORK 
 
 
The synthesis of the macrocyclic compounds 4.3, 4.4, 4.15-4.19 provided a range of 
peptidomimetic inhibitors.  The assay results and structure-activity relationships are 
discussed in Chapter Six. 
   
It is envisaged that future work would involve optimisation of the N-terminal group (A), 
amino acid sidechain (R1) and warhead (R2) on Figure 4.8 below, for fine-tuning of the 
potency, selectivity and solubility of such macrocyclic inhibitors.  Alternative warheads, 
especially those non-reactive in nature, of interest are listed below.  The University of 
Canterbury is currently in the process of provisional patenting compounds of this nature 
with an application for topical treatment of cataracts. 
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O
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Figure 4.8 Future compounds will be of this formula or a pharmaceutically acceptable salt, solvate, hydrate 
or prodrug thereof. 
 
Wherein:   
A is –C(=O)R3 or –S(=O)2R4; 
R3 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy or 
heteroarylalkoxy; and 
R4 is optionally substituted aryl, heteroaryl, aryloxy, heteroaryloxy, arylalkoxy or 
heteroarylalkoxy; 
R1 is a side chain of a natural or non-natural α-amino acid; 
R2 is –CH2OH, –CH2OR5, –CH2NR6R7, –CH(OH)R8, –CHO, –C(=O)C(=O)NHR9 or  
–C(=O)R10; 
 R5 is C1-C6 alkyl, aryl or arylalkyl; 
 R6 is hydrogen, C1-C6 alkyl, aryl or arylalkyl; 
 R7 is hydrogen, C1-C6 alkyl, aryl or arylalkyl; 
R8 is C1-C6 alkyl, alkoxy, thioalkoxy, aryl, arylalkyl, heteroaryl or heteroarylalkyl; 
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R9 is C1-C6 alkyl, hdroxyalkyl, aryl or arylalkyl; and 
R10 is C1-C6 alkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl. 
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5.1  INTRODUCTION TO PROTEASE INHIBITION ASSAYS 
 
The biological activity of the cysteine protease inhibitors reported in this thesis were 
determined by measuring the inhibition constants (IC50) in an in vitro assay.  IC50 indicates 
the concentration of inhibitor required to decrease the activity of the target protease by 
50%.  It should be noted that the irreversible inhibitors of Chapter Three were assayed in 
an identical manner to the reversible inhibitors of Chapters Two and Four to allow 
comparison of the warheads.  This chapter will cover the assay protocols that were 
established for each protease  
 
 
5.2  THE BODIPY-CASEIN FLUORESCENCE ASSAY FOR 
CALPAIN 
 
Collaboration with Lincoln University allowed access to the materials required for the 
biological assay of cysteine protease inhibitors.  An established assay protocol for the 
determination of m-calpain inhibition based on a fluorogenic methodology used by 
Thompson and co-workers1 was used.   This assay protocol utilises casein, a water soluble 
protein, labelled with the fluorophore 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-propionic acid (BODIPY).  The principle behind this methodology is shown 
schematically in Figure 5.1.  Fluorescence increases as proteolysis of the substrate (casein) 
occurs.  Without proteolysis, fluorescence is not observed as adjacent intramolecular 
fluorophores cause auto-quenching of fluorescence.  Thus the inhibitory activity of a 
proposed inhibitor can be measured by calculating the change in fluorescence over a 
known period of time. 
 
m-Calpain and µ-calpain were partially purified from sheep lung by ion-exchange 
chromatography and diluted to give a linear response over the course of the assay.*  The 
BODIPY-FL labelled casein was prepared by Lincoln University students according to the 
protocol set out by Jones et al.2  The substrate solution (0.0005% BODIPY-FL casein in 10 
                                                 
*
 Calpain was provided courtesy of Matthew Muir of Lincoln University 
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mM TRIS-HCl, pH 7.5 containing 10 mM CaCl2, 0.1 mM NaN3, and 0.1% 
mercaptoethanol) was prepared fresh each day.   
 
    
Figure 5.1: Schematic illustration of calpain IC50 assay 
 
The assays were performed in 96-well black Whatman plates.  Two types of blank controls 
were utilised, a calcium blank and an EDTA blank.  The calcium blanks contained 100 µL 
of 100 mM calcium chloride, and the EDTA blanks 25 µL of 10 mM EDTA solution, 25 
µL distilled water and 50 µL of the enzyme.   Calpain control assays contained 50 µL 
calpain (m- or µ-) in sample buffer (20 mM TRIS-HCl, pH 7.5 containing 1 mM EDTA, 1 
mM EGTA, and 2 mM dithiothreitol) and 50 µL distilled water (see Figure 5.2 for a 
schematic layout).  The reaction was initiated by the addition of 100 µL of substrate 
solution at 25 °C and the progress followed for 10 min in a BMG Fluostar with excitation 
of 485 nm and emission of 530 nm.  For the inhibitor assays the sample buffer was 
replaced by 50 µL of inhibitor diluted in distilled water.†  The percentage inhibition was 
determined as 100 times the activity with inhibitor present divided by the activity of the 
control assay.  Assays were performed in triplicate with serial dilutions of inhibitor 
concentrations from 50 µM to 50 nM (see Appendix A1 for a raw data and IC50 
calculation). 
 
 
 
 
 
                                                 
†
 This will be discussed in more detail in Section 5.2 
Calpain 
Auto quenching Fluorescence 
BODIPY 
Casein 
hυ 
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Calcium blank EDTA blank Enzyme activity blank 
          
         100 µL 10 mM CaCl2 
 
  25 µL 100 mM EDTA 
 
  50 µL H20 
         100 µL BODIPY-casein   25 µL H20   50 µL calpain 
 
  50 µL calpain 100 µL BODIPY-casein 
 
100 µL BODIPY-casein 
 
 
                           Inhibitor samples  
 
          50 µL inhibitor 
            50 µL calpain 
          100 µL BODIPY-casein 
 
Figure 5.2 Schematic diagram of a 96 well plate and the layout of a calpain (m- or µ-) assay run. 
 
 
5.2.1 Validation of the BODIPY-casein Assay Protocol 
 
The aldehyde 2.3 (see Table 5.1) was used as a reference compound to validate the assay 
protocol.  Repeated assay of 2.3 with the BODIPY-casein protocol above mentioned gave 
an average value of 80 ± 10 nM;‡ comparable to the IC50 obtained by Inoue (78 nM).3  The 
difference in the IC50 values of 2.3 obtained against µ-calpain  with this fluorogenic assay 
(134 nM) and the value reported by Inoue3 (7 nM) is attributed to the assay protocol. The 
Coomassie Blue colorimetric assay4 that Inoue3 et al utilised can only detect 5-10 µg of 
calpain, making it a less sensitive and less reliable assay than the BODIPY-casein used 
herein (under these conditions it is possible to detect 50-100 ng of calpain).1,5  A similar 
trend was seen in the µ-calpain IC50 values compared for the aldehyde 2.27; the difference 
                                                 
‡
 SJA6017 was assayed over 20 times against m-calpain and µ-calpain 
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being attributed to the sensitivity and reliability of the two methods used.  The aldehyde 
2.27 was found to have an IC50 value of 60 nM under the BODIPY-casein assay 
conditions, significantly different from the value of 350 nM reported by Inoue.3  Again, the 
difference is attributed to the greater accuracy of the BODIPY-casein assay in comparison 
with the less reliable Coomassie Blue conditions.  The IC50 values for the aldehydes 2.3 
and 2.27 obtained herein for µ-calpain are therefore thought be more accurate than those 
reported in the literature.    
 
 
IC50 (nM) 
 
Compound 
 
m-calpain  
 
µ-calpain 
Reported 
 
Calcd Reported 
 
Calcd 
 
 
 
2.3 
 
 
O2S
N
H
F
H
N
O
H
O
 
 
783 
 
80 
 
83 
 
134 
 
 
2.27 O N
H
O H
N
O
H
O
 
 
- 
 
145 
 
296 
 
375  
 
Table 5.1 Comparison of IC50 values for aldehyde 2.3 against m-calpain and mu-calpain  
 
Once the BODIPY-casein assay was validated for both m- and µ-calpain and 
reproducibility of IC50 results demonstrated for 2.3, attention turned to finding a suitable 
assay system for the proteases papain, cathepsin B, α-chymotrypsin and pepsin. 
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5.3  MODIFICATION OF THE FLUORESCENCE ASSAY 
TO ACCOMMODATE OTHER PROTEASES 
 
A number of points for consideration arise regarding the modification of the BODIPY-
casein assay for use with other proteases: 
 
• Will the alternative enzymes recognise BODIPY-casein as a substrate? 
• Will the assays be comparable? 
• Calpains are the only enzymes that require calcium for activation – both the blanks 
and the substrate contain calcium so modification is needed 
 
 
5.3.1 Turnover of BODIPY-casein by Other Proteases 
 
From observations of the change in the IC50 value of SJA6017, it was noted that the 
optimum activity of m- and µ- calpain was represented by a change in fluorescence of 
between 600-1200 FU (where FU denotes arbitrary fluorescence units), see Table 5.2.  
When the enzyme has minimal activity (change in fluorescence of 200 units or less) over 
10 min, the calculated IC50 is far below the value it should be.  This highlights the 
importance of maintaining the activity of the enzyme above a certain threshold in order to 
obtain meaningful results. 
 
m-calpain 
 
µ-calpain 
Change in 
Fluorescence 
IC50 of SJA6017 
(nM) 
Change in 
Fluorescence 
IC50 of SJA6017 
(nM) 
 
 
204 
 
9 
 
150 
 
15 
650 77 637 134 
856 80 1265 130 
1235 83 1504 164 
    
 
Table 5.2 Effect of enzyme activity on the calculated IC50 value of SJA6017 against m- and µ- calpain 
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Papain, cathepsin B, α-chymotrypsin and pepsin were tested for their turnover of 
BODIPY-casein.  The results of this are summarised in Table 5.3 and show that BODIPY-
casein is a suitable substrate for papain, α-chymotrypsin and pepsin.  This primary testing 
utilised the proteases at 1 mg/ml and the resulting change in fluorescence values show that 
the concentration of each enzyme must be optimised (according to the observations made 
in Table 5.2).  This optimisation also allows comparison of potency across the range of 
proteases tested.  The optimised concentrations of each enzyme were found to be the 
following: papain, 2 mg/ml; pepsin, 0.2 mg/ml; α-chymotrypsin, 0.05 mg/ml.  These 
concentrations were found by observing enzyme activity, as determined in Figure 5.3 and 
Table 5.4.  
 
 
Enzmye 
 
Fluorescence at t0 
(FU) 
 
Fluorescence at t10 
(FU) 
 
Change in 
Fluorescence 
 
 
m-calpain 
 
1051 
 
1872 
 
821 
µ-calpain 878 1881 1003 
papain 459 569 110 
pepsin 937 2658 1721 
α-chymotrypsin 2352 5115 2763 
cathepsin B 300 310 10 
 
 
Table 5.3 Activity of proteases over 10 min.  Concentration of each enzyme is 1 mg/ml; fluorescence is 
given in arbitrary fluorescence units (FU)   
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Figure 5.3 Graph of change in fluorescence versus enzyme concentration, the lines represent fluorescence at 
500 and 1200 FU.   Enzyme concentration must correspond to a change in fluorescence between these two 
values. 
 
 
 
Enzyme 
 
Concentration 
(mg/ml) 
 
Fluorescence 
at t0 
 
Fluorescence 
at t10 
 
Change in 
Fluorescence 
 
 
Papain 
 
2.00 
 
216 
 
758 
 
542 
 
1.00 459 569 110 
     
Pepsin 1.00 937 2658 1721 
 0.20 549 1305 756 
 
0.10 443 852 424 
 
0.01 390 393 3 
     
α-Chymo 1.00 2677 5642 2965 
 
0.10 1830 3458 1628 
 0.05 749 1593 844 
 
0.01 1005 1083 78 
     
 
Table 5.4 Determining the optimal concentration of papain, pepsin and α-chymotrypsin for assay 
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5.3.2 Adjustment of the Substrate Solution 
 
The calpain assay protocol as described above uses the BODIPY-casein substrate in a 
solution containing: 0.0005% BODIPY-FL casein in 10 mM TRIS-HCl (pH 7.5), 10 mM 
CaCl2, 0.1 mM NaN3, and 0.1% mercaptoethanol.  This is unnecessary for papain, α-
chymotrypsin and pepsin as they do not require calcium for activation.  A simplified 
solution of 1% BODIPY-casein in distilled water was substituted for the original solution; 
use of this solution gave similar results for enzyme activity.  Only 10 µL of this substrate 
solution was used in each assay well because of its increased concentration (for calpain 
assays, 100 µL of the original substrate solution containing 0.0005% BODIPY-casein was 
used per assay well).   
 
Adjustment of buffer solutions  
Each enzyme has different requirements for stabilisation in solution, thus optimised buffer 
solutions were found.  These were: 10 mM HCl (pH 2.0) for pepsin; 10 mM TRIS-HCl 
(pH 7.8) for α-chymotrypsin; 10 mM MES (pH 6.2) for papain as identified by the 
CalBiochem catalogue. 
 
The modified enzyme assays were performed in black 96-well Whatman plates.  Blank 
control assays contained 190 µL of appropriate buffer (10 mM MES, 10 mM HCl or 10 
mM TRIS-HCl).   The control assays contained 10 µL of the protease (papain, pepsin or α-
chymotrypsin) in 180 µL of appropriate buffer (see Figure 5.3 for a schematic plate 
layout) and the inhibitor assays 130 µL of appropriate buffer, 50 µL inhibitor solution and 
10 µL of the protease solution.  The reaction was initiated by the addition of 10 µL of 
substrate solution at 25 °C and the progress of the reaction followed for 10 min in a BMG 
Fluostar with excitation of 485 nm and emission of 530 nm.  For the inhibitor assays the 
sample buffer was replaced by 50 µL of inhibitor diluted in distilled water§.  The 
percentage inhibition was determined as 100 times the activity with inhibitor present 
divided by the activity of the control assay.  Assays were performed in triplicate with serial 
dilutions of inhibitor concentrations from 50 µM to 50 nM.       
 
                                                 
§
 This will be discussed in more detail in Section 5.2 
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              Blank  Enzyme Activity                 Inhibitor Assay 
          
            190 µL buffer 
 
   180 µL buffer 
 
  130 µL buffer 
              10 µL BODIPY-casein      10 µL enzyme   10 µL enzyme 
 
     10 µL BODIPY-casein   10 µL BODIPY-casein 
 
Figure 5.3 Schematic diagram of a 96 well plate and the layout of a papain, pepsin or α-chymotrypsin assay 
run 
 
 
5.3.3 Cathepsin B Assay Protocol 
 
Cathepsin B showed a change of only 10 fluorescence units over 10 min when tested 
against the BODIPY-casein substrate (refer to Table 5.3), indicating that the BODIPY-
casein was not a suitable substrate (optimal change in fluorescence units between 500-1200 
is required).  Angliker7 and co-workers described a fluorescent assay protocol for cathepsin 
B, where the cathepsin B was at a concentration of 1 mg/ml, the buffer 10 mM sodium 
acetate (pH 5.4) and the substrate used was benzyloxycarbonyl-Phe-Arg-7-amido-4-methyl 
coumarin (10 µM final concentration).  Repeating the activity tests using these conditions 
showed this to be a viable assay protocol for cathepsin B (see Table 5.5).  Cathepsin B was 
tested at concentrations of 0.1 mg/ml, 0.05 mg/ml and 0.02 mg/ml to determine the optimal 
concentration of the enzyme.  The optimal concentration of cathepsin B was found to be 
0.02 mg/ml, this having a change in fluorescence units of 664 over 10 min.  
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Enzyme 
Concentration (mg/ml) 
 
Fluorescence 
at t0 (FU) 
 
Fluorescence 
at t10 (FU) 
 
Change in 
Fluorescence (FU) 
 
 
0.1 
 
704 
 
4519 
 
3815 
0.05 267 1654 1626 
0.02 220 884 664 
 
 
Table 5.5 Determining the optimal concentration of cathepsin B for assay. 
 
The modified cathepsin B assays were performed in black 96-well Whatman plates.  The 
blank control assays contained 190 µL of 10 mM sodium acetate (pH 5.4) buffer.  The 
enzyme control assays contained 10 µL of the cathepsin B 0.02 mg/mL solution and 180 
µL of 10 mM sodium acetate buffer (pH 5.4) (see Figure 5.4 for a schematic plate layout), 
while the inhibitor assays contained 130 µL of 10 mM sodium acetate buffer (pH 5.4), 50 
µL of inhibitor solution and 10 µL of.  The reaction was initiated by the addition of 10 µL 
of 200 µM Cbz-Phe-Arg-7-amido-4-methyl coumarin solution at 25 °C and the progress of 
the reaction followed for 10 min in a BMG Fluostar with excitation of 360 nm and 
emission of 460 nm.  The percentage inhibition was determined as 100 times the activity 
with inhibitor present divided by the activity of the control assay.  Assays were performed 
in triplicate with serial dilutions of inhibitor concentrations from 50 µM to 50 nM.      
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             Blank  Enzyme Activity                  Inhibitor Assay 
          
            190 µL NaOAc buffer 
 
   180 µL NaOAc buffer 
 
   130 µL NaOAc buffer 
              10 µL BODIPY-casein      10 µL cathepsin B      10 µL cathepsin B 
 
     10 µL BODIPY-casein      10 µL BODIPY-casein 
 
Figure 5.4 Schematic diagram of a 96 well plate and the layout of a cathepsin B assay run 
 
 
5.3.4 Validation of the Modified Assay Protocols 
 
Known inhibitors of pepsin, α-chymotrypsin and cathepsin B were used to validate the 
modified assays.  The aspartic acid inhibitor pepstatin A** 5.1 was used for validation of 
the pepsin assay; correspondingly an in-house boronic acid†† 5.2 was used for validation of 
the α-chymotrypsin assay.  The structures of these compounds are pictured in Figure 5.2.  
Comparison of previously reported potency with the IC50 values calculated herein show 
that the modified assays are viable (see Table 5.6).  The inhibition of pepsin by pepstatin 
observed correlated well with the results of Marchiniszyn8 (100% inhibition of pepsin at 
inhibitor concentration of 120 nM versus 96% inhibition at inhibitor concentration of 100 
nM).  Similarly, the boronic ester was shown to have an IC50 of 1100 nM under the 
modified assay conditions as compared to a value of 1200 nM in independent assay.  The 
aldehyde 2.3 was used for validation of the cathepsin B assay protocol.  Previously, Inoue3 
et al had reported an IC50 value of 16 nM for 2.3 against cathepsin B; the IC50 value of 22 
nM obtained with this assay protocol correlated well. 
 
                                                 
**
 isovaleryl-Val-Val-Sta-Ala-Sta, where Sta is 4-amino-3-hydroxy-6-methylheptanoic acid 
††
 Synthesised and independently assayed by David Pearson 
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Figure 5.5 The structures of a) pepstatin A 5.1 and b) a boronic acid 5.2.  These are inhibitors of Pepsin and 
α-chymotrypsin respectively 
 
 
Enzyme 
 
 
Inhibitor 
 
Reported potency (IC50) 
 
Calculated potency 
 
Pepsin 
 
5.1 
 
100% at 120 nM8 
 
96% at 100 nM 
α-Chymotrypsin 
Cathepsin B 
 
5.2 
2.3 
1200 nM9 
16 nM3 
1100 nM 
22 nM 
   
Table 5.6 Comparison of known inhibitors for validation of modified enzyme assays.  Potency given as IC50 
values unless otherwise stated. 
   
The inhibitors synthesised in Chapters Two-Four were not expected to show inhibition 
against pepsin or α-chymotrypsin as they were designed as cysteine protease inhibitors; 
thus the validation of the pepsin and α-chymotrypsin assay protocols was necessary to 
ensure that any lack of inhibition observed was a real observation and not a false negative 
result. 
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5.4 SOLVENT EFFECTS ON PROTEASE ACTIVTY 
 
Biological assay of the inhibitors herein synthesised required solutions containing known 
concentrations of these inhibitors.  Ideally, the same buffer solution used in making stock 
solutions of the enzymes would be utilised; however, due to the limited solubility of most 
organic compounds in aqueous media, an organic solvent was utilised.  Dimethyl sulfoxide 
was the solvent of choice because its high boiling point ensured that no evaporation of the 
solvent occurred over the course of the assay. Further, dimethyl sulfoxide is water 
miscible, a requirement for the solvent used in the assays due to the presence of aqueous 
based media such a buffers. 
 
Before calculating and reporting IC50 values, a study was performed on the effect dimethyl 
sulfoxide had on the assay protocol.  This study entailed running enzyme control assays 
against enzyme assays containing a variable amount of dimethyl sulfoxide (50 µL to 0 µL).  
The enzyme control assays are as described above for calpain, cathepsin B and other 
proteases.  Results shown in Table 5.7 and Figure 5.6 below provide evidence that 
dimethyl sulfoxide  above 5% of the total well volume does adversely affect the activity of 
the enzyme with m-calpain, µ-calpain, papain, cathepsin B and pepsin all showing an 
activity less than half of their natural activity.  α-Chymotrypsin gave anomalous results for 
higher concentrations of dimethyl sulfoxide, with the enzyme activity shown being greater 
than it should be (over 100%).  However, at lower concentrations of dimethyl sulfoxide, 
activity was restored to normal.  This same trend was observed in an independent assay 
performed at Canterbury University.10  One suggestion for this trend is that the dimethyl 
sulfoxide partly denatures α-chymotrypsin which promotes its activity.  
 
The inhibitors were made up as 1 mM solutions in dimethyl sulfoxide and subsequently 
diluted by the addition of distilled water to give a range of concentrations.  The highest 
concentration of inhibitor used in determining IC50 values was 50 µM, corresponding to a 
200 µM solution of inhibitor.  To achieve this the initial 1 mM solution of the inhibitor was 
diluted 5-fold with distilled water, resulting in the solution being 20% dimethyl sulfoxide.  
Further dilution of this solution occurs when setting up the assay wells, as the 50 µL of 
inhibitor solution makes up only a quarter of the total volume.  Thus the final amount of 
dimethyl sulfoxide present comes to 5% of the total well volume (10 µL out of 200 µL) 
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and so no solvent effect will be observed.  This means that 50 µM is the highest 
concentration at which inhibition can be reliably measured.  
 
 Protease activity (%) 
Volume DMSO 
(µL) 
m-
calpain 
µ-
calpain 
 
cat B 
 
papain 
 
pepsin 
α-
chymotrypsin 
 
50 
 
5 
 
2 
 
16 
 
40 
 
20 
 
140 
30 45 47 55 66 59 118 
10 95 98 96 92 98 97 
2 100 100 96 97 100 99 
 
 
Table 5.7 Effect of DMSO on the activity of enzymes.   
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Figure 5.6 Visual representation of the effect of DMSO on the activity of proteases.  The amount of DMSO 
is relative to a total well volume of 200 µL 
   
 
25% DMSO        15% DMSO          5% DMSO           1% DMSO 
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5.5 CONCLUSION AND FUTURE WORK 
 
The optimised conditions for biological testing of inhibitors against each of the proteases 
m-calpain, µ-calpain, papain, cathepsin B, pepsin and α-chymotrypsin using a fluorogenic 
assay system are summarised in Table 5.8 below.  General considerations were: 
 
• The maximum amount of dimethylsulfoxide present in any well of the assay must 
be no greater than 5% of the total well volume 
 
• The enzyme concentration must correspond to a change in fluorescence between 
500-1200 units for consistent results 
 
• Inhibitor samples were serially diluted: 50 µM, 10 µM, 2 µM, 0.4 µM, 0.2 µM, 0.1 
µM and 0.05 µM 
 
• The substrate solutions used were as follows: 
BODIPY A BODIPY B AMC 
8440 µL distilled H2O 
1000 µL 10 mM CaCl2 
  500 µL digestion buffer‡‡ 
    50 µL BODIPY stock 
    10 µL β-mercaptoethanol 
  60 µL BODIPY stock 
540 µL distilled water 
200 µM solution of Cbz-
Phe-Arg-AMC in NaOAc 
buffer (pH 5.4) 
 
• Assays using either BODIPY A or B as the substrate required excitation of 485 nm 
and emission of 530 nm for fluorescence measurement; however, use of AMC as a 
substrate required excitation of 360 nm and emission of 460 nm 
 
 
                                                 
‡‡
 Where Digestion buffer:2 mL 100 mM tris(hydroxymethyl) methylamine 
   2 mL 10 mM sodium azide 
   Adjust pH to 7.8 and make up to 10 mL with H2O  
 
  
Enzyme 
 
Concentration 
 
Buffer 
 
Assay Protocol 
 
  
   Blanks Enyme activity Inhibitor assay 
 
m and µ-calpain used as provided by 
Lincoln University 
distilled water calcium blank  
100 µL 10 mM CaCl2 
100 µL BODIPY A 
 
EDTA blank 
 25 µL 100 mM EDTA 
 25 µL water 
 50 µL enzyme 
100 µL BODIPY A 
 
 50 µL water 
 50 µL enzyme 
100 µL BODIPY A 
 
 
 
 50 µL inhibitor 
 50 µL enzyme 
100 µL BODIPY A 
papain  2.0 mg/ml in buffer  
 
10 mM MES 
buffer (pH 6.2) 
 
190 µL buffer 
  10 µL BODIPY B 
 
180 µL buffer 
  10 µL enzyme 
  10 µL BODIPY B 
 
130 µL buffer 
  50 µL inhibitor  
  10 µL enzyme 
10 µL BODIPY B 
 
pepsin  0.2 mg/ml in buffer 
 
10 mM HCl 
buffer (pH 2.0) 
190 µL buffer 
  10 µL BODIPY B 
 
180 µL buffer 
  10 µL enzyme 
  10 µL BODIPY B 
 
130 µL buffer 
  50 µL inhibitor  
  10 µL enzyme 
  10 µL BODIPY B 
 
α-chymotrypsin 0.05 mg/ml in buffer  
 
10 mM TRIS-
HCl buffer  
(pH 7.8) 
 
190 µL buffer 
  10 µL BODIPY B 
 
180 µL buffer 
  10 µL enzyme 
  10 µL BODIPY B 
 
130 µL buffer 
  50 µL inhibitor  
  10 µL enzyme 
  10 µL BODIPY B 
 
cathepsin B  0.02 mg/ml in buffer  
 
10 mM NaOAc 
buffer (pH 5.4) 
190 µL buffer 
  10 µL AMC  
 
 180 µL buffer 
  10 µL enzyme 
  10 µL AMC  
 
130 µL buffer 
  50 µL inhibitor  
  10 µL enzyme 
  10 µL AMC  
 
Table 5.8 Summary of the optimised conditions for each assay protocol established 
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6.1  INTRODUCTION TO INHIBITOR STRUCTURE-
ACTIVITY RELATIONSHIPS  
 
 
The only cysteine protease inhibitors that have proceeded to clinical development to date 
are those that target caspases, cathepsin K, cruzain or rhinovirus.1,2  Of these the cathepsin 
K inhibitors are undergoing clinical trials for the treatment of osteroperosis.1,3  Recent 
reviews1,2 of clinical protease inhibitors highlight target selectivity as a major problem in 
the development of new drugs and state that “attaining selectivity between members of 
cysteine proteases belonging to the same family is of the utmost concern”.2  The aim of 
this chapter is to show that selectivity can be conferred upon cysteine protease inhibitors 
through the choice of warhead.*  
 
The inhibitors synthesised within this thesis (see Chapters Two-Four) were assayed 
according to the protocols established in Chapter Five with a view to establishing 
structure-activity relationships with regard to selectivity.  What follows is a discussion of 
structure-activity relationships for the different warheads. Special mention is made of 
selectivity for cathepsin B over the other cysteine proteases tested due its role in human 
diseases such as tumour metastasis (see Chapter One for more detail).4  
 
 The peptidyl backbone and the N-protecting group were retained as common structural 
features in all the synthesised inhibitors (see Tables 6.1-6.20) while the warhead was 
changed.  This allowed both the effect of the warhead on inhibitor potency and structure-
activity relationships to be studied.  The two generic families of synthesised inhibitors 
were based on the scaffolds shown in Figure 6.1, these being a) 4-fluorobenzenesulfonyl-
Val-Leu-warhead and b) benzyloxycarbonyl-Val-Leu-warhead respectively.  These 
scaffolds were chosen to allow comparison to literature inhibitors and also because both 
the 4-fluorbenzyesulfonyl-Val-Leu dipeptide and the benzyloxycarbonyl-Val-Leu 
dipepetide are known to provide the basis of potent inhibitors of cysteine proteases. 
 
 
                                                 
*
 The term ‘warhead’ is used to define the part of the inhibitor that interacts with the active site cysteine thiol.  
More detail can be found in Chapter One. 
Chapter Six – Synthesised Inhibitors: Assay Results and SAR  139 
O2
S
N
H
H
N
O
warhead
F
N
H
H
N
O
O
O
warhead
 
            a)      b) 
Figure 6.1 The two scaffolds used for establishing structure-activity relationships of warheads a) 4-
fluorobenzenesulfonyl-Val-Leu-warhead and b) benzyloxycarbonyl-Val-Leu-warhead 
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6.2 REVERSIBLE CYSTEINE PROTEASE INHIBITORS: 
ASSAY RESULTS AND DISCUSSION 
 
 
6.2.1 Peptidyl Alcohols and Aldehydes 
 
Over the last decade non-covalent moieties have become increasingly significant as 
protease inhibitor ‘warheads’5 due to the increased drug-like properties and in vivo 
selectivity such inhibitors.  Non-covalent warheads include alcohol, methylene amine and 
azidomethylene moieties like those shown in Figure 6.2.  Most non-covalent inhibitors 
target serine and aspartic acid proteases, with few examples targeting cysteine proteases.5   
Hence the alcohols 2.6, 2.26, 2.29, 2.30, 2.34, and 2.35 and the corresponding aldehydes 
2.3, 2.27, 2.19, 2.2, 2.21 and 2.22 respectively (as prepared in Chapter Two), were 
assayed against the cysteine proteases.  The results of these assays are shown in Table 6.1.  
 
OH NR N3
a b c
 
Figure 6.2 Three non-covalent warheads utilised in protease inhibitors: a) alcohol; b) methylene amine and 
c) azidomethylene groups 
 
IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
2.6 
O2
S
F
N
H
H
N
O
OH
 
 
>50 
 
50 
 
9.2 
 
>50 
 
2.3 
O2
S
F
N
H
H
N
O
H
O
 
 
0.080 
 
0.13 
 
0.022 
 
0.023 
 
2.26 
O2
S
F
N
H
H
N
O
OH
 
 
2.3 
 
1.5 
 
0.075 
 
6.3 
 
 
2.27 
O2
S
F
N
H
H
N
O
H
O
 
 
0.072 
 
0.012 
 
0.016 
 
0.033 
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IC50 (µM) Compound 
m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
2.29 O NH
O
H
N
O
OH
 
 
>50 
 
>50 
 
26 
 
>50 
 
2.19 O NH
O
H
N
O
H
O
 
 
0.15 
 
0.38 
 
0.042 
 
0.66 
 
2.30 O NH
O
H
N
O
OH
 
 
22 
 
28 
 
1.2 
 
>50 
 
 
2.2 O NH
O H
N
O
H
O
 
 
0.060 
 
0.027 
 
0.027 
 
1.1 
 
2.35 NH
H
N
O
OH
OH
N
 
 
>50 
 
>50 
 
12 
 
>50 
 
2.21 NH
H
N
O
H
OH
N
O
 
 
0.32 
 
0.65 
 
0.032 
 
0.053 
 
2.36 NH
H
N
O
OH
O
S
 
 
>50 
 
>50 
 
23 
 
>50 
 
2.22 NH
H
N
O
H
OO
S
 
 
0.25 
 
1.1 
 
0.016 
 
0.040 
 
Table 6.1 Comparison of IC50 values of aldehydes and corresponding alcohols 
 
The alcohols 2.26 and 2.30 (see Figure 6.3) are noteworthy as the only members of the 
alcohol series that display significant inhibition of cathepsin B (IC50 = 0.075 µM and 1.2 
µM respectively).  Alcohol 2.26 also shows significant potency against the other cysteine 
proteases tested {IC50 = 2.3 µM (m-calpain), 1.5 µM (µ-calpain) and 6.3 µM (papain)}.  
The analogous alcohol 2.30, which differs only in the N-protecting group 
(benzyloxycarbonyl instead of 4-fluorobenzenesulfonyl), is less potent than 2.26, with IC50 
values greater than 20 µM against m-calpain, µ-calpain and papain (see Table 6.1).  These 
results suggest that having an alcohol moiety at the C-terminus and the 4-
fluorobenzenesulfonyl moiety as the N-terminal protecting group is a significant 
combination towards the design and synthesis of a potent, cathepsin B specific inhibitor. 
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Figure 6.3 The alcohol 2.26 is a novel, potent inhibitor of cysteine proteases. 
 
The alcohols 2.26 and 2.30 both contain the dipeptide Val-Phe, indicating that the large 
aromatic hydrophobic side chain of Phe may be more favourable in the P1 position than 
smaller hydrophobic side chains such as Leu or Val (compare with IC50 values of alcohols 
2.6 and 2.29).  The corresponding Val-Phe aldehydes 2.27 and 2.2 are similarly more 
potent cysteine proteases inhibitors than the Val-Leu analogues 2.3 and 2.19 (up to 40-fold 
difference in potency over the cysteine proteases tested).  These results refine the previous 
suggestion by Currier et al6 that Leu and Phe were equally favourable in the P1 position for 
µ-calpain 
 
The remainder of the alcohols (2.6, 2.29, 2.35, and 2.36) are significantly weaker cysteine 
protease inhibitors than 2.26 and 2.27; however, the Leu-Val backbone still provides 
between 2- to 5-fold specificity for cathepsin B (IC50 = 9.2 µM, 26 µM, 12 µM and 23 µM 
respectively) over the other cysteine proteases tested. 
 
The aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 and 2.22 were assayed against the cysteine 
proteases: m-calpain, µ-calpain, cathepsin B and papain.  The resulting IC50 values (see 
Table 6.1) show that all the aldehydes are broad spectrum cysteine proteases (IC50 values 
<0.70 µM).  The aldehydes are, however, specific for cysteine protease being inactive 
against pepsin and α-chymotrypsin (see Appendix A2).  The broad cysteine protease 
specificity observed for the aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 and 2.22 compares well 
with the aldehyde examples 2.1-2.5, which are also non-specific cysteine protease 
inhibitors (discussed in Chapter Two, Table 2.2). 
IC50 Values: 
m-calpain         2.3      µM     22   µM  
µ-calpain          1.5     µM     28   µM 
cathepsin B      0.075  µM     1.2  µM 
papain              6.3      µM                 >50  µM 
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The alcohol 2.6 and aldehyde 2.3 (see Chapter Two) were modelled to allow direct 
comparison to literature7 and to provide representative data for related compounds.  Both 
of these structures were docked into the rigid µ-calpain model and the best poses are 
shown in Figure 6.4.†  The molecular modelling results suggest that the both alcohol 2.6 
and aldehyde 2.3 adopt a β-strand conformation that is known to be important for binding 
to cysteine proteases (the β-strand is defined by hydrogen bonds A, B and C, see Chapter 
One for more detail).  The alcohol 2.6 is suggested to form an additional hydrogen bond 
between the alcohol oxygen group and Gly271, which is not observed in the case of 
aldehyde 2.3.  Since both of these compounds appear to bind in a similar region of the 
active site and form similar hydrogen bonds, the difference in activity {2.3 IC50 = 0.080 
µM (m-calpain), 0.13 µM (µ-calpain), 0.022 µM (cathepsin B) and 0.023 µM (papain) 
versus 2.6 IC50 = 50 µM (m-calpain), 50 µM (µ-calpain), 9.2µM (cathepsin B) and 50 µM 
(papain)} is attributable to the reactivity of the aldehyde moiety over the non-reactive 
alcohol moiety.  The differences in potency between the alcohol 2.6 and aldehyde 2.3 are 
similar to those observed between the other alcohol and aldehyde pairings, with the 
exception of alcohols 2.26 and 2.30 (as previously discussed).  
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Gly271
Gly208
Gly271
 
 
    a)     b) 
Figure 6.4 Molecular modelling results comparing the hydrogen bonds of a) alcohol 2.6 and b) aldehyde 2.3 
 
                                                 
†
 See Chapter Two  for details of molecular modelling  
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A systematic search of the literature reveals few examples of non-covalent cathepsin B 
specific inhibitors.  Fairlie et al5 synthesised cathepsin B inhibitor 6.1 utilising the non-
covalent azide moiety in place of a warhead (see Chapter Two for details).  Conroy et al8 
reported the cyclohexanone based cathepsin B inhibitors 6.2 and 6.3 (see Figure 6.5), 
which were designed to bridge the active site by means of interactions between  the Orn 
residue and the S2 subsite and the Pro residue and the S2’ subsite.  The free acid of the Pro 
forms hydrogen bonds to the His110 and His111 of the protease.  These two active site 
bridging inhibitors, however, show only weak inhibition of cathepsin B (6.2, Ki = 6600 
µM; 6.3, Ki = 6100 µM).  Yamamoto et al9 designed the non-covalent inhibitor 6.4 (see 
Figure 6.5) that was a potent cathepsin B inhibitor (IC50 <0.10 µM); however, specificity 
was not addressed.  The alcohol 2.26 appears to be an unprecedented example of a potent 
non-covalent cathepsin B specific inhibitor. 
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IC50 = 0.058 µM
 
Figure 6.5 The non-covalent cathepsin B azide 6.45; active site bridging inhibitors 6.2 and 6.38 and the amide 
6.49  
 
 
6.2.2 Semicarbazone Inhibitors 
 
The semicarbazones 2.37-2.40 exhibited inhibitory activity against m-calpain, µ-calpain, 
cathepsin B and papain (IC50 values in the low µM range) (see Table 6.2).  At 
concentrations of 50 µM the semicarbazones 2.37-2.40 were inactive against pepsin and α-
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chymotrypsin.  The semicarbazone 2.37 {IC50 = 1.1 µM (µ-calpain)} is a literature 
compound synthesised by Senju Pharmaceuticals10 {reported IC50 = 0.68 µM (µ-calpain)}; 
the 1.6-fold difference in IC50 values being attributed to the increased sensitivity of the 
BODIPY-casein protocol used herein (see Chapter Five for details).  Selectivity within 
the papain superfamily has not previously been studied for semicarbazone 2.37.   
 
The semicarbazones 2.37-2.40 were all significantly less potent than the aldehyde 2.3 
(refer to Table 6.1); which agrees with trends observed in the literature (see Chapter Two, 
Section 2.2.111).  The semicarbazones 2.37-2.40 are between 12- and 190-fold less potent 
against m-calpain and µ-calpain respectively than the parent aldehyde 2.3.  Activity against 
papain and cathepsin B was also reduced, but to a lesser degree (between 7- and 40-fold); 
however, the resulting IC50 values of all the semicarbazones 2.37-2.40 remained sub-µM.   
 
The nature of the semicarbazone substituent adjacent to its carbonyl group (extending into 
the S’ pocket) does not seem to have a significant influence on inhibitory activity, with the 
IC50 values of 2.37, 2.39 and 2.40 being similar against papain (0.92 µM, 0.96 µM and 
0.96 µM respectively), m-calpain (1.5 µM, 1.5 µM and 3.8 µM respectively), µ-calpain 
(1.1 µM, 3.5 µM and 4.8 µM respectively) and cathepsin B (0.69 µM, 0.24 µM and 0.32 
µM respectively).  The semicarbazones 2.37, 2.39 and 2.40 display up to 4-fold selectivity 
for cathepsin B over the other cysteine proteases tested.  The thiosemicarbazone 2.38 was 
significantly more potent than the semicarbazone 2.37 against cathepsin B (0.69 µM and 
0.16 µM respectively) and papain (0.92 µM and 0.19 µM respectively). 
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IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
  2.3 
O2
S
F
N
H
H
N
O
H
O
 
 
0.080 
 
0.13 
 
0.022 
 
0.023 
 
  2.37 
O2
S
F
N
H
H
N
O
N
H
N NH2
O
 
 
1.5 
 
1.1 
 
 
0.69 
 
 
0.92 
 
 
2.38 
O2
S
F
N
H
H
N
O
N
H
N NH2
S
 
 
1.6 
 
 
1.6 
 
 
0.16 
 
 
0.19 
 
 
2.39 
O2
S
F
N
H
H
N
O
N
H
N
H
N
O
 
 
1.5 
 
 
3.5 
 
 
0.24 
 
 
0.96 
 
 
2.40 
O2
S
F
N
H
H
N
O
N
H
N
 
 
3.8 
 
 
4.8 
 
 
0.32 
 
 
0.96 
 
 
Table 6.2 Inhibition of cysteine proteases by semicarbazones 2.37-2.40. 
 
The synthesised compounds 2.37-2.40 containing semicarbazone warheads are potent 
inhibitors of the cysteine proteases tested (IC50 < 4.8 µM).  4-Phenylsemicarbazone 2.39 is 
the most specific inhibitor within this series, showing greater than 4-fold selectivity for 
cathepsin B over the other cysteine proteases tested.  A structural difference between the 
S1’ pockets of cathepsin B and papain is highlighted by the presence of a phenyl group at 
the P1’ position; both the 4-phenylsemicarbazone 2.39 and phenylhydrazine 2.40 are 
significantly more potent against cathepsin B (IC50 = 0.24 µM and 0.32 µM respectively) 
than papain (IC50 = 0.96 µM and 0.96 µM respectively);  the semicarbazone 2.37 and 
thiosemicarbazone 2.38 (which have a free amide and thioamide respectively) have similar 
potencies (only 1.2-fold difference) against cathepsin B (IC50 = 0.69 µM and 0.16 µM 
respectively) and papain (IC50 = 0.92 µM and 0.19 µM respectively).    
 
The mechanism by which semicarbazones are thought to inhibit cysteine proteases has 
recently been revised.  Adkison11 and co-workers co-crystallised semicarbazone inhibitors 
(see Chapter Two) with cathepsin K.  The majority of these X-crystal structures contained 
only the parent aldehyde, leading to the hypothesis that the active inhibitor is the parent 
aldehyde, while the semicarbazone moiety acts only as a pro-drug.  This was investigated 
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using a 13C labelled semicarbazone inhibitor. A 13C NMR which showed enhanced 
resonances at 150 ppm for the imine carbon and also at 92 ppm (smaller) for the 
corresponding hydrate.  The labelled inhibitor was then added to cathepsin K and a 13C 
NMR spectrum revealed enhanced resonances at 91 ppm (hydrate) and 204 ppm. The latter 
resonance, on comparison with the 13C NMR spectrum of the parent aldehyde, was found 
to represent the aldehyde carbonyl carbon; hence Adkison concluded that the 
semicarbazone moiety most likely functioned as a pro-drug.  On this basis, it is proposed 
that the semicarbazones 2.37-2.40 also act as pro-drugs (‘masked’ aldehydes) such that 
each example then gives a similar IC50 value. 
  
 
6.2.3 Oxadiazole Inhibitors and Precursors 
 
Two dipeptidyl carboxylic acids (2.7 and 2.46) and the corresponding methyl esters 2.44 
and 2.45 were assayed against m-calpain, µ-calpain, cathepsin B and papain (results in 
Table 6.3).  The acid 2.7 and corresponding ester 2.44 are potent and selective cathepsin B 
specific inhibitors (IC50 = 0.39 µM, selectivity 127-fold; 1.4 µM, selectivity 35-fold 
respectively); while inhibition of the other cysteine proteases was not observed at an 
inhibitor concentration of 50 µM.  The analogous acid 2.46 and ester 2.45 are over 14-fold 
less potent inhibitors of cathepsin B (IC50 = 15 µM and 19 µM respectively) than the 
methyl esters 2.44 and 2.45. 
 
As highlighted previously (see Section 6.2.1), the 4-fluorobenzenesulfonyl N-protecting 
group is favoured over the benzyloxycarbonyl group for inhibition of cathepsin B.  This is 
reflected in the acid 2.7 (IC50 = 0.39 µM) being 40-fold more potent than the 
corresponding acid 2.46 (IC50 = 15 µM) and the methyl ester 2.44 (IC50 = 1.4 µM) being 
13-fold more potent than the corresponding methyl ester 2.45 (IC50 = 19 µM).   
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IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
2.44 
O2
S
N
H
H
N
O
OMe
O
F
 
 
>50 
 
>50 
 
1.4 
 
>50 
 
2.7 
O2S
N
H
H
N
O
OH
O
F
 
 
>50 
 
>50 
 
0.39 
 
>50 
 
2.48 
O2
S
N
H
H
N
O
O
O
N NH2
F
 
 
50 
 
50 
 
>50 
 
>50 
 
2.41 
O2
S
N
H
H
N
O
O
N
N
F
 
 
>50 
 
>50 
 
18 
 
50 
 
2.45 NH
H
N
O
OMe
O
O
O
 
 
>50 
 
>50 
 
19 
 
>50 
2.46 
N
H
H
N
O
OH
O
O
O
 
 
>50 
 
>50 
 
15 
 
>50 
 
2.49 NH
H
N
O
O
O
N NH2O
O
 
 
>50 
 
>50 
 
>50 
 
>50 
 
2.50 N
H
H
N
O
O
N
N
O
O
 
 
>50 
 
>50 
 
23 
 
>50 
 
Table 6.3 Potency of 1,2,4-oxadiazoles 2.41 and 2.50 and corresponding precursors 
 
The amidoximes 2.48 and 2.49 were inactive against m-calpain, µ-calpain, cathepsin B and 
papain at a concentration of 50 µM (see Table 6.3); however, the corresponding 
oxadiazoles 2.41 and 2.50 were weak and selective inhibitors of cathepsin B (IC50 = 18 µM 
and 23 µM respectively); inhibition of m-calpain, µ-calpain and papain was not observed. 
 
This selectivity for cathepsin B may be due to the 1,2,4-oxadiazole acting as a bioisostere 
of carboxylic acids and esters.12,13  Evidence for this is seen on comparison of the assay 
results of the oxadiazoles 2.41 and 2.50 with the methyl esters 2.44 and 2.45 and 
carboxylic acids 2.7 and 2.46. All six of these inhibitors are cathepsin B specific (IC50 = 18 
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µM, 23 µM, 1.4 µM, 19 µM, 0.39 µM and 15 µM respectively); inhibition of m-calpain, µ-
calpain and papain was not observed (see Table 6.3).   
 
Bioisosteres are defined as “groups or molecules which have chemical and physical 
properties producing broadly similar biological properties” and is usually on the basis of 
two compounds having an atom or a group of atoms with the same number of valence 
electrons;14 this can be reflected in similar hydrogen bonding patterns of the two groups to 
an enzyme active site.  The carboxylic acid and the 1,2,4-oxadiazole moieties have the 
potential to form the same hydrogen bonding patterns within cysteine protease active sites 
due to the presence the hydrogen bond accepting oxygen atom within both moieties (see 
Figure 6.6). 
OH
O
N
O N
a b
 
Figure 6.6 The carboxylic acid moiety (a) and the oxadiazole moiety (b) are bioisosteres due to the similar 
chemical and physical properties of the two groups of atoms 
  
Cathepsin B acts as both an endopeptidase and an exopeptidase.15  This dual property is 
largely due a unique structural feature of the enzyme referred to as the occluding loop (see 
Chapter One) located near the active site.  The occluding loop contains two positively 
charged His111 and His110 residues which can form hydrogen bonds with carboxylate 
anions (or bioisosteres of these).16,17  Two modes of binding of the carboxylic acids 2.7 
(see Figure 6.7) have been proposed but further molecular modelling is required to 
determine which occurs.  These investigations could be extended to include the acid 2.46 
and the oxadiazoles 2.41 and 2.50. 
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Figure 6.7 The two proposed modes of binding of the acid 2.7 to cathepsin B a) the carboxylic acid forms 
hydrogen bonds to the His110 and His111 of the occluding loop, effectively blocking the active site or b) the 
acid 2.7 with Val in the S1 subsite and Leu in the S1’ subsite with cleavage occurring at the indicated amide 
bond  
 
Notably, a literature search reveals an absence of potent cysteine protease inhibitors that 
incorporate a 1,2,4-oxadiazole warhead.  This suggests that 1,2,4-oxadiazole warheads 
have had limited success or have not been investigated as potent inhibitors of cysteine 
proteases.  Several patents18-20 have been filed regarding inhibitors with oxadiazole 
moieties as warheads for the use of cysteine protease inhibition; however, the inhibitors 
specified in these patents contain α-keto-1,3,4-oxadiazole warheads with P1’ substitution at 
the 2’ position of the oxadiazole (see Figure 6.8a) or α-keto-1,2,4-oxadiazole warheads18 
with substitution at the 3’ position of the oxadiazole (see Figure 6.8b).  The potency of the 
α-ketooxadiazole moiety appears due to it being an α-ketoamide bioisostere (the potency of 
α-ketoamides is discussed in Chapter Two). 
 
O N
N R
O
NN
R
3
2
OO
 
              a         b 
Figure 6.8 The structure of the oxadiazole warheads that have been included in patents for use as cysteine 
protease inhibitors a) α-keto-1,2,4-oxadiazoles, substituted at the 3 position and b) α-keto-1,3,4-oxadiazoles, 
substituted at the 2 position18  
 
As discussed above 1,2,4-oxadiazoles 2.41 and 2.50 are only weak cathepsin B inhibitors;  
however, a modification that could enhance the potency of these 1,2,4-oxadiazoles would 
be the insertion of a carbonyl group between the P1 Leu and the 1,2,4-oxadiazole, making 
the resulting inhibitors α-ketoamide bioisosteres rather than carboxylic acid bioisosteres.  
Palmer et al21 reported 6.5a-d as the first potent cathepsin K specific inhibitors that 
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incorporated an α-keto-1,3,4-oxadiazole warhead (see Table 6.4).  Palmer also showed that 
the nature of the oxadiazole substituent, especially its size and electronics was important 
for both potency and selectivity between cathepsins; these properties could be exploited for 
the design of potent specific inhibitors of the papain superfamily.    
 
F3CO
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6.5a-d 
 
 Ki (µM) 
 R Cathepsin K Cathepsin B Cathepsin L Cathepsin S 
 
6.5a 
 
0.029 73 19 45 
 
 
6.5b O
 
0.037 2.1 7.5 10 
 
 
6.5c CF3
 
0.054 1.1 1.4 3.3 
 
 
6.5d O
 
0.033 0.093 0.16 0.32 
 
 
Table 6.4 Literature examples of potent cathepsin K inhibitors with keto-1,3,4-oxadiazole warheads21 
 
 
6.2.4 α-Ketoheterocycles and Precursors 
 
α-Ketooxazolines and α-ketotetrazoles are thought to inhibit calpain by similar 
mechanisms. The carbonyl carbon adjacent to the ring in each case is δ+ and reacts with the 
δ
-
 active site cysteine thiol to form a thiohemiacetal.22  Binding to the active site is further 
enhanced by hydrogen bonds between the oxygen in the oxazoline ring (δ-) or the nitrogen 
in the tetrazole ring and the positively charged histidine residue of the catalytic triad (see 
Chapter Two for the hydrogen bonds suggested to form). 
 
The α-hydroxytetrazoles 2.53 and 2.54 are potent cathepsin B inhibitors (IC50 = 2.1 µM 
and 1.3 µM respectively) that have greater than 18-fold specificity for cathepsin B over the 
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other cysteine proteases tested (IC50 >25 µM; see Table 6.5).  The α-ketotetrazoles 2.43 
and 2.55 are selective inhibitors of papain (IC50 = 6.0 µM and 20 µM respectively); 
inhibition of calpain and cathepsin B was not observed at inhibitor concentrations of 50 
µM.  The α-hydroxytetrazole moiety appears to be a better fit within the active site of 
cathepsin B than the α-ketotetrazole moiety, as evidenced by the α-hydroxytetrazole 2.53 
(IC50 = 2.1 µM) being 24-fold more potent than the α-ketotetrazole 2.43 (IC50 = >50 µM); 
and α-hydroxytetrazole 2.54 (IC50 = 1.3 µM) 38-fold more potent than α-ketotetrazole 2.55 
(IC50 = >50 µM).  A suggestion for this difference in activity is that the α-
hydroxytetrazoles might be stabilised by the oxyanion hole of cathepsin B; however, 
further molecular modelling studies are required to confirm this.   
 
The α-ketotetrazole 2.43 (IC50 = 6.0 µM) is 8-fold more potent against papain than the 
corresponding α-hydroxytetrazole 2.53 (IC50 = 50 µM); while the α-ketotetrazole 2.55 
(IC50 = 20 µM) has similar potency to its corresponding α-hydroxytetrazole 2.54 (IC50 = 25 
µM).  These results suggest that the carbonyl oxygen of the α-ketotetrazole moiety is better 
positioned than the alcohol of the α-hydroxytetrazole for hydrogen bonding to the active 
site cleft.  The N-protecting group again plays an important role in binding of the inhibitor 
to the active site, with the 4-fluorobenzenesulfonyl N-protected α-ketotetrazole 2.43 being 
4-fold more potent than the corresponding benzyloxycarbonyl N-protected 2.53. 
 
There are few literature examples of potent cysteine protease inhibitors containing α-
ketotetrazole warheads.  Tao et al23 designed and evaluated a series of peptidyl α-
ketoheterocycles for the inhibition of µ-calpain that included the α-ketotetrazole 6.6 (see 
Figure 6.9); subsequent assay against µ-calpain showed it to be a weak inhibitor only 
(11% inhibition at a concentration of 10 µM).  The activity of α-ketotetrazole 6.6 was not 
reported against any other cysteine proteases, nor was its α-hydroxytetrazole precursor 
tested as a potential cysteine protease inhibitor.  The analogous α-ketotetrazole 2.55 (see 
Table 6.5), which differs only in the P2 residue (Val rather than Leu as in 6.6) shows a 
similar potency against µ-calpain (IC50 > 50 µM).  Thus the α-ketotetrazole moiety does 
not appear to inhibit calpains; α-hydroxytetrazoles could be used as the warhead for 
selective cathepsin B inhibitors and α-ketotetrazoles the warhead for papain selective 
inhibitors.      
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Figure 6.9 The α-ketotetrazole 6.6 designed for the inhibition of µ-calpain 
 
 
IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
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50 
 
>50 
 
1.3 
 
25 
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N
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>50 
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N
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27 
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26 
 
 
11 
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N
O O
O
N
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Compound IC50 (µM) 
  m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
 
2.58 
 
N
H
H
N
O O
O
NO
O
 
 
 
26 
 
 
>50 
 
 
29 
 
 
37 
 
Table 6.5 Inhibition constants for α-hydroxy and α-ketoheterocycles 
 
The α-hydroxyoxazolines 2.56 and 2.57 are broad spectrum cysteine protease inhibitors 
(IC50 = 27 µM, 21 µM (m-calpain); 50 µM; 50 µM (µ-calpain); 26 µM, 40 µM (cathepsin 
B) and 11 µM, 14 µM (papain) respectively) (see Table 6.5).  The α-ketooxazoline 2.58 
{IC50 = 26 µM (m-calpain); >50 µM (µ-calpain); 29 µM (cathepsin B) and 37 µM 
(papain)} is similarly potent to its corresponding α-hydroxyoxazoline 2.57.  The α-
ketooxazoline 2.42 {IC50 = 1.2 µM (m-calpain), 3.2 µM (µ-calpain), 0.20 µM (cathepsin 
B) and 1.2 µM (papain)}, however, is at least 12-fold more potent than its corresponding 
α-hydroxyoxazoline 2.56 across all cysteine proteases tested (see Table 6.5).  The N-
protecting group again plays a pivotal role in the potency of the inhibitors as the 4-
fluorobenzenesulfonyl N-protected α-ketooxazoline 2.42 is at least 15-fold more potent 
than the corresponding benzyloxycarbonyl N-protected α-ketooxazoline 2.58.  The 4-
fluorobenzenesulfonyl N-protecting group in conjunction with the α-ketooxazoline 
warhead thus provide the basis of potent and selective cathepsin B inhibition. 
 
The most potent cathepsin B inhibitor within the heterocyclic series is the α-ketooxazoline 
2.42 (IC50 = 0.20 µM), showing at least 6-fold selectivity for cathepsin B over the other 
cysteine proteases tested. 
 
 
6.2.5 Nitrogen-Containing Warheads 
 
The cyanohydrins 2.51 and 2.52 are potent broad spectrum cysteine protease inhibitors 
{IC50 = 0.34 µM, 0.34 µM (m-calpain); 0.55 µM, 1.2 µM (µ-calpain); 0.086 µM, 0.14 µM 
(cathepsin B) and 0.030 µM and 1.6 µM (papain)} (see Table 6.6).  Comparison of the 
cyanohydrins 2.51 and 2.52 with the corresponding parent aldehydes (2.3 and 2.19 
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respectively, refer to Table 6.1) shows that the cyanohydrins are approximately 3-fold less 
potent (over all enzymes assayed) than the aldehydes 2.3 and 2.19.   
 
IC50 (µM)   
Compound 
m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
 
2.51 
 
O2S
N
H
H
N
O
OH
F
CN
 
 
 
0.34 
 
 
0.55 
 
 
0.086 
 
 
0.030 
 
 
2.52 
 
N
H
H
N
O
OH
CN
O
O
 
 
 
0.34 
 
 
1.2 
 
 
0.14 
 
 
1.6 
 
 
2.60 
O2S
N
H
H
N
O
O
F
CN
O
 
 
 
7.5 
 
 
22 
 
 
0.35 
 
 
>50 
 
 
2.61 NH
H
N
O
O
CN
O
O
O
 
 
 
25 
 
 
50 
 
 
2.4 
 
 
>50 
 
Table 6.6 Inhibition constants of the nitriles synthesised against a range of proteases. 
 
The O-protected cyanohydrins 2.60 and 2.61 are at least 2.5-fold less active than the 
corresponding free cyanohydrins 2.51 and 2.52; however, the presence of a large aryl 
group capable of extending into the P’ subsites appears to be favourable for binding to 
cathepsin B.  This was evidenced by the assay results of the O-protected cyanohydrins 2.60 
and 2.61, which are potent cathepsin B inhibitors (IC50 = 0.35 µM and 2.5 µM 
respectively) that show more than 10-fold selectivity for cathepsin B over the other 
cysteine proteases tested.  Selectivity observed for cathepsin B is presumably due its wider 
active site cleft in comparison to that of calpain and papain (see Chapter One for 
diagrams) and possible stabilisation of the thioimidate-like intermediate through 
interactions with the oxyanion hole of cathepsin B. 
 
The cyanohydrin moiety appears to be an unprecedented warhead for the inhibition of 
cysteine proteases, as a literature search reveals few examples of cysteine protease 
Chapter Six – Synthesised Inhibitors: Assay Results and SAR  156 
inhibitors containing nitrogen based warheads.  Closely related peptidyl nitriles such as 6.7 
(see Figure 6.10) are potent cathepsin B inhibitors (IC50 = 0.0018 µM);16 although a 
comprehensive study of the specificity of peptidyl nitriles against proteases of the papain 
superfamily does not appear to have been performed to date. 
N
H
O
H
N
O
O
N
O
OH
6.7
IC50 = 0.0018 µM (cat B)
 
Figure 6.10 The peptidyl nitrile 6.7, a potent cathepsin B inhibitor 
 
 
6.2.6 Azide Inhibitor 
 
The azide 2.62 (see Table 6.7) is a weak cysteine protease inhibitor {IC50 >50 µM (m-
calpain); >50 µM (µ-calpain); 22 µM (cathepsin B) and 25 µM (papain)}.  The azide 
moiety is a non-covalent warhead which relies on hydrophobic interactions and hydrogen 
bonds between the inhibitor and the target protease to block the active site from the 
binding of substrate.5   
 
IC50 (µM)  
Compound m-calpain µ-calpain cathepsin 
B 
papain 
 
2.62 NH
H
N
O
N3
O2
S
F
 
 
>50 
 
>50 
 
22 
 
25 
 
2.6 
O2
S
F
N
H
H
N
O
OH
 
 
>50 
 
>50 
 
9.2 
 
>50 
 
Table 6.7 Potency of an azide against cysteine proteases 
 
The alcohol 2.6 is a direct analogue of the azide 2.62, the two inhibitors differing only at 
the ‘warhead’ position (an alcohol and azide group respectively, see Table 6.7).  Both the 
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azide 2.62 and the alcohol 2.6 are weak inhibitors of m-calpain, µ-calpain and papain (IC50 
>50 µM); however, the alcohol 2.6 (IC50 = 9.2 µM) is 4-fold more potent against cathepsin 
B than the azide 2.62.  Docking of the alcohol 2.6 and the azide 2.62 into the rigid µ-
calpain model suggests that both inhibitors adopt an extended β-strand (see Figure 6.11); 
however, the alcohol 2.6 is suggested to from an additional hydrogen bond between the 
alcohol oxygen group and Gly271; for the azide 2.61 this is a mismatched hydrogen bond 
and so is not observed.  Thus the increased inhibition of alcohol 2.6 in comparison with 
azide 2.62 against cathepsin B may be due to an additional hydrogen bond that affords 
greater stability of the alcohol 2.6 within the protease active site. 
  
 
Figure 6.11 Molecular modelling suggests the hydrogen bonds shown between the µ-calpain active site 
residues and azide 2.62 (top); between the µ-calpain active site residues and alcohol 2.6 (bottom)  
 
 
 
 
O2
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6.3 IRREVERSIBLE CYSTEINE PROTEASE INHIBITORS: 
ASSAY RESULTS AND DISCUSSION 
 
 
6.3.1 α,β-Unsaturated Carbonyl Inhibitors 
 
The α,β-unsaturated carbonyls 3.14-3.17 are weak inhibitors of m-calpain and µ-calpain 
(IC50 values greater than 47 µM; see Table 6.8); but are more potent against cathepsin B 
and papain {IC50 = 20 µM, 27 µM, 21 µM and 24 µM (cathepsin B) and 14 µM, 37 µM, 18 
µM and >50 µM (papain), respectively}.   
 
Michael acceptor warheads are characterised by a double bond that is activated by an 
electrophilic substituent.  The double bond of both 3.14 and 3.16 appears to be activated to 
a greater degree by the methyl ester substituent than that of 3.15 and 3.17 which are 
substituted with an ethyl ester group. This is reflected by the α,β-unsaturated methyl esters 
3.14 (IC50 = 14 µM) and 3.16 (IC50 = 18 µM) being approximately 3-fold more potent than 
the corresponding α,β-unsaturated ethyl esters 3.15 (IC50 = 37 µM) and 3.17 (IC50 >50 
µM).  The nature of the N-protecting group does not appear to be as important for binding 
affinity as it is for the alcohol and α-ketooxazoline series previously discussed (see Section 
6.2 for details) as the 4-fluorobenzenesulfonyl N-protected 3.14 and 3.15 have a similar 
potency to that of the benzyloxycarbonyl N-protected 3.16 and 3.17 against the cysteine 
proteases tested. 
 
The most potent inhibitor within this series is the α,β-unsaturated aldehyde 3.18  {IC50 = 
2.0 µM (m-calpain); 2.1 µM (µ-calpain), 0.13 µM (cathepsin B) and 1.6 µM (papain)}; 
which is at least 9-fold more potent than the α,β-unsaturated carbonyls 3.14-3.17 across all 
the cysteine proteases tested.  α,β-Unsaturated aldehyde 3.18 has a 12-fold selectivity for 
cathepsin B over the other cysteine proteases tested.  
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IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
  3.14 NH
H
N
O
CO2Me
O2
S
F
 
 
>50 
 
>50 
 
20 
 
14 
 
3.15 NH
H
N
O
CO2Et
O2
S
F
 
 
>50 
 
>50 
 
27 
 
37 
 
3.16 NH
H
N
O
O
O
CO2Me
 
 
47 
 
>50 
 
21 
 
18 
 
3.17 NH
H
N
O
O
O
CO2Et
 
 
>50 
 
>50 
 
24 
 
>50 
 
3.18 NH
H
N
O
O2
S
F
H
O
 
 
2.0 
 
2.1 
 
0.13 
 
1.6 
 
Table 6.8 Inhibition constants for α,β-unsaturated carbonyls 
 
The two most potent inhibitors within this series (3.18 and 3.14) were docked into the rigid 
µ-calpain model and the best poses shown in Figure 6.11.  The molecular modelling 
suggests that both the α,β-unsaturated aldehyde 3.18 and α,β-unsaturated ester 3.14 adopt a 
β-strand conformation, and have an additional hydrogen bond between the dienyl carbonyl 
oxygen group and His272 (see Figure 6.12).  Thus, the increased potency of α,β-unsaturated 
aldehyde 3.18, in comparison with the α,β-unsaturated carbonyls 3.14-3.17, is attributed to 
the reactive aldehyde moiety present in 3.18.  
 
   a)          b) 
Figure 6.12 Molecular modelling results of a) α,β-unsaturated aldehyde 3.18 and b) α,β-unsaturated ester 
3.14 showing the same proposed hydrogen bonding pattern 
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The α,β-unsaturated aldehyde 3.18 {IC50 = 2.0 µM (m-calpain); 2.1 µM (µ-calpain), 0.13 
µM (cathepsin B) and 1.6 µM (papain)}is less potent than its parent aldehyde 2.3 {IC50 = 
0.080 µM (m-calpain); 0.13 µM (µ-calpain); 0.022 µM (cathepsin B) and 0.023 µM 
(papain)}.  The reduced potency of the α,β-unsaturated aldehyde 3.18 in comparison with 
the aldehyde 2.3 is attributable to the reduced electrophilic nature of the double bond 
carbon of 3.18 (compared to the carbonyl carbon of 2.3).  The double bond carbon of the 
α,β-unsaturated aldehyde 3.18 forms an irreversible covalent bond to the active site 
cysteine thiol, and is activated for this reaction by the presence of the electrophilic 
aldehyde moiety.  In comparison, it is the aldehyde moiety of aldehyde 2.3 that directly 
reacts with the active site cysteine thiol to give a thiohemicacetal species.  
   
The α,β-unsaturated aldehyde 3.18 is a potent and specific inhibitor of cathepsin B (IC50 = 
0.13 µM, selectivity 12-fold). 
 
 
6.3.2 Vinyl Sulfone Inhibitors 
 
The vinyl sulfones 3.20-3.23 are more potent (by 2-fold) against cathepsin B (IC50 = 1.9 
µM, 5.9 µM, 21 µM and 27 µM respectively) than m-calpain (IC50 = 25 µM, >50 µM, >50 
µM and >50 µM respectively), µ-calpain (IC50 = 22 µM, >50 µM, >50 µM and >50 µM 
respectively) and papain (IC50 = 30 µM, 21 µM, >50 µM and >50 µM respectively; see 
Table 6.9).  The vinyl sulfones 3.20 and 3.21 are at least 5-fold more potent against 
cathepsin B than vinyl sulfones 3.22 and 3.23, suggesting that the 4-
fluorobenezenesulfonyl N-protecting group is favoured over the benzyloxycarbonyl (see 
Sections 6.2 and 6.3.1 for more examples that show the same trend). 
 
Vinyl sulfone 3.20 (IC50 = 1.9 µM, selectivity 11-fold) is the most potent cathepsin B 
within this series.  
  
Leu appears to be favoured over Phe in the S1 pocket of cathepsin B.  This is supported by 
the Val-Leu vinyl sulfones 3.20 and 3.22 being 1.5-fold and 3-fold more potent than the 
corresponding Val-Phe vinyl sulfones 3.21 and 3.23 respectively and is the reverse of that 
observed within the alcohol series (see Section 6.2.1) where Val-Phe alcohol 2.26 (IC50 = 
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0.075 µM) was 120-fold more favourable for cathepsin B than the Val-Leu alcohol 2.6 
(IC50 = 9.2 µM).  These results suggest that potent non-covalent inhibition of cathepsin B 
requires the hydrophobic interactions and hydrogen bonds between the P2 and P1 residues 
and the S2 and S1 pockets to be optimised. Potent covalent inhibition of cathepsin B 
(whether reversible or irreversible), however, is more dependent on the warhead being in 
close enough proximity to react with the active site cysteine thiol; although the amino acid 
residues must still be those favourable for binding affinity to cathepsin B 
  
IC50 (µM)  
Compound m-
calpain 
µ-
calpain 
cathepsin 
B 
papain 
 
3.20 NH
H
N
O
SO2Me
O2
S
F
 
 
25 
 
22 
 
1.9 
 
30 
 
3.21 NH
H
N
O
SO2Me
O2S
F
 
 
>50 
 
>50 
 
5.9 
 
21 
 
3.22 NH
H
N
O
O
O
SO2Me
 
 
>50 
 
>50 
 
21 
 
>50 
 
3.23 NH
H
N
O
O
O
SO2Me
 
 
>50 
 
>50 
 
27 
 
>50 
 
Table 6.9 Inhibition constants for vinyl sulfones synthesised; comparison to parent aldehydes. 
 
The vinyl sulfones 3.20 and 3.21 (with IC50 = 1.9 µM and 21 µM against cathepsin B 
respectively, see Table 6.9) are more potent than the α,β-unsaturated carbonyls 3.14-3.17 
(IC50 >20 µM against cathepsin B, see Table 6.8).  This increased potency is attributable to 
a sulfone being more electrophilic than an ester; thus a sulfone group will activate the 
double bond carbon for the formation of a covalent bond with the active site cysteine thiol 
to a greater degree than an ester group. 
 
Vinyl sulfone warheads have previously been incorporated into cysteine protease 
inhibitors.  Gotz24 and co-workers synthesised a range of allyl and vinyl sulfones 6.8a-c 
(see Table 6.10) and assayed these against µ-calpain, papain and cathepsin B.  The allyl 
sulfone 6.8b was over 5-fold more potent than the corresponding vinyl sulfone 6.8c.  
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Interestingly, inhibition of cathepsin B was not observed in Gotz’s study.24 By comparison 
the vinyl sulfone inhibitors 3.20-3.23 synthesised in this thesis are selective cathepsin B 
inhibitors, suggesting that the nature of the P1’ substituent of the sulfone moiety (for 3.20-
3.23 this is a methyl group; for 6.8a-c it was a phenyl group) can affect the selectivity of 
the inhibitor.   
 
 
Ki (M-1s-1) 
 
Compound 
µ-calpain papain cathepsin B 
 
 
6.8a 
 
O N
H
O H
N
O
O2
S
 
 
 
3 
 
 
 
9 
 
 
- 
 
6.8b 
O N
H
O H
N
O
O2
S
 
 
23 
 
49 
 
- 
 
6.8c 
O N
H
O H
N
O
O2
S
 
 
550 
 
10 
 
- 
 
Table 6.10 Allyl and vinyl sulfones reported to inhibit cysteine proteases24 
 
 
6.3.3 Diazoketone Inhibitors 
 
Diazoketones 3.25 and 3.26 (see Table 6.11) are potent inhibitors of cathepsin B (with 
IC50 = 1.1 µM and 0.23 µM respectively); but are less potent against m-calpain (IC50 = >50 
µM and 11 µM); µ-calpain (IC50 >50 µM and 21 µM); and papain (IC50 = 28 µM and 13 
µM).  
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IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
 3.25 
O2
S
N
H
H
N
O
O
N2
F
 
 
>50 
 
>50 
 
 
1.1 
 
28 
 
3.26 NH
H
N
O
O
N2O
O
 
 
11 
 
21 
 
0.23 
 
13 
 
Table 6.11 Inhibition constants of the diazoketones 3.11 and 3.12 
 
The benzyloxycarbonyl N-protected diazoketone 3.26 is at least 2-fold more potent than 
the corresponding 4-fluorobenzenesulfonyl N-protected diazoketone 3.25 across all of the 
cysteine proteases tested (see Table 6.11).  This differs from the previous observation that 
the 4-fluorobenzenesulfonyl moiety is favoured over the benzyloxycarbonyl group (see 
previous Sections 6.2.1-6.3.2).  Subsequent docking of the diazoketones 3.25 and 3.26 into 
the rigid µ-calpain model (see Figure 6.13) suggests that the benzyloxycarbonyl moiety is 
in a more extended conformation than the 4-fluorobenzenesulfonyl moiety, thus it may be 
a better fit within the active site of the proteases.  This could account for the increased 
potency of the benzyloxycarbonyl protected 3.26 in comparison with 3.25. 
 
 
       a)      b) 
Figure 6.13 Molecular modelling results of a) diazoketone 3.25 and b) diazoketone 3.26 with the suggesting 
hydrogen bond pattern shown. 
 
Compounds containing diazoketone warheads are reported in the literature as potent 
inhibitors of papain and the cathepsins B and L;17 however, to date this type of inhibitor 
has not been tested for selectivity between cysteine proteases of the papain superfamily.  
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The results presented in Table 6.11 show that the diazoketones 3.25 and 3.26 are both 
potent and selective cathepsin B inhibitors (IC50 = 1.1 µM, selectivity 25-fold; and 0.23 
µM, selectivity 48-fold respectively).  
 
 
6.3.4 α-Bromomethyl Ketone Inhibitors and Precursors   
 
The α-bromomethyl ketones 3.28 and 3.29 are potent cathepsin B inhibitors (IC50 = 0.025 
µM and 0.077 µM respectively; see Table 6.12); but are less potent against m-calpain 
(IC50 = >50 µM and 29 µM respectively) and µ-calpain (IC50 = 33 µM and 36 µM 
respectively) papain (IC50 = 0.40 µM and 0.18 µM respectively).  The 4-
fluorobenezenesulfonyl N-protected 3.28 is 3-fold more potent than the benzyloxycarbonyl 
N-protected 3.29, suggesting that the 4-fluorobenezenesulfonyl moiety has better binding 
affinity to the active site cleft than the benzyloxycarbonyl (see Section 6.2 for further 
examples). 
  
The enantiomerically pure‡ α-bromomethyl 3R-alcohols§ 3.30 and 3.31 inhibit the cysteine 
proteases tested as follows: IC50 = 30 µM and >50 µM (m-calpain); 23 µM and >50 µM 
(µ-calpain); 9.9 µM and 9.8 µM (cathepsin B); and 15 µM and 50 µM (papain) 
respectively (see Table 6.12).  The diastereomeric α-bromomethyl 3-S/R-alcohols 3.32 and 
3.33 inhibit the cysteine proteases tested as follows: IC50 = 31 µM and >50 µM (m-
calpain); 27 µM and 27 µM (µ-calpain); 0.76 µM and 0.39 µM (cathepsin B); and 7.1 µM 
and 1.2 µM (papain) respectively (see Table 6.12).   
 
The α-bromomethyl ketones 3.28 and 3.29 are over 30-fold more potent than the α-
bromomethyl alcohols 3.30-3.33.  This is attributed to the carbonyl carbon of the ketone 
being more electrophilic than the β-carbon of the alcohol, thus the formation of a covalent 
bond with the cysteinyl thiol is more likely to occur.    
 
 
 
                                                 
‡
 A discussion of the absolute configuration of the α-bromomethyl alcohols 3.30-3.33 can be found in 
Chapter Three 
§
 Where 3R denotes the third carbon stereocentre, counting in the P3 to P1’ direction 
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IC50 (µM)  
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
 
3.28 
O2
S
N
H
H
N
O
O
Br
F
 
 
>50 
 
33 
 
0.025 
 
0.40 
 
3.30 
O2S
N
H
H
N
O
OH
Br
F
 
 
30 
 
23 
 
9.9 
 
15 
 
3.32 
O2S
N
H
H
N
O
OH
Br
F
 
 
31 
 
27 
 
0.76 
 
7.1 
 
3.29 NH
H
N
O
O
Br
O
O
 
 
29 
 
36 
 
0.077 
 
0.18 
 
3.31 NH
H
N
O
OH
BrO
O
 
 
>50 
 
>50 
 
 
9.8 
 
>50 
 
 
3.33 NH
H
N
O
OH
BrO
O
 
 
>50 
 
27 
 
0.39 
 
1.2 
 
   Table 6.12 Assay results for α-bromomethyl ketones and alcohols 
 
The absolute configuration of the alcohol group at C3 is important for binding affinity to 
cysteine proteases; this is evidenced by the diastereomeric 3-R/S-alcohols 3.32 and 3.33 
(IC50 = 0.76 and 0.39 µM respectively) being 13-fold and 25-fold more potent than the 
enantiomerically pure 3R-alcohols 3.30 and 3.31 (IC50 = 9.9 and 9.8 µM respectively).  
Separate docking of the two diastereoisomers (1S,2S,3R and 1S,2S,3S) of α-bromomethyl 
alcohol 3.32 (see Figure 6.14) into the rigid µ-calpain model suggests that the 3S-alcohol 
forms only two of the three hydrogen bonds required for a β-sheet conformation (hydrogen 
bonds A and B), plus another hydrogen bond between the 3S-alcohol oxygen group and 
Cys115.  The 3R-alcohol is suggested to adopt a β-sheet conformation and also form 
additional hydrogen bonds between the sulfonamide oxygen group and Ser251 and the 3R-
alcohol oxygen group and Gly113.  The assay results (see Table 6.12) and the predicted 
hydrogen bonding pattern suggest that the 3S-alcohol would be more potent against 
cathepsin B than the 3R-alcohol and further supports the hypothesis that cysteine proteases 
bind substrates in an extended β-strand conformation.  
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    a)             b) 
Figure 6.14 Comparison of the purported hydrogen bond pattern between a) α-bromomethyl C3-R-alcohol 
3.32 and b) α-bromomethyl C3-S-alcohol 3.32 
 
 
6.3.5 Epoxide Inhibitors 
 
The epoxides 3.27, 3.34-3.36 are significantly more potent against cathepsin B (IC50 = 12 
µM, 0.49 µM, 19 µM and 5.7 µM respectively) compared to m-calpain, µ-calpain and 
papain (all IC50 values >50 µM; see Table 6.13).  The 3R-epoxides** 3.27 and 3.34 (IC50 = 
12 µM and 0.49 µM) are 1.5-fold and 11-fold more potent than the corresponding 
diastereomeric 3-R/S-epoxides 3.35 and 3.36 (IC50 = 19 µM and 5.7 µM respectively). 
 
Like the α-bromomethyl alcohol series (see Section 6.3.4), where the absolute 
configuration of the 3C-alcohol was important for binding affinity, the absolute 
configuration of the 3C-epoxide is also important for binding affinity.  The 3R-epoxides 
3.27 and 3.34 (IC50 = 12 µM and 0.49 µM respectively) are 2-fold and 116-fold more 
potent than the corresponding diastereomeric 3-S/R-mixed epoxides 3.35 and 3.36 (IC50 = 
19 µM and 5.7 µM respectively).  Molecular modelling suggests this difference in potency 
is attributable to the 3S-epoxide adopting the β-strand conformation required for binding to 
                                                 
**
 The absolute configuration of the peptidyl epoxides 3.33-3.36 is based on that of the α-bromomethyl 
alcohol used in its preparation.  A discussion of this can be found in Chapter Three 
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cysteine proteases; while the 3R-epoxide only forms hydrogen bonds A and C of the three 
(A, B and C) hydrogen bonds that define a β-strand conformation (refer back to Chapter 
Three, Section 3.3.2). 
   
The epoxides 3.34 and 3.36 are more potent (by 25-fold and 3-fold respectively) against 
cathepsin B than the corresponding epoxides 3.27 and 3.35, suggesting that the 
benzyloxycarbonyl N-protecting group is a better fit within the active site cleft of cathepsin 
B than the 4-fluorobenzenesulfonyl moiety (this agrees with the results observed earlier for 
the diazoketones 3.25 and 3.26; see Section 6.3.3). 
 
IC50 (µM)  
Compound m-
calpain 
µ-calpain cathepsin 
B 
papain 
 
3.27 
O2S
N
H
H
N
O
F
O
 
 
>50 
 
>50 
 
12 
 
>50 
 
3.34 NH
H
N
O
O
O O
 
 
>50 
 
>50 
 
0.49 
 
>50 
 
3.35 
O2S
N
H
H
N
O
F
O
 
 
50 
 
>50 
 
19 
 
>50 
 
3.36 NH
H
N
O
O
O O
 
 
>50 
 
>50 
 
5.7 
 
>50 
 
Table 6.13 Assay results for the amino epoxides 3.27, 3.34-3.36 
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6.4 β-STRAND CONSTRAINED INHIBITORS: ASSAY 
RESULTS AND DISCUSSION 
 
 
Proteases (including cysteine, serine, aspartic and metallo proteases) are known to 
recognise and bind substrates in an extended β-strand conformation, with over 99% of 
known substrates and inhibitors binding in such a manner25 (see Chapter Four for more 
details).   
 
Acyclic peptidyl inhibitors, while being able to adopt a β-strand conformation, are 
conformationally flexible and exist as random conformations in aqueous solution.26  
Inhibitors that are in a fixed β-strand conformation are thought to have increased binding 
affinity to protease active sites in comparison to flexible inhibitors.27  One method of 
fixing or constraining protease inhibitors into a β-strand conformation is by restricting 
flexibility through cyclisation of the peptidyl backbone of the inhibitor.  Macrocyclic 
protease inhibitors†† are thus of increasing interest due to having a rigid β-strand 
conformation and showing increased resistance to degradation over acyclic protease 
inhibitors (see Chapter Four for an example). 
 
Macrocycles have been described28 as “excellent mimics of the β-strand required for 
binding to aspartic, serine and metallo proteases… but have yet to be described for 
cysteine proteases.”  A literature search confirms that macrocyclic inhibitors have been 
designed for the inhibition of serine and aspartic acid proteases (particularly the Hepatitis 
C Virus (HCV)29 and Human Immunodeficiency Virus (HIV-1) protease30; see Figure 
6.15 for representative inhibitors) but no examples of macrocyclic compounds for the 
inhibition of cysteine proteases were found.   
 
                                                 
††
 Where the term macrocycle refers to a ring size of 7 atoms or larger; generally macrocycles are synthesised 
utilizing ring-closing metathesis (see Chapter Four) 
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   a)      b)  
Figure 6.15 Two β-strand constrained inhibitors: a) macrocycle 6.9 a potent inhibitor of HCV and b) 
macrocycle 6.10, a potent inhibitor of HIV-1 protease  
 
The macrocyclic inhibitors: alcohol 4.3, aldehyde 4.4, methyl ester 4.13, aldehyde 4.14, 
semicarbazone 4.15, cyanohydrin 4.16 and azide 4.19 (see Figure 6.15) all of which adopt 
a β-strand conformation,‡‡ are unprecedented examples of cysteine protease inhibitors. 
   
N
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H
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O
N
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4.3 R = Val, X = CH2OH
4.4 R = Val, X = CHO
4.13 R = Val, X = CO2Me
4.14 R = Leu, X = CHO
4.15 R = Leu, X = CH=NNHC(O)NH2
4.16 R = Leu, X = CH(OH)CN
4.19 R = Leu, X = CH2N3
 
Figure 6.15 The macrocyclic inhibitors synthesised in this thesis are unprecedented cysteine protease 
inhibitors 
    
 
6.4.1 Macrocyclic Aldehydes and Precursors 
 
The macrocyclic ester 4.13, alcohol 4.3 and aldehydes 4.4 and 4.14 were assayed for 
activity against m-calpain, µ-calpain, cathepsin B and papain in order to determine the 
effect of the macrocyclic constraint on cysteine protease inhibition.  The macrocyclic 
inhibitors 4.13, 4.3, 4.4 and 4.14 are also compared with the closely related acyclic 
                                                 
‡‡
 For a discussion of how a β-strand conformation is determined see Chapter Four 
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analogues 2.45, 2.29 and 2.19 to determine relationships between potency and selectivity 
of the macrocyclic and acyclic series. 
 
The macrocyclic aldehydes 4.4 and 4.14 are broad spectrum cysteine protease inhibitors 
{IC50 = 0.24 µM and 0.03 µM (m-calpain); 2.7 µM and 0.22 µM (µ-calpain); 0.23 µM and 
0.070 µM (cathepsin B) and 0.61 µM and >50 µM (papain)}.  This lack of specificity is 
similar to that observed for the acyclic aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 and 2.22 (see 
Section 6.2.1).  The similar potency of the macrocyclic and acyclic aldehydes suggests that 
the presence of a highly reactive warhead (such as an aldehyde) is the determining factor 
of potency rather than the conformation of the inhibitor backbone. 
 
The P2-Leu macrocyclic aldehyde 4.14 is at least 3-fold more potent than the P2-Val 
containing aldehyde 4.4 against m-calpain, µ-calpain and cathepsin B which suggests that 
Leu is favoured over Val in the S2 pocket for these three cysteine proteases.  Iqbal31 
reported that µ-calpain possesses a strict requirement for Leu in the S2 pocket; this is 
supported by the macrocyclic aldehyde 4.14 (IC50 = 0.22 µM) being 12-fold more potent 
than macrocyclic aldehyde 4.4 (IC50 = 2.7 µM) against µ-calpain. 
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IC50 (µM)  
Compound m-
calpain 
µ-
calpain 
cathepsin 
B 
Papain 
 
 
 
4.13 NH
H
N
O
O
O
N
H
O
O
OMe
O
 
 
 
>50 
 
 
>50 
 
 
16 
 
 
>50 
 
 
 
4.3 
 
N
H
H
N
O
O
O
N
H
O
O
OH
 
 
 
 
1.6 
 
 
 
5.2 
 
 
 
19 
 
 
 
28 
 
 
 
4.4 
 
N
H
H
N
O
O
O
N
H
O
O
H
O
 
 
 
 
0.24 
 
 
 
2.7 
 
 
 
0.23 
 
 
 
0.61 
 
 
 
4.14 
N
H
H
N
O
O
O
N
H
O
O
H
O
 
 
0.03 
 
0.22 
 
0.070 
 
>50 
 
Table 6.14 Assay results of a macrocyclic alcohol and aldehyde. 
 
Comparison of the acyclic and macrocyclic methyl esters (2.45 and 4.13) and alcohols (2.6 
and 4.3) (see following discussion) provides more insight into the effect of β-strand 
constraint as the methyl ester is less reactive than the aldehyde warhead and the alcohol is 
a non-covalent ‘warhead’; therefore hydrophobic interactions and hydrogen bonds between 
the active site cleft and the inhibitor backbone become the important determining factors of 
binding affinity to the protease and thus potency of the inhibitor (see Section 6.3.2 for 
more evidence).      
 
The macrocyclic ester 4.13 is more potent (by 3-fold) against cathepsin B (IC50 = 16 µM) 
than against m-calpain (IC50 = >50 µM); µ-calpain (IC50 >50 µM) and papain (IC50 >50 
µM).  These results are similar to those observed for the acyclic ester 2.45, which is also a 
selective inhibitor of cathepsin B (IC50 = 19 µM, selectivity 3-fold; see Table 6.3).  The 
1.2-fold increase in potency of the macrocyclic ester 4.13 compared to the acyclic ester 
2.45 suggests that constraining the inhibitor into a β-strand conformation does improve 
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binding affinity to the active site of cathepsin B and this is reflected in an increased 
potency against cathepsin B. 
   
The macrocyclic alcohol 4.3 {IC50: 1.6 µM (m-calpain), 5.2 µM (µ-calpain), 19 µM 
(cathepsin B), 28 µM (papain)} is over 2-fold more potent than the acyclic alcohol 2.29 
{IC50: >50 µM (m-calpain), >50 µM (µ-calpain), 26 µM (cathepsin B), >50 µM (papain)} 
which again suggests that the conformational constraint of the macrocyclic inhibitors 
increases binding affinity to the cysteine proteases tested (see Table 6.14 and Table 6.1). 
  
The alcohol 4.3 and the aldehydes 4.4 and 4.14 are selective for m-calpain over µ-calpain 
(3-fold, 11-fold and 7-fold respectively).  Selectivity between m-calpain and µ-calpain will 
be discussed in the following Section 6.5. 
 
 
6.4.2 Macrocyclic Warhead Derivatives 
 
Section 6.4.1 establishes β-strand constrained non-covalent cysteine protease inhibitors as 
being more potent than the acyclic analogues (this increase in potency is assumed to be due 
to better binding affinity within the active site of the proteases); however, the macrocyclic 
aldehydes 4.4 and 4.14 had potency similar to that of the acyclic aldehyde series (see 
above).  The macrocyclic inhibitors 4.15, 4.16 and 4.19 (see Table 6.15) were assayed 
against m-calpain, µ-calpain, cathepsin B and papain to further determine the effect β-
strand constraint has on warhead potency and selectivity in comparison with acyclic 
analogues (see Sections 6.2 and 6.3).  Four warheads utilised in the acyclic series (see 
Chapters Two and Three) were chosen as warheads for macrocyclic inhibitors: the 
semicarbazone, cyanohydrin, α-ketotetrazole and azide moieties; the rationale for each of 
these choices being the following: 
  
Semicarbazone warhead: The acyclic semicarbazone series 2.37-2.40 are broad spectrum 
cysteine protease inhibitors (IC50 values < 4.8 µM; see Section 6.2.2); the semicarbazone 
warhead of 2.37 was chosen as it gave the highest yield of product in the acyclic series (see 
Chapter Two) and its solubility was compatible with that of the macrocycle 4.14.   
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Cyanohydrin Warhead: acyclic cyanohydrins 2.60 and 2.61 are also broad spectrum 
cysteine protease inhibitors (IC50 < 1.2 µM), further the cyanohydrin is the intermediate in 
the formation of the α-ketotetrazole and α-ketooxazoline warheads; thus the cyanohydrin 
of 4.14 was synthesised. 
   
α-Ketotetrazole Warhead: the acyclic α-ketotetrazoles 2.43 and 2.55 were selective 
inhibitor of papain (IC50 = 6.0 µM and 20 µM); the α-ketotetrazole moiety was chosen for 
use as a macrocyclic warhead in order to determine the effect of β-strand constraint on 
selectivity.  The limited solubility of the macrocycle 4.14 was also considered; the reaction 
conditions for synthesis of α-ketooxazoline rings (see Chapter Two) were not compatible 
with the solubility of the macrocycle.   
 
Non-covalent Azide: The azide moiety was chosen for application to a macrocycle because 
of the increased potency of the non-covalent macrocycles 4.13 and 4.3 in comparison with 
the acyclic analogues 2.45 and 2.29 (see above Section 6.4.1).  It was thought that 
constraint of the backbone into a β-strand would increase the potency against cysteine 
proteases.   
 
These four moieties (semicarbazone, cyanohydrin, α-ketotetrazole and azide) were utilised 
as warheads on the macrocycle 4.14§§ as it is more potent than the macrocycle 4.4 and is 
currently being trialled as a topical drug for the treatment of cataract. 
 
 
 
 
 
 
 
 
 
 
                                                 
§§
 See Chapter Four for further rationale behind the used of macrocycle 4.14 for the application of various 
warheads 
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IC50 (µM)   
Compound m-
calpain 
µ- 
calpain 
cathepsin 
B 
papain 
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O
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N
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O
 
 
 
 
0.16 
 
 
 
1.3 
 
 
 
3.7 
 
 
 
2.0 
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O
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O
O
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8.9 
 
35 
 
 
 
2.4 
 
12 
 
4.19 
N
H
H
N
O
O
O
N
H
O
O
N3
 
 
>50 
 
>50 
 
>50 
 
>50 
 
Table 6.15 Potency of macrocycles with a variety of warheads. 
 
The macrocyclic semicarbazone 4.15 is a potent cysteine protease inhibitor {IC50: 0.16 µM 
(m-calpain), 1.3 µM (µ-calpain), 3.7 µM (cathepsin B), 2.0 µM (papain); see Table 6.15}.  
Similarly, the acyclic semicarbazone 2.37 is also a broad spectrum cysteine protease {IC50: 
1.5 µM (m-calpain), 1.1 µM (µ-calpain), 0.69 µM (cathepsin B), 0.92 µM (papain) 
 
The macrocyclic semicarbazone 4.15 is 9-fold more potent against m-calpain than its 
acyclic analogue 2.37; has a similar potency against µ-calpain (IC50 = 1.3 µM) in 
comparison with the acyclic semicarbazone 2.37 (IC50 = 1.1 µM); and is less potent against 
cathepsin B and papain (by 2- to 5-fold) than the acyclic semicarbazone 2.37.  These 
observations suggest that m-calpain has a much more stringent requirement for a β-strand 
conformation than µ-calpain, cathepsin B and papain; this is attributable to the narrow 
active site cleft of m-calpain (in comparison with that of cathepsin B and papain; see 
Chapter One).  A rigid β-strand appears to be a promising conformation for the design of 
inhibitors selective for m-calpain. 
 
The macrocyclic cyanohydrin 4.16 is a more potent inhibitor of cathepsin B (IC50 = 2.4 
µM) than of m-calpain (IC50 = 8.9 µM); µ-calpain (IC50 = 35 µM) and papain (IC50 = 12 
µM).  The acyclic cyanohydrin analogue 2.52 is more potent than the macrocyclic 
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cyanohydrin 4.16 {IC50 = 0.34 µM (m-calpain); 1.2 µM (µ-calpain); cathepsin B (IC50 = 
0.14 µM) and 1.6 µM (papain); see Table 6.6}.  A proposed explanation of the reduced 
potency of the macrocyclic cyanohydrin 4.16 in comparison to the acyclic cyanohydrin 
2.52 is attributed to the increased length of the macrocyclic cyanohydrin (tripeptide 
backbone) in comparison with the acyclic cyanohydrin (dipeptide backbone).  The 
insertion of an amino acid into the backbone means the alcohol group of the macrocyclic 
cyanohydrin may no longer be in close proximity to the oxyanion hole (see Chapter One 
for detail) of the cysteine proteases (m-calpain, µ-calpain, cathepsin B and papain), thus 
hydrogen bonds between the oxygen of the secondary alcohol group and the oxyanion hole 
cannot form; the acyclic cyanohydrin 2.51, which is proposed to form hydrogen bonds to 
the oxyanion hole, is more stabilised within the active site of the proteases than the 
macrocyclic 4.16.   
 
Several failed attempts were made to synthesise the macrocyclic α-ketotetrazole 4.18 (see 
Figure 6.16 and Chapter Four).  Synthesis of the macrocyclic α-ketotetrazole 4.18 for 
this thesis was abandoned due to time constraints; future work will include the examination 
of suitable reaction conditions for the successful synthesis of this macrocyclic α-
ketotetrazole. 
 
N
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O
N
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O
O
O
N
N
NHN
4.18
 
Figure 6.16 The proposed macrocyclic α-ketotetrazole 4.18; synthesis was abandoned 
 
Azide 4.19 is a weak cysteine protease inhibitor (IC50 > 50 µM for all cysteine proteases 
tested; see Table 6.15).  Comparison of the macrocyclic azide 4.19 with the acyclic 
analogue 2.62 shows a similar trend of low potency (refer to Table 6.7).  It was envisaged 
that the application of the azide moiety to the constrained β-strand conformation of the 
macrocycle would result in improved inhibition against cysteine proteases of the papain 
superfamily; however, this was not the case, as seen by the lack of inhibition against m-
calpain, µ-calpain, cathepsin B and papain.  A suggestion for this lack of activity is that the 
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orientation of the azide moiety precludes any interaction with the oxyanion hole of the 
proteases and is thus not stabilised within the active site cleft. 
 
The β-strand constrained macrocycles 4.3, 4.4, 4.13-4.16 and 4.19 are unprecedented 
examples of cysteine protease inhibitors.  The macrocyclic semicarbazone 4.15 is a potent 
and selective inhibitors of m-calpain (IC50 = 0.16 µM, selectivity 8-fold);  the macrocyclic 
cyanohydrin 4.16 is a potent and selective inhibitor of cathepsin B (IC50 = 2.4 µM, 
selectivity 4-fold). 
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6.5 SELECTIVITY BETWEEN m-CALPAIN AND  
µ-CALPAIN 
 
Structural features of m-calpain and µ-calpain that have been reported to date are 
remarkably similar.  Both m-calpain and µ-calpain are polypeptides made up of a large 
subunit (around 80 kDa) and a small subunit (around 30 kDa); other properties include 
cellular distribution and the requirement of calcium for activation (see Table 6.16 for a 
summary).32  The one difference that has been clearly identified between m- and µ-calpain 
is the level of calcium required for activation (mM and µM respectively), but structural 
evidence for this difference has so far eluded researchers.33   
 
 
Structural Feature 
 
 
m-calpain 
 
µ-calpain 
 
Size of large subunit 
 
80 kDa 
 
80 kDa 
Size of small subunit 30 kDa 30 kDa 
Ca2+ level required for activation 400-800 µM 3-50 µM 
Optimum pH 7.2-8.2 7.2-8.2 
Occurrence Mammals and plants Mammals and plants 
Distribution Intracellular Intracellular 
 
 
Table 6.16 Known properties and structural features m-calpain and µ-calpain32 
 
The physiological roles of m-calpain and µ-calpain appear to be identical (see Chapter 
One for a detailed discussion) and m-calpain and µ-calpain have similar subsite 
specificities, thus it is assumed that these two calpains have virtually identical overall 
structures.34,35  This implies that the structure of the active sites of m-calpain and µ-calpain 
are also very similar; however, if this were the case, compounds that are designed as potent 
m-calpain inhibitors should show similar potency against µ-calpain (and vice versa).   
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Within this thesis, however, 11 inhibitors are observed to be selective*** for m-calpain over 
µ-calpain (see Table 6.17).  The potency and selectivity of these inhibitors for m-calpain 
are as follows: aldehyde 2.3 (IC50 = 0.080 µM, selectivity 2-fold); aldehyde 2.19 (IC50 = 
0.15 µM, selectivity 3-fold); aldehyde 2.21 (IC50 = 0.32 µM, selectivity 2-fold); aldehyde 
2.22 (IC50 = 0.25 µM, selectivity 4-fold); semicarbazone 2.37 (IC50 = 1.5 µM, selectivity 8-
fold); cyanohydrin 2.51 (IC50 = 7.5 µM, selectivity 3-fold); diazoketone 3.26 (IC50 = 11 
µM, selectivity 2-fold); macrocyclic alcohol 4.3 (IC50 = 1.6 µM, selectivity 3-fold); 
macrocyclic aldehyde 4.4 (IC50 = 0.24 µM, selectivity 11-fold); aldehyde 4.14 (IC50 = 0.03 
µM, selectivity 7-fold) and macrocyclic semicarbazone 4.16 (IC50 = 1.6 µM, selectivity 8-
fold).  Additionally, over 90% of the inhibitors assayed have at least a 1.2-fold difference 
in potency against m-calpain and µ-calpain (see Tables 6.1-6.20). 
 
 
IC50 (µM) 
 
Compound 
m-calpain µ-calpain 
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1.5 
 
 
11 
 
 
8 
 
 
 
 
   
                                                 
***
 Where the term selective refers to  a difference in potency of at least 2-fold 
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Compound 
 
IC50 (µM) 
m-calpain       µ-calpain 
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N
H
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O
N
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O
N
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N
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0.16 
 
1.3 
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Table 6.17 Synthesised inhibitors that show selectivity for m-calpain over µ-calpain 
 
Only two inhibitors, the aldehydes 2.27 and 2.2 show selectivity for µ-calpain over m-
calpain (by 6-fold and 2-fold respectively) as shown in Table 6.18 below.  Both of the 
aldehydes 2.27 and 2.2 contain the dipeptide Val-Phe; the acyclic inhibitors that are 
selective for m-calpain over µ-calpain all contain the dipeptide Val-Leu (see Table 6.17), 
thus indicating that the S1 pocket of µ-calpain may be larger and more hydrophobic than 
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that of m-calpain.  The dipeptide Val-Phe thus provides a basis for the design of specific µ-
calpain inhibitors. 
 
 
Compound 
 
IC50 (µM) 
    m-calpain           µ-calpain 
 
Selectivity 
Ratio (µ/m) 
 
 
2.27 
O2
S
F
N
H
H
N
O
H
O
 
 
0.072 
 
0.012 
 
6 
 
2.2 O N
H
O H
N
O
H
O
 
 
0.060 
 
0.027 
 
2 
 
Table 6.18 The two synthesised inhibitors that show selectivity for µ-calpain over m-calpain 
 
The overwhelming number of inhibitors within this thesis that show selectivity between the 
calpains suggest that a structural difference between the active sites of m-calpain and µ-
calpain does exist; numerous journal articles also present assay data for inhibitors that are 
selective between  m-calpain and µ-calpain, further strengthening this argument.7,36,37  One 
example is that of the literature aldehyde 2.37 (see Figure 6.17) which is reported as being 
10-fold more potent against µ-calpain (IC50 = 0.008 µM) than m-calpain (IC50 = 0.080 
µM).  As a note: the assays utilised within thesis are based on a fluorogenic substrate (see 
Chapter Five for details); the majority of IC50 values reported in the literature were 
obtained using colorimetric assays that have been shown to be less sensitive than 
fluorogenic assays;38 hence an absolute comparison of the IC50 values obtained herein with 
those found in the literature must be undertaken with caution because of the dependency of 
the results on the conditions used.  The literature aldehyde 2.3 was thus used as a reference 
compound in the validation of the assay protocols (see Chapter Five).   
O2
S
F
N
H
H
N
O
H
O
2.3
IC50 = 0.080 µM (m-calpain)
IC50 = 0.008 µM (µ-calpain)
 
Figure 6.17 The literature IC50 values of aldehyde 2.3 show a 10-fold selectivity for µ-calpain 
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The results presented in Tables 6.17 and 6.18 thus suggest that a structural difference 
exists between the active site clefts of m-calpain and µ-calpain that can be exploited for the 
design of specific calpain inhibitors.  Further investigation is required, however, to define 
the active sites of m-calpain and µ-calpain unambiguously. 
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6.6 SELECTIVITY FOR CATHEPSIN B 
 
 
6.6.1 Selectivity Between Cathepsin B and Papain 
 
Identifying selective inhibitors of papain proved problematic.  Nine inhibitors have IC50 
values of less than 1.0 µM against papain, these are: aldehyde 2.3 (IC50 = 0.023 µM); 
aldehyde 2.21 (IC50 = 0.053 µM); aldehyde 2.22 (IC50 = 0.040 µM); aldehyde 2.27 (IC50 = 
0.033 µM); thiosemicarbazone 2.38 (IC50 = 0.19 µM); phenylhydrazine 2.39 (IC50 = 0.96 
µM); cyanohydrin 2.51 (IC50 = 0.030 µM); α-bromomethyl ketone 3.27 (IC50 = 0.18 µM) 
and macrocyclic aldehyde 4.4 (IC50 = 0.61 µM; see Table 6.19); however, eight of these 
nine inhibitors are up to 3-fold more potent against cathepsin B than papain. 
 
The one inhibitor that shows selectivity for papain is cyanohydrin 2.51 (IC50 = 0.030 µM), 
which is at least 3-fold more potent against papain than against cathepsin B).  A suggested 
reason for the cyanohydrin 2.50 being selective for papain over cathepsin B is that the 
alcohol of the cyanohydrin moiety is positioned such that it cannot be stabilised by the 
oxyanion hole of cathepsin B.  This is supported by the fact that the cyanohydrin is the 
only potent inhibitor of papain that contains an alcohol group (see Table 6.19). 
 
The main structural difference between the active sites of cathepsin B and papain is the 
large occluding loop unique to cathepsin B that endows it with exopeptidase properties 
(see Section 6.2.3 and Chapter One for a discussion of the occluding loop).  The overall 
structures of papain and cathepsin B are highly conserved, and peptidyl substrates are 
proposed to bind in the active site of cathepsin B in a manner analogous to that of papain,39 
explaining the similar potency of many inhibitors (see Tables 6.1-6.15) assayed against 
these two proteases.  However, this lack of distinction is not overly troublesome as 
cathepsin B is a mammalian protease while papain is exclusively found in plants. 
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Compound 
 
 
IC50 papain (µM) 
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Table 6.19 Potent papain inhibitors: only compounds with IC50 values lower than 1.0 µM were included.  
Negative selectivity values indicate that the inhibitor is more selective for cathepsin B than papain.  A dash 
indicates that there was no selectivity observed 
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6.6.2 Warhead Rankings for Cathepsin B 
 
Many of the inhibitors discussed above (see Sections 6.2-6.4) are both highly potent and 
selective for cathepsin B; for this reason the following Table 6.20 lists all of inhibitors 
synthesised within this thesis of the skeleton: 4-fluorobenzenesulfonyl-Val-Leu-warhead, 
in order of most potent to least potent against cathepsin B.  The use of this fixed scaffold 
for the Tables 6.20 and 6.21 allows for a direct comparison of the potency and selectivity 
for each of the warheads (aldehyde, alcohol, semicarbazone, methyl ester, carboxylic acid, 
amidoxime, 1,2,4-oxadiazole, α-hydroxytetrazole, α-ketotetrazole, α-hydroxyoxazoline, α-
ketooxazoline, cyanohydrin, O-protected cyanohydrin, azide, α,β-unsaturated methyl ester, 
α,β-unsaturated ethyl ester, α,β-unsaturated aldehyde, vinyl sulfone, diazoketone, α-
bromomethyl ketone, α-bromomethyl-3R-alcohol, α-bromomethyl-3-S/R-alcohol, 3R-
epoxide and 3-S/R-epoxide).  Table 6.21 contains the same set of inhibitors but listed 
according to the selectivity shown for cathepsin B. 
 
Sixteen of the compounds listed in Table 6.20 are potent cathepsin B inhibitors (IC50 <5.0 
µM).  These are the: aldehyde 2.3 (IC50 = 0.022 µM); α-bromomethyl ketone 3.28 (IC50 = 
0.075 µM); cyanohydrin 2.51 (IC50 = 0.086 µM); α,β-unsaturated aldehyde 3.18 (IC50 = 
0.13 µM); thiosemicarbazone 2.40 (IC50 = 0.16 µM); α-ketooxazoline 2.42 (IC50 = 0.20 
µM); 4-phenylsemicarbzone 2.38 (IC50 = 0.24 µM); phenylhydrazone 2.39 (IC50 = 0.32 
µM); O-protected cyanohydrin 2.60 (IC50 = 0.35 µM); carboxylic acid 2.7 (IC50 = 0.39 
µM); semicarbazone 2.37 (IC50 = 0.69 µM); α-bromomethyl-3-S/R-alcohol 3.32 (IC50 = 
0.76 µM); diazoketone 3.25 (IC50 = 1.1 µM); methyl ester 2.44 (IC50 = 1.4 µM); vinyl 
sulfone 3.20 (IC50 = 1.9 µM) and α-hydroxytetrazole 2.53 (IC50 = 2.1 µM). 
 
The remaining compounds (IC50 >5.0 µM) are: alcohol 2.6 (IC50 = 9.2 µM); α-
bromomethyl-3R-alcohol 3.30 (IC50 = 9.9 µM); 3R-epoxide 3.27 (IC50 = 12 µM); 1,2,4-
oxadiazole 2.41 (IC50 = 18 µM); 3-S/R-epoxide 3.35 (IC50 = 19 µM); α,β-unsaturated 
methyl ester 3.14 (IC50 = 20 µM); azide 2.62 (IC50 = 22 µM); α-hydroxyoxazoline 2.56 
(IC50 = 24 µM); α,β-unsaturated methyl ester 3.15 (IC50 = 27 µM); α-ketotetrazole 2.43 
(IC50 >50 µM) and amidoxime 2.48 (IC50 >50 µM). 
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F
O2
S
N
H O
H
N X
 
 
Compound X IC50 (µM) Ranking 
 
 
2.3 
 
CHO 
 
0.022 
 
1 
3.28 C(O)CH2Br 0.075 2 
2.51 CH(S,R-OH)CN 0.086 3 
3.18 CH=CHCHO 0.13 4 
2.38 CH=NNHC(S)NH2 0.16 5 
2.42 CO-oxz 0.20 6 
2.39 CH=NNHC(O)NHPh 0.24 7 
2.40 CH=NNHPh 0.32 8 
2.60 CH(S,R-CN)OC(O)CH2Ph 0.35 9 
2.7 COOH 0.39 10 
2.37 CH=NNHC(O)NH2 0.69 11 
3.31 CH(S,R-OH)CH2Br 0.76 12 
3.25 C(O)CHN2 1.1 13 
2.44 CO2Me 1.4 14 
3.20 CH=CHSO2Me 1.9 15 
2.53 CH(S,R-OH)-tet 2.1 16 
2.6 CH2OH 9.2 17 
3.30 CH(3R-OH)CH2Br 9.9 18 
3.27 3S-epox 12 19 
2.41 oxd 18 20 
3.35 3-S/R-epox 19 21 
3.14 CH=CHCO2Me 20 22 
2.62 CH2N3 22 23 
2.56 CH(S,R-OH)-oxz 24 24 
3.15 CH=CHCO2Et 27 25 
2.43 CO-tet >50 26 
2.48 C(O)ONCH(CH3)NH2 >50 27 
 
 
Table 6.20 Ranking of warheads according to potency.  Where epox = epoxide ring; oxd = oxadiazole ring; 
tet = tetrazole ring and oxz = oxazoline ring. 
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Twenty-seven compounds were synthesised within this thesis that contain the 4-
fluorobenzenesulfone-Val-Leu-warhead scaffold; of these, fifteen are at least 2-fold more 
selective for cathepsin B than m-calpain, µ-calpain or papain (see Table 6.21).  These are: 
carboxylic acid 2.7 (IC50 = 0.39 µM, selectivity 127-fold); methyl ester 2.44 (IC50 = 1.4 
µM, selectivity 35-fold); diazoketone 3.25 (IC50 = 1.1 µM, selectivity 25-fold); O-
protected cyanohydrin 3.60 (IC50 = 0.35 µM, selectivity 22-fold); α-hydroxytetrazole 2.53 
(IC50 = 2.1 µM, selectivity 18-fold); α-bromomethyl ketone 3.28 (IC50 = 0.075 µM, 
selectivity 16-fold); α,β-unsaturated aldehyde 3.18 (IC50 = 0.13 µM, selectivity 13-fold); 
vinyl sulfone 3.20 (IC50 = 1.9 µM, selectivity 12-fold); α-bromomethyl-3-S/R-alcohol 3.32 
(IC50 = 0.76 µM, selectivity 9-fold); α-ketooxazoline 2.42 (IC50 = 0.20 µM, selectivity 6-
fold); alcohol 2.6 (IC50 = 9.2 µM, selectivity 5-fold); 4-phenylsemicarbazone 2.39 (IC50 = 
0.24 µM, selectivity 4-fold); 3R-epoxide 3.27 (IC50 = 0.12 µM, selectivity 4-fold); 
phenylhydrazine 2.40 (IC50 = 0.32 µM, selectivity 3-fold) and semicarbazone 2.37 (IC50 = 
0.69 µM, selectivity 2-fold). 
 
The remaining twelve compounds are not significantly selective for cathepsin B 
(selectivity lower than 1.5-fold): 3-S/R-epoxide 3.35 (IC50 = 19 µM); α-bromomethyl-3R-
alcohol 3.29 (IC50 = 9.9 µM); α,β-unsaturated ethyl ester 3.15 (IC50 = 27 µM); 
thiosemicarbazone 2.38 (IC50 = 0.16 µM); aldehyde 2.3 (IC50 = 0.022 µM); cyanohydrin 
2.51 (IC50 = 0.086 µM); 1,2,4-oxadiazle 2.41 (IC50 = 18 µM); α,β-unsaturated methyl ester 
3.14 (IC50 = 20 µM); azide 2.62 (IC50 = 22 µM); α-hydroxyoxazoline 2.56 (IC50 = 24 µM); 
amidoxime 2.48 (IC50 >50 µM) and α-ketotetrazole 2.43 (IC50 >50 µM).       
 
The choice of warhead plays a major role in the design of potent and selective cathepsin B 
inhibitors, as the above results indicate (refer to Tables 6.20 and 6.21).  The outstanding 
compound is the carboxylic acid 2.7, which is not only a potent cathepsin B (IC50 = 0.39 
µM) inhibitor but also has 125-fold selectivity for cathepsin B. 
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Compound 
 
X 
 
Selectivity††† 
 
Activity 
Ranking 
 
IC50 (µM) 
 
 
2.7 
 
COOH 
 
127-fold 
 
10 
 
0.39 
2.44 CO2Me 35-fold 14 1.4 
3.25 C(O)CHN2 25-fold 13 1.1 
2.60 CH(S,R-CN)OC(O)CH2Ph 22-fold 9 0.35 
2.53 CH(S,R-OH)-tet 18-fold 16 2.1 
3.28 C(O)CH2Br 16-fold 2 0.075 
3.18 CHCHCHO 13 fold 4 0.13 
3.20 CH=CHSO2Me 12-fold 22 1.9 
3.32 CH(S,R-OH)CH2Br 9-fold 12 0.76 
2.42 CO-oxz 6-fold 6 0.20 
2.6 CH2OH 5-fold 17 9.2 
2.38 CH=NNHC(O)NHPh 4-fold 7 0.24 
3.27 S-epox 4-fold 19 12 
2.39 CH=NNHPh 3-fold 8 0.32 
2.37 CH=NNHC(O)NH2 2-fold 11 0.69 
3.35 (S,R)-epox 1.5-fold 21 19 
3.29 CH(R-OH)CH2Br 1.5-fold 18 9.9 
3.15 CH=CHCO2Et 1.5-fold 25 27 
2.40 CH=NNHC(S)NH2 1.2 fold 5 0.16 
2.3 CHO - 1 0.022 
2.51 CH(S,R-OH)CN - 3 0.086 
2.41 oxd - 20 18 
3.14 CH=CHCO2Me - 22 20 
2.62 CH2N3 - 23 22 
2.56 CH(S,R-OH)-oxz - 24 24 
2.48 C(O)ONCH(CH3)NH2 - 27 >50 
2.43 CO-tet - 26 >50 
 
 
Table 6.21 Ranking of warheads according to selectivity for cathepsin B.  Where epox = epoxide ring; oxd = 
oxadiazole ring; tet = tetrazole ring and oxz = oxazoline ring. 
                                                 
†††
 Where selectivity is calculated according to the difference between IC50 for cathepsin B and the nearest 
IC50 value of the other cysteine proteases and is at least as selective as shown. 
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6.7 INHIBITION OF α-CHYMOTRYPSIN AND PEPSIN 
 
For screening purposes, all inhibitors were initially assayed against m-calpain, µ-calpain, 
cathepsin B, papain, pepsin and α-chymotrypsin at a concentration of 50 µM.  Compounds 
with inhibition greater than 50% were diluted further to determine an IC50 value; while 
those with inhibition under 50% were disqualified from further assay (see Appendix A2 
for a table of % inhibition of synthesised compounds at a concentration of 50 µM).  The 
previous Sections 6.2-6.6 discuss the inhibition of the cysteine proteases: m-calpain, µ-
calpain, cathepsin B and papain; this section discusses inhibition that was observed against 
α-chymotrypsin and pepsin. 
 
 
6.7.1 Inhibition of α-Chymotrypsin 
 
The compounds synthesised within this thesis (see Chapters Two-Four) showed no 
inhibition of α-chymotrypsin (percentage inhibition at 50 µM between 0% and 40%; see 
Appendix A2). This lack of inhibition of α-chymotrypsin was expected as the dipeptide 
Val-Leu and Val-Phe comprising the inhibitors were selected for specific cysteine protease 
inhibition; whereas α-Chymotrypsin strictly favours large hydrophobic residues such as 
Phe, Try and Leu in the P1 position40 and the S2 and S3 subsites display little specificity.41  
Arg and Lys are favoured at the P1’ position of α-chymotrypsin due to interactions with 
nearby Asp residues along the active site cleft.41   
 
 
6.7.2 Inhibition of Pepsin 
 
Most of the compounds synthesised in this thesis (see Chapters Two-Four) were inactive 
against pepsin at a concentration of 50 µM.  However, seven compound showed inhibition 
greater than or equal to 50% at an inhibitor concentration of 50 µM (see Table 6.22).  
These compounds are: aldehyde 2.2 (IC50 = 32 µM); cyanohydrin 2.51 (IC50 = 25 µM); α-
ketotetrazole 2.55 (IC50 = 11 µM); α-hydroxyoxazoline 2.57 (IC50 = 37 µM); O-protected 
cyanohydrin 2.61 (IC50 = 1.6 µM); 3-R/S-expoxide 3.35 (IC50 = 50 µM) and macrocyclic 
aldehyde 4.4 (IC50 = 16 µM).        
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16 
 
2.57 N
H
H
N
O O
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O
 
 
57 
 
37 
  
Table 6.22 Compounds that exhibited some inhibitory potency against pepsin 
 
To explain why these seven compounds are inhibitors of pepsin, the mechanism of 
substrate hydrolysis employed by pepsin is shown in Figure 6.18. Aspartic acid proteases, 
such as pepsin, have an ‘acid-base’ mechanism of hydrolysis.  The scissile amide bond 
undergoes nucleophilic attack by an activated water molecule that has been deprotonated 
by an aspartic acid residue in the active site.  A charged species (b) is formed as the 
intermediate.  This collapses to give the cleaved products (c).  Typical inhibitors of aspartic 
acid proteases are of the nature shown in Figure 6.19 and include hydroxyethylene, 
hydroxyethylurea and reduced amides as mimics of the tetrahedral intermediate.  Pepsin 
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hydrolyses peptide bonds that connect bulky hydrophobic and aromatic residues such as 
Phe, Trp and Tyr.  Residues that show favourable binding in the active site are: 
hydrophobic residues at P3 and P3’; Ala or Val at P2’.42,43 
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Figure 6.18 The catalytic mechanism of substrate hydrolysis by aspartic acid proteases; a) nucleophilic 
attack on the scissile bond by an activated water molecule followed by b) protonation of the amide nitrogen 
to give a charged species which collapses c) to give the cleaved products. 
 
 
N
H
H
N
OR1
R2
N
H
OR1
R2OH
N
H
N
H
R1
OH
R2
O
N
H
P
O
R1
OH
O
N
H
R1
OH
O
N
H
N
H
N
H
R1
OH
O
N
H
N
H
N
R1
OH R2 O
a b c
d e f g
  
 
Figure 6.19 Transition state analogues for aspartic acid proteases: a) reduced amide; b) hydroxyethylene; c) 
hydroxyethylamine; d) phosphonic; e) α-hydroxy-β-amino acid; f) hydroxyethylurea; g) hydroxyethyl 
hydrazide moieties 
 
A key structural element of aspartic acid protease inhibitors is the presence of a hydroxyl 
or hydroxyl-like moiety that can bind to the two aspartic acid residues in the active site 
(refer to figure 6.15).44  It is thus suggested that the warhead of inhibitors 2.2, 3.35, 2.52, 
2.60, 2.55, 2.57 and 4.4 mimics a hydroxyl moiety.  The aldehydes 2.2 and 4.4 can exist as 
hemiacetals, the cyanohydrin 2.51 is similar in nature to an aminoalcohol analogue (see 
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Figure 6.16) and the epoxide is not active unless it has been protonated (for example by a 
water molecule).  The exception is the O-protected cyanohydrin 2.60, which shows good 
inhibition of pepsin (IC50 = 1.6 µM).  The O-protected cyanohydrin 2.60 shows at least 
1.5-fold selectivity for pepsin over any of the cysteine proteases {IC50 values: 25 µM (m-
calpain), 50 µM (µ-calpain), 20 µM (cathepsin B) and >50 µM (papain)}. 
 
Noteworthy also is the observation that the inhibitors 2.2, 2.52, 2.55, 2.57, 2.61, 3.36 and 
4.4 in Table 6.21 all have benzyloxycarbonyl as the N-protecting group.  The 4-
fluorobenzenesulfonyl protected analogues (2.27, 2.51, 2.43, 2.56 and 3.35) are inactive 
against pepsin at a concentration of 50 µM.  This suggests that the benzyloxycarbonyl is a 
better fit in the active site cleft of pepsin than the 4-fluorobenezenesulfonyl.  Further, the 
alcohol, aldehyde, ester, carboxylic acid, 1,2,4-oxadiazole, α-ketotetrazole, α-
ketooxazoline, cyanohydrin and Michael accepter series of inhibitors with the 4-
fluorobenezenesulfonyl moiety as the N-protecting group are more potent against m-
calpain, µ-calpain, cathepsin B and papain than those within the same series containing the 
benzyloxycarbonyl N-protecting group.  The 4-fluorobenzenesulfonyl group is thus an 
essential N-protecting group for the design protease inhibitors that are selective for 
cysteine proteases over serine or aspartic acid proteases. 
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6.8 CONCLUSION AND FUTURE WORK 
 
 
6.8.1 Summary of Inhibitors with Reversible Warheads 
 
The assay results of the acyclic aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 and 2.22 against the 
papain superfamily of cysteine proteases agreed with trends observed in the literature; with 
the aldehydes being potent and broad spectrum cysteine protease inhibitors.   
 
The alcohol 2.26 is an unprecedented example of a non-covalent inhibitor of cathepsin B. 
It is a highly potent and specific inhibitor of cathepsin B (IC50 = 0.075 µM; selectivity 85-
fold over m-calpain, µ-calpain and papain).  Future work would involve the investigation 
of other non-covalent warheads on the 4-fluorobenezenesulfonyl-Val-Phe scaffold to 
examine the effect of both potency and selectivity on cathepsin B and other proteases of 
the papain superfamily 
 
The semicarbazones 2.37-2.40 were between 5- and 100-fold less potent than the parent 
aldehyde 2.3 against m-calpain, µ-calpain, cathepsin B and papain. The most potent 
inhibitor within this series was the thiosemicarbazone 2.38 {IC50 = 1.6 µM (m-calpain); 
1.6 µM (µ-calpain); 0.16 µM (cathepsin B) and 0.19 µM (papain)}.  All the 
semicarbazones 2.37-2.40 were selective for cathepsin B by 1.2- to 4-fold.  
 
The oxadiazoles 2.41 and 2.50 were weak inhibitor of all the cysteine proteases tested (IC50 
values >18 µM). The α-hydroxytetrazoles 2.53 and 2.54 were potent and selective 
inhibitors of cathepsin B (IC50 = 2.1 µM, selectivity 18-fold and 1.3 µM, selectivity19-fold 
respectively). The α-ketotetrazoles 2.43 was a potent and selective inhibitor of papain (IC50 
= 6.0 µM, selectivity 8-fold).  The outstanding inhibitor within the heterocyclic series was 
α-ketooxazoline 2.42, which was a potent, selective inhibitor of cathepsin B (IC50 = 0.20 
µM, selectivity 6-fold). 
 
The cyanohydrins 2.51 and 2.52 were potent and broad spectrum cysteine protease 
inhibitors (IC50 values < 1.6 µM).  The O-protected cyanohydrins 2.60 and 2.61 were 
potent and selective inhibitors of cathepsin B (IC50 = 0.35 µM, selectivity 22-fold and 2.4 
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µM, 10-fold respectively).  The cyanohydrins 2.51, 2.52, 2.60 and 2.61 appear to be 
unprecedented cysteine protease inhibitors.  Azide 2.62 was a weak inhibitor of cathepsin 
B and papain only (IC50 = 22 µM and 23 µM respectively).   
 
Table 6.23 summarises the best reversible inhibitors synthesised for each of the proteases 
tested, these being chosen for potency and selectivity against individual proteases.  Where 
no selective inhibitors were found, the most potent against that protease was chosen and 
the lack of specificity denoted by a dash. 
 
The reversible inhibitors that met the above criteria were: cyanohydrin 2.52 (m-calpain, 
IC50 = 0.34 µM), cyanohydrin 2.51 (µ-calpain, IC50 = 0.55 µM), acid 2.7 (cathepsin B, IC50 
= 0.39, selectivity 127-fold), α-ketotetrazole 2.53 (papain, IC50 = 6.0 µM, selectivity 8-
fold) and O-protected cyanohydrin 2.61 (pepsin, IC50 = 1.6 µM, selectivity 1.5-fold).  
Inhibition against α-chymotrypsin was not observed. 
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Table 6.23 Summary of the best reversible inhibitor synthesised (balance of potency and selectivity) for each 
enzyme tested. 
 
 
6.8.2 Summary of Inhibitors with Irreversible Warheads 
 
The α,β-unsaturated carbonyls 3.14-3.17 and the vinyl sulfones 3.19-3.21 were between 5- 
to 12-fold weaker inhibitors of  the calpains and papain (IC50 > 14 µM); than of cathepsin 
B {IC50 = 20 µM (3.14); 27 µM (3.15); 21 µM (3.16); 24 µM (3.17); 1.9 µM (3.20); 5.9 
µM (3.21); 21 µM (3.22); 27 µM (3.23)}.  The α,β-unsaturated aldehyde 3.18 was a potent 
and selective inhibitor of cathepsin B (IC50 = 0.13 µM, selectivity 4-fold) within the 
Michael acceptor series.  
 
Chapter Six – Synthesised Inhibitors: Assay Results and SAR  195 
Diazoketones 3.25 and 3.26 were potent and selective inhibitors of cathepsin B (IC50 
values of 1.1 µM and 0.22 µM respectively).  The α-bromomethyl ketones 3.28 and 3.29 
were potent and selective inhibitors of cathepsin B (IC50 = 0.025 µM, selectivity 16-fold 
and 0.077 µM, selectivity 2-fold respectively).  The α-bromomethyl alcohols 3.30-3.33 
were less potent against cathepsin B than the α-bromomethyl ketones 3.28 and 3.29 by at 
least 3.5-fold. It was also suggested that the absolute configuration of the hydroxyl group is 
important for binding affinity and potency (the 3S-alcohol was preferred).  The epoxides 
3.27, 3.34-3.36 were cathepsin B specific; the absolute configuration of the epoxide was 
suggested to be important for binding affinity (the 3R-epoxide being the preferred). 
   
Table 6.24 summarises the best irreversible inhibitors synthesised for each of the proteases 
tested, these being chosen for potency and selectivity against individual proteases.  Where 
no selective inhibitors were found, the most potent against that protease was chosen, the 
lack of specificity denoted by a dash. 
 
The irreversible inhibitors that met the above criteria were: diazoketone 3.26 (m-calpain, 
IC50 = 1.0 µM), α,β-unsaturated aldehyde 3.18 (µ-calpain, IC50 = 2.1 µM), diazoketone 
3.26 (cathepsin B, IC50 = 0.23, selectivity 49-fold) and α,β-unsaturated ester 3.14 (papain, 
IC50 = 14 µM, selectivity 1.4-fold).  Inhibition against pepsin and α-chymotrypsin was not 
observed.  
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Table 6.24 Summary of the best irreversible inhibitors synthesised (balance of potency and selectivity) 
against each of the proteases tested 
 
 
6.8.3 Summary of β-Sheet Constrained Inhibitors 
 
The macrocyclic aldehyde 4.4 was a potent broad spectrum cysteine protease, a 
characteristic in common with the acyclic range of aldehydes 2.3, 2.27, 2.19, 2.2, 2.21 and 
2.22 tested.  Constraining the backbone into a β-strand was suggested to increase the 
binding affinity of the inhibitors, as evidenced by the macrocyclic alcohol 4.3 showing 
increased potency of the cysteine proteases tested in comparison to the acyclic alcohols 
2.6, 2.29, 2.30, 2.34 and 2.35, which showed little inhibition of m-calpain, µ-calpain and 
papain. 
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The macrocyclic semicarbazone 4.15 was a potent and selective inhibitor of m-calpain 
(IC50 = 0.16 µM, selectivity 8-fold).  The macrocyclic cyanohydrin 4.16 was a potent and 
selective inhibitor of cathepsin B (IC50 = 2.4 µM, selectivity 4-fold).  The macrocyclic 
azide 4.19 was a very weak cysteine protease inhibitor (IC50 values >50 µM). 
 
Table 6.25 summarises the best irreversible inhibitors synthesised for each of the proteases 
tested, these being chosen for potency and selectivity against individual proteases.  Where 
no selective inhibitors were found, the most potent against that protease was chosen, the 
lack of specificity denoted by a dash. 
 
The irreversible inhibitors that met the above criteria were: macrocyclic semicarbazone 
4.15 (m-calpain, IC50 = 0.16 µM, selectivity 8-fold), macrocyclic semicarbazone 4.15 (µ-
calpain, IC50 = 1.3 µM), macrocyclic cyanohydrin 4.16 (cathepsin B, IC50 = 2.4, selectivity 
4-fold), macrocyclic semicarbazone 4.15 (papain, IC50 = 3.7 µM) and macrocyclic 
aldehyde 4.4 (pepsin, IC50 = 16 µM).  Inhibition against α-chymotrypsin was not observed.  
 
The macrocyclic compounds 4.3, 4.4, 4.13, 4.14-4.16 and 4.19 are unprecedented 
examples of cysteine protease inhibitors. 
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Table 6.25 Summary of the best macrocyclic inhibitors synthesised (balance of potency and selectivity) 
against each of the proteases tested. 
 
 
6.8.4 Summary of Findings 
 
This thesis, through the design, synthesis and biological assay of cysteine protease 
inhibitors has shown that the nature of the warhead has a significant effect on the potency 
and selectivity of inhibitors against cysteine proteases of the papain superfamily (clan CA). 
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Through comparison of the IC50 values of the synthesised inhibitors it was possible to 
identify structure-activity relationship.  Twenty seven compounds had the scaffold of 4-
fluorobenezenesulfonyl-Val-Leu-warhead and were inhibitors of cathepsin B.  Ranking of 
these compounds in terms of potency and selectivity against cathepsin B allowed for a 
comparison of warhead effect.   The top ten most potent warheads were (in order of most 
potent to least potent): aldehyde, α-bromomethyl ketone, cyanohydrin, α,β-unsaturated 
aldehyde, thiosemicarbazone, 4-phenylsemicarbazone, phenyl hydrazone, esterified 
cyanohydrin, carboxylic acid and semicarbazone (see Figure 6.20).  These warheads on 
the 4-fluorobenzenesulfonyl-Val-Leu-warhead scaffold were potent cathepsin B inhibitors 
(IC50 values from 0.022 to 0.69 µM).   
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Figure 6.20 The top ten most selectivity warheads for cathepsin B based on the 4-fluorobenzenesulfonyl-
Val-Leu-X scaffold: 1) carboxylic acid; 2) methyl ester; 3) diazoketone; 4) O-protected cyanohydrin; 5) α-
bromomethyl ketone; 6) α,β-unsaturated aldehyde; 7) vinyl sulfone; 8) α-bromomethyl-(S,R)-alcohol; 9) 
alcohol and 10) α,β-unsaturated ethyl ester 
 
Further ranking of the warheads in terms of selectivity for cathepsin B gave the top ten 
most selective warheads: carboxylic acid, methyl ester, diazoketone, esterified 
cyanohydrin, α-bromomethyl ketone, α,β-unsaturated aldehyde, vinyl sulfone, α-
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bromomethyl (S,R)-alcohol, alcohol and α,β-unsaturated ethyl ester (see Figure 6.13).  The 
selectivity of these warheads was between 5- and 130-fold for cathepsin B. 
  
Using potency and selectivity in combination, the best inhibitors for cathepsin B were the 
α,β-unsaturated aldehyde 3.18, α-bromomethyl ketone 3.25 and the esterified cyanohydrin 
3.60 (see Figure 6.21) 
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Figure 6.21 The three best inhibitors of cathepsin B, based on a balance of potency and selectivity.    
3.18 
IC50 = 0.025 µM 
Selectivity 16-fold 
3.25 
IC50 = 0.13 µM 
Selectivity 13-fold 
3.60 
IC50 = 0.35 µM 
Selectivity 22-fold 
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7.1 GENERAL METHODS AND EXPERIMENTAL     
PROCEDURES 
 
 
7.1.1 General Practice 
 
Infrared Spectroscopy 
Infrared spectra were obtained using a Shimadzu 9201PC series FTIR interfaced with an 
Intel 486 PC operating Shimadzu’s HyperIR software.  Diffuse reflectance spectra were 
obtained in a solid KBr matrix. 
 
 
Nuclear Magnetic Resonance 
Proton detected NMR spectra were obtained on a Varian Inova or Varian Unity 
spectrometer operating at 500 MHz or 300 MHz respectively.  Carbon detected NMR 
spectra were obtained on a Varian Unity 300 spectrometer operating at 75 MHz with a 
delay (D1) of 1 s.  Unless otherwise stated, all spectra were obtained at 23 °C.  Two-
dimensional cosy experiments were obtained on the Inova 500 spectrometer at 500 MHz. 
 
Solvents used in NMR analysis (reference peak listed) included CDCl3 (CHCl3 at δH 7.26 
ppm, CDCl3 at δC 77.0 ppm); CD3OD (CHD2OD at δH 3.31 ppm, CD3OD at δC 49.05 
ppm); (CD3)2SO ((CHD2)2SO at δH 2.50 ppm, (CD3)2SO at δC 49.43 ppm). 
 
 
Small Molecule Mass Spectrometry 
Electron impact (EI) mass spectra were obtained on a Kratos MS80 RFA mass 
spectrometer operating at 4000V (accelerating potential) and 70 eV (ionization energy).  
The source temperature was 200-250o C.  Electrospray ionization (ESI) mass spectra were 
detected on a micromass LCT TOF mass spectrometer, with a probe voltage of 3200V, 
temperature of 150o C and a source temperature of 80 oC.  Direct ionization used 10µL of a 
10µg mL-1 solution, using a carrier solvent of 50% acetonitrile/water at a flow rate of 20µL 
min-1.  Ionization was assisted by the addition of 0.5% formic acid. 
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Microanalysis 
Microanalysis was performed at the University of Otago Microanalytical Laboratory.  All 
reported values are within ±0.4% of the calculated value. 
 
 
Melting Points 
Melting points were taken on an Electrothermal apparatus and are uncorrected.  Melting 
points are not reported for diastereomeric mixtures, oils or glassy solids. 
 
 
Optical Rotary Dispersion 
Optical rotation measurements were performed on a Perkin Elmer polarimeter Model 341 
with 100 mm path length. Measurements were taken at 20 °C in HPLC grade methanol or 
chloroform at λ = 589 nm.  [α]D values are given in units of °.mL/g.dm and the sample 
concentration given in units of 10 mg/mL.  Optical rotation measurements were not 
performed for diastereomeric mixtures. 
 
 
Molecular Modelling 
All molecular modelling experiments were conducted by Wanting Jiao and Steven 
McNabb with the Schrödinger suite 2005.  Conformational searches were carried out with 
MacroModel 9.0 to generate an ensemble of low energy conformers to establish a suitable 
starting conformation of each compound for the docking.  The searches were conducted 
with the MCMM method using a GB/SA water model and either the OPLS2001 force field 
or MM2 force field.  The minimisation was stopped with the default gradient convergence 
threshold of δ = 0.05 kJ/(mol*Ǻ).  The default Polak-Ribiere Conjugate Gradient method 
was used for all minimisations.  The crystal structure of mini mu-calpain (pdb code 1KXR) 
was prepared by: deleting water and ions, adding hydrogen atoms, mutation of Ser115 ⇒ 
Cys115, deprotonation of Cys115, and protonation of His272.  This structure was minimised 
using the OPLS2001 force field with a GB/SA water model over 500 iterations.  All 
residues within a 5 Ǻ distance to the calcium ions of the crystal structure were kept frozen 
during this minimisation.  The RMSD of the minimised structure to the crystal structure 
was 0.96 Ǻ for the heavy atoms (C, N, O, S).  The centre of the docking grid was defined 
as the centroid of the residues Cys115, Gly208, and Gly271 and was generated with GLIDE 
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3.5 using default settings.  The centre of the docked ligands was defined within a 12 Ǻ box.  
The docking of flexible ligands to the rigid receptor model with GLIDE was performed 
with the following parameters: OPLS2001 force filed, extra precision mode, 90000 poses 
per ligand for the initial docking, scoring window for keeping initial poses: 5000, keep best 
1000 poses per ligand for energy minimisation, energy minimisation with a distance 
dependent dielectric constant of two and a maximum of 5000 conjugate gradient steps.  
Ten poses per ligand were saved for evaluation.  The amino acids Cys115 and His272 were 
uncharged in the induced fit calpain model.  The centroid of Cys115, Gly208, Gly271, Glu349 
and Asn253 was chosen for the docking grid generation and the size of the box was chosen 
by default van der Waals radii of the ligand and the protein atoms were scaled to 0.5.  The 
side chain of Lys347 was removed for the docking and the 20 best poses of this initial 
docking were retained.  All protein residues with a 5 Ǻ of the respective ligand pose were 
refined with PRIME 1.2, including Lys347.  The ligands were re-docked with a van der 
Waals radius of 0.8 to the newly generated protein structures if within 30 kcal/mol of the 
best protein structure and only if within the top 20 structures.  For each of these protein 
structures, one ligand pose was kept for evaluation. 
 
 
Reagents and Solvents 
Oven-dried glassware was used in all reactions performed under an inert atmosphere 
(either dry nitrogen or argon).  All starting materials and reagents were obtained 
commercially and used without further purification unless otherwise stated.   
 
Concentration in vacuo refers to the removal of solvents “under reduced pressure” by 
rotary evaporation (low vacuum pump) followed by application of high vacuum (oil pump) 
for a minimum of thirty minutes.   
 
Analytical thin layer chromatography (TLC) was performed on plastic-backed Merck 
Kieselgel KG60F254 silica plates.  Visualisation was achieved using short wave ultraviolet 
light, potassium permanganate or vanillin dip.  Flash chromatography was performed using 
230-400 mesh Merck Silica gel 60 either under a positive pressure of dry nitrogen or using 
the Buchi sepacore flash chromatography system. 
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All reagents were purified by established techniques.  THF and diethyl ether were distilled 
from sodium benzophenone ketyl under an inert atmosphere immediately prior to use.  
Dichloromethane, petroleum ether,* ethyl acetate, benzene, toluene, triethylamine and 
1,1,2-trichloroethane were distilled from calcium hydride under an inert atmosphere.  
Anhydrous N,N-dimethylformamide was obtained from commercial sources. 
 
 
Cooled Solutions 
The cooled solutions comprise the following: 5 °C refers to the reaction taking place in a 
controlled 5 °C refrigerated room; -78 °C using a mixture of CO2(s) acetone; -30 °C, -25 
°C and -10 °C using mixtures of methanol/water. 
 
 
Sonication 
Contained solutions were sonicated in a water trough at rt for 15 min using a Branson 2510 
sonicator.  
 
 
7.1.2 General Procedures 
 
General Procedure A: Amide bond formation from an acid chloride 
 
R' X
O X = Cl
X = NHR''
 
 
To a stirred solution of the acid chloride (1.0 equiv) in dry N,N-dimethylformamide was 
added the amine (1.0 equiv) and DIPEA (2.0 equiv) and the resulting solution stirred at rt 
overnight.  The reaction mixture was diluted with ethyl acetate and washed successively 
with 1M aqueous HCl, saturated aqueous sodium bicarbonate and brine.  The organic 
phase was separated and dried over MgSO4. Concentrating in vacuo gave a colourless oil 
that was purified by column chromatography, details are given with individual compounds. 
 
                                                 
*
 Where petroleum ether refers to the fractions distilled between 50-70 °C 
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General Procedure B: HATU mediated peptide coupling 
 
R' X
O X = OH
X = NHR''
 
 
To an anhydrous solution of N,N-dimethylformamide was added the acid (1.0 equiv), 
amine (1.1 equiv) and HATU (1.1 equiv).  The reaction mixture was stirred for 10 min at rt 
followed by the addition of DIPEA (4.0 equiv) and subsequently stirred at rt for 18 h.  The 
reaction mixture was partitioned between ethyl acetate and 1M aqueous HCl.  The organic 
phase was separated and washed sequentially with 1M aqueous HCl
 
and brine.  The 
organic phase was dried over MgSO4, filtered and concentrated in vacuo.  If required, 
products were purified by flash chromatography on silica.   
 
 
General Procedure B2: Modified HATU mediated peptide coupling 
 
R' X
O X = OH
X = NHR''
 
 
To a stirred solution of the acid (1.0 equiv) in dry N,N-dimethylformamide was added the 
amino alcohol (1.0 equiv), DIPEA (2.5 equiv), and HATU (1.2 equiv). The solution was 
stirred at rt overnight then diluted with ethyl acetate and washed with water and brine. The 
organic phase was separated, then dried over MgSO4 and the solvent removed in vacuo to 
give a colourless oil. Purification by column chromatography afforded the desired product. 
 
 
General Procedure C: EDCI mediated peptide coupling 
 
R' X
O X = OH
X = NHR''
 
 
To an anhydrous solution of N,N-dimethylformamide was added the acid (1.0 equiv), 
EDCI (1.1 equiv), HOBt.H2O (1.1 equiv) and the amine (1.5 equiv).  The reaction mixture 
was stirred for 10 min at rt followed by the addition of DIPEA (4.0 equiv) and subsequent 
stirring at rt for a further 18 h.  The reaction mixture was partitioned between ethyl acetate 
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and 1M aqueous HCl.  The organic phase was separated and sequentially washed with 1M 
aqueous HCl
 
and brine.  The organic phase was dried over MgSO4, filtered and 
concentrated in vacuo to yield the dipeptide.  Purification details are given with individual 
compounds. 
 
 
General Procedure C2: Modified EDCI mediated peptide coupling 
 
R' X
O X = OH
X = NHR''
 
 
To an anhydrous solution of dichloromethane:N,N-dimethylformamide (9:1) at -10 °C was 
added the acid (1.0 equiv), EDCI (1.2 equiv), HOBt.H2O (1.2 equiv) and N-
hydroxyacetamidine (1.2 equiv).  The reaction mixture was stirred for 30 min at -10 °C 
followed by the addition of DIPEA (1.2 equiv) and subsequently stirred at rt for a further 
1.5 h.  The solvents were concentrated in vacuo and the residue dissolved in ethyl acetate. 
The organic phase was separated and washed sequentially with saturated aqueous sodium 
bicarbonate, water, 0.5 M aqueous potassium hydrogen sulfate
 
and brine.  The organic 
phase was dried over MgSO4, filtered and concentrated in vacuo to yield the product.  
Purification details are given with individual compounds. 
 
 
General Procedure D: N-hydroxysuccinimide mediated peptide coupling 
 
R' OH
O
R' O
O
N
O
O
 
 
To a solution of N-hydroxysuccinimide ester (1.0 equiv) and amine (1.3 equiv) in 
dichloromethane was added DIPEA (1.5 equiv) and the resulting reaction mixture stirred at 
rt for 2 h.  The reaction mixture was partitioned between dichloromethane and 1M aqueous 
HCl.  The organic phase was separated and sequentially washed with saturated aqueous 
sodium bicarbonate and brine, dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give a white solid.  Recrystallisation from ethyl acetate/petroleum 
ether gave the pure product.     
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General Procedure E: N-Boc cleavage  
 
O
O
NHR TFA.NH2R
 
 
The N-Boc protected compound was dissolved in dichloromethane and 10% trifluoroacetic 
acid (v/v) added.  The reaction mixture was stirred at rt for 18 h, then concentrated in 
vacuo to give the free amine as the trifluoroacetate salt. 
 
 
General Procedure F: N-Boc protection of amino acids 
 
O
O
NHR
NH2R
 
 
The amino acid was dissolved in a 1:1 biphasic mixture of water and dichloromethane.  To 
this was added triethylamine (2.8 equiv) and di-tert-butyl dicarbonate (1.2 equiv).  The 
reaction mixture was stirred at rt for 18 h then concentrated in vacuo.  The residue was 
partitioned between ethyl acetate and 10% (w/w) aqueous citric acid.  The organic phase 
was separated and the aqueous phase was extracted twice more with ethyl acetate.  The 
combined organic phases were washed with brine, dried over MgSO4, filtered and 
concentrated in vacuo.  
 
 
General Procedure G: Ester hydrolysis with base 
 
R' X
O X = OMe
X = OH
 
 
The ester was dissolved in a 3:1 mixture of methanol and water.  Lithium hydroxide (5.0 
equiv) was added and the mixture stirred at rt for 18 h.  The reaction mixture was 
concentrated in vacuo and the resulting residue partitioned between ethyl acetate and 1M 
aqueous HCl.  The organic phase was separated and the aqueous phase extracted twice 
more with ethyl acetate. The combined organic extracts were washed with brine, dried over 
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MgSO4, filtered and concentrated in vacuo.  Purification details are given with individual 
compounds.   
 
 
General Procedure H: Esterification of acids 
 
R' X
O X = OH
X = OMe
 
 
The carboxylic acid was suspended in ice-cold methanol and 20% (v/v) thionyl chloride 
was added in portions until the carboxylic acid was completely soluble.  The ice-cold 
solution of the reaction mixture was stirred 1 h, followed by a further 18 h at rt before 
being concentrated in vacuo to give a white solid.  No purification was necessary. 
 
 
General Procedure I: Cyanohydrin formation 
 
R' H
O
R' CN
OH
 
 
To a cooled solution (5 °C) of the aldehyde (1.0 equiv) in methanol was added a cooled (5 
°C) aqueous solution of sodium hydrogen sulfite (1.0 equiv).  The solution was stirred for 
16 h at 4 °C then potassium cyanide (1.0 equiv) in ethyl acetate added.  The biphasic 
reaction mixture was stirred for 4 h at rt. The organic layer was separated and the aqueous 
phase was extracted (x 2) with ethyl acetate.  The separated organic phases were combined, 
washed with distilled water, dried over MgSO4 and the solvent removed to yield the 
cyanohydrin as a mixture of diastereoisomers (1:1).  Purification details are given with 
individual compounds. 
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General Procedure J: Horner-Emmons-Wadsworth reaction of aldehydes 
 
R' H
O
R'
SO2Me
 
 
Ethylmethanesulfonylmethylphosphinoyl ethane (1.0 equiv) was dissolved in 
tetrahydrofuran and cooled to -78 °C.  15% butyllithium in tetrahydrofuran was added over 
10 min and the reaction mixture stirred for 20 min at -78 °C.  The aldehyde in 
tetrahydrofuran was added to the reaction mixture and subsequently stirred for a further 2 h 
at -78 °C.  The solvent was removed in vacuo and the residue partitioned between water 
and ethyl acetate.  The aqueous phase was separated and extracted twice more with ethyl 
acetate.  The combined organic phases were successively washed with saturated aqueous 
sodium bicarbonate and brine, dried over MgSO4, filtered and the solvent removed under 
reduced pressure to give the crude product.  Purification was achieved by either column 
chromatography or recrystallisation; details are given with individual compounds.   
 
 
General Procedure K: Reduction via lithium aluminium hydride 
 
R' OHR' OMe
O
 
 
A solution of the methyl ester (1.0 equiv) tetrahydrofuran was cooled in an ice bath and 
1M lithium aluminium hydride in diethyl ether (1.1 equiv) added.  The ice cold reaction 
mixture was stirred for 1 h then warmed to rt and stirred for a further 17 h, after which 
methanol was added to quench the reaction. The reaction mixture was stirred at rt for 10 
min then concentrated in vacuo.  The resulting residue was partitioned between ethyl 
acetate and 1M aqueous potassium hydrogen sulfate.  The aqueous phase was separated 
and extracted twice more with chloroform. The combined organic phases were washed 
with brine, dried over MgSO4, filtered and concentrated in vacuo.  Purification details are 
given with individual compounds. 
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General Procedure L: Oxidation via sulfur trioxide-pyridine (Parikh-Doering)1 
 
R' R'' R' R''
OOH
 
 
A solution of the alcohol in a 1:3 mixture dimethylsulfoxide and dichloromethane was 
cooled over an ice bath, followed by the addition of DIPEA (4.3 equiv).  To this ice-cold 
reaction mixture a solution of SO3.Pyr complex (4.5 equiv) dissolved in dimethylsulfoxide 
was added.  The reaction mixture was maintained at a low temperature for a further 2 h (or 
until TLC indicated complete consumption of the starting alcohol).  The reaction mixture 
was diluted with ethyl acetate and partitioned between ethyl acetate and 1M aqueous HCl.  
The organic phase was washed with saturated aqueous sodium bicarbonate and brine, dried 
over MgSO4, filtered and concentrated in vacuo.  Purification details are given with 
individual compounds.  
 
 
General Procedure M: Oxidation via TEMPO-NaOCl2 
 
R' R'' R' R''
OOH
 
 
A buffered solution of sodium hypochlorite (5.25%, 9.7 mL commercial bleach, 15.3 mL 
distilled water) was prepared by addition of solid NaHCO3 (ca.  300 mg) until the pH lay 
within the range 8.6-9.5.† 
 
To a solution of the alcohol (1.0 equiv) in ice-cold dichloromethane (35 mL/mmol) was 
added KBr (0.2 equiv) and TEMPO (0.1 equiv).  Buffered NaOCl (0.5 mL/mL 
dichloromethane) was added drop-wise and the reaction mixture stirred rapidly for 2 h over 
ice.  The bi-phasic mixture was diluted with ethyl acetate and the organic phase separated, 
then washed with brine, dried over MgSO4, filtered and concentrated in vacuo.  Further 
purification of the crude product was achieved by recrystallisation or column 
chromatography; details are given with individual compounds. 
 
                                                 
†
  The required pH range for HOCl distribution between both phases 
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General Procedure M2: Modified Oxidation via TEMPO-NaOCl3 
 
R' R'' R' R''
OOH
 
 
To an ice-cold solution of the alcohol (1.0 equiv) in dichloromethane (12.5 mL/mmol) was 
added buffered aqueous NaOCl solution (2.6%, 0.35 M, pH 8.6), (1.25 equiv), aqueous 
KBr solution (50 mM, 0.1 equiv) and TEMPO (0.01 equiv) in dichloromethane (400 µM).  
The ice-cold bi-phasic mixture was rapidly stirred for 2 h, diluted with a 4 x volume of 
ethyl acetate, washed with water then brine, dried over MgSO4, filtered and concentrated in 
vacuo.  Further purification of the crude product was achieved by recrystallisation or 
column chromatography; details are given with individual compounds. 
 
 
General Procedure N: Preparation of diazomethane 
 
H2C N2
 
 
Aqueous potassium hydroxide (3.00 g in 10 ml) was added to dimethyl digol (20 ml) at 75 
°C in one arm of a two-armed distillation apparatus.  The biphasic mixture was stirred 
vigorously throughout the addition of Diazald (10.75 g) in ether (50 ml) over 40 min.  The 
yellow ethereal diazomethane solution was collected over ice-cold potassium hydroxide.  
WARNING: diazomethane is explosive.  Avoid contact with broken glass, ground glass 
joints and rough surfaces.  No purification was needed.   
    
 
General Procedure O: Semicarbazone reaction of aldehydes 
 
R' H
O
R' N
H
N
R''
 
 
To an aqueous solution of sodium acetate (1.1 equiv) and semicarbazone (1.1 equiv) was 
added the aldehyde dissolved in a water miscible solvent.  The reaction mixture was stirred 
for 20 h at rt, then water added until precipitation occurred.  Ethyl acetate was added, the 
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organic phase separated, dried over MgSO4, filtered and solvent removed to give the 
semicarbazone as a coloured solid.  If purification was required the solid was 
recrystallised; details are given with individual compounds.  
 
 
General Procedure P: Wittig Reaction of aldehydes 
 
R' H
O
R'
R''
 
 
To a solution of the aldehyde (1.0 equiv) in dichloromethane was added the ylide (1.0 
equiv).  The reaction mixture was stirred at rt for 16 h then the solvent removed in vacuo.  
The resulting white solid was purified by column chromatography (diethyl ether) to 
remove the triphenylphosphine oxide by-product. 
 
 
General Procedure Q: Epoxidation of bromomethyl alcohols 
 
R' Br
OH
R'
O
 
 
To a solution of the bromomethyl alcohol (1.0 equiv) in anhydrous methanol was added 
potassium carbonate (2.0 equiv).  The reaction mixture was stirred for 1 h at rt then solvent 
removed in vacuo.  The resulting residue was dissolved in ethyl acetate and successively 
washed with water and brine, dried over MgSO4 and solvent removed in vacuo to give the 
epoxide.  Purification details are given with individual compounds. 
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General Procedure R: Oxazoline ring formation 
 
R' CN
OH
R'
OH
O
N
 
 
A solution of anhydrous methanol (19.0 equiv) in chloroform was cooled over an ice bath, 
after which acetyl chloride (16.0 equiv) was added dropwise.  The reaction mixture was 
stirred for 15 min at low temperature then the cyanohydrin (1.0 equiv) in chloroform 
added.  The reaction mixture was stirred for 16 h with gradual return to rt.  The solvent and 
volatiles were removed in vacuo to give the intermediate imidate as an oily residue.  The 
imidate was dissolved in dichloromethane along with ethanolamine (1.0 equiv) and 
triethylamine (1.0 equiv).  The reaction mixture was stirred at rt for 16 h then diluted with 
ethyl acetate.  The organic phase was washed with 1M aqueous sodium hydroxide and 
brine, dried over MgSO4, filtered and the solvent removed in vacuo to give the crude 
product.  Further purification was achieved using column chromatography; details are 
given with individual compounds. 
 
 
General Procedure S: Tetrazole ring formation 
 
R' CN
OH
R'
OH
N N
N
H
N
 
 
Triethylamine hydrochloride was prepared by the careful addition of triethylamine (3 mL) 
to hydrogen chloride in ether (10.5 mL) and subsequent removal of excess solvent. 
 
The cyanohydrin (1.0 equiv), triethylamine hydrochloride (2.0 equiv) and sodium azide 
(2.0 equiv) were suspended in toluene.  The reaction mixture was heated at reflux for 20 h.  
Upon cooling to rt, the reaction mixture was diluted with toluene and extracted with water 
(3 x 200 mL).  The combined aqueous phases were acidified to pH 2 with 1M aqueous 
HCl.  The resulting white precipitate was extracted with ethyl acetate (2 x 200 mL).  The 
combined organic phases were washed with brine, dried over MgSO4 and concentrated in 
vacuo to give the product as a colourless glassy solid.  If purification was necessary, 
Chapter Seven – Experimental  218   
recrystallisation from a minimal amount of ethyl acetate gave the pure product; details are 
given with individual compounds. 
 
 
General Procedure T: Hydrogenation of a double bond 
 
R'
R''
R'
R''
 
 
The olefin was dissolved in methanol and 20% (w/w) of 10% palladium on carbon catalyst 
added.  The mixture was subjected to hydrogenation at rt and atmospheric pressure for 18 
h. The resulting black suspension was filtered through celite and concentrated in vacuo.  
Recrystallisation from ethyl acetate afforded the pure product. 
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7.2 EXPERIMENTAL WORK AS DESCRIBED IN 
CHAPTER TWO 
 
 
7.2.1 Synthesis of Peptidyl Aldehydes 
 
 Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methylbutyric acid (2.24) 
 
F
O2
S
N
H
O
OH
 
 
L-Valine (2.11 g, 18.0 mmol) and 1M aqueous sodium hydroxide (18 mL) were dissolved 
in an ice cold solution of 1:1 water:tetrahydrofuran.  1M aqueous sodium hydroxide (18 
mL) and 4-fluorobenzenesulfonyl chloride 2.23 (3.05 g, 15.7 mmol) were added and the 
reaction mixture stirred at rt for 24 h.  The reaction mixture was cooled over an ice bath 
and partitioned between ethyl acetate and 1M aqueous HCl.  The organic phase was 
separated and washed with brine, dried over MgSO4, filtered and solvent removed in vacuo 
to give the crude product.  Purification was achieved by rinsing the crude product with 5% 
EtOAc in petroleum ether to give the pure product as a white solid (2.41g, 57%).   
mp = 125-126 °C;  
Spectral properties are in agreement with the literature.4  
1H NMR δ(CDCl3) 7.88-7.84 (2H, m, ArH (Fps)), 7.19-7.14 (2H, m, ArH (Fps)), 5.36 (1H, 
m, NH), 3.78 (1H, dd, J = 4.7 and 10.1 Hz, CHCH(CH3)2), 2.14-2.08 (1H, m, 
CHCH(CH3)2), 0.96 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.87 (3H, d, J = 6.8 Hz, 
CHCH(CH3)2);  
13C NMR δ(CDCl3) 176.44, 165.16 (d, J = 255.4 Hz), 135.55 (d, J = 3.2 Hz), 130.00 (d, J 
= 9.4 Hz), 116.24 (d, J = 22.6 Hz), 60.7, 31.26, 18.98, 17.05; 
[α]D = +42.0 (c = 0.1 in CHCl3); 
HRMS (ES) 276.0697 (MH+) C11H15FNO4S requires 276.0706; 
νmax (KBr) 3250 (SO2NH), 1699 (CO2H). 
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methylbutyric acid 2,5-dioxo-
pyrrolidin-1-yl ester (2.25) 
F
O2
S
N
H
O
O
N
O
O
 
 
The N-terminal protected acid 2.24 (2.31 g, 8.39 mmol) and N-hydroxysuccinimide (1.16 
g, 10.30 mmol) were dissolved in tetrahydrofuran (25 ml) and cooled over an ice bath.  A 
solution of EDCI (2.01 g, 10.48 mmol) in dichloromethane (20 ml) was added dropwise to 
the reaction mixture at a low temperature.   The reaction mixture was warmed to rt and 
stirred for a further 4 h then the solvent removed in vacuo.  The resulting residue was 
dissolved in ethyl acetate.  The organic phase was washed successively with 1M aqueous 
HCl, saturated aqueous sodium bicarbonate and brine, dried over MgSO4, filtered and 
solvent removed in vacuo to give the crude product.  Purification was achieved by rinsing 
the crude product with 5% ethyl acetate in petroleum ether to give the pure product as a 
white solid (2.99 g, 96%). 
mp = 166-167 °C; 
Spectral properties are in agreement with the literature.4  
1H NMR δ(CDCl3)  7.87-7.83 (2H, m, ArH (Fps)), 7.20-7.15 (2H, m, ArH (Fps)), 5.30 
(1H, d, J = 10.3 Hz, NH), 4.22 (1H, dd, J = 4.6 and 10.3 Hz, CHCH(CH3)2), 2.77 (4H, s, 
CH2CH2), 2.38-2.27 (1H, m, CHCH(CH3)2), 1.10 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.98 
(3H, d, J = 6.8 Hz, CHCH(CH3)2);  
13C NMR δ(CDCl3) 168.23, 167.21, 165.25 (d, J = 255.0 Hz), 135.42 (d, J = 3.1 Hz), 
129.71 (d, J = 9.6 Hz), 116.62 (d, J = 22.8 Hz), 59.24, 32.08, 25.45, 18.79, 16.77; 
[α]D = +10.0 (c = 0.1 in CHCl3); 
HRMS (ES) 373.0859 (MH+) C15H18FN2O6S requires 373.0870; 
νmax (KBr)  3290 (SO2NH), 1741 (C=O), 1591 (C=O(Suc)). 
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-hydroxymethyl-3-methyl-
butyl)-3-methylbutyramide (2.6) 
 
F
O2S
N
H
O
H
N OH
 
 
The ester 2.25 (1.28 g, 3.44 mmol) was coupled to L-leucinol (0.48 mL, 4.47 mmol) 
according to General Procedure D to afford the alcohol 2.6 as a white solid. No 
purification was required (0.80 g, 62 %). 
mp >300 °C; 
Spectral properties are in agreement with the literature.4  
1H NMR δ(CD3OD) 7.91-7.87 (2H, m, ArH (Fps)), 7.27-7.23 (2H, m, ArH (Fps)), 3.76-
3.71 (1H, m, CHCH2CH(CH3)2), 3.55 (1H, d, J = 6.2 Hz, CHCH(CH3)2), 3.37 (1H, dd, J = 
5.2 and 10.9 Hz, CH2OH), 3.33 (1H, dd, J = 5.5 and 10.9 Hz, CH2OH), 1.26-1.20 (2H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.17-1.11 (1H, m, CHCH2CH(CH3)2 ), 0.94 
(3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.88 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.85 (3H, d, J = 
6.2 Hz, CHCH2CH(CH3)2), 0.77 (3H, d, J = 6.0 Hz, CHCH2CH(CH3)2);  
13C NMR δ(CD3OD) 172.57, 166.33 (d, J = 252.1 Hz), 138.49 (d, J = 3.3 Hz), 131.18 (d, J 
= 9.4 Hz), 117.10 (d, J = 22.8 Hz), 65.29, 63.23, 50.54, 41.03, 33.12, 25.54, 23.65, 22.38, 
19.49, 18.20; 
[α]D = +8.0 (c = 0.1 in CH3OH); 
HRMS (ES) 397.1577 (MNa+) C17H27FN2O4 SNa requires 397.1573; 
νmax (KBr) 3609 (CH2OH), 3280 (SO2NH), 2974 (C(O)NH). 
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-formyl-3-methylbutyl)-3-
methylbutyramide (2.3) 
 
F
O2
S
N
H
H
N
O
H
O
 
 
The alcohol 2.6 (0.40 g, 1.06 mmol) was oxidised according to General procedure L to 
afford the product as a white solid.  Purification was not necessary (0.32 g, 82 %).  
mp = 127-129 °C;  
Spectral properties are in agreement with the literature.4  
1H NMR δ(CDCl3) 9.39 (1H, s, CHO), 7.88-7.85 (2H, m, ArH (Fps)), 7.16-7.11 (2H, m, 
ArH (Fps)), 6.72 (1H, d, J = 7.4 Hz, NH), 5.90 (1H, d, J = 8.8 Hz, NH), 4.32-4.28 (1H, m, 
CHCH2CH(CH3)2), 3.63 (1H, dd, J = 5.7 and 8.8 Hz, CHCH(CH3)2), 2.08-2.04 (1H, m, 
CHCH(CH3)2), 1.55-1.47 (1H, m, CHCH2CH(CH3)2), 1.42-1.35 (1H, m, 
CHCH2CH(CH3)2), 1.30-1.23 (1H, m, CHCH2CH(CH3)2), 0.93 (3H, d, J = 6.8 Hz, 
CHCH2CH(CH3)2), 0.88 (3H, d, J = 6.6 Hz, CHCH(CH3)2), 0.85 (3H, d, J = 6.8 Hz, 
CHCH2CH(CH3)2), 0.83 (3H, d, J = 6.6 Hz, CHCH(CH3)2); 
13C NMR δ(CDCl3) 199.30, 170.58, 164.27 (d, J = 255.2 Hz), 136.06 (d, J = 3.2 Hz), 
129.43 (d, J = 9.3 Hz), 115.45 (d, J = 22.5 Hz), 61.43, 56.56, 36.60, 31.25, 23.86, 22.58, 
21.00, 18.86, 16.94; 
[α]D = +16.0 (c = 0.1 in CHCl3); 
HRMS (ES) 373.1613 (MH+) C17H26FN2O4 S requires 373.1597; 
νmax (KBr) 3260 (SO2NH), 2968 (CONH), 1730 (CHO).  
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Preparation of N-(1S-benzyl-2-hydroxyethyl)-2S-(4-fluorobenzenesulfonylamino) -3-
methylbutyl)-3-methylbutyramide (2.26) 
 
F
O2
S
N
H
H
N
O
OH
 
 
The ester 2.25 (1.28 g, 3.44 mmol) was couple to L-phenylalaninol (0.68 g, 4.47 mmol) 
according to General Procedure D to afford the crude alcohol 2.26.  Recrystallisation 
from ethyl acetate/petroleum ether gave the pure product as a white solid (1.28 g, 91 %).   
mp = 125-126 °C; 
Spectral properties are in agreement with the literature.4  
1H NMR δ(CD3OD) 7.86-7.82 (2H, m, ArH (Fps)), 7.81 (1H, d, J = 8.2 Hz, NH), 7.28-
7.25 (2H, m, ArH (Fps)), 7.22, 7.17 (5H, m, ArH (Phe)), 3.90-3.93 (1H, m, CHCH2C), 
3.52 (1H, d, J = 6.4 Hz, CHCH(CH3)2), 3.37 (2H, d, J = 5.0 Hz, CHCH2C), 2.73 (1H, dd, J 
= 7.4 and 13.7 Hz, CH2OH), 2.50 (1H, dd, J = 7.2 and 13.7 Hz, CH2OH), 1.91-1.84 (1H, 
m, CHCH(CH3)2), 0.82 (6H, dd, J = 6.9 and 7.7 Hz, CHCH(CH3)2);  
13C NMR δ(CD3OD) 172.86, 166.37 (d, J = 252.4 Hz), 139.67, 138.32 (d, J = 3.2 Hz), 
131.18 (d, J = 9.4 Hz), 130.32, 129.49, 127.46, 117.07 (d, J = 22.9 Hz), 63.79, 63.39, 
54.35, 37.79, 32.73, 19.71, 18.29; 
[α]D = -20.0 (c = 0.1 in CH3OH); 
HRMS (ES) 409.1586 (MH+) C20H26FN2O4S requires 409.1597; 
νmax (KBr) 3600 (CH2OH), 3277 (SO2NH), 2966 (C(O)NH). 
 
 
Preparation of N-(1S-benzyl-2-oxoethyl)-2S-(4-fluorobenzenesulfonylamino)-3-
methylbutyramide (2.27) 
F
O2
S
N
H
H
N
O
O
H
 
 
The alcohol 2.26 (1.28 g, 3.13 mmol) was oxidised according to General procedure L to 
afford the product as a white solid.  Purification was not necessary (1.02 g, 79 %).  
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mp = 154-155 °C; 
Spectral properties are in agreement with the literature.4  
1H NMR δ((CD3)2CO) 9.33 (1H, s, CHO), 7.90-7.84 (2H, m, ArH (Fps)), 7.31-7.16 (7H, 
m, ArH (Fps and Phe)), 6.58 (1H, d, J = 9.4 Hz, NH), 4.33-4.27 (1H, m, CHCH2C), 3.80-
3.78 (1H, m, CHCH(CH3)2), 3.09 (1H, dd, J = 5.4 and 14.3 Hz, CHCH2C), 2.87 (1H, dd, J 
= 8.4 and 14.3 Hz, CHCH2C), 2.02-1.94 (1H, m, CHCH(CH3)2 ), 0.87 (3H, d, J = 6.8 Hz, 
CHCH(CH3)2), 0.82 (3H, d, J = 6.8 Hz, CHCH(CH3)2);  
13C NMR δ((CD3)2CO) 206.33, 199.30, 171.52, 165.59 (d, J = 251.6 Hz), 138.05 (d, J = 
5.6 Hz), 130.89 (d, J = 9.4 Hz), 130.00, 129.24, 127.41, 116.68 (d, J = 22.7 Hz), 62.20, 
60.99, 34.81, 32.34, 19.58, 17.56; 
[α]D = +37.0 (c = 0.1in CHCl3); 
HRMS (ES) 407.1444 (MH+) C20H23FN2O4S requires 407.1441; 
νmax (KBr) 3261 (SO2NH), 2968 (C(O)NH), 1732 (CHO)  
 
 
Preparation of [1S-(1S-hydroxymethyl-3-methylbutylcarbamoyl)-2-methylpropyl]-
carbamic acid benzyl ester (2.29) 
O N
H
O
H
N
O
OH
 
 
Cbz-L-valine 2.28 (2.00 g, 8.36 mmol) was coupled to L-leucinol (1.07 mL, 8.36 mmol) 
according to General procedure B2 to give the crude alcohol 2.29.  Flash chromatography 
(60:40 ethyl acetate:petroleum ether) gave the pure product as a white solid (2.11 g, 72%). 
mp = 119-120 °C;  
Spectral properties are in agreement with the literature.5 
1H NMR δ(CD3OD) 7.37-7.28 (5H, m, ArH (Cbz)), 5.12 (1H, d, J = 12.5 Hz, CCH2O), 
5.06 (1H, d, J = 12.5 Hz, CCH2O), 4.01-3.96 (1H, m, CHCH2CH(CH3)2), 3.90-3.87 (1H, 
m, CHCH(CH3)2), 3.49-3.41 (2H, m, CH2OH), 2.06-2.00 (1H, m, CHCH(CH3)2), 1.70-
1.62 (1H, m, CHCH2CH(CH3)2), 1.44-1.33 (2H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2 ), 0.96-0.88 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 173.92, 158.50, 138.19, 129.44, 128.98, 128.80, 67.63, 65.57, 62.38, 
50.66, 41.03, 31.83, 25.79, 23.84, 22.29, 19.82, 18.65; 
[α]D = -23.0 (c = 0.1 in CH3OH); 
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HRMS (ES) 351.2278 (MH+) C19H31N2O4 requires 351.2284; 
νmax (KBr) 3330 (CH2OH), 2976 (CONH), 1693 (OC=O).  
 
 
Preparation of [1S-(1S-formyl-3-methylbutylcarbamoyl)-2-methylpropyl]carbamic 
acid benzyl ester (2.19) 
O N
H
O
H
N
O
O
H
 
 
The alcohol 2.29 (2.00 g, 5.71 mmol) was oxidised according to General procedure L to 
give the pure product as a white solid.  Purification was not necessary (1.83 g, 91%). 
mp = 136-138 °C; 
Spectral properties are in agreement with the literature.5 
1H NMR δ(CDCl3) 9.56 (1H, s, CHO), 7.38-7.32 (5H, m, ArH (Cbz)), 6.34 (1H, d, J = 7.3 
Hz, NH), 5.36 (1H, d, J = 8.7 Hz, NH), 5.41 (2H, s, CCH2O), 4.57-4.53 (1H, m, 
CHCH2CH(CH3)2), 4.05 (1H, t, J = 8.3 Hz, CHCH(CH3)2), 2.18-2.12 (1H, m, 
CHCH(CH3)2), 1.75-1.66 (2H, m, CHCH2CH(CH3)2), 1.47-1.40 (1H, m, 
CHCH2CH(CH3)2), 0.99 (3H, d, J = 6.8 Hz, CHCH2CH(CH3)2), 0.94 (9H, m, 
CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 199.11, 171.49, 156.38, 128.53, 128.20, 127.97, 67.07, 60.33, 57.27, 
37.72, 30.97, 24.72, 23.00, 21.84, 21.84, 19.19, 17.76; 
[α]D = +12.0 (c = 0.1 in CHCl3); 
HRMS (ES) 349.2119 (MH+) C19H28N2O4 requires 349.2127; 
νmax (KBr) 2958 (CONH), 1732 (CHO), 1693 (OC=O).  
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Preparation of [1S-(1S-hydroxymethyl-2-phenylethylcarbamoyl)-2-methylpropyl]-
carbamic acid benzyl ester (2.30) 
 
O N
H
O
H
N
O
OH
 
 
Cbz-L-valine 2.28 (1.00 g, 4.18 mmol) was coupled to L-phenylalaninol (0.63 g, 4.18 
mmol) according to General procedure B2. The crude alcohol 2.30 was recrystallised 
from ethyl acetate/petroleum ether to afford the pure product (1.32 g, 82%). 
mp = 108-110 °C; 
1H NMR δ((CD3)2CO) 7.39-7.18 (10H, m, ArH (Cbz and Phe)), 6.93 (1H, d, J = 9.2 Hz, 
NH), 5.09 (2H, bs, CCH2O), 4.16-4.10 (1H, m, CHCH2C), 3.89-3.83 (1H, m, 
CHCH(CH3)2), 3.50 (2H, d, J = 5.3 Hz, CHCH2OH), 2.91 (1H, dd, J = 6.1 and 13.5 Hz, 
CHCH2C), 2.72 (1H, dd, J = 8.6 and 13.5 Hz CHCH2C), 2.01-1.91 (1H, CHCH(CH3)2), 
0.88-0.83 (6H, m, CHCH(CH3)2); 
13C NMR δ((CD3)2CO) 207.39, 207.20, 140.92, 130.98, 130.112, 129.99, 129.90, 129.73, 
129.39, 127.55, 67.35, 64.27, 62.28, 54.46, 38.36, 32.52, 20.62, 19.30; 
[α]D = -11.0 (c = 0.1 in CH3OH); 
HRMS (ES) 407.1947 (MNa+) C22H28N2O4Na requires 407.1947; 
νmax (KBr) 3278 (CH2OH), 2961 (C(O)NH), 1691 (OC=O). 
 
 
Preparation of [1S-(1S-benzyl-2-oxoethylcarbamoyl)-2-methylpropyl]carbamic acid 
benzyl ester (2.2) 
N
H
H
N
O
O
O
O
H
 
 
The alcohol 2.30 (1.26 g, 3.74 mmol) was oxidised according to General procedure L to 
give the pure product as a white solid.  Purification was not necessary (1.30 g, 91%). 
mp = 112-113 °C; 
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Spectral properties are in agreement with the literature.6 
1H NMR δ((CD3)2CO) 9.61 (1H, s, CHO), 7.70 (1H, d, J = 8.6 Hz, NH), 7.38-7.35 (5H, m, 
ArH (Cbz)), 7.27-7.23 (5H, m, ArH (Phe)), 6.34 (1H, d, J = 9.2 Hz, NH), 5.10 (1H, d, J = 
12.5 Hz, CCH2O), 5.07 (1H, d, J = 12.5 Hz, CCH2O) , 4.55-4.51 (1H, m, CHCH2C), 4.10-
4.06 (1H, m, CHCH(CH3)2), 3.25 (1H, dd, J = 5.1 and 14.2 Hz, CHCH2C), 2.97 (1H, dd, J 
= 8.8 and 14.2 Hz, CHCH2C), 2.15-2.06 (1H, m, CHCH(CH3)2), 0.93 (3H, d, J = 6.8 Hz, 
CHCH(CH3)2), 0.89 (3H, d, J = 6.8 Hz, CHCH(CH3)2); 
13C NMR δ((CD3)2CO) 207.20, 200.94, 173.55, 158.14, 139.25, 139.13, 131.13, 130.18, 
129.61, 129.57, 128.30, 67.79, 62.11, 61.98, 35.88, 32.57, 20.71, 19.02;  
 [α]D = -6.0 (c = 0.1 in CH3OH); 
HRMS (ES) 383.1979 (MH+) C22H26N2O4 requires 383.1971; 
νmax (KBr) 2966 (CONH), 1730 (CHO), 1639 (OC=O). 
 
 
Preparation of [1S-(1S-hydroxymethyl-3-methylbutylcarbamoyl)-2-methylpropyl]-
carbamic acid tert-butyl ester (2.32) 
BocH2N
O
H
N
OH
 
 
N-Boc-L-valine 2.31 (4.63 g, 21.35 mmol) was coupled to L-leucinol (2.73 mL, 21.35 
mmol) according to General Procedure B2.  The crude material was purified by flash 
chromatography on silica using a gradient of EtOAc and (50/70) pet ether to yield a white 
solid (2.30 g, 68%).   
mp = 54-56 ºC ; 
1H NMR δ(CDCl3)  6.24 (1H, d, J = 7.9 Hz, NH Leu), 5.10 (1H, d, J = 7.32 Hz, NH Val), 
3.99–4.06 (1H, m, CHCH2CH(CH3)2), 3.80 (1H, dd, J = 7.3 and 7.3 Hz, CHCH(CH3)2), 
3.65 (1H, dd, J = 3.2 and 11.1 Hz, CH2OH), 3.50 (1H, dd J = 5.6Hz and 11.1 Hz, 
CH2OH), 2.06-2.16 (1H, m, CHCH(CH3)2), 1.58-1.62 (1H, m, CHCH2CH(CH3)2), 1.43 
(9H, s, C(CH3)3), 0.88-0.97 (12H, m, CHCH2CH(CH3)2 and CHCH(CH3)2); 
13C NMR δ(CD3OD) 172.95, 163.32, 79.20, 64.31, 60.74, 49.32, 39.80, 30.45, 27.48, 
24.46, 22.69, 21.05, 18.56, 17.32; 
HRMS (ES) 317.2249 (MH+) C16H32N2O4 requires 317.2240. 
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Preparation of 2S-amino-N-(1S-hydroxymethyl-3-methylbutyl)-3-methylbutyr-amide 
trifluoroacetate salt (2.33) 
TFA
.
H2N
O
H
N
OH
 
 
N-Boc protected compound 2.32 (2.30 g, 7.23 mmol) was deprotected using General 
Procedure E to afford a white solid.  Purification was not necssary (1.57 g, 100%). 
mp = 64-66 ºC; 
1H NMR δ((CD3)2SO) 8.13 (2H, bs, NH2) 4.72-4.77 (1H, m, CHCH2CH(CH3)2), 3.79-3.87 
(1H, m, CHCH(CH3)2) 3.52-3.56 (1H, m, CH2OH), 3.26 (1H, dd, J = 6.0 and 16.0 Hz, 
CH2OH), 2.02-2.08 (1H, m, CHCH(CH3)2), 1.60-1.68 (1H, m, CHCH2CH(CH3)2), 1.30-
1.33 (2H, m, CHCH2CH(CH3)2), 0.85-0.94 (12H, m, CHCH2CH(CH3)2 and 
CHCH(CH3)2); 
13C NMR δ((CD3)2SO) 167.19 63.43, 57.35, 49.25, 29.71, 23.94, 23.33, 21.97, 18.21, 
17.90;  
HRMS (ES) 217.1910 (MH+) C11H24N2O2 requires 217.1916.  
 
 
Preparation of 1H-pyrrole-2-carboxylic acid [1S-(1S-hydroxymethylbutyl-
carbamoyl)-2-methylpropyl]amide (2.35) 
 
N
H O
H
N
OH
OH
N
 
 
Reaction of the free amine 2.33 (0.70 g, 2.77 mmol) with 2-pyrrole carboxylic acid (0.31 g, 
2.77 mmol) according to General procedure C gave 2.35 as an orange solid (0.73 g, 
85%).  
mp = 110-112 ºC ; 
1H NMR δ(CD3OD)  7.85 (1H, d, J = 9.8 Hz, NH), 7.60 (1H, d, J = 9.8 Hz, NH),  6.86-
6.87 (1H, m, CHCHCH), 6.91-6.92 (1H, m, CHCHCH), 6.16-6.17 (1H, m, CHCHCH), 
4.26 (1H, dd, J = 9.8 and 2.1 Hz, CHCH(CH3)2), 3.98-4.02 (1H, m, CHCH2CH(CH3)2), 
3.43-3.48 (2H, m, CH2OH), 2.11-2.12 (1H, m, CH(CH3)2), 1.55-1.59 (1H, m, 
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CH2CH(CH3)2), 1.35-1.40 (2H, m, CH2CH(CH3)2), 0.97-1.00 (6H, m, CHCH2CH(CH3)2), 
0.89 (3H, d, J = 7.2 Hz, CHCH(CH3)2), 0.86 (3H, d, J = 7.2 Hz, CHCH(CH3)2); 
13C NMR δ(CD3OD) 174.21, 163.67, 126.76, 123.56, 112.82, 110.60, 65.83, 60.62, 51.09, 
41.32,  31.94,  26.15, 24.03, 22.69, 20.26, 19.48; 
HRMS (ES) 310.2134 (MH+) C16H28N3O3 requires 310.2131;  
νmax (KBr) 3415 (CH2OH), 2648 (CONH). 
 
 
Preparation of 1H-pyrrole-2-carboxylic acid [1S-(1S-formyl-3-methylbutyl-
carbamoyl)-2-methylpropyl]amide (2.21) 
 
N
H O
H
N
H
OH
N
O
 
 
Oxidation of 2.35 (0.37 g, 1.18 mmol) according to General procedure L gave the pure 
product 2.21 as a colourless crystalline solid (0.26 g, 84%).  
mp = 165-167 ºC; 
1H NMR δ(CD3OD) 11.45 (1H, s, NH), 9.36 (1H, s, CHO), 8.40 (1H, d, J = 9.4 Hz, NH),  
7.92 (1H, d, J = 9.1 Hz, NH), 6.85-6.87 (1H, m, CHCHCH), 6.83-6.85 (1H, m, 
CHCHCH), 6.03-6.05 (1H, m, CHCHCH), 4.30 (1H, m, CHCH(CH3)2), 4.02-4.07 (1H, m, 
CHCH2CH(CH3)2), 2.10-2.15 (1H, m, CH(CH3)2), 1.53-1.56 (1H, m, CH2CH(CH3)2), 
1.33-1.38 (2H, m, CH2CH(CH3)2), 0.89 (3H, d, J = 12.0 Hz, CHCH2CH(CH3)2), 0.87 (3H, 
d, J = 12.0 Hz, CHCH2CH(CH3)2), 0.81 (3H, d, J = 11.5 Hz, CHCH(CH3)2), 0.79 (3H, d, J 
= 10.5 Hz, CHCH(CH3)2);  
13C NMR δ((CD3)2SO) 201.36, 172.08, 160.53, 125.91, 121.60, 111.23, 108.76, 57.99, 
56.89, 36.41, 30.34, 23.28, 21.42, 19.44, 18.80, 18.72; 
HRMS (ES) 308.1961 (MH+) C16H26N3O3 requires 308.1974;  
νmax (KBr) 1741 (CHO), 1651 (CONH). 
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Preparation of N-(1S-hydroxymethyl-3-methylbutyl)-3-methyl-2S-(2-thiophen-2-
ylacetylamino)butyramide (2.36) 
 
N
H O
H
N OH
O
S
 
Reaction of the free amine 2.33 (0.70 g, 2.77 mmol) with 2-thiophene acetyl chloride 
according to General procedure A gave 2.36 as an orange solid.  Flash chromatography 
on silica (1:1 ethyl acetate/petroleum ether) gave the pure product (0.46 g, 49%). 
mp = 158-160 ºC;   
1H NMR δ(CD3OD), 8.03 (1H, d, J = 9.3 Hz, NH), 7.75 (1H, d, J = 9.4 Hz, NH), 7.25 
(1H, d, J  = 5.5 Hz, CHCHCH), 6.93-6.94 (2H, m, CHCHCH), 4.11 (1H, t, J = 7.5 Hz, 
CHCH(CH3)2), 3.96-3.97 (1H, m, CHCH2CH(CH3)2), 3.73-3.81 (2H, m, CH2C(O)NH), 
3.39-3.47 (2H, m, CH2OH), 2.00-2.05 (1H, m, CH(CH3)2), 1.59-1.61 (1H, m, 
CH2CH(CH3)2), 1.33-1.37 (2H, m, CH2CH(CH3)2), 0.93 (3H, d, J = 7.2 Hz, 
CHCH2CH(CH3)2),  0.91 (3H, d, J = 7.2 Hz, CHCH2CH(CH3)2), 0.88 (3H, d, J = 7.0 Hz, 
CHCH(CH3)2), 0.85 (3H, d, J = 7.0 Hz, CHCH(CH3)2);  
13C NMR δ(CD3OD), 173.5, 173.0, 138.4, 128.1, 127.9, 126.0, 65.9, 60.9, 51.1, 38.0, 32.1, 
30.1, 26.0, 24.1, 22.5, 20.0, 19.0;  
HRMS (ES) 341.1893 (MH+) C17H29N2O3S requires 341.1899;  
νmax (KBr) 3350 (CH2OH), 1647 (CONH).   
 
 
Preparation of N-(1S-formyl-3-methylbutyl)-3-methyl-2S-(2-thiophen-2-ylacetyl-
amino)butyramide (2.22) 
N
H O
H
N
O
H
O
S
 
 
Oxidation of 2.36 (0.40 g, 1.17 mmol) according to General procedure L gave 2.22 as a 
colourless crystalline solid (0.26 g, 84%). 
mp =  134-136 °C;  
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1H NMR δ((CD3)2SO) 8.51 (1H, d, J = 6.5 Hz, NH), 8.28 (1H, d, J = 9.0 Hz, NH), 7.42-
7.44 (1H, m, CHCHCH), 7.02-7.04 (1H, m, CHCHCH), 6.99-7.01 (2H, m, CHCHCH),  
4.32 (1H, t, J = 8.5 Hz, CHCH(CH3)2), 4.19-4.21 (1H, m, CHCH2CH(CH3)2), 3.73-3.81 
(2H, dd, J = 38.0 and J = 15.5 Hz, CH2C(O)NH), 2.07-2.09 (1H, m, CH(CH3)2), 1.60-1.62 
(1H, m, CH2CH(CH3)2), 1.50-1.53 (2H, m, CH2CH(CH3)2), 0.98 (3H, d, J = 6.5 Hz, 
CHCH2CH(CH3)2), 0.94 (3H, d, J = 8.3 Hz, CHCH2CH(CH3)2), 0.93 (3H, d, J = 7.4 Hz, 
CHCH(CH3)2), 0.91 (3H, d, J = 10.3 Hz, CHCH(CH3)2);  
13C NMR δ((CD3)2SO) 18.20, 19.32, 21.44, 23.18, 24.16, 30.73, 36.38, 39.02, 56.88, 
57.65, 124.87,  126.01, 126.69, 138.04, 169.25, 171.58, 201.24; 
HRMS (ES) 339.1753 (MH+) C17H27N2O3S requires 339.1742;  
νmax (KBr) 1726 (CHO), 1638 (CONH);  
 
 
7.2.2 Synthesis of Semicarbazones 
 
Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-semicarbazone-3-
methylbutyl)-3-methylbutyramide (2.37)  
 
F
O2
S N
H
H
N
O
N
H
N NH2
O
 
 
The aldehyde 2.3 (0.10 g, 0.268 mmol) in 1:1 tetrahydrofuran:water was reacted with 
semicarbazide hydrochloride (0.033 g, 0.295 mmol) according to General Procedure O to 
give the product as a white solid (0.10 g, 90%) 
mp = 104-106 °C (lit.7 mp = 100-102 °C); 
1H NMR δ((CD3)2SO) 9.86 (1H, s, CH=NNHC(O)NH2), 7.92 (1H, d, J = 8.0 Hz, 
CHCH=N), 7.83-7.80 (2H, m, ArH (Fps)), 7.38-7.34 (2H, m, ArH (Fps)), 7.00 (1H, d, J = 
4.1 Hz, NH), 6.23 (1H, bs, NH2), 4.23-4.16 (1H, m, CHCH2CH(CH3)2), 3.58-3.52 (1H, m, 
CHCH(CH3)2), 1.85-1.77 (1H, m, CHCH(CH3)2),  1.24-1.12 (2H, m, CHCH2CH(CH3)2 
and CHCH2CH(CH3)2), 1.07-0.98 (1H, m, CHCH2CH(CH3)2), 0.81-0.77 (9H, m, 
CHCH(CH3)2 and CHCH2CH(CH3)2), 0.72 (3H, d, J = 5.7 Hz, CHCH(CH3)2); 
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13C δ((CD3)2SO) 169.19, 162.91, 161.35 (d, J = 256.3 Hz), 156.69, 141.86, 137.63 (d, J = 
3.0 Hz), 129.44 (d, J = 9.4 Hz), 115.82 (d, J = 22.9 Hz), 61.29, 47.69, 41.65, 31.15, 23.74, 
22.58, 21.95, 19.08, 18.08; 
HRMS (ES) 430.1935 (MH+) C18H29FN5O4S requires 430.1924; 
[α]D = +6.0 (c = 0.1 in (CH3)2SO); 
 
 
Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-thiosemicarbazone-3-
methylbutyl)-3-methylbutyramide (2.28) 
 
F
O2
S N
H
H
N
O
N
H
N NH2
S
 
 
The aldehyde 2.3 (0.10 g, 0.268 mmol) in 1:1 tetrahydrofuran:water was reacted with 
thiosemicarbazone hydrochloride (0.027 g, 0.295 mmol) according to General Procedure 
O to give the product as a yellow solid (0.067 g, 54%) 
mp = 101-103 °C; 
1H NMR δ((CD3)2SO) 9.13 (1H, s, CH=NNHC(O)NH2), 7.96 (1H, d, J = 4.9 Hz, NH), 
7.95 (1H, d, J = 6.1 Hz, CHCH=N) 7.83-7.80 (2H, m, ArH (Fps)), 7.37-7.33 (2H, m, ArH 
(Fps)), 7.26 (1H, d, J = 4.1 Hz, NH), 5.57 (1H, bs, NH2), 4.30-4.23 (1H, m, 
CHCH2CH(CH3)2), 4.06-4.03 (1H, m, CHCH(CH3)2), 1.87-1.77 (1H, m, CHCH(CH3)2),  
1.20-1.11 (2H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.07-1.00 (1H, m, 
CHCH2CH(CH3)2), 0.84-0.73 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C δ((CD3)2SO) 162.98, 156.79 (d, J = 250.8 Hz), 137.68, 128.79 (d, J = 3.3 Hz), 121.63 
(d, J = 9.4 Hz), 107.5 (d, J = 22.9 Hz), 53.80, 32.96, 23.26, 15.96, 13.50, 12.87, 10.17, 
8.68; 
[α]D = +66.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 446.1695 (MH+) C18H29FN5O3S2 requires 446.1696; 
νmax (KBr)  3269 (SO2NH), 2959 (C(O)NH), 1593 (NHS=C). 
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-[1S-(4-phenylsemicarbazone)-3-
methylbutyl]-3-methylbutyramide (2.39) 
F
O2
S N
H
H
N
O
N
H
N
H
N
O
 
 
The aldehyde 2.3 (0.10 g, 0.268 mmol) in methanol was reacted with 4-phenyl 
semicarbazide hydrochloride (0.055 g, 0.295 mmol) according to General Procedure O to 
give the product as a brown solid (0.11 g, 82%) 
mp = 200-201 °C; 
1H NMR δ((CD3)2SO) 10.40 (1H, s, NNHC(O)NHPh), 8.60 (1H, s, NNHC(O)NHPh), 8.10 
(1H, d, J = 8.6 Hz, NH), 7.96 (1H, d, J = 9.4 Hz, NH), 7.85-7.82 (2H, m, ArH (Fps)), 7.55 
(2H, d, J = 7.6 Hz, ArH (Ph)), 7.39-7.36 (2H, m, ArH (Fps)), 7.27 (2H, t, J = 7.6 Hz, ArH 
(Ph)), 7.13 (1H, d, J = 4.1 Hz, CHCH=NNHC(O)NHPh), 6.99 (1H, t, J = 7.6 Hz, 
ArH(Ph)), 4.36-4.31 (1H, m, CHCH2CH(CH3)2), 3.63-3.60 (1H, m, CHCH(CH3)2), 1.89-
1.83 (1H, m, CHCH(CH3)2), 1.27-1.22 (1H, m, CHCH2CH(CH3)2), 1.19-1.13 (1H, m, 
CHCH2CH(CH3)2), 1.10-1.05 (1H, m, CHCH2CH(CH3)2), 0.84 (3H, d, J = 6.5 Hz, 
CHCH(CH3)2), 0.81 (3H, d, J = 3.0 Hz, CHCH2CH(CH3)2), 0.79 (3H, d, J = 3.0 Hz, 
CHCH2CH(CH3)2), 0.75 (3H, d, J = 6.5 Hz, CHCH(CH3)2); 
13C NMR δ((CD3)2SO) 169.29, 168.07 (d, J = 252.4 Hz), 162.97, 152.97, 152.90, 143.42, 
138.94 (d, J = 2.0 Hz), 129.45 (d, J = 9.4 Hz), 128.59, 122.40, 119.14, 115.88 (d, J = 22.5 
Hz), 61.30, 47.71, 41.90, 31.30, 23.83, 22.75, 21.86, 19.15, 18.04; 
[α]D = +3.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 506.2242 (MH+) C24H33FN5O4S requires 506.2237; 
νmax (KBr)  3499 (C(O)NH2), 3283 (SO2NH), 2963 (C(O)NH), 2503 (C=NNH).  
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methyl-N-[3-methyl-1S-(phenyl-
hydrazono)butyl]butyramide (2.40) 
 
F
O2
S N
H
H
N
O
N
H
N
 
 
The aldehyde 2.3 (0.10 g, 0.268 mmol) in methanol was reacted with phenylhydrazine 
hydrochloride (0.043 g, 0.295 mmol) according to General Procedure O to give the 
product as a brown solid (0.097 g, 80%) 
mp = 176-178 °C; 
1H NMR δ((CD3)2SO) 9.79 (1H, s, CH=NNHPh), 8.06 (1H, d, J = 7.8 Hz, CH=NNHPh), 
7.85-7.79 (2H, m, ArH (Fps)), 7.70 (2H, d, J = 6.9 Hz, ArH (Ph)), 7.37-7.33 (2H, m, ArH 
(Fps)), 7.06 (2H, t, J = 6.9 Hz, ArH (Ph)), 6.66-6.62 (1H, m, ArH (Ph)), 4.12-4.07 (1H, m, 
CHCH2CH(CH3)2), 3.61 (1H, dd, J = 6.6 and 9.4 Hz, CHCH(CH3)2), 1.86-1.78 (1H, m, 
CHCH(CH3)2), 1.34-1.19 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.86 (3H, d, J 
= 6.1 Hz, CHCH(CH3)2), 0.81 (3H, d, J = 6.8 Hz, CHCH2CH(CH3)2), 0.78 (3H, d, J = 6.8 
Hz, CHCH2CH(CH3)2), 0.75 (3H, d, J = 6.1 Hz, CHCH(CH3)2); 
13C NMR δ((CD3)2SO) 171.381, 169.68, 163.92 (d, J = 248.7 Hz), 149.06, 137.45 (d, J = 
3.0 Hz), 129.57 (d, J = 9.9 Hz), 128.51, 118.34, 115.81 (d, J = 22.48 Hz), 112.04, 60.80, 
49.30, 40.77, 31.23, 23.92, 22.62, 21.90, 19.08, 17.96; 
[α]D = +9.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 463.2174 (MH+) C23H32FN4O3S requires 463.2179; 
νmax (KBr)  3260 (SO2NH), 2963 (C(O)NH), 2365 (C=NNH).  
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7.2.3 Synthesis of Heterocycles 
 
Preparation of 2S-[-2S-(4-fluorobenzenesulfonylamino)-3-methylbutyrylamino]-4-
methylpentanoic acid methyl ester (2.44) 
 
F
O2
S N
H
H
N
O
OMe
O
 
 
The acid 2.24 (1.00 g, 3.63 mmol) was coupled to L-leucine methyl ester hydrochloride 
(0.727 g, 4.00 mmol) according to General Procedure B to give the crude product which 
was purified by flash chromatography on silica (1:4 ethyl acetate:petroleum ether).  The 
pure product was isolated as a white solid (1.25 g, 86%). 
mp = 110-111 °C; 
Spectral properties are in agreement with the literature.8 
1H NMR δ(CDCl3) 7.83-7.89 (2H, m, ArH (Fps)), 7.10-7.16 (2H, m, ArH (Fps)), 6.16 (1H, 
d, J = 8.1 Hz, NH), 5.63 (1H, d, J = 8.8 Hz, NH), 4.35-4.44 (1H, m, CHCH2CH(CH3)2), 
4.11 (1H, dd, J = 7.1 and 8.1 Hz, CHCH(CH3)2), 3.69 (3H, s, CO2CH3), 1.99-2.08 (1H, m, 
CHCH(CH3)2), 1.41-1.54 (1H, m,  CHCH2CH(CH3)2), 1.21-1.37 (2H, m, 
CHCH2CH(CH3)2), 0.94 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.84 (3H, d, J = 6.8 Hz, 
CHCH(CH3)2), 0.84 (3H, d, J = 6.5 Hz, CHCH2CH(CH3)2), 0.80 (3H, d, J = 6.5  Hz, 
CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 172.83, 170.18, 164.93 (d, J = 252.3 Hz), 132.88 (d, J = 3.4 Hz) 
130.98 (d, J = 9.4 Hz), 115.70 (d, J = 23.1 Hz), 61.49, 52.22, 50.64, 41.12, 31.86, 24.48, 
22.43, 21.54, 19.02, 17.04; 
[α]D = +3.4 (c = 0.1 in CHCl3); 
HRMS (ES) 403.1706 (MH+) C18H28FN2O5 S requires 403.1703; 
νmax (KBr)  3273 (SO2NH), 2961 (C(O)NH), 1720 (CO2Me).  
Chapter Seven – Experimental  236   
Preparation of 2S-[-2S-(4-fluorobenzenesulfonylamino)-3-methylbutyrylamino]-4-
methylpentanoic acid (2.7) 
 
F
O2
S N
H
H
N
O
OH
O
 
 
The methyl ester 2.44 (1.00 g, 2.49 mmol) was hydrolysed according to General 
Procedure G2 to give the pure product 2.7 as a white solid (0.93 g, 96%). 
mp = 167-168 °C; 
Spectral properties are in agreement with the literature.9 
1H NMR δ(CD3OD) 7.81-7.78 (2H, m, ArH (Fps)), 7.31 (1H, d, J = 5.8 Hz, NH), 7.11-
7.08 (2H, m, ArH (Fps)), 4.20-4.16 (1H, m, CHCH2CH(CH3)2), 3.51 (1H, d, J = 5.7 Hz, 
CHCH(CH3)2), 1.97 (1H, m, CHCH(CH3)2), 1.48-1.42 (1H, m, CHCH2CH(CH3)2), 1.31-
1.21 (2H, m, CHCH2CH(CH3)2), 0.90 (3H, d, J = 6.5 Hz, CHCH2CH(CH3)2), 0.82 (3H, d, 
J = 2.4 Hz, CHCH(CH3)2), 0.81 (3H, d, J = 2.4 Hz, CHCH(CH3)2), 0.75 (3H, d, J = 6.5 
Hz, CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 175.53, 172.81, 166.30 (d, J = 252.1 Hz), 138.57 (d, J = 3.2 Hz), 
131.22 (d, J = 9.4 Hz), 117.05 (d, J = 22.8 Hz), 62.86, 51.92, 41.70, 33.11, 25.73, 23.24, 
22.01, 19.80, 18.28; 
[α]D = -8.0 (c = 0.1 in CH3OH); 
HRMS (ES) 389.1543 (MH+) C23H34N2O6 requires 389.1546; 
νmax (KBr)  3344 (COOH), 3184 (SO2NH), 2968 (C(O)NH).  
 
 
Preparation of N-hydroxyacetamidine (2.47) 
 
NH
N
H
OH
 
 
A 50% aqueous hydroxylamine solution (3.7 mL, 56 mmol) was added to acetonitrile (30 
mL) and heated at for 24 h.  After cooling to rt the solvent was removed in vacuo to yield a 
glassy solid (2.45 g, 59%).  
Spectral properties are in agreement with the literature.10 
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1H NMR δ(CDCl3) 4.55 (3H, bs, OHNH and C=NH), 1.86 (3H, s, CH3); 
 
 
Preparation of 2S-[-2S-(4-fluorobenzenesulfonylamino)-3-methylbutyrylamino]-4-
methylpentanoic-N-hydroxyacetamidine (2.48) 
 
F
O2
S N
H
H
N
O
O
O
N NH2
 
 
The acid 2.44 (0.50 g, 1.29 mmol) was coupled to N-hydroxyacetamidine 2.47 (0.17 g, 
1.54 mmol) according to General Procedure E2 to give the crude product as a glassy 
solid.  Recrystallisation from a minimal amount of ethyl acetate gave the pure product as a 
colourless glassy solid (0.47 g, 82 %). 
1H NMR δ(CDCl3) 7.90-7.85 (2H, m, ArH (Fps)), 7.19-7.14 (2H, m, ArH (Fps)), 6.36 (1H, 
d, J = 8.2 Hz, NH), 5.61 (1H, d, J = 8.6 Hz, NH), 4.53-4.48 (1H, m, CHCH2CH(CH3)2), 
3.55 (1H, dd, J = 5.1 and 8.6 Hz, CHCH(CH3)2), 2.08-2.03 (1H, m, CHCH(CH3)2), 1.96 
(3H, s, N=C(NH2)CH3), 1.62-1.53 (2H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
1.46-1.36 (1H, m, CHCH2CH(CH3)2), 0.92-0.86 (12H, m, CHCH(CH3)2 and 
CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 173.72, 172.04, 165.61 (d, J = 255.1 Hz), 137.18 (d, J = 3.5 Hz), 
130.55 (d, J = 9.4 Hz), 116.82, 116.58 (d, J = 22.6 Hz), 62.84, 52.49, 45.43, 40.93, 32.43, 
25.21, 22.92, 21.84, 19.45, 17.89, 16.27; 
[α]D = -10.0 (c = 0.1 in CHCl3); 
HRMS (ES) 445.1923 (MH+) C19H30FN4O5S requires 445.1921. 
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methyl-N-[3-methyl-1S-(3-
methyl-[1,2,4]oxadiazole-5-yl)-butyl]butyramide (2.41) 
 
F
O2
S N
H
H
N
O
O
N
N
 
 
Sodium acetate (0.20 g, 0.25 mmol, 1.1 equiv) dissolved in water was added to a stirred 
solution of 2.48 (0.10 g, 0.23 mmol, 1.0 equiv) in ethanol and the resulting mixture heated 
at reflux for 5 h.  The solution was allowed to cool to rt, then the solvents were removed in 
vacuo to give a colourless residue.  The residue was partitioned between ethyl acetate and 
water.  The aqueous layer was extracted and the subsequent organic layer dried over 
MgSO4, filtered and solvent removed under reduced pressure to give the crude product.  
Recrystallisation from ethyl acetate/petroleum ether gave the pure product as a colourless 
glassy solid (0.06 g, 58%). 
1H NMR δ(CDCl3) 7.89-7.84 (2H, m, ArH (Fps)), 7.17-7.13 (2H, m, ArH (Fps)), 6.50 (1H, 
bs, NH), 5.69 (1H, bs, NH), 5.16-5.12 (1H, m, CHCH2CH(CH3)2), 3.62-3.59 (1H, m, 
CHCH(CH3)2), 2.35 (3H, s, NC(=N)CH3), 2.04-2.01 (1H, m, CHCH(CH3)2), 1.64-1.60 
(1H, m, CHCH2CH(CH3)2), 1.56-1.48 (1H, m, CHCH2CH(CH3)2), 1.35-1.29 (1H, m, 
CHCH2CH(CH3)2), 0.91-0.88 (6H, m, CHCH2CH(CH3)2), 0.83-0.81 (3H, m, 
CHCH(CH3)2); 
13C NMR δ(CDCl3) 179.62, 171.88, 167.63, 165.53 (d, J = 254.0 Hz), 137.02 (d, J = 3.1 
Hz), 130.48 (d, J = 22.6 Hz), 116.55 (d, J = 9.3 Hz), 62.08, 45.34, 42.02, 32.30, 24.85, 
22.61, 21.92, 19.40, 17.81, 11.52; 
[α]D = -30.0 (c = 0.1 in CHCl3); 
HRMS (ES) 427.1813 (MH+) C19H28FN4O4S requires 427.1815. 
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Preparation of 2S-(2S-benzyloxycarbonylamino-3-methylbutyrylamino)-4-methyl-
pentanoic acid methyl ester (2.45) 
 
O N
H
O
H
N
O
OMe
O
 
 
Cbz-L-valine 2.28 (2.00 g, 7.96 mmol) was coupled to L-leucine methyl ester 
hydrochloride (1.59 g, 8.76 mmol) according to General Procedure B to give the crude 
product which was purified by flash chromatography on silica (1:5 ethyl acetate:petroleum 
ether).  The pure product was isolated as a white solid (2.66 g, 88%). 
mp = 99-100 °C; 
Spectral properties are in agreement with the literature.8 
1H NMR δ(CDCl3) 7.35 (5H, m, ArH (Cbz)), 6.53 (1H, d, J = 7.8 Hz, NH), 5.51 (1H, d, J 
= 8.9 Hz, NH), 5.13-5.07 (2H, m, CCH2O), 4.63-4.59 (1H, m, CHCH2CH(CH3)2), 4.09-
4.06 (1H, m, CHCH(CH3)2), 3.72 (3H, s, CO2CH3), 2.13-2.07 (1H, m, CHCH(CH3)2), 
1.67-1.60 (2H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.54-1.52 ( 1H, m, 
CHCH2CH(CH3)2), 0.97 (3H, d, J = 6.7 Hz, CHCH2CH(CH3)2), 0.94-0.91 (9H, m, 
CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 174.24, 174.16, 158.28, 138.04, 129.36, 128.88, 128.67, 67.50, 61.67, 
52.58, 51.97, 41.23, 32.00, 25.73, 23.31, 21.89, 19.69, 18.70; 
[α]D = -12.5 (c = 0.1 in CHCl3); 
HRMS (ES) 379.2236 (MH+) C20H31N2O5 requires 379.2233; 
νmax (KBr)  2962 (C(O)NH), 22428 (C(O)NH), 1751 (CO2Me).  
 
 
 
 
 
 
 
 
 
Chapter Seven – Experimental  240   
Preparation of 2S-(2S-benzyloxycarbonylamino-3-methylbutyrylamino)-4-methyl-
pentanoic acid (2.46) 
O N
H
O
H
N
O
OH
O
 
 
The methyl ester 2.45 (1.00 g, 2.64 mmol) was hydrolysed according to General 
Procedure G2 to give the pure product 2.46 as a white solid (0.98 g, 92%). 
mp = 137-139 °C (lit11 mp = 138-139 °C)  
1H NMR δ(CDCl3) 7.36-7.28 (5H, m, ArH (Cbz)), 6.97 (1H, d, J = 7.8 Hz, NH), 5.99 (1H, 
d, J = 9.1 Hz, NH), 5.08 (2H, s, CCH2O), 4.61-4.57 (1H, m, CHCH2CH(CH3)2),  4.08-4.05 
(1H, m, CHCH(CH3)2), 2.05-2.01 (1H, m, CHCH(CH3)2), 1.71-1.62 (2H, m, 
CHCH2CH(CH3)2), 1.58-1.55 (1H, m, CHCH2CH(CH3)2), 0.94-0.89 (12H, m, 
CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 175.70, 174.18, 158.42, 138.11, 129.42, 128.93, 128.72, 67.60, 61.80, 
51.92, 41.57, 32.06, 25.85, 23.43, 21.90, 19.77, 18.66; 
[α]D = -25.0 (c = 0.1 in CH3OH); 
HRMS (ES) 365.2074 (MH+) C19H29N2O5 requires 365.2076; 
νmax (KBr)  3352 (COOH), 2961 (C(O)NH), 2872 (C(O)NH).  
 
 
Preparation of 2S-(2S-benzyloxycarbonylamino-3-methylbutyrylamino)-4-methyl-
pentanoic-N-hydroxyacetamidine (2.49) 
 
N
H O
H
NO
O
O
O
N NH2
 
 
The acid 2.46 (0.50 g, 1.37 mmol) was coupled to N-hydroxyacetamidine 2.47 (0.12 g, 
1.65 mmol) according to General Procedure E2 to give the crude product as a glassy 
solid.  Recrystallisation from a minimal amount of ethyl acetate gave the pure product as a 
colourless glassy solid (0.50 g, 87 %). 
1H NMR δ(CDCl3) 7.38-7.32 (5H, m, ArH (Cbz)), 6.37 (1H, d, J = 7.6 Hz, NH), 5.32 (1H, 
d, J = 8.0 Hz, NH), 5.10 (2H, s, CCH2O), 4.66-4.61 (1H, m, CHCH2CH(CH3)2), 4.03-4.00 
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(1H, m, CHCH(CH3)2), 2.17-2.10 (1H, m, CHCH(CH3)2), 1.96 (3H, s, N=CCH3), 1.77-
1.57 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.97-0.90 (12H, m, CHCH(CH3)2 
and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 171.72, 170.14, 156.86, 156.40, 136.03, 128.76, 128.15, 127.62, 
66.96, 60.07, 50.95, 40.75, 30.99, 24.57, 22.50, 21.79, 19.00, 17.71, 16.60; 
[α]D = +2.0 (c = 0.1 in CHCl3) 
HRMS (ES) 421.2443 (MH+) C21H33N4O5 requires 421.2451; 
νmax (KBr)  3449 (N=CNH2), 3328 (C(O)NH) 2976 (C(O)NH), 1647 (CO2N=C).  
 
 
Preparation of [2-methyl-1S-(3-methyl-1S-[1,2,4]oxadiazol-5-yl-3-methylbutyl-
carbamoyl)-propyl]carbamic acid benzyl ester (2.50) 
 
N
H O
H
NO
O
O
N
N
 
 
Sodium acetate (0.17 g, 0.21 mmol, 1.1 equiv) dissolved in water was added to a stirred 
solution of 2.49 (0.08 g, 0.19 mmol, 1.0 equiv) in ethanol and the resulting mixture heated 
at reflux for 5 h.  The solution was allowed to cool to rt, then solvents removed in vacuo to 
give a colourless residue.  The residue was partitioned between ethyl acetate and water.  
The aqueous layer was extracted and the organic layer subsequently dried over MgSO4, 
filtered and solvent removed under reduced pressure to give the crude product.  
Recrystallisation from ethyl acetate/petroleum ether gave the pure product as a colourless 
glassy solid (0.05 g, 61%). 
1H NMR δ(CDCl3) 7.38-7.33 (5H, m, ArH (Cbz)), 6.87 (1H, d, J = 7.5 Hz, NH), 5.51 (1H, 
d, J = 8.6 Hz, NH), 5.37 (1H, q, J = 8.0 Hz, CHCH2CH(CH3)2), 5.14-5.10 (2H, m, 
CCH2O), 4.09 (1H, t, J = 7.6 Hz, CHCH(CH3)2),  2.37 (3H, s, N=C(N)CH3), 2.14-2.08 
(1H, m, CHCH(CH3)2),  1.81-1.56 (3H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
0.98-0.90 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 178.96, 171.33, 167.08, 156.49, 136.03, 128.78, 128.19, 127.60, 
67.045, 60.03, 45.69, 44.32, 42.41, 31.00, 24.76, 22.36, 21.75, 18.99, 17.78; 
[α]D = -27.0 (c = 0.1 in CHCl3); 
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HRMS (ES) 403.2336 (MH+) C21H31N4O4 requires 403.2345; 
νmax (KBr)  3300 (C(O)NH), 2963 (C(O)NH), 1661 (CHC=NC), 1539 (NC=NO), 1244 
(CHCON).  
 
 
Preparation of N-[1S-(cyano-(R,S)-hydroxymethyl)-3-methylbutyl]-2S-(4-fluoro-
benzenesulfonylamino)-3-methylbutyramide (2.51) 
 
F
O2
S N
H
H
N
O
CN
OH
 
 
The aldehyde 2.3 (2.73 g, 7.33 mmol) was reacted according to General Procedure I to 
give the cyanohydrin 2.51 as a colourless glassy solid (2.81 g, 96%).  No further 
purification was necessary. 
NMR data reported for the mixture of diastereoisomers (1:1). 
1H NMR δ(CDCl3) 7.91-7.87 (4H, m, ArH (Fps)), 7.24-7.18 (4H, m, ArH (Fps)), 6.49 (1H, 
d, J = 8.7 Hz, NH), 6.38 (1H, d, J = 8.3 Hz, NH), 5.38 (1H d, J = 7.3 Hz, NH), 5.30 (1H, 
d, J = 6.7 Hz, NH), 4.55 (1H, d, J = 6.7 Hz, CHOH(CN)), 4.49 (1H, d, J = 3.0 Hz, 
CHOH(CN)),4.26-4.21 (1H, m, CHCH(CH3)2), 4.08-4.03 (1H, m, CHCH(CH3)2), 3.54 
(1H, dd, J = 4.4 and 7.2 Hz, CHCH2CH(CH3)2), 3.47 (1H, dd, J = 5.2 and 6.5 Hz, 
CHCH2CH(CH3)2), 2.20-2.08 (2H, m, CHCH(CH3)2), 1.68 (2H, bs, CHOH(CN)), 1.60-
1.39 (6H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.97-0.82 (24H, m, CHCH(CH3)2) 
and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 171.30, 171.29, 164.91 (d, J = 252.7 Hz), 164.86 (d, J = 251.7 Hz), 
129.68 (d, J = 9.2 Hz), 129.73 (d, J = 9.7 Hz), 118.62 (d, J = 3.6 Hz), 118.31 (d, J = 3.5 
Hz), 115.99 (d, J = 23.5 Hz), 115.93 (d, J = 23.1 Hz), 105.75, 104.66, 62.76, 61.44, 50.35, 
48.59, 37.96, 37.84, 37.59, 37.48, 31.74, 31.54, 24.12, 24.05, 22.95, 22.87, 21.21, 21.08, 
18.94, 18.87. 16.81, 16.73; 
HRMS (ES) 400.1696 (MH+) C18H27FN3O4S requires 400.1706; 
νmax (KBr)  3335 (SO2NH), 2964 (C(O)NH), 2220 (CN).  
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Preparation of {1S-[1S-(cyano-(R,S)-hydroxymethyl)-3-methylbutylcarbamoyl]-2-
methyl-propyl}carbamic acid benzyl ester (2.52) 
 
N
H
H
N
O
O
O OH
CN
 
The aldehyde 2.19 (1.18 g, 3.39 mmol) was reacted according to General Procedure I to 
give the cyanohydrin 2.52 as a colourless glassy solid (1.07 g, 84%).  No further 
purification was necessary. 
NMR data reported for the mixture of diastereoisomers (1:1) 
1H NMR δ(CDCl3) 7.36-7.31 (10H, m, ArH (Cbz)), 6.92 (1H, d, J = 7.9 Hz, NH), 6.80 
(1H, d, J = 6.9 Hz, NH), 5.69 (1H, d, J = 8.0 Hz, NH), 5.45 (1H, d, J = 7.5 Hz, NH), 5.17 
(1H, d, J = 7.3 Hz, HCN), 5.13-5.06 (4H, m, CCH2O), 5.02 (1H, d, J = 6.1 Hz, HCN), 
4.62-2.57 (1H, m, CHCH2CH(CH3)2), 4.52-4.47 (1H, m, CHCH2CH(CH3)2), 4.08-4.03 
(1H, m, CHCH(CH3)2), 4.02-3.97 (1H, m, CHCH(CH3)2), 2.15-2.06 (2H, m, 
CHCH(CH3)2), 1.68-1.51 (5H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.41-1.35 
(1H, m, CHCH2CH(CH3)2), 1.02-0.85 (24H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 174.02, 172.99, 156.65, 156.61, 136.02, 135.85, 128.45, 128.41, 
128.15, 128.04, 127.88, 127.72, 118.56, 118.10, 67.24, 67.02, 66.60, 64.46, 60.72, 60.59, 
51.70, 51.11, 38.39, 36.85, 30.79, 30.72, 24.60, 24.55, 23.13, 22.84, 21.51, 21.45, 19.17, 
19.08; 
HRMS (ES) 376.2231 (MH+) C20H30N3O4 requires 376.2236. 
 
 
Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-{1S-[(R,S)-hydroxy-(1H-
tetrazol-5-yl)-methyl]-3-methylbutyl}-3-methylbutyramide (2.53) 
 
F
O2
S
N
H
H
N
O
OH
N N
N
H
N
 
The cyanohydrin 2.51 (0.60 g, 1.60 mmol) was reacted according to General Procedure S 
to yield the α-hydroxy tetrazole as a pale orange glassy solid (0.54 g, 75%).  
1H NMR ((CD3)2SO) 7.84-7.77 (4H, m, ArH (Fbs)), 7.38-7.27 (4H, m, ArH (Fbs)), 4.85 
(1H, d, J = 3.8 Hz, CHOH), 4.76 (1H, d, J = 4.1 Hz, NH), 4.72 (1H, d, J = 4.0 Hz, NH), 
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4.69 (1H, d, J = 6.2 Hz, CHOH), 4.09-3.97 (2H, m, CHCH2CH(CH3)2), 3.62 (1H, dd, J = 
5.0 and 9.1 Hz, CHCH(CH3)2), 3.54 (1H, dd, J = 5.0 and 9.2 Hz, CHCH(CH3)2), 1.89-1.77 
(2H, m, CHCH(CH3)2), 1.24-0.99 (6H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.77-
0.69 (24H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR ((CD3)2SO) 169.52, 169.43, 163.93 (d, J = 250.1 Hz), 137.47 (d, J = 3.0 Hz), 
137.47 (d, J = 3.3 Hz), 129.56 (d, J = 15.8 Hz), 129.47 (d, J = 15.1 Hz), 115.76 (d, J = 22.6 
Hz), 115.72 (d, J = 22.4 Hz), 67.21, 67.08, 66.49, 66.18, 62.11, 61.82, 60.63, 60.46, 31.21, 
30.93, 23.60, 23.46, 23.35, 23.23, 21.26, 21.12, 20.89, 20.72, 19.28, 19.04, 17.26, 16.78; 
HRMS (ES) 443.1855 (MH+) C18H28 FN6O4S requires 443.1877; 
νmax (KBr)  3418 (CH(OH), 3120 (SO2NH), 2964 (C(O)NH), 2256 (N=N), 2129 (C=N).  
 
 
Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methyl-N-[3-methyl-1S-(1H-
tetrazole-5-carbonyl)butyl]butyramide (2.43) 
 
F
O2
S
N
H
H
N
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N
 
 
The α-hydroxy tetrazole 2.53 (0.54 g, 1.20 mmol) was oxidised according to General 
Procedure M to give the product as an orange glassy solid.  Recrystallisation ethyl 
acetate/petroleum ether gave the pure 2.43 as an orange glassy solid (0.34 g, 64%). 
1H NMR ((CD3)2SO) 8.15 (1H, d, J = 8.4 Hz, NH), 8.04 (1H, d, J = 7.9 Hz, NH), 7.82-
7.80 (2H, m, ArH (Fbs)), 7.35-7.32 (2H, m, ArH (Fbs)), 5.22-5.17 (1H, m, 
CHCH2CH(CH3)2), 3.67-3.60 (1H, m, CHCH(CH3)2), 1.89-1.84 (1H, m, CHCH(CH3)2), 
1.36-1.32 (1H, m, CHCH2CH(CH3)2), 1.27-1.19 (2H, m, CHCH2CH(CH3)2), 0.81-0.72 
(12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR ((CD3)2SO) 192.39, 169.74, 163.99 (d, J = 250.04 Hz), 160.07, 129.61 (d, J = 
9.3 Hz), 137.86 (d, J = 2.9 Hz), 115.86 (d, J = 22.7 Hz), 62.29, 60.90, 54.27, 31.22, 24.39, 
23.27, 21.10, 19.21, 17.92; 
 [α]D = +37.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 463.1562 (MNa+) C18H25 FSN6O4Na requires 463.1540; 
νmax (KBr)  2963 (SO2NH), 2873 (C(O)NH), 2257 (N=N), 2129 (C=N), 1664 (CHC(O)C). 
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Preparation of (1S-{1S-[(R,S)-hydroxy-(1H-tetrazol-5-yl)methyl]-3-methylbutyl-
carbamoyl}-2-methylpropyl)carbamic acid benzyl ester (2.54) 
 
N
H
H
N
O
O
O OH
N N
N
H
N
 
 
The cyanohydrin 2.52 (0.60 g, 1.60 mmol) was reacted according to General Procedure S 
to yield the α-hydroxy tetrazole as a pale orange glassy solid (0.54 g, 75%). 
Spectral data reported for the mixture of diastereoisomers (1:1)  
1H NMR δ(CD3OD) 7.74 (1H, d, J = 8.9 Hz, NH), 7.57 (1H, d, J = 9.2 Hz, NH), 7.35-7.30 
(10H, m, ArH (Cbz)), 6.76 (1H, d, J = 8.6 Hz, NH), 6.68 (1H, d, J = 8.7 Hz, NH), 5.10 
(1H, d, J = 3.9 Hz, CHCHC=N), 5.08-5.07 (4H, m, CCH2O), 4.99 (1H, d, J = 5.45 Hz, 
CHCHC=N), 4.41-4.34 (2H, m, CHCH2CH(CH3)2), 3.87-3.82 (2H, m, CHCH(CH3)2), 
1.99-1.88 (2H, m, CHCH(CH3)2), 1.64-1.53 (2H, m, CHCH2CH(CH3)2), 1.45-1.38 (2H, m, 
CHCH2CH(CH3)2), 1.31-1.24 (2H, m, CHCH2CH(CH3)2), 0.91-0.77 (24H,  CHCH(CH3)2 
and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 174.07, 173.88, 158.74, 158.64, 154.80, 154.73, 138.16, 138.14, 
129.50, 129.46, 129.03, 129.01, 128.87, 128.86, 67.77, 67.70, 62.15, 62.22, 52.96, 52.92, 
40.65, 39.69, 31.63, 31.52, 25.83, 25.62, 24.11, 23.75, 22.24, 22.04, 21.72, 21.51, 19.73, 
19.70, 18.29, 18.19;   
HRMS (ES) 419.2322 (MH+) C20H31N6O4 requires 419.2407; 
νmax (KBr)  3292 (C(O)NH), 2872 (C(O)NH), 2469 (CHOH), 1692 (N=N), 1649 (N=N).  
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Preparation of {2-methyl-1S-[3-methyl-1S-(1H-tetrazole-5-carbonyl)butylcarbamoyl]-
propyl}carbamic acid benzyl ester (2.55) 
 
N
H
H
N
O
O
O O
N N
N
H
N
 
 
The α-hydroxy tetrazole 2.54 (0.09 g, 0.20 mmol) was oxidised according to General 
Procedure M2 to give the product as a colourless glassy solid (0.04 g, 42%). 
1H NMR ((CD3)2SO) 8.11 (1H, d, J = 8.4 Hz, NH), 8.03 (1H, d, J = 7.2 Hz, NH), 7.50-
7.34 (5H, m, ArH (Cbz)), 5.51-5.45 (1H, m, CHCH2CH(CH3)2), 5.03 (2H, bs, CCH2O), 
3.96-3.91 (1H, m, CHCH(CH3)2), 2.02-1.93 (1H, m, CHCH(CH3)2), 1.75-1.65 (1H, m, 
CHCH2CH(CH3)2), 1.61-1.52 (1H, m, CHCH2CH(CH3)2), 1.47-1.40 (1H, m, 
CHCH2CH(CH3)2), 0.88-0.74 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2);    
13C NMR ((CD3)2SO) 193.02, 171.60, 156.47, 137.32, 128.72, 128.16, 127.88, 65.81, 
65.78, 60.45, 54.90, 48.95, 30.73, 24.92, 23.50, 21.43, 19.50, 18.31; 
 [α]D = +3.5 (c = 0.2 in (CH3)2SO); 
HRMS (ES) 417.2262 (MH+) C20H29N6O4 requires 417.2250; 
νmax (KBr)  3429 (C(O)NH), 2964 (C(O)NH), 2254 (N=N), 2128 (C=N), 1658 (C=O) 
 
 
Preparation of N-{1S-[(4,5-dihydrooxazol-2-yl)-(R,S)-hydroxymethyl]-3-
methylbutyl}-2S-(4-fluorobenzenesulfonylamino)-3-methylbutyramide (2.56) 
 
F
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H
H
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The cyanohydrin 2.51 (0.43 g, 1.09 mmol) was reacted according to General Procedure R 
to give the α-hydroxyoxazoline as a colourless oil.  Flash chromatography on silica (2:5 
ethyl acetate:dichloromethane) gave the pure product as a colourless oil (0.29 g, 61%). 
Spectral data reported for the mixture of diastereoisomers (1:1) 
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1H NMR δ(CD3OD) 7.91-7.88 (4H, m, ArH (Fps)), 7.27-7.23 (4H, m, ArH (Fps)), 4.33 
(4H, m, C=NCH2CH2O), 4.24 (4H, m, C=NCH2CH2O), 4.18 (2H, bs CHCHOH), 4.09-
4.04 (2H, m, CHCH2CH(CH3)2), 3.80-3.73 (4H, m, C=NCH2CH2O), 3.65 (2H, dd, J = 2.1 
and 5.1 Hz, CHCH(CH3)2), 1.97-1.90 (2H, m, CHCH(CH3)2), 1.26-1.13 (6H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.95-0.94 (6H, m, CHCH(CH3)2), 0.85-0.78 
(18H, m, CHCH(CH3)2 and CHCH2CH(CH3)2);      
HRMS (ES) 444.1957 (MH+) C20H31FN3O5S requires 444.1968; 
νmax (KBr)  3442 (CH(OH)), 3002 (SO2NH), 2963 (C(O)NH), 1643 (COCH2CH2). 
 
 
Preparation of N-[1S-(4,5-dihydrooxazole-2-carbonyl)-3-methylbutyl]-2S-(4-fluoro-
benzenesulfonylamino)-3-methylbutyramide (2.42) 
 
F
O2
S
N
H
H
N
O
O
O
N
 
 
The α-hydroxyoxazoline 2.56 (0.20 g, 0.045 mmol) was according to General Procedure 
L to give the crude product.  Column chromatography on silica (2:5 ethyl 
acetate:dichloromethane) gave the pure product as a colourless oil (0.17 g, 88%) 
1H NMR δ(CDCl3) 7.87-7.84 (2H, m, ArH (Fps)), 7.17-7.13 (2H, m, ArH (Fps)), 6.33 (1H, 
d, J = 8.5 Hz, NH), 5.49 (1H, d, J = 8.6 Hz, NH), 5.17-5.13 (1H, m, CHCH2CH(CH3)2), 
4.42-4.37 (2H, m, C=NCH2CH2O), 4.13-4.10 (2H, m, C=NCH2CH2O), 3.56 (1H, dd, J = 
4.7 and 8.5 Hz, CHCH(CH3)2), 2.07-2.01 (1H, m, CHCH(CH3)2), 1.63-1.58 (1H, m, 
CHCH2CH(CH3)2), 1.34-1.24 (2H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.92 
(3H, d, J = 6.7 Hz, CHCH(CH3)2), 0.86-0.85 (6H, m, CHCH(CH3)2 and 
CHCH2CH(CH3)2) 0.82 (3H, d, J = 6.9 Hz, CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 190.48, 170.06, 165.04 (d, J = 254.9 Hz), 159.27, 135.74 (d, J = 3.1 
Hz), 130.03 (d, J = 9.3 Hz), 116.16 (d, J = 22.5 Hz), 68.07, 61.59, 55.16, 54.93, 40.89, 
31.81, 24.89, 23.01, 21.17, 19.12, 16.95; 
 [α]D = +7.0 (c = 0.1 in CHCl3); 
HRMS (ES) 442.1829 (MH+) C20H29 FN3O5S requires 442.1812. 
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Preparation of (1S-{1S-[(4,5-dihydrooxazol-2-yl)-(R,S)-hydroxymethyl]-3-methyl-
butylcarbamoyl}-2-methylpropyl)carbamic acid benzyl ester (2.57) 
 
N
H
H
N
O
O
O OH
O
N
 
 
The cyanohydrin 2.52 (0.75 g, 2.00 mmol) was reacted according to General Procedure R 
to give the α-hydroxyoxazoline as a colourless oil.  Flash chromatography on silica (2:5 
ethyl acetate:dichloromethane) gave the pure product as a colourless oil (0.59 g, 70%). 
Spectral data reported for the mixture of diastereoisomers (1:1) 
1H NMR δ(CD3OD) 7.32-7.24 (10H, m, ArH (Cbz)), 5.05 (4H, s, CCH2O), 4.29-4.18 (8H, 
m, CHCH2CH(CH3)2 and CHCHOH and CHC=NCH2CH2O), 3.93-3.90 (2H, m, 
CHCH(CH3)2), 3.76-3.70 (4H, m, CHC=NCH2CH2O), 2.06-1.98 (2H, m, CHCH(CH3)2), 
1.63-1.46 (4H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.35-1.30 (2H, m, 
CHCH2CH(CH3)2), 0.92-0.80 (24H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 173.89, 170.57, 158.52, 138.23, 129.47, 129.00, 128.83, 70.96, 
70.16, 69.41, 69.63, 62.33, 62.27, 54.38, 54.35, 51.45, 51.33, 41.15, 39.70, 31.84, 31.72, 
25.82, 25.68, 24.18, 24.66, 22.37, 21.83, 19.92, 19.90, 18.49, 18.41; 
HRMS (ES) 420.2480 (MH+) C22H34N3O5 requires 420.2498; 
νmax (KBr)  3308 (CH(OH)), 2969 (C(O)NH), 1660 (COCH2CH2), 1578 (OC(O)). 
 
 
Preparation of {1S-[1S-(4,5-dihydrooxazole-2-carbonyl)-3-methylbutylcarbamoyl]-2-
methylpropyl}carbamic acid benzyl ester (2.58) 
 
N
H
H
N
O
O
O O
O
N
 
 
The α-hydroxyoxazoline 2.57 (0.50 g, 0.12 mmol) was oxidised according to General 
Procedure L to give the crude product.  Column chromatography on silica (2:5 ethyl 
acetate:dichloromethane) gave the pure product as a colourless oil (0.037 g, 74%). 
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1H NMR δ(CDCl3) 7.30-7.21 (5H, m, ArH (Cbz)), 6.45 (1H, d, J = 5.0 Hz, NH), 5.99 (1H, 
d, J = 4.6 Hz, NH), 4.98 (2H, s, CCH2O), 4.43-4.32 (3H, m, CHCH2CH(CH3)2 and 
CHC=NCH2CH2O), 3.98 (1H, dd, J = 4.3 and 7.9 Hz, CHCH(CH3)2), 3.82-3.75 (2H, m, 
CHC=NCH2CH2O), 1.98-1.95 (1H, m, CHCH(CH3)2), 1.67-1.52 (2H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.39-1.34 (2H, m, CHCH2CH(CH3)2), 0.98-0.82 
(12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 
 [α]D = +3.0 (c = 0.1 in CHCl3); 
HRMS (ES) 418.2339 (MH+) C22H33N3O5 requires 418.2342; 
νmax (KBr)  2972 (C(O)NH), 1681 (COCH2CH2), 1660 (C=O), 1559 (OC(O)). 
 
 
7.2.4 Synthesis of Peptidyl Nitriles 
 
Preparation of phenylacetic hydroxysuccinimide (2.59) 
 
O
O
N
O
O
 
 
To a solution of phenylacetic acid (1.00 g, 7.34 mmol, 1.0 equiv) in tetrahydrofuran at 0 °C 
was added N-hydroxysuccinimide (1.01 g, 9.55 mmol, 1.3 equiv) and EDCI (1.83 g, 9.55 
mmol, 1.3 equiv) in dichloromethane.  The reaction mixture was stirred at rt for 3 h after 
which the solvent was removed.  The residue was dissolved in ethyl acetate and washed 
sequentially with 1M aqueous HCl, saturated aqueous sodium carbonate and brine, dried 
over MgSO4 and the solvent removed to give the product as a white solid.  
Recrystallisation from ethyl acetate/petroleum ether gave pure phenylacetic hydroxy-
succinimide (1.47 g, 86%). 
 
Spectral properties are in agreement with the literature.12 
1H NMR δ(CDCl3) 7.37 (5H, m, ArH (Ph)), 3.93 (2H, s, CHCH2CO), 2.81 (4H, s, 
C(O)CH2CH2C(O)) 
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Preparation of phenylacetic acid 1(R,S)-cyano-2S-[2S-(4-fluorobenzenesulfonyl-
amino)-3-methylbutyrylamino]-4-methylpentyl ester (2.60) 
 
F
O2
S
N
H
H
N
O
CN
O
O
 
 
To a stirred solution of 2.59 (0.30 g, 1.32 mmol, 1.0 equiv) in dichloromethane was added 
cyanohydrin 2.51 (0.53 g, 1.32 mmol, 1.0 equiv) and DIPEA (0.34 mL, 1.98 mmol, 1.5 
equiv).  The reaction mixture was stirred at rt overnight then diluted with dichloromethane.  
The organic phase was washed with water and brine, dried over MgSO4 and the solvent 
removed to give the product as a white solid.  Flash chromatography on silica (3:7 ethyl 
acetate/petroleum ether) afforded the pure product as a 1:1 mixture of diastereoisomers 
(0.56 g, 82%). 
Spectral data given for the mixture of diastereoisomers (1:1) 
1H NMR δ((CD3)2SO) 8.03-7.98 (4H, m, ArH (Fps)), 7.81-7.78 (4H, m, ArH (Fps)), 7.27-
7.16 (10H, m, ArH (Ph)), 5.31 (1H, d, J = 4.5 Hz, CHCHCN), 5.22 (1H, d, J = 4.1 Hz, 
CHCHCN), 4.10-4.06 (1H, m, CHCH2CH(CH3)2), 4.02-4.00 (1H, m, CHCH2CH(CH3)2), 
3.68 (2H, s, OC(O)CH2Ph), 3.60 (2H, s, OC(O)CH2Ph), 3.58-3.55 (2H, m, CHCH(CH3)2), 
1.87-1.80 (2H, m, CHCH(CH3)2), 1.29-0.99 (6H, m, CHCH2CH(CH3)2 and 
CHCH2CH(CH3)2), 0.88-0.86 (6H, m, CHCH(CH3)2), 0.78-0.73 (12H, m, CHCH(CH3)2 
and CHCH2CH(CH3)2), 0.60 (3H, d, J = 5.8 Hz, CHCH2CH(CH3)2), 0.56 (3H, d, J = 6.1 
Hz, CHCH2CH(CH3)2); 
13C NMR δ((CD3)2SO) 170.62, 170.36, 169.78, 169.68, 163.99 (d, J = 250.3 Hz), 140.52, 
137.53 (d, J = 3.0 Hz), 134.45, 133.25, 131.12, 130.33, 129.55 (d, J = 9.4 Hz), 129.44, 
129.35, 128.43, 128.40, 127.15, 126.29, 115.83 (d, J = 22.5 Hz), 64.62, 63.34, 60.82, 
60.77, 47.24, 46.92, 37.92, 37.89, 31.47, 23.42, 23.31, 22.97, 20.98, 20.96, 19.24, 19.10, 
17.52, 17.41; 
HRMS (ES) 518.2122 (MH+) C26H33FN3O5S requires 518.2125; 
νmax (KBr)  3366 (SO2NH), 2974 (C(O)NH), 2417 (CN), 1757 (CHOC(O)).  
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Preparation of phenylacetic acid 2S-(2S-benzyloxycarbonylamino-3-methyl-
butyrylamino)-1(R,S)-cyano-4-methylpentyl ester (2.61) 
 
N
H
H
N
O
O
O O
CN
O
 
 
To a stirred solution of 2.59 (0.18 g, 0.79 mmol, 1.0 equiv) in dichloromethane was added 
cyanohydrin 2.52 (0.30 g, 0.79 mmol, 1.0 equiv) and DIPEA (0.21 mL, 1.19 mmol, 1.5 
equiv).  The reaction mixture was stirred at rt overnight then diluted with dichloromethane.  
The organic phase was washed with water and brine, dried over MgSO4 and the solvent 
removed to give the product as a white solid.  Flash chromatography on silica (3:7 ethyl 
acetate/petroleum ether) afforded the pure product as a 1:1 mixture of diastereoisomers 
(0.29 g, 74%). 
Spectral data given for the mixture of diastereoisomers (1:1) 
1H NMR δ((CD3)2SO) 7.36-7.28 (20H, m, ArH (Cbz and Ph)), 5.52 (1H, d, J = 5.4 Hz, 
CHCHCN), 5.46 (1H, d, J = 4.5 Hz, CHCHCN), 5.06-5.02 (6H, m, CCH2O and NH), 
4.40-4.29 (2H, m, CHCH2CH(CH3)2), 3.98-3.93 (2H, m, CHCH(CH3)2), 3.81-3.80 (2H, m, 
OC(O)CH2Ph), 3.75-3.74 (2H, m, OC(O)CH2Ph), 2.05-1.97 (2H, m,  CHCH(CH3)2), 1.71-
1.59 (2H, m, CHCH2CH(CH3)2), 1.57-1.47 (2H, m, CHCH2CH(CH3)2), 1.32-1.24 (2H, m, 
CHCH2CH(CH3)2), 0.95-0.86 (18H, m, CHCH(CH3)2 and CHCH2CH(CH3)2), 0.79-0.77 
(6H, m, CHCH2CH(CH3)2); 
13C NMR δ((CD3)2SO) 171.93, 171.78, 169.80, 169.72, 156.12, 156.10, 137.09, 137.06, 
133.27, 133.22, 129.53, 129.46, 129.40, 129.36, 128.40, 128.36, 128.29, 128.25, 127.68, 
127.54, 127.51, 127.10, 127.06, 115.99, 115.86, 65.33, 65.30, 63.43, 63.32, 60.39, 60.21, 
47.42, 47.09, 37.89. 37.79, 30.22, 30.12, 23.71, 23.21, 23.10, 20.94, 20.30, 20.19, 19.18, 
19.11, 18.10, 18.00;  
HRMS (ES) 482.2664 (MH+) C27H36N3O5 requires 482.2655; 
νmax (KBr)  3281 (C(O)NH), 2968 (C(O)NH), 2230 (CN), 1753 (CHOC(O)).  
 
 
 
Chapter Seven – Experimental  252   
Preparation of N-(1S-azidomethyl-3-methylbutyl)-2S-(4-fluorobenzenesulfonyl-
amino)-3-methylbutyramide (2.62) 
 
F
O2
S
N
H O
H
N
N3
 
 
To the alcohol 2.6 (0.10 g, 0.26 mmol, 1.0 equiv) in dichloromethane was added 
triethylamine (0.10 mL, 0.67 mmol, 2.5 equiv) and mesyl chloride (0.02 mL, 0.26 mmol, 
1.0 equiv).  The reaction mixture was stirred at rt overnight, then the solvent removed in 
vacuo.  The residue was dissolved in N,N-dimethylformamide and sodium azide (0.02 g, 
0.26 mmol, 1.0 equiv) added and the reaction mixture stirred at rt for 4 h after which it was 
diluted with ethyl acetate.  The organic phase was separated and washed with brine, dried 
over MgSO4 and solvent removed under reduced pressure to give the crude material.  
Recrystallisation from ethyl acetate/petroleum ether afforded the product as a white solid 
(0.065 g, 63%) 
1H NMR δ(CDCl3) 7.87-7.85 (2H, m, ArH (Fps)), 7.16-7.12 (2H, m, ArH (Fps)), 5.26 (1H, 
d, J = 9.7 Hz, NH), 4.11 (1H, dd, J = 8.1 and 9.2 Hz, CHCH2N3), 3.88-3.81 (1H, m, 
CHCH2CH(CH3)2), 3.79 (1H, dd, J = 5.1 and 9.5 Hz, CHCH(CH3)2), 3.62-3.59 (1H, m, 
CHCH2N3), 2.03-1.96 (1H, m, CHCH(CH3)2), 1.59-1.50 (1H, m, CHCH2CH(CH3)2), 1.29-
1.24 (1H, m, CHCH2CH(CH3)2), 1.14-1.08 (1H, m, CHCH2CH(CH3)2), 0.99 (3H, d, J = 
6.8 Hz, CHCH(CH3)2), 0.89 (3H, d = 6.8 Hz, CHCH(CH3)2), 0.88-0.85 (6H, m, 
CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 189.20, 161.52 (d, J = 255.84 Hz), 130.14 (d, J = 8.8 Hz), 130.02 (d, J 
= 3.4 Hz), 116.04 (d, J = 21.7 Hz), 61.74, 48.12, 47.79, 40.61, 31.97, 24.49, 22.53, 22.04, 
19.18, 17.08; 
[α]D = -24.0 (c = 0.1 in CH3OH) 
νmax (KBr)  3297 (SO2NH), 2976 (C(O)NH), 2100 (CH2N3). 
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7.3 EXPERIMENTAL WORK AS DESCRIBED IN    
CHAPTER THREE 
 
 
7.3.1 Synthesis of Michael Acceptors 
 
Preparation of 4S-[2S-(4-fluorobenzenesulfonylamino)-3-methylbutyrylamino]-6-
methylhept-2-enoic acid methyl ester (3.14) 
 
F
O2
S N
H
H
N
O
CO2Me
 
 
The aldehyde 2.3 (0.40 g, 1.07 mmol) was reacted with methyl(triphenyl-
phosphoranylidene) acetate according to General Procedure P to give the product as a 
white solid (0.43 g, 93%). 
mp = 147-149 °C; 
1H NMR δ(CDCl3) 7.88-7.86 (2H, m, ArH (Fps)), 7.18-7.14 (2H, m, ArH (Fps)), 6.74 (1H, 
dd, J = 5.8 and 15.9 Hz, CH=CHCO2CH3), 6.08 (1H, d, J = 8.0 Hz, NH), 5.90 (1H, d, J = 
15.9 Hz, CH=CHCO2CH3), 5.53 (1H, d, J = 7.9 Hz, NH), 4.53-4.48 (1H, m, 
CHCH(CH3)2), 3.72 (3H, s, CH=CHCO2CH3), 3.54 (1H, dd, J = 4.7 and 7.9 Hz, 
CHCH2CH(CH3)2), 2.11-2.04 (1H, m, CHCH(CH3)2), 1.40-1.22 (3H, m, CHCH2CH(CH3)2 
and CHCH2CH(CH3)2), 0.86 (3H, d, J = 6.4 Hz, CHCH(CH3)2), 0.83-0.80 (9H, m, 
CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 169.87, 164.93 (d, J = 254.8 Hz), 166.27, 146.22, 135.47, 130.05 (d, J 
= 9.4 Hz), 120.07, 116.24 (d, J = 22.5 Hz), 61.80, 61.58, 48.57, 43.20, 32.52, 24.28, 22.49, 
20.90, 19.14, 16.85; 
[α]D = -40.0 (c = 0.1 in CHCl3); 
HRMS (ES) 429.1845 (MH+) C20H30FN2O5S requires 429.1859; 
νmax (KBr)  3364 (SO2NH), 3082 (C(O)NH), 1726 (CO2Me), 1649 (CH=CH).  
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Preparation of 4S-[2S-(4-fluorobenzenesulfonylamino)-3-methylbutyrylamino]-6-
methylhept-2-enoic acid ethyl ester (3.15) 
 
F
O2
S N
H
H
N
O
CO2Et
 
 
The aldehyde 2.3 (0.40 g, 1.07 mmol) was reacted with ethyl(triphenylphosphoranylidene) 
acetate according to General Procedure P to give the product as a white solid (0.45 g, 
95%). 
mp = 117-119 °C ; 
1H NMR δ(CDCl3) 7.88 (2H, m, ArH (Fbs)), 7.17-7.14 (2H, m, ArH (Fbs)), 6.72 ( 1H, dd, 
J = 5.8 and 15.7 Hz, CH=CH), 6.09 (1H, d, J = 5.7 Hz, NH), 5.87 (1H, d, J = 15.6 Hz, 
CH=CH), 5.57 (1H, d, J = 6.3 Hz, NH), 4.54 (1H, m, CHCH2CH(CH3)2), 4.17 (2H, t, J = 
7.1 Hz, CH2CH3), 3.55-3.53 (1H, m, CHCH(CH3)2), 2.10-2.03 (1H, m, CHCH(CH3)2), 
1.38-1.20 (3H, m, CHCH2CH(CH3)2and CHCH2CH(CH3)2), 1.27 (3H, t, J = 7.1 Hz, 
CH2CH3), 0.86-0.80 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 169.77, 165.08 (d, J = 255.3 Hz), 166.24, 147.22, 135.46, 130.05 (d, J 
= 9.33 Hz), 121.07, 116.25 (d, J = 22.6 Hz), 61.81, 60.58, 48.51, 43.22, 31.52, 24.48, 
22.47, 21.90, 19.19, 16.82, 14.14; 
[α]D = -35.0 (c = 0.1 in CHCl3); 
HRMS (ES) 443.1935 (MH+) C21H32FN2O5S requires 443.1938; 
νmax (KBr)  3358 (SO2NH), 3082 (C(O)NH), 1717 (CO2Et), 1651 (CH=CH).  
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Preparation of 4S-(2S-benzyloxycarbonylamino-3-methylbutyrylamino)-6-methyl-
hept-2-enoic acid methyl ester (3.16) 
 
N
H
H
N
O
CO2MeO
O
 
 
The aldehyde 2.19 (0.40 g, 1.15 mmol) was reacted with methyl(triphenyl-
phosphoranylidene) acetate  according to General Procedure P to give the product as a 
white solid (0.41 g, 89%). 
mp = 109-111 °C;  
1H NMR δ(CDCl3) 7.36 (5H, s, ArH (Cbz)), 6.81 (1H, dd, J = 5.6 and 15.9 Hz, 
CH=CHCO2CH3), 5.90 (1H, d, J = 15.9 Hz, CH=CHCO2CH3), 5.82 (1H, d, J = 8.6 Hz, 
NH), 5.24 (1H, d, J = 7.9 Hz, NH), 5.11 (2H, s, CCH2O), 4.71-4.65 (1H, m, 
CHCH2CH(CH3)2), 3.93 (1H, t, J = 6.7 Hz, CHCH(CH3)2), 2.20-2.13 (1H, m, 
CHCH(CH3)2),  1.64-1.55 (1H, m, CHCH2CH(CH3)2), 1.43-1.40 (2H, m, 
CHCH2CH(CH3)2), 0.97 (3H, d, J = 6.7 Hz, CHCH(CH3)2), 0.92-0.89 (9H, m, 
CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 170.85, 166.65, 156.51, 148.10, 136.04, 128.48, 128.14, 127.84, 
120.46, 67.02, 60.54, 51.59, 48.35, 43.29, 30.87, 24.66, 22.55, 22.12, 19.33, 17.83 
[α]D = -20.0 (c = 0.1 in CHCl3); 
HRMS (ES) 405.2393 (MH+) C22H33N2O5 requires 405.2389; 
νmax (KBr)  3298 (C(O)NH), 2968 (C(O)NH), 1705 (CO2Me), 1653 (CH=CH).  
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Preparation of 4S-(2S-benzyloxycarbonylamino-3-methylbutyrylamino)-6-methyl-
hept-2-enoic acid ethyl ester (3.17) 
 
N
H
H
N
O
CO2EtO
O
 
 
The aldehyde 2.19 (0.40 g, 1.15 mmol) was reacted with methyl(triphenyl-
phosphoranylidene) acetate according to General Procedure P to give the product as a 
white solid (0.43 g, 91%). 
mp = 86-88 °C; 
1H NMR δ(CDCl3) 7.37-7.31 (5H, m, ArH (Cbz)), 6.80 (1H, dd, J = 5.8 and 15.6 Hz, 
CH=CHCO2CH2CH3), 6.12 (1H, d, J = 7.6 Hz, NH), 5.90 (1H, d, J = 15.7 Hz, 
CH=CHCO2CH2CH3), 5.36 (1H, d, J = 7.9 Hz, NH), 5.10 (2H, s, CCH2O), 4.70-4.64 (1H, 
m, CHCH2CH(CH3)2), 4.17 (2H, dd, J = 7.1 and 14.2 Hz, CO2CH2CH3) 3.96 (1H, dd, J = 
6.7 and 8.5 Hz, CHCH(CH3)2), 2.16-2.10 (1H, m, CHCH(CH3)2), 1.63-1.57 (1H, m, 
CHCH2CH(CH3)2), 1.43-1.39 (2H, m, CHCH2CH(CH3)2), 1.27 (3H, t, J = 7.1 Hz, 
CO2CH2CH3), 0.96 (3H, d, J = 6.7 Hz, CHCH(CH3)2), 0.92-0.88 (9H, m, CHCH(CH3)2 
and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 170.87, 166.21, 156.46, 147.85, 136.05, 128.42, 128.05, 127.73, 
120.81, 66.91, 60.39, 52.85, 48.27, 43.23, 30.99, 24.61, 22.51, 22.11, 19.28, 17.85, 14.10 
[α]D = -26.0 (c = 0.1 in CHCl3) 
HRMS (ES) 419.2552 (MH+) C23H35N2O5 requires 419.2546; 
νmax (KBr)  3287 (C(O)NH), 2962 (C(O)NH), 1721 (CO2Et), 1649 (CH=CH).  
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-isobutyl-4-oxobut-2-enyl)-3-
methylbutyramide (3.18) 
 
F
O2
S N
H
H
N
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The aldehyde 2.3 (0.40 g, 1.07 mmol) was reacted with triphenylphosphoranylidene 
acetaldehyde according to General Procedure P to give the product as a pale yellow solid 
(0.29 g, 68%). 
mp = 49-51 °C; 
1H NMR δ((CD3)2CO) 9.62 (1H, dd, J = 2.3 and 7.7 Hz, CHO), 8.03 (2H, m, ArH (Fps)), 
7.53 (1H, d, J = 7.9 Hz, NH), 7.42-7.38 (2H, m, ArH (Fps)), 6.94 ( 1H, m, CH=CH), 6.74 
(1H, d, J = 7.5 Hz, NH), 6.19 ( 1H, m, CH=CH), 4.73-4.62 (1H, m, CHCH2CH(CH3)2), 
3.84-3.78 (1H, m, CHCH(CH3)2), 2.17-2.11 (1H, m, CHCH(CH3)2), 1.48-1.38 (3H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.11-0.88 (12H, m, CHCH(CH3)2 and 
CHCH2CH(CH3)2); 
13C NMR δ((CD3)2CO) 194.98, 171.63, 166.50 (d, J = 251.6 Hz), 159.29, 138.94 (d, J = 
3.0 Hz), 132.64, 131.82 (d, J = 9.4 Hz), 117.69 (d, J = 22.7 Hz), 63.28, 50.19, 44.28, 
33.57, 26.00, 24.00, 22.96, 20.68, 18.40; 
[α]D = -42.0 (c = 0.1 in CHCl3); 
HRMS 399.1741 (MH+) C19H28FN2O4S requires 399.1754; 
νmax (KBr)  2873 (SO2NH), 2723 (C(O)NH), 1693 (CHO), 1593 (CH=CH).  
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Preparation of 2S-(4-fluorobenzenesulfonylamino)-N-(1S-isobutyl-3-methane-
sulfonylallyl)-3-methylbutyramide (3.20) 
 
F
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H
H
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Butyllithium (1.0 M solution, 0.41 mL, 0.40 mmol) was reacted with ethyl-
methanesulfonylmethylphosphinoyl ethane 3.24 (0.097 g, 0.44 mmol) and aldehyde 2.3 
(0.15 g, 0.40 mmol) according to General Procedure J to give the crude product.  
Recrystallisation from ethyl acetate/petroleum ether afforded the pure product as a white 
solid (0.16 g, 89%) 
mp = 84-86 °C;  
1H NMR δ(CDCl3) 7.90-7.87 (2H, m, ArH (Fbs)), 7.23-7.20 (2H, m, ArH (Fbs)), 6.82 (1H, 
dd, J = 4.5 and 15.1 Hz, CH=CHSO2CH3), 6.68 (1H, d, J = 15.1 Hz, CH=CHSO2CH3), 
6.42 (1H, d, J = 8.5 Hz, NH), 5.13 (1H, d, J = 6.8 Hz), 4.71-4.66 (1H, m, CHCH(CH3)2), 
3.50 (1H, dd, J = 4.4 and 7.1 Hz, CHCH2CH(CH3)2), 2.94 (3H, s, SO2CH3), 2.20-2.14 (1H, 
m, CHCH(CH3)2), 1.52-1.47 (1H, m, CHCH2CH(CH3)2), 1.42-1.39 (2H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 0.92 (3H, d, J = 6.4 Hz, CHCH(CH3)2), 0.87 
(3H, d, J = 6.4 Hz, CHCH(CH3)2), 0.78 (3H, d, J = 6.9 Hz, CHCH2CH(CH3)2), 0.71 (3H, 
d, J = 6.9 Hz, CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 170.11, 165.38 (d, J = 256.1 Hz), 147.38, 134.59, 130.24 (d, J = 9.4 
Hz), 129.34, 116.51 (d, J = 22.7 Hz), 62.08, 48.01, 42.74, 42.64, 30.87, 24.74, 22.73, 
21.54, 19.17, 16.61;  
[α]D = -35.0 (c = 0.1 in CH3OH); 
HRMS (ES) 449.1599 (MH+) C19H30FN2O5S2 requires 449.1580; 
νmax (KBr)  3321 (SO2NH), 2873 (C(O)NH), 1659 (CH=CH), 1304 (O=S=O), 1134 
(O=S=O).  
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Preparation of N-(1S-benzyl-3-methanesulfonylallyl)-2S-(4-fluorobenzene-
sulfonylamino)-3-methylbutyramide (3.21) 
 
F
O2
S
N
H
H
N
O
SO2Me
 
 
Butyllithium (1.0 M solution, 0.34 mL, 0.34 mmol) was reacted with 
ethylmethanesulfonylmethylphosphinoyl ethane 3.24 (0.087 g, 0.38 mmol) and aldehyde 
2.27 (0.14 g, 0.34 mmol) according to General Procedure J to give the crude product.  
Flash chromatography on silica (1:4 ethyl acetate/petroleum ether) afforded the pure 
product as a colourless oil (0.14 g, 84%) 
1H NMR δ(CDCl3) 7.87-7.85 (2H, m, ArH (Fps)), 7.32-7.29 (2H, m, ArH (Fps), 7.24-7.14 
(5H, m, ArH (Phe)), 6.92 (1H, dd, J = 4.1 and 15.2 Hz, CH=CHSO2CH3), 6.69 (1H, d, J = 
15.2 Hz, CH=CHSO2CH3), 6.33 (1H, d, J = 10.6 Hz, NH), 5.46 (1H, bs, NH), 5.04-4.97 
(1H, m, CHCH(CH3)2), 3.42-3.38 (1H, m, CHCH2C), 3.03 (1H, dd, J = 3.7 and 11.4 Hz, 
CHCH2C), 2.91 (3H, s, CH=CHSO2CH3), 2.81 (1H, dd, J = 3.7 and 13.5 Hz, CHCH2C), 
2.10 (1H, m, CHCH(CH3)2), 0.51 (3H, d, J = 6.4 Hz, CHCH(CH3)2), 0.46 (3H, d, J = 6.4 
Hz, CHCH(CH3)2); 
13C NMR δ(CDCl3) 170.39, 165.29 (d, J = 252.4 Hz), 146.13, 136.04, 134.58 (d, J = 2.3 
Hz), 130.18 (d, J = 9.3 Hz), 129.76, 129.06, 128.73, 127.12, 116.34 (d, J = 23.4 Hz), 
62.48, 50.86, 42.67, 39.66, 30.54, 18.88, 16.50; 
[α]D = -49.0 (c = 0.1 in CHCl3); 
HRMS (ES) 483.1428 (MH+) C22H28FN2O5S2 requires 483.1424; 
νmax (KBr)  3267 (SO2NH), 2976 (C(O)NH), 1659 (CH=CH), 1296 (O=S=O), 1155 
(O=S=O).  
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Preparation of [1S-(1S-isobutyl-3-methanesulfonylallylcarbamoyl)-2-methylpropyl]-
carbamic acid benzyl ester (3.22) 
 
N
H
H
N
O
SO2MeO
O
 
 
Butyllithium (1.0 M solution, 0.97 mL, 1.55 mmol) was reacted with 
ethylmethanesulfonylmethylphosphinoyl ethane 3.24 (0.39 g, 1.71 mmol) and aldehyde 
2.19 (0.50 g, 1.55 mmol) according to General Procedure J to give the crude product.  
Flash chromatography on silica (2:3 ethyl acetate:petroleum ether) gave the pure product 
as a white solid. (0.51 g, 78%) 
mp = 170-171 °C; 
1H NMR δ(CDCl3) 7.38-7.32 (5H, m, ArH (Cbz)), 6.80 (1H, dd, J = 5.1 and 15.0 Hz, 
CH=CHSO2CH3), 6.52 (1H, d, J = 15.0 Hz, CH=CHSO2CH3), 6.30 (1H, d, J = 8.5 Hz, 
NH), 5.28 (1H, d, J = 7.6 Hz, NH), 5.11 (2H, s, CCH2O), 4.76-4.70 (1H, m, 
CHCH(CH3)2), 3.98 (1H, dd, J = 6.2 and 8.1 Hz, CHCH2CH(CH3)2), 2.91 (3H, s, 
CH=CHSO2CH3), 2.21-2.15 (1H, m, CHCH(CH3)2), 1.65-1.57 (1H, m, 
CHCH2CH(CH3)2), 1.44-1.41 (2H, m, CHCH2CH(CH3)2), 0.98 (3H, d, J = 6.8 Hz, 
CHCH(CH3)2), 0.92-0.91 (6H, m, CHCH(CH3)2 and CHCH2CH(CH3)2), 0.89 (3H, d, J = 
6.5 Hz, CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 171.18, 156.46, 147.53, 135.90, 129.24, 128.42, 128.07, 127.71, 
66.93, 60.49, 47.73, 42.26, 42.40, 30.70, 24.55, 22.53, 21.74, 19.24, 17.71;  
[α]D = -31.0 (c = 0.1 in CHCl3) 
HRMS (ES) 425.2116 (MH+) C21H33N2O5S requires 425.2110; 
νmax (KBr)  3269 (C(O)NH), 2926 (C(O)NH), 1745 (CH=CH), 1537 (O=S=O).  
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Preparation of [1S-(1S-benzyl-3-methansulfonylallylcarbamoyl)-2-methylpropyl]-
carbamic acid benzyl ester (3.23) 
 
N
H
H
N
O
SO2MeO
O
 
 
Butyllithium (1.0 M solution, 1.83 mL, 1.83 mmol) was reacted with 
ethylmethanesulfonylmethylphosphinoyl ethane 3.23 (0.463 g, 2.01 mmol) and aldehyde 
2.2 (0.70 g, 1.83 mmol) according to General Procedure J to give the crude product.  
Flash chromatography on silica (1:4 ethyl acetate/petroleum ether) afforded the pure 
product as a colourless oil (0.55 g, 66%). 
1H NMR δ(CDCl3) 7.39-7.34 (5H, m, ArH (Cbz)), 7.30-7.21 (3H, m, ArH (Phe)), 7.13 
(2H, d, J = 7.2 Hz, ArH (Phe)), 6.89 (1H, dd, J = 4.4 and 15.0 Hz, CHCH=CHSO2CH3), 
6.43 (1H, d, J = 15.0 Hz, CHCH=CHSO2CH3), 6.13 (1H, d, J = 8.3 Hz NH,), 5.11 (2H, s, 
CCH2O), 5.03-4.96 (CHCH2Ph), 3.90 (1H, dd, J = 5.8 and 7.7 Hz, CHCH(CH3)2), 2.97 
(1H, dd, J = 6.6 and 13.9 Hz, CHCH2Ph), 2.83 (1H, J = 8.0 and 13.9 Hz, CHCH2Ph), 2.17-
2.11 (1H, m, CHCH(CH3)2), 1.58 (3H, s, SO2CH3), 0.88 (3H, d, J = 6.7 Hz, 
CHCH(CH3)2), 0.74 (3H, d, J = 6.7 Hz, CHCH(CH3)2);  
13C NMR δ(CDCl3) 170.95, 146.24, 135.86, 135.62, 130.11, 129.14, 128.75, 128.63, 
128.36, 128.10, 127.21, 67.34, 60.77, 50.47, 42.66, 39.87, 30.23, 19.30, 17.34; 
[α]D = +27.0 (c = 0.1 in CHCl3) 
HRMS (ES) 459.1958 (MH+) C24H31N2O5S requires 459.1954; 
νmax (KBr)  3306 (C(O)NH), 2966 (C(O)NH), 1701 (CH=CH), 1304 (O=S=O), 1240 
(O=S=O).  
 
Preparation of (ethylmethanesulfonylmethylphosphinoyl)ethane (3.24) 
 
P
O
SO2Me
 
 
Diethyl(methylthiomethyl) phosphonate (0.90 g, 4.56 mmol, 1.0 equiv) was added to a 
biphasic mixture of dichloromethane and distilled water (1:2).  Benzyltriethylammonium 
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chloride (0.10 g, 0.46 mmol, 0.1 equiv) and potassium permanganate (1.44 g, 9.12 mmol, 
2.0 equiv) were added with vigorous stirring.  The purple biphasic solution was stirred 
vigorously at rt for 20 h.  The resulting brown precipitous mixture was filtered and rinsed 
with dichloromethane.  The aqueous phase was separated and extracted twice more with 
dichloromethane.  The combined organic phases were washed with 1% aqueous hydrazine 
hydrochloride until colourless then brine and dried over MgSO4.  The solvent was removed 
to give the sulfone as a glassy solid (0.80 g, 89%).  No purification was necessary.      
1H NMR δ(CDCl3) 4.21-4.15 (4H, m, CH2CH3), 3.58 (2H, d, J = 16.5 Hz, CH2CH3), 3.15 
(3H, s, S(O2)CH3), 1.32 (6H, t, J = 7.1 Hz, CH3); 
13C NMR δ(CDCl3) 63.29 (d, J = 6.5 Hz), 51.63 (d, J = 138.9 Hz), 42.31, 15.94 (d, J = 6.3 
Hz); 
[α]D = +3.0 (c = 0.1 in CHCl3); 
νmax (KBr)  1306 (SO2), 1248 (P=O), 1158 (SO2) 
HRMS could not be obtained for this compound as the electrospray conditions did not 
allow detection. 
 
 
7.3.2 Diazoketones and Derivatives 
 
Preparation of N-[1S-(2-diazoacetyl)-3-methylbutyl]-2S-(4-fluorobenzenesulfonyl-
amino)-3-methylbutyramide (3.25) 
 
F
O2
S N
H
H
N
O
O
N2
 
 
The dipeptidyl acid 2.7 (1.10 g, 2.83 mmol) in tetrahydrofuran was cooled to -25oC.  
Triethylamine (0.39 mL, 2.83 mmol) and ethyl chloroformate (0.27 mL, 2.83 mmol) were 
added and the reaction mixture was stirred at -25oC for 20 min until it had a precipitous 
appearance.  The reaction mixture was then cooled over an ice bath and ethereal 
diazomethane (~1.2 equiv prepared according to General Procedure N) added dropwise 
over 10 min until the solution maintained a consistent yellow colour over 10 min.  The 
reaction mixture was stirred over an ice bath for 2 h followed by a further 16 h at rt.  
Glacial acetic acid was added to quench the reaction, followed by the addition of enough 
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1M aqueous sodium hydroxide to result in a basic solution.  The reaction mixture was 
partitioned between ethyl acetate and water.  The aqueous phase was separated and 
extracted twice more with ethyl acetate.  The combined organic phases were washed 
sequentially with saturated aqueous ammonium chloride and brine, dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product.  Purification was achieved by 
column chromatography (1:4 ethyl acetate:petroleum ether) to afford the pure product as a 
pale yellow solid ( 0.95 g, 83%). 
mp = 136-138 °C; 
1H NMR δ(CDCl3) 7.89-7.86 (2H, m, ArH (Fbs)), 7.18-7.14 (2H, m, ArH (Fbs)), 6.41 (1H, 
d, J = 8.5 Hz, NH), 5.52 (1H, s, CHN2), 5.51 (1H, bs, NH), 4.41-4.35 (1H, m, 
CHCH2CH(CH3)2), 3.55 (1H, dd, J = 4.8 and 8.1 Hz, CHCH(CH3)2), 2.10-2.03 (1H, m, 
CHCH(CH3)2), 1.50-1.45 (1H, m, CHCH2CH(CH3)2), 1.35-1.28 (2H, m, CHCH2CH(CH3)2 
and CHCH2CH(CH3)2), 0.88-0.81 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C
 
NMR δ(CDCl3) 193.53, 170.15, 165.10 (d, J = 255.3 Hz), 135.47 (d, J = 3.4 Hz), 
130.09 (d, J = 9.3 Hz), 116.22 (d, J = 22.5 Hz), 61.84, 54.54, 54.33, 41.44, 31.59, 24.51, 
22.89, 21.63, 19.11, 16.98; 
[α]D = -87.0 (c = 0.1 in CHCl3); 
HRMS (ES) 435.1467 (MNa+) C18H26FN4O4 SNa requires 435.1478; 
νmax (KBr) 3267 (SO2NH), 3084 (C(O)NH), 2102 (C=N2). 
 
 
Preparation of {1S-[1S-(2-diazoacetylo)-3-methylbutylcarbamoyl]-2-methylpropyl}-
carbamic acid benzyl ester (3.26) 
 
O N
H
O
H
N
O
O
N2
 
 
The dipeptidyl acid 2.46 (0.89 g, 2.44 mmol) in tetrahydrofuran was cooled to -25oC.  
Triethylamine (0.34 mL, 2.44 mmol) and ethyl chloroformate (0.25 mL, 2.44 mmol) were 
added and the reaction mixture was stirred at -25oC for 20 min until it had a precipitous 
appearance.  The reaction mixture was then cooled over an ice bath and ethereal 
diazomethane (~1.2 equiv prepared according to General Procedure N) added dropwise 
over 10 min until the solution maintained a consistent yellow colour over 10 min.  The 
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reaction mixture was stirred over an ice bath for 2 h followed by a further 16 h at rt.  
Glacial acetic acid was added to quench the reaction, followed by the addition of enough 
1M aqueous sodium hydroxide to result in a basic solution.  The reaction mixture was 
partitioned between ethyl acetate and water.  The aqueous phase was separated and 
extracted twice more with ethyl acetate.  The combined organic phases were washed 
sequentially with saturated aqueous ammonium chloride and brine, dried over MgSO4, 
filtered and concentrated in vacuo to give the crude product.  Purification was achieved by 
column chromatography (1:4 ethyl acetate:petroleum ether) to afford the pure product as a 
pale yellow solid ( 0.58 g, 61% ) 
mp = 111-112 °C; 
1H NMR δ(CDCl3), 7.37-7.31 (5H, m, ArH (Cbz), 6.62 (1H, bs, NH), 5.48 (1H, bs, NH), 
5.43 (1H, s, CHN2), 5.11 (2H, s, CCH2O), 4.56-5.57 (1H, m, CHCH2CH(CH3)2), 4.07-4.02 
(1H, m, CHCH(CH3)2), 2.16-2.09 (1H, m, CHCH(CH3)2), 1.65-1.57 (2H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.52-1.47 (1H, m, CHCH2CH(CH3)2), 0.96 (3H, 
d, J = 6.8 Hz, CHCH2CH(CH3)2), 0.92-0.90 (9H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CDCl3) 193.50, 171.16, 156.38, 136.14, 128.50, 128.16, 127.96, 67.05, 60.30, 
54.40, 54.13, 41.10, 31.04, 24.74, 22.96, 21.84, 19.19, 17.74; 
[α]D = -55.5 (c = 0.1 in CHCl3); 
HRMS (ES) 411.1999 (MNa+) C20H29N4O4Na requires 411.2008; 
νmax (KBr)  2976 (C(O)NH), 2871 (C(O)NH), 2117 (C=N2).  
 
 
Preparation of N-[1S-(2-bromoacetyl)-3-methylbutyl]-2S-(4-fluorobenzenesulfonyl-
amino)-3-methylbutyramide (3.28) 
 
F
O2
S
N
H
H
N
O
O
Br
 
 
Hydrogen bromide in glacial acetic acid (33%) was added dropwise (~1-2 mL) to a 
solution of the diazoketone 3.25 (1.89 g, 4.72 mmol) in dichloromethane at rt until the 
yellow colour disappeared.  The solvent was immediately removed in vacuo and the 
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residue rinsed with dichloromethane until no acid was present.  The product was isolated 
as a pale yellow solid, no purification necessary (1.78 g, 81%). 
mp = 148-150 °C; 
1H NMR δ(CD3OD)  7.86-7.81 (2H, m, ArH (Fps)), 7.40 (1H, d, J = 5.6 Hz, NH), 7.19-
7.12 (2H, m, ArH (Fps)), 4.50-4.44 (1H, m, CHCH2CH(CH3)2), 4.04 (1H, d, J = 5.6 Hz, 
CH2Br), 3.99 (1H, d, J = 5.6 Hz, CH2Br), 3.55-3.52 (1H, m, CHCH(CH3)2), 2.01-1.92 
(1H, m, CHCH(CH3)2 ), 1.53-1.46 (1H, m, CHCH2CH(CH3)2), 1.40-1.28 (2H, m, 
CHCH2CH(CH3)2), 0.89-0.78 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 202.00, 173.17, 166.35 (d, J = 252.2 Hz), 138.45 (d, J = 3.2 Hz), 
131.21 (d, J = 9.4 Hz), 117.11 (d, J = 22.9 Hz), 62.86, 56.08, 40.20, 33.73, 32.98, 25.84, 
23.56, 21.69, 19.82, 18.13; 
[α]D =  -52.0 (c = 0.1 in CH3OH); 
HRMS (ES) 465.0873 (MH+) C23H34N2O6 requires 465.0859; 
νmax (KBr)  3283 (SO2NH), 2874 (C(O)NH), 2446 (C(O)CH2), 1649 (CH2Br).  
 
 
Preparation of {1S-[1S-(2-bromoacetyl)-3-methylbutylcarbamoyl]-2-methylpropyl}-
carbamic acid benzyl ester (3.29) 
N
H
H
N
O
O
Br
O
O
 
 
Hydrogen bromide in glacial acetic acid (33%) was added dropwise (~1-2 mL) to a 
solution of the diazoketone 3.26 (1.06 g, 2.73 mmol) in dichloromethane at rt until the 
yellow colour disappeared.  The solvent was immediately removed in vacuo and the 
residue rinsed with dichloromethane until no acid was present.  The product was isolated 
as a pale yellow solid, no purification necessary (0.96 g, 80%) 
mp = 129-130 °C; 
1H NMR δ(CD3OD) 7.38-7.31 (5H, m, ArH (Cbz)), 5.12 (2H, d, J = 12.5, CCH2O), 5.07 
(2H, d, J = 12.5, CCH2O), 4.67 (1H, dd, J = 4.2 and 10.4 Hz, CHCH2CH(CH3)2), 4.21 
(2H, m, CH2Br), 3.94 (1H, d, J = 7.3 Hz, CHCH(CH3)2), 2.09-2.00 (1H, m, 
CHCH(CH3)2), 1.74-1.65 (1H, m, CHCH2CH(CH3)2), 1.64-1.55 (2H, m, 
CHCH2CH(CH3)2), 0.98-0.94 (9H, m, CHCH(CH3)2 and CHCH2CH(CH3)2), 0.91 (3H, d, J 
= 6.4 Hz, CHCH(CH3)2); 
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13C NMR δ(CD3OD) 202.20, 174.71, 138.25, 129.52, 129.06, 128.91, 122.21, 67.73, 
62.20, 56.34, 40.10, 33.76, 31.81, 25.98, 23.67, 21.56, 19.82, 18.70; 
[α]D = -51.0 (c = 0.1 in CH3OH); 
HRMS (ES) 441.1396 (MH+) C20H29BrN2O4 requires 441.1389; 
νmax (KBr)  2961 (C(O)NH), 2872 (C(O)NH), 2411 (C(O)CH2), 1651 (CH2Br). 
 
 
Preparation of N-[1S-(2-bromo-1S-hydroxyethyl)-3-methylbutyl]-2S-(4-fluoro-
benzenesulfonylamino)-3-methylbutyramide (3.30) 
 
F
O2
S N
H
H
N
O
OH
Br
 
 
Tri-tert-butyllithium aluminium hydride13 was prepared by the dropwise addition of tert-
butanol (3.00 mL, 31.50 mmol. 3.15 equiv) to lithium aluminium hydride (10.00 mL, 10.0 
mmol, 1.0 equiv) followed by removal of the solvent to give the product as a white solid. 
 
Solid tri-tert-butoxylithium aluminium hydride (1.11 g, 4.36 mmol) was cooled to -78 °C.  
Ethanol:tetrahydrofuran 1:1 (25 mL) was added dropwise and the solution stirred 
vigorously at -78 °C.  A cold (5 °C) solution of α-bromoketone 3.28 in the same solvent 
(90 mL) was added slowly and the reaction mixture stirred for 1 h at -78 °C after which the 
reaction was quenched with 1M aqueous HCl (5 mL) and warmed to rt.  Solvent was 
removed in vacuo to give a colourless residue that was dissolved in a minimal amount of 
ethyl acetate.  The resulting slushy residue was sonicated for 15 min and the resulting 
suspension washed sequentially with 1M aqueous HCl and brine, dried over MgSO4 and 
solvent removed under reduced pressure to give the product as a white solid.  No further 
purification was necessary (0.86 g, 89%). 
mp = 149-151°C; 
1H NMR δ(CD3OD) 7.92 (2H, m, ArH (Fps)), 7.77 (1H, d, J  = 9.1 Hz, NH) 7.28-7.24 
(2H, m, ArH (Fps), 3.91-3.85 (1H, m, CHCH2CH(CH3)2), 3.61-3.59 (1H, m, 
CHCH(CH3)2), 3.42 (1H, dd, J = 4.4 and 10.6 Hz, CHCH2Br), 3.27 (1H, dd, J = 7.5 and 
10.6 Hz, CHCH2Br), 2.00 (1H, m, CHCH(CH3)2), 1.34-1.29 (2H, m, CHCH2CH(CH3)2), 
1.19-1.13 (1H, m, CHCH2CH(CH3)2), 0.93 (3H, d, J = 6.8 Hz, CHCH(CH3)2), 0.85 (3H, d, 
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J = CHCH(CH3)2), 0.83 (d, J = 6.9 Hz, CHCH2CH(CH3)2), 0.74 (d, J = 6.9 Hz, 
CHCH2CH(CH3)2) ;        
13C NMR δ(CD3OD) 172.68, 166.85 (d, J = 253.5 Hz), 136.90 (d, J = 3.1 Hz), 131.43 (d, J 
= 9.5 Hz), 117.57 (d, J = 23.1 Hz), 74.99, 62.75, 56.20, 44.13, 32.46, 25.38, 23.01, 22.54, 
18.73, 18.25, 17.77; 
[α]D = -30.0 (c = 0.1 in CH3OH); 
HRMS (ES) 467.1023 (MH+) C18H29BrFN2O4S requires 467.1015; 
νmax (KBr)  3489 (CHOH), 3271 (SO2NH), 2961 (C(O)NH), 1240 (CH2Br). 
 
  
Preparation of {1S-[1S-(2-bromo-1S-hydroxyethyl)-3-methylbutylcarbamoyl]-2-
methylpropyl}carbamic acid benzyl ester  (3.31) 
 
O N
H
O
H
N
O
OH
Br
 
 
Solid tri-tert-butoxylithium aluminium hydride (1.11 g, 4.36 mmol) was cooled to -78 °C.  
Ethanol:tetrahydrofuran 1:1 (25 mL) was added dropwise and the solution stirred 
vigorously at -78 °C.  A cold (5 °C) solution of α-bromoketone 3.29 in the same solvent 
(90 mL) was added slowly and the reaction mixture stirred for 1 h at -78 °C after which the 
reaction was quenched with 1M aqueous HCl (5 mL) and warmed to rt.  Solvent was 
removed in vacuo to give a colourless residue that was dissolved in a minimal amount of 
ethyl acetate.  The resulting slushy residue was sonicated for 15 min and the resulting 
suspension washed sequentially with 1M aqueous HCl and brine, dried over MgSO4 and 
solvent removed under reduced pressure to give the product as a white solid.  No further 
purification was necessary (0.86 g, 89%). 
mp = 165-166 °C; 
1H NMR δ(CD3OD) 7.80 (1H, d, J = 9.1 Hz, NH), 7.37-7.32 (5H, m, ArH (Cbz)), 7.04 
(1H, d, J =8.2 Hz, NH), 5.12 (1H, d, J = 12.4 Hz, CCH2O), 5.08 (1H, d, J = 12.4 Hz, 
CCH2O), 4.07-4.01 (1H, m, CHCH2CH(CH3)2), 3.88 (1H, m, CHCHOH), 3.67-3.64 (1H, 
m, CHCH(CH3)2), 3.94 (1H, dd, J = 4.0 and 10.6 Hz, CHCH2Br), 3.33 (1H, dd, J = 7.7 and 
10.6 Hz, CHCH2Br), 2.08-2.01 (1H, m, CHCH(CH3)2), 1.66-1.58 (1H, m, 
CHCH2CH(CH3)2), 1.51-1.40 (1H, m, CHCH2CH(CH3)2), 0.97 (3H, d, J = 6.8 Hz, 
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CHCH2CH(CH3)2), 0.95 (3H, d, J = 6.8 Hz, CHCH2CH(CH3)2), 0.91 (3H, d, J = 6.6 Hz, 
CHCH(CH3)2), 0.86 (3H, d, J = 6.6 Hz, CHCH(CH3)2); 
13C NMR δ(CD3OD) 172.68, 157.30, 137.89, 129.02, 128.49, 128.36, 74.29, 66.57, 61.82, 
51.09, 37.09, 30.98, 24.89, 24.11, 21.59, 21.48, 19.61, 18.42; 
[α]D = -28.0 (c = 0.1 in CH3OH); 
HRMS (ES) 443.1547 (MH+) C20H32BrN2O4 requires 443.1545; 
νmax (KBr)  3275 (CHOH), 2959 (C(O)NH), 2872 (C(O)NH), 1246 (CH2Br). 
 
 
Preparation of N-[1S-(2-bromo-1(R,S)-hydroxyethyl)-3-methylbutyl]-2S-(4-fluoro-
benzenesulfonylamino)-3-methylbutyramide (3.32) 
 
F
O2
S N
H
H
N
O
OH
Br
 
 
Solid sodium borohydride (0.11 g, 2.83 mmol) was cooled to -78 °C and tetrahydrofuran 
added dropwise to give a slurry that was stirred vigorously at -78 °C.  A cold (5 °C) 
solution of the α-bromoketone 3.28 (0.66 g, 1.41 mmol) in tetrahydrofuran was added 
dropwise.  The reaction mixture was stirred at -78 °C for 1.5 h after which time the 
reaction was quenched with 1M aqueous HCl (5 mL) and warmed to rt.  The solvent was 
removed in vacuo and the residue sonicated in ethyl acetate.  The resulting suspension was 
diluted with ethyl acetate then sequentially washed with 1M aqueous HCl and brine, dried 
over MgSO4, filtered and solvent removed to give the crude material.  Recrystallisation 
from ethyl acetate gave the product, a white solid, as a mixture of diastereoisomers (1:1) 
(0.48 g, 73%). 
Spectral data reported for the diastereomeric mixture (1:1). 
1H NMR δ(CD3OD) 7.92-7.89 (4H, m, ArH (Fbs)), 7.77 (1H, d, J = 8.8 Hz, NH), 7.56 
(1H, d, J = 9.3 Hz, NH), 7.28-7.24 (4H, m, ArH (Fbs)), 4.04-3.99 (1H, m, CHCH2(CH3)2), 
3.91-3.84 (1H, m, CHCH2CH(CH3)2), 3.72-3.69 (1H, m, CHCH(CH3)2), 3.62 (1H, dd, J = 
5.0 and 10.0 Hz, CHCHOH), 3.60-3.58 (2H, m, CHCH(CH3)2 and CHCHOH), 3.42 (1H, 
dd, J = 4.4 and 10.6 Hz, CHCH2Br), 3.32-3.25 (2H, m, CHCH2Br), 3.20 (1H, dd, J = 7.2 
and 10.2 Hz, CHCH2Br), 2.00-1.93 (2H, m, CHCH(CH3)2), 1.37-1.27 (4H, m, 
CHCH2CH(CH3)2), 1.21-1.12 (2H, m, CHCH2CH(CH3)2), 0.93 (3H, d, J = 4.2 Hz,  
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CHCH2CH(CH3)2), 0.92 (3H, d, J = 4.2 Hz, CHCH2CH(CH3)2), 0.86-0.83 (18H, m, 
CHCH(CH3)2  and CHCH2CH(CH3)2), 0.80 (3H, d, J = 6.1 Hz, CHCH(CH3)2), 0.74 (3H, 
d, J = 6.1 Hz, CHCH(CH3)2); 
13C NMR δ(CD3OD) 170.06, 169.71, 164.68 (d, J = 252.7 Hz), 164.20 (d, J = 250.5 Hz), 
137.54 (d, J = 2.7 Hz), 136.07 (d, J = 2.3 Hz), 129.99 (d, J = 5.8 Hz), 129.75 (d, J = 5.8 
Hz), 116.63 (d, J = 22.8 Hz), 115.98 (d, J = 22.5 Hz), 72.21, 712.82, 54.13, 52.98, 49.91, 
49.04, 42.31, 42.25, 36.98, 35.81, 31.51, 30.79, 23.79, 22.97, 22.47, 22.14, 21.88, 21.21, 
19.22, 18.90, 18.24, 17.37; 
HRMS (ES) 467.0995 (MH+) C18H29BrFN2O4S requires 467.1015; 
νmax (KBr)  3545 (CHOH), 3298 (SO2NH), 2953 (C(O)NH), 1337 (CH2Br).  
 
 
Preparation of {1S-[1S-(2-bromo-1(R,S)-hydroxyethyl)-3-methylbutylcarbamoyl]-2-
methylpropyl}carbamic acid benzyl ester (3.33) 
 
O N
H
O
H
N
O
OH
Br
 
 
Solid sodium borohydride (0.07 g, 1.84 mmol) was cooled to -78 °C and tetrahydrofuran 
added dropwise to give a slurry that was stirred vigorously at -78 °C.  A cold (5 °C) 
solution of the α-bromoketone 3.29 (0.41 g, 0.92 mmol) in tetrahydrofuran was added 
dropwise.  The reaction mixture was stirred at -78 °C for 1.5 h after which time the 
reaction was quenched with 1M aqueous HCl (5 mL) and warmed to rt.  The solvent was 
removed in vacuo and the residue sonicated in ethyl acetate.  The resulting suspension was 
diluted with ethyl acetate then sequentially washed with 1M aqueous HCl and brine, dried 
over MgSO4, filtered and solvent removed to give the crude material.  Recrystallisation 
from ethyl acetate gave the product, a white solid, as a mixture of diastereoisomers (1:1) 
(0.30 g, 74%). 
Spectral data reported for the diastereomeric mixture (1:1). 
1H NMR δ(CD3OD) 7.81 (1H, d, J = 7.8 Hz, NH), 7.54 (1H, d, J = 8.5 Hz, NH), 7.37-7.28 
(10H, m, ArH (Cbz)), 5.15-5.06 (4H, m, CCH2O), 4.23-4.18 (1H, m, CHCH2CH(CH3)2), 
4.06-4.01 (1H, m, CHCH2CH(CH3)2), 3.94-3.87 (2H, m, CHCHOH), 3.78-3.75 (1H, m, 
CHCH(CH3)2), 3.67-3.64 (1H, m, CHCH(CH3)2), 3.50 (1H, dd, J = 3.9 and 10.5 Hz, 
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CHCH2Br), 3.39-3.25 (3H, m, CHCH2Br), 2.09-2.01 (2H, m, CHCH(CH3)2), 1.66-1.53 
(4H, m, CHCH2CH(CH3)2), 1.48-1.42 (1H, m, CHCH2CH(CH3)2), 1.36-1.29 (1H, m, 
CHCH2CH(CH3)2), 0.98-0.85 (24H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 173.44, 173.37, 173.22, 173.11, 138.46, 138.42, 129.67, 129.66, 
129.13, 129.11, 129.00, 128.97, 74.86, 74.03, 67.29, 67.20, 62.41, 62.38, 37.84, 36.87, 
31.60, 31.53, 25.70, 25.66, 24.11, 24.00, 22.88, 22.80, 22.20, 21.99, 20.31, 20.22, 19.18, 
19.13, 19.11, 19.05; 
HRMS (ES) 443.1559 (MH+) C20H32BrN2O4 requires 443.1545; 
νmax (KBr)  3302 (CHOH), 2961 (C(O)NH), 2872 (C(O)NH), 1244 (CH2Br). 
 
  
Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methyl-N-(3-methyl-1S-S-
oxiranylbutyl)butyramide (3.27) 
 
F
O2
S N
H
H
N
O
O
 
 
Epoxidation of α-bromomethyl alcohol 3.30 (0.080 g, 0.17 mmol) was achieved in the 
presence of potassium carbonate (0.044 g, 0.34 mmol) according to General Procedure Q 
to give the product as a colourless oil (0.058 g, 88%) 
1H NMR δ(CD3OD) 7.90-7.87 (2H, m, ArH (Fps)), 7.28-7.24 (2H, m, ArH (Fps)), 4.02-
3.99 (1H, m, CHCH2CH(CH3)2), 3.73 (1H, d, J = 7.6 Hz, CHCH(CH3)2), 3.53 (1H, m, 
CHCHOCH2), 3.35 (1H, dd, J = 3.9 and 12.0 Hz, CHCHOCH2), 3.18 (1H, dd, J = 6.9 and 
12.0 Hz, CHCHOCH2), 1.98 (1H, m, CHCH(CH3)2), 1.66-1.61 (1H, m,  
CHCH2CH(CH3)2), 1.22-1.17 (1H, m, CHCH2CH(CH3)2), 1.07-1.02 (1H, m, 
CHCH2CH(CH3)2), 0.97-0.86 (12H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
[α]D = -6.0 (c = 0.1 in CH3OH); 
HRMS (ES) 387.1750 (MH+) C18H28FN2O4S requires 387.1754; 
νmax (KBr)  3369 (SO2NH), 3068 (C(O)NH), 1265 (epox).  
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Preparation of [2-methyl-1S-(3-methyl-1S-S-oxiranylbutylcarbamoyl)propyl]-
carbamic acid benzyl ester (3.34) 
O N
H
O
H
N
O
O
 
 
Epoxidation of α-bromomethyl alcohol 3.31 (0.090 g, 0.20 mmol) was achieved in the 
presence of potassium carbonate (0.056 g, 0.41 mmol) according to General Procedure Q 
to give the product as a white solid (0.036 g, 89%) 
mp = 124-126 °C; 
1H NMR δ(CD3OD) 7.36-7.32 (5H, m, ArH (Cbz)), 5.79 (1H, d, J = 6.4 Hz, NH), 5.32 
(1H, d, J = 7.2 Hz, NH), 5.11 (2H, s, CCH2O), 3.94-3.89 (2H, m, CHCH(CH3)2 and 
CHCH2CH(CH3)2), 2.84 (1H, bs, CHCHCH2O), 2.72 (2H, bs, CHCHCH2O), 1.70-1.58 
(1H, m, CHCH2CH(CH3)2), 1.43-1.34 (2H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 
0.96 (3H, dd, J = 1.6 and 6.7 Hz, CHCH(CH3)2), 0.92-0.91 (6H, m, CHCH2CH(CH3)2 and 
CHCH(CH3)2), 0.87 (3H, dd, J = 1.7 and 6.4 Hz, CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 174.17, 158.44, 138.27, 129.46, 129.00, 128.82, 67.60, 62.41, 54.88, 
49.85, 45.63, 41.33, 31.86, 25.56, 23.80, 23.13, 22.01, 19.71, 18.79; 
[α]D = -39.6 (c = 0.1 in CHCl3); 
HRMS (ES) 363.2291 (MH+) C20H31N2O4 requires 363.2284; 
νmax (KBr)  2961 (C(O)NH), 2872 (C(O)NH), 1244 (epox).  
 
 
Preparation of 2S-(4-fluorobenzenesulfonylamino)-3-methyl-N-(3-methyl-1S-(R,S)-
oxiranyl-butyl)butyramide (3.35) 
 
F
O2
S N
H
H
N
O
O
 
 
Epoxidation of the diastereomeric α-bromomethyl alcohol 3.32 (0.080 g, 0.17 mmol) was 
achieved in the presence of potassium carbonate (0.044 g, 0.34 mmol) according to 
General Procedure Q to give the product as a white solid (0.049 g, 74%) 
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1H NMR δ(CD3OD) 7.87-7.83 (4H, m, ArH (Fps)), 7.29-7.26 (4H, m, ArH (Fps)), 4.00-
3.92 (2H, m, CHCH2CH(CH3)2), 3.65-3.61 (2H, m, CHCH(CH3)2), 3.55-3.51 (2H, m, 
CHCHOCH2), 3.33 (1H, dd, J = 3.9 and 12.0 Hz, CHCHOCH2), 3.30 (1H, dd, J = 2.8 and 
11.7 Hz, CHCHOCH2), 3.13-3.09 (2H, m, CHCHOCH2), 1.98-1.92 (2H, m, 
CHCH(CH3)2), 1.67-1.61 (2H, m, CHCH2CH(CH3)2), 1.22-1.07 (4H, m, CHCH2CH(CH3)2  
and CHCH2CH(CH3)2), 0.98-0.81 (24H, m, CHCH(CH3)2 and CHCH2CH(CH3)2); 
13C NMR δ(CD3OD) 172.97, 172.74, 166.34 (d, J = 252.3 Hz), 166.28 (d, J = 252.2 Hz),  
138.83 (d, J = 3.2 Hz), 138.38 (d, J = 3.2 Hz), 131.23 (d, J = 9.5 Hz), 131.16 (d, J = 9.4 
Hz), 117.11 (d, J = 22.8 Hz), 117.08 (d, J = 22.8 Hz), 75.03, 74.00, 63.17, 63.13, 51.84, 
50.93, 41.65, 39.21, 36.17, 35.53, 33.12, 33.07, 25.56, 25.40, 24.29, 23.40, 22.53, 21.75, 
19.99, 19.95, 17.78, 17.69; 
HRMS (ES) 387.1756 (MH+) C18H28FN2O4S requires 387.1754;  
νmax (KBr)  3354 (SO2NH), 3064 (C(O)NH), 1258 (epox). 
 
 
Preparation of [2-methyl-1S-(3-methyl-1S-(R,S)-oxiranylbutylcarbamoyl)propyl]-
carbamic acid benzyl ester (3.36) 
 
O N
H
O
H
N
O
O
 
 
Epoxidation of the diastereomeric α-bromomethyl alcohol 3.33 (0.080 g, 0.18 mmol) was 
achieved in the presence of potassium carbonate (0.050 g, 0.36 mmol) according to 
General Procedure Q to give the product as a white solid (0.054 g, 83%). 
1H NMR δ(CD3OD) 7.35-7.32 (10H, m, ArH (Cbz)), 5.11-5.07 (4H, m, CCH2O), 4.26-
4.16 (4H, m, CHCH(CH3)2 and CHCH2CH(CH3)2), 3.32-3.30 (2H, m, CHCHCH2O), 3.27-
3.24 (4H, m, CHCHCH2O), 2.13-2.00 (2H, m, CHCH(CH3)2), 1.69-1.26 (6H, m, 
CHCH2CH(CH3)2 and CHCH2CH(CH3)2), 1.03-0.85 (24H, m, CHCH2CH(CH3)2 and 
CHCH(CH3)2;  
13C NMR δ(CD3OD) 174.38, 174.36, 168.06, 166.37, 138.26, 138.21, 129.48, 129.47, 
129.02, 128.85, 128.83, 87.56, 84.78, 74.52, 70.76, 66.50, 65.49, 64.64, 63.96, 61.23, 
59.74, 50.10, 49.92, 41.53, 41.27, 25.66, 24.54, 23.76, 23.10, 22.30, 21.61, 20.00, 19.60, 
18.81, 18.44; 
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HRMS (ES) 363.2272 (MH+) C20H31N2O4 requires 363.2284 
νmax (KBr)  2953 (C(O)NH), 2870 (C(O)NH), 1254 (epox).  
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7.4 EXPERIMENTAL WORK AS DESCRIBED IN 
CHAPTER FOUR 
 
 
7.4.1 Synthesis of a Macrocyclic Aldehyde 
 
Preparation of 2S-[3-(4-allyloxyphenyl)-2S-tert-butoxycarbonylaminopropionyl-
amino]-3-methylbutyric acid methyl ester (4.6) 
 
BocHN
H
N
O
O
CO2Me
 
 
N-Boc-O-allyltyrosine 4.5 (5.00g, 16.3 mmol) was reacted with L-valine methyl ester 
using General Procedure B.  The crude material was purified by flash chromatography on 
silica (1:4 ethyl acetate and petroleum ether) to yield a white solid (6.08g, 69%). 
mp = 74-76 oC; 
1H NMR δ(CDCl3) 7.09 (2H, m, ArH (Tyr)), 6.80 (2H, m, ArH (Tyr)), 6.47 (1H, bs, NH), 
5.97-6.05 (1H, m, CH=CH2), 5.01-5.40 (2H, m, CH=CH2), 5.12 (1H, bs, NH), 4.47-4.49 
(2H, m, OCH2CH=CH2), 4.37-4.46 (1H, m, CHCH2Ph), 4.30-4.34 (1H, m, CHCH(CH3)2), 
3.66 (3H, s, CO2CH3), 3.01-3.04 (2H, m, CHCH2Ph), 2.04-2.11 (1H, m, CHCH(CH3)2), 
1.39 (9H, s, C(CH3)3), 0.85 (3H, d J = 6.8 Hz, CHCH(CH3)2), 0.82 (3H, d J = 6.8 Hz, 
CHCH(CH3)2);  
13C NMR δ(CDCl3) 174.7, 171.9, 157.5, 133.2, 130.3, 128.6, 117.6, 114.8, 68.7, 57.2, 
37.0, 31.0, 28.2, 18.8, 17.6; 
[α]D = -5.0 (c = 0.1 in CHCl3); 
HRMS (ES) 435.2501 (MH+) C23H34N2O6 requires 435.2495 
Microanalysis C, 62.58; H, 7.66; N, 6.58 C23H34N2O6 requires C, 62.84; H, 7.67; N, 6.66. 
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Preparation of 2S-[3-(4-allyloxyphenyl)-2S-tert-butoxycarbonylaminopropionyl-
amino]-3-methylbutyric acid (4.7) 
 
BocHN
H
N
O
O
CO2H
 
 
Methyl ester 4.6 (4.90 g, 11.3 mmol) in tetrahydrofuran was hydrolysed according to 
General Procedure G.  This gave the product as a colourless glassy solid (4.60 g, 97%). 
1H NMR δ(CDCl3) 7.11 (2H, m, ArH (Tyr)), 6.83 (2H, m, ArH (Tyr)), 6.64 (1H, d J = 8.2 
Hz,  NH), 5.98-6.07 (1H, m, CH=CH2), 5.00-5.39 (2H, m, CH=CH2), 5.19 (1H, bs,  NH), 
4.51 (3H, m, CHCH2Ph and OCH2CH=CH2), 4.36-4.40 (1H, m, CHCH(CH3)2), 2.97-3.02 
(2H, m, CHCH2Ph), 2.16-2.23 (1H, m, CHCH(CH3)2), 1.40 (9H, s, C(CH3)3), 0.88-0.93 
(6H, m, CHCH(CH3)2); 
13C NMR δ(CDCl3)  174.31, 172.03, 157.40, 155.73, 133.19, 130.25, 128.57, 117.48, 
114.73, 80.29, 68.67, 57.19, 55.70, 37.12, 31.04, 28.16, 18.79, 17.59; 
[α]D = +19.0 (c = 0.1 in CHCl3); 
HRMS (ES) 421.2332 (MH+) C22H32N2O6 requires 421.2339 
νmax (KBr)  3315 (CO2H), 2968 (C(O)NH), 2905 (C(O)NH), 1500 (CH=CH2). 
 
 
Preparation of 2S-aminopent-4-enoic acid methyl ester (4.8) 
  
HCl.H2N CO2Me
 
 
L-Allylglycine (5.00g, 43.4 mmol) was esterified using General Procedure H to afford a 
colourless oil (7.19g, 100%).  
1H NMR δ(CD3OD) 5.78 (1H, m, CH2CHCH2), 5.25-5.31 (2H, m, CH2CHCH2), 4.16 (1H, 
dd, J = 6.2 and 6.2 Hz, CHCO2CH3), 3.84 (3H, s, CHCO2CH3), 2.69 (2H, m, CH2CHCH2); 
13C NMR δ(CD3OD) 169.12, 130.35, 120.34, 52.39, 52.13, 34.42;   
LRMS (ES) 130.5 (MH+) C6H11NO2 requires 130.1; 
[α]D = +2.0 (c = 1.0 in CHCl3); 
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HRMS could not be obtained as the mass lies outside the range of the mass spectrometer 
used. 
νmax (KBr)  1638 (CO2Me), 1618 (CH=CH2). 
 
 
Preparation of 2S-{2S-[3-(4-allyloxyphenyl)-2S-tert-butoxycarbonylaminopropionyl-
amino]-3-methylbutyrylamino}pent-4-enoic acid methyl ester (4.9) 
 
BocHN
H
N
O
O
O
N
H
CO2Me
 
 
The dipeptidyl acid 4.7 (1.00g, 2.38 mmol) was reacted with alkene 4.8 using General 
Procedure B.  The crude material was purified by flash chromatography on silica (1:4 
ethyl acetate: pet ether to yield a white solid (1.05g, 83%).   
mp =  106-108 oC; 
1H NMR δ(CDCl3) 7.09 (2H, m, ArH (Tyr)), 6.82 (2H, m, ArH (Tyr)), 6.61 (1H, d, J = 8.4 
Hz, NH), 6.56 (1H, d, J = 6.8 Hz, NH), 6.03 (1H, tdd, J = 5.3, 10.6 and 17.2 Hz, 
OCH2CHCH2), 5.62-5.71 (1H, m, CHCH2CHCH2), 5.10-5.41 (4H, m, OCH2CHCH2 and 
CHCH2CHCH2), 5.05 (1H, d, J = 5.5 Hz, NH), 4.58-4.62 (1H, m, CHCH2CHCH2), 4.48-
4.50 (2H, m, OCH2CHCH2), 4.30-4.33 (1H, m, CHCH2Ph), 4.25 (1H, dd, J = 6.5 and 8.4 
Hz, CHCH(CH3)2), 3.73 (3H, s, CO2CH3), 2.96-3.05 (2H, m, CHCH2Ph), 2.46-2.59 (2H, 
m, CHCH2CHCH2), 2.07-2.14 (1H, m, CHCH(CH3)2), 1.39 (9H, s, C(CH3)3), 0.90 ( 3H, d, 
J = 6.8 Hz, CHCH(CH3)2), 0.86 (3H, d, J = 6.8 Hz, CHCH(CH3)2); 
13C NMR δ(CDCl3) 171.72, 171.40, 170.45, 157.63, 133.29, 132.22, 130.01, 128.60, 
119.30, 117.62, 114.97, 68.74, 58.42, 52.38, 51.78, 36.25, 30.75, 28.22, 19.04; 
[α]D = +5.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 532.3010 (MH+) C28H42N3O7 requires 532.3023; 
νmax (KBr)  2957 (C(O)NH), 2870 (C(O)NH), 1730 (CO2Me), 1686 (CH=CH2), 1671 
(CH=CH2)  
Microanalysis C, 63.10; H, 7.76; N, 7.90 C28H42N3O7 requires C, 63.26; H, 7.77; N, 7.90. 
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Preparation of (E)-13S-tert-butoxycarbonylamino-10S-isopropyl-9,12-dioxo-2-oxa-
8,11-diaza-bicyclo[13.2.2]nonadeca-1(18),4,15(19),16-tetraene-7S-carboxylic acid 
methyl ester (4.10) 
BocNH
H
N
O
O
O
N
H
CO2Me
 
 
The diene 4.9 (1.80 g, 3.39 mmol, 1.0 equiv) was dissolved in anhydrous 1,1,2-
trichloroethane (0.01M) under an atmosphere of argon.  To this were added 1M chloro-
dicyclohexyl borane in hexanes (0.34 mL, 0.34 mmol, 0.10 equiv) and Grubbs second 
generation catalyst (0.23 g, 0.34 mmol, 0.10 equiv).  The mixture was heated at reflux in 
the microwave (1200 W) for 20 min.  Two further additions of Grubbs second generation 
catalyst (0.10 equiv) were added and after each the reaction mixture was subjected to a 
further 20 min heating in the microwave. The mixture was then cooled and concentrated in 
vacuo.  The crude material was purified by recrystallisation from methanol (1.11 g, 65%). 
mp = 105-107 oC; 
1H NMR δ(CDCl3) 7.05 (2H, m, ArH (Tyr)), 6.75 (2H, m, ArH (Tyr)), 5.74-5.75 (2H, m, 
NH), 5.43-5.56 (2H, m, OCH2CHCHCH2 and OCH2CHCHCH2), 5.32 (1H, d, J = 8.7 Hz, 
NH), 4.76 (1H, ddd J = 3.4 Hz, J = 9.2 and 10.1 Hz, CHCO2CH3), 4.58-4.64 (2H, m, 
OCH2CHCHCH2), 4.21 (1H, ddd, J = 5.2, 8.7 and11.6 Hz, CHCH2Ph), 3.99 (1H, dd, J = 
4.8 and 7.5 Hz, CHCH(CH3)2), 3.75 (3H, s, CHCO2CH3), 3.13 (1H, dd, J = 5.2 and 12.5 
Hz, CHCH2Ph), 2.66-2.75 (2H, m, CHCH2Ph and OCH2CHCHCH2), 2.26-2.32 (1H, m, 
OCH2CHCHCH2), 2.07-2.14 (1H, m, CHCH(CH3)2), 1.45 (9H, s, C(CH3)3), 0.81-0.83 
(6H, m, CHCH(CH3)2); 
13C δ((CD3)2SO) 171.70, 170.24, 170.10, 155.41, 154.76, 129.80, 128.50, 128.34, 127.65, 
114.72, 77.89, 65.66, 56.73, 55.32, 51.92, 51.85, 36.42, 32.37, 32.19, 28.10, 18.57, 18.04; 
[α]D = -14.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 504.2718 (MH+) C26H37N3O7 requires 504.2710 
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Preparation of 13S-tert-butoxycarbonylamino-10S-isopropyl-9,12-dioxo-2-oxa-8,11-
diaza-bicyclo[13.2.2]nonadeca-1(18),15(19),16-triene-7S-carboxylic acid methyl ester 
(4.11) 
BocHN
H
N
O
O
O
N
H
CO2Me
 
 
The unsaturated macrocycle 4.10 (1.36 g, 2.70 mmol) was hydrogenated in 50 mL of 
methanol using General Procedure T to afford a white solid (1.36 g, 100%). 
mp =  225-228 oC; 
1H NMR δ((CD3)2SO) 7.05 (2H, m, ArH (Tyr)), 6.78 (2H, m, ArH (Tyr)), 6.23 (1H, d, J = 
7.1 Hz, NH), 5.90 (1H, d, J = 8.2 Hz, NH), 5.29 (1H, d, J = 8.6 Hz, NH), 4.56 (1H, dt, J = 
3.9 and 8.2 Hz, CHCO2CH3), 4.21-4.30 (2H, m, CHCH2Ph, OCH2CH2CH2CH2) 4.09-4.13 
(1H, m, OCH2CH2CH2CH2), 3.84-3.86 (1H, m, CHCH(CH3)2), 3.72 (3H, s, CHCO2CH3), 
3.10 (1H, dd, J = 5.4 and 12.2 Hz, CHCH2Ph), 2.67 (1H, dd, J = 12.2 and 12.2 Hz, 
CHCH2Ph), 1.95-2.02 (1H, m, CHCH(CH3)2), 1.86-1.92 (1H, m, OCH2CH2CH2CH2), 1.80 
(1H, m, OCH2CH2CH2CH2), 1.49-1.57 (2H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 1.44 (9H, s, C(CH3)3), 1.25-1.35 (2H, m, OCH2CH2CH2CH2), 0.87 
(3H, d, J = 6.6 Hz, CHCH(CH3)2), 0.81 (3H, d, J = 6.6 Hz, CHCH(CH3)2); 
13C NMR δ((CD3)2SO) 172.72, 170.32, 169.85, 156.90, 155.11, 130.05, 128.42, 115.95, 
79.64, 66.88, 57.65, 56.84, 52.32, 51.08, 38.43, 32.34, 31.74, 28.20, 21.73, 18.26, 18.17; 
[α]D = -11.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 506.2871 (MH+) C26H40N3O7 requires 506.2866; 
νmax (KBr)  2967 (C(O)NH), 2887 (C(O)NH), 1754 (CO2Me) 
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Preparation of 13S-benzyloxycarbonyl-10S-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-
bicyclo[13.2.2]nonadeca-1(18),15(19),16-triene-7S-carboxylic acid methyl ester (4.13) 
 
N
H
H
N
O
O
O
N
H
CO2MeO
O
 
 
N-Boc protected saturated methyl ester 4.11 (1.00g, 1.97 mmol) was reacted using 
General Procedure E to afford the free amine as the TFA salt 4.12 (0.87 g, 100%) which 
was reacted immediately in the next reaction. 
1H NMR δ((CD3)2SO) 8.51 (2H, bs, NH2), 8.16 (1H, d, J = 7.2Hz, NH), 7.90 (1H, d, J = 
6.4 Hz, NH), 6.98 (2H, d, J = 6.8 Hz, ArH (Cbz)), 6.75 (4H, m, ArH (Tyr)), 4.31-4.36 
(2H, m, OCH2CH2CH2CH2), 4.18-4.25 (1H, m, CHCO2CH3), 4.03-4.08 (1H, m, 
CHCH2Ph) 3.84 (1H, dd, J = 5.2 and 7.2 Hz, CHCH(CH3)2), 3.60 (3H, s, CHCO2CH3), 
3.08 (1H, dd, J = 5.6 and 11.2 Hz, CHCH2Ph), 2.60 (1H, dd, J = 11.2 and 11.2 Hz, 
CHCH2Ph), 1.96-2.01 (1H, m, CHCH(CH3)2), 1.76-1.83 (1H, m, OCH2CH2CH2CH2), 
1.65-1.74 (1H, m, OCH2CH2CH2CH2), 1.48-1.57 (2H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 1.22-1.36 (2H, m, OCH2CH2CH2CH2), 0.84 (3H, d, J = 6.4 Hz, 
CHCH(CH3)2), 0.77 (3H, d, J = 6.4 Hz, CHCH(CH3)2); 
LRMS (ES) 406.3 (MH+) C21H31N3O5 requires 406.2 
 
To the amino acid TFA salt 4.12 (0.87 g, 2.15 mmol, 1.0 equiv) in ice cold ethyl 
acetate/water (1:1) was added potassium bicarbonate (1.08 g, 10.75 mmol, 5.0 equiv).  
Benzyl chloroformate (0.34 mL, 2.37 mmol, 1.1 equiv) in ice cold ethyl acetate was added 
dropwise and a white precipitate immediately formed.  The suspension was allowed to 
return to rt and stirred overnight after which the precipitate was filtered off and washed 
sequentially with 1M aqueous HCl and water, then dried (0.99 g, 86%).  Recrystallisation 
from ethyl acetate gave the pure product as a white solid. 
mp > 250 °C 
1H NMR δ((CD3)2SO) 8.11 (1H, d, J = 9.2 Hz, NH), 7.58 (1H, d, J = 6.5 Hz, NH), 7.35-
7.32 (2H, m, ArH (Cbz)) 7.01 (2H, m, ArH (Tyr)), 6.89, (1H, d, J = 8.2 Hz, NH), 6.74 
(2H, m, ArH (Tyr)), 5.03 (2H, bs, CCH2O), 4.38-4.27 (2H, m, OCH2CH2CH2CH2), 4.01 
(1H, t, J = 9.3 Hz, CHCO2CH3), 3.80-3.77 (1H, m, CHCH2Ph) 3.61-3.55 (4H, m, 
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CHCH(CH3)2 and CHCO2CH3), 2.86 (1H, dd, J = 5.6 and 11.2 Hz, CHCH2Ph), 2.65-2.60 
(1H, m, CHCH2Ph), 1.80-1.67 (3H, m, CHCH(CH3)2 and OCH2CH2CH2CH2), 1.58-1.52 
(1H, m, OCH2CH2CH2CH2), 1.30-1.20 (4H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 0.89 (1H, m, OCH2CH2CH2CH2), 0.75 (6H, d, J = 6.6 Hz, 
CHCH(CH3)2), 0.68-0.60 (1H, m, OCH2CH2CH2CH2); 
13C NMR δ((CD3)2SO) 172.48, 169.80, 169.77, 155.48, 137.09, 130.15, 128.24, 127.69, 
127.62, 115.29, 115.27, 65.97, 65.15, 56.48, 56.20, 51.78, 49.42, 36.74, 32.06, 29.61, 
26.17, 21.45, 18.41, 18.05 
[α]D = -6.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 540.2723 (MH+) C29H38N3O7 requires 540.2710; 
νmax (KBr)  3035 (C(O)NH), 2960 (C(O)NH), 1738 (CO2Me), 1688 (OC(O)). 
 
 
Preparation of (7S-hydroxymethyl-10S-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-
bicyclo[13.2.2]nonadeca-1(18),15(19),16-trien-13S-yl)carbamic acid benzyl ester (4.3) 
 
N
H
H
N
O
O
O
N
H
O
O
OH
 
 
The methyl ester 4.13 (0.90 g, 1.67 mmol) was suspended in tetrahydrofuran and reduced 
according to General Procedure K to give the alcohol 4.3 as a white solid (0.72 g, 84%).  
Recrystallisation from methanol gave the pure product. 
mp >250 °C; 
1H NMR δ((CD3)2SO) 7.57 (1H, d, J = 7.0 Hz, NH), 7.45 (1H, d J = 9.1 Hz, NH), 7.35-
7.34 (5H, m, ArH (Cbz)), 7.01 (2H, m, ArH (Tyr)), 6.80 (1H, d J = 7.9 Hz, NH), 6.74 (2H, 
m, ArH (Tyr)), 5.03 (2H, s, CCH2O), 4.62-4.60 (1H, m, CH2OH), 4.35-4.28 (2H, m, 
CHCH2Ph and OCH2CH2CH2CH2), 4.04-3.99 (1H, m, OCH2CH2CH2CH2), 3.76-3.64 (2H, 
m, CHCH(CH3)2 and CHCH2OH), 3.20-3.14 (1H, m, CH2OH), 3.09-3.05 (1H, m, 
CH2OH), 2.85 (1H, dd, J = 5.6 and 12.8 Hz, CHCH2Ph), 2.65-2.60 (1H, m, CHCH2Ph), 
1.78-1.68 (2H, m, CHCH(CH3)2) and OCH2CH2CH2CH2), 1.51-1.43 (1H, m, 
OCH2CH2CH2CH2), 1.32-1.13 (2H, m, OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 0.86-
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0.80 (1H, m, OCH2CH2CH2CH2), 0.73-0.71 (3H, m, CHCH(CH3)2), 0.64-0.59 (1H, m, 
OCH2CH2CH2CH2); 
13C NMR δ((CD3)2SO) 170.17, 169.62, 156.32, 155.87, 137.30, 130.43, 128.68, 128.43, 
128.17, 127.98, 115.76, 66.73, 65.67, 64.56, 57.05, 56.91, 49.44, 37.00, 32.36, 30.11, 
27.88, 22.22, 18.92, 18.43; 
[α]D = -8.0 (c = 0.1 in (CH3)2SO); 
HRMS (ES) 512.2763 (MH+) C28H38N3O6 requires 512.2761; 
νmax (KBr)  3288 (CH2OH), 2958 (C(O)NH), 2872 (C(O)NH), 1765 (OC(O)).  
 
 
Preparation of (7S-formyl-10S-isopropyl-9,12-dioxo-2-oxa-8,11-diazabicyclo[13.2.2]-
nonadeca-1(18),15(19),16-trien-13S-yl)carbamic acid benzyl ester (4.4) 
 
N
H
H
N
O
O
O
N
H
O
O
O
H
 
 
The alcohol 4.3 (0.70 g, 1.37 mmol) was oxidised according to General Procedure L to 
afford the aldehyde as a white solid (0.55 g, 79%). 
mp = 193-195 °C; 
1H NMR δ((CD3)2SO) 9.23 (1H, s, CHO), 7.56 (1H, d, J = 6.7 Hz, NH ), 7.40 (1H, d J = 
9.4 Hz, NH), 7.33-7.31 (5H, m, ArH (Cbz)), 7.00 (2H, m, ArH (Tyr)), 6.82 (1H, d J = 7.7 
Hz, NH), 6.72 (2H, m, ArH (Tyr)), 5.00 (2H, s, CCH2O), 4.30-4.26 (2H, m, CHCH2Ph 
and OCH2CH2CH2CH2), 4.04-3.99 (1H, m, OCH2CH2CH2CH2), 3.70-3.64 (2H, m, 
CHCH(CH3)2 and CHCHO), 2.83 (1H, dd, J = 5.4 and 12.4 Hz, CHCH2Ph), 2.63-2.57 
(1H, m, CHCH2Ph), 1.78-1.68 (2H, m, CHCH(CH3)2), and OCH2CH2CH2CH2), 1.50-1.43 
(1H, m, OCH2CH2CH2CH2), 1.32-1.10 (2H, m, OCH2CH2CH2CH2 and 
OCH2CH2CH2CH2), 0.92-0.90 (1H, m, OCH2CH2CH2CH2), 0.83-0.81 (3H, m, 
CHCH(CH3)2), 0.74-0.69 (1H, m, OCH2CH2CH2CH2); 
13C NMR δ((CD3)2SO) 201.61, 170.75, 170.56, 156.46, 156.12, 137.84, 130.91, 129.07, 
128.97, 128.41, 128.35, 116.09, 66.78, 65.93, 57.41, 57.19, 56.96, 37.53, 32.73, 27.47, 
27.18, 22.13, 19.39, 18.80; 
[α]D = -2.2 (c = 0.4 in (CH3)2SO); 
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HRMS (ES) 510.2590 (MH+) C28H36N3O6 requires 510.2604; 
νmax (KBr)  2984 (C(O)NH), 2960 (C(O)NH), 1735 (CHO), 1637 (OC(O)).  
 
 
7.4.2 Derivatives of the Macrocyclic Aldehyde 
 
Preparation of (7S-semicarbazone-10S-isopropyl-9,12-dioxo-2-oxa-8,11-diaza-
bicyclo[13.2.2]nonadeca-1(18),15(19),16-trien-13S-yl)carbamic acid benzyl ester 
(4.15) 
N
H
H
N
O
O
O
N
H
O
O
N
N
H
NH2
O
 
 
The macrocyclic aldehyde 4.14 (0.20 g, 0.38 mmol) was reacted according to General 
Procedure O to give the crude semicarbazone.  Recrystallisation from ethanol gave the 
pure product as a white solid (0.16 g, 71%). 
mp = 226 °C (Dec);  
1H NMR δ((CD3)2SO) 9.33 (1H, s, CNNHC(O)NH2), 8.07 (1H, d, J = 7.9 Hz, NH), 7.55 
(1H, d, J = 4.0 Hz, CHCH=NNH), 7.52 (1H, d, J = 6.1 Hz, NH), 7.39-7.35 (5H, m, ArH 
(Cbz)), 7.17 (1H, d, J = 9.4 Hz, NH), 7.05-6.98 (2H, m, ArH (Tyr)), 6.78-6.74  (2H, m, 
ArH (Tyr)), 5.06-5.02 (2H, m, CCH2O), 4.36-4.26 (2H, m, CHCH2Ph and 
OCH2CH2CH2CH2), 4.09-4.00 (1H, m, OCH2CH2CH2CH2), 3.66-3.57 (1H, m, 
CHCH2CH(CH3)2), 3.18-3.13 (1H, m, CHCH=NNH), 2.88-2.84 (1H, m, CHCH2Ph), 2.66-
2.58 (1H, m, CHCH2Ph), 1.78-1.67 (1H, m, OCH2CH2CH2CH2),  1.53-1.45 (1H, m, 
OCH2CH2CH2CH2), 1.35-1.13 (7H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2  and 
OCH2CH2CH2CH2 and OCH2CH2CH2CH2), 1.05-1.00 (1H, m, OCH2CH2CH2CH2), 0.84-
0.69 (7H, m, CHCH2CH(CH3)2  and OCH2CH2CH2CH2); 
13C NMR δ((CD3)2SO)  200.99, 171.30, 169.52, 155.80, 155.30, 137.12, 130.11, 128.23, 
127.67, 127.59, 115.46, 104.25, 66.05, 65.14, 56.50, 55.99, 50.58, 43.29, 37.03, 26.89, 
26.39, 23.83, 22.78, 21.84, 21.41, 18.50; 
[α]D = -3.0 (c = 1.3 in (CH3)2SO); 
HRMS (ES) 581.3086 (MH+) C30H41N6O6 requires 581.3088; 
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νmax (KBr)  2952 (C(O)NH), 2880 (C(O)NH), 2254 (C=NNH), 1654 (C(O)NH2).  
 
 
Preparation of [7-(R,S)-(cyanohydroxymethyl)-10S-isobutyl-9,12-dioxo-2-oxa-8,11-
diaza-bicyclo[13.2.2]nonadeca-1(18),15(19),16-trien-13S-yl]carbamic acid benzyl ester 
(4.16) 
 
N
H
H
N
O
O
O
N
H
O
O
CN
OH
 
 
The macrocyclic aldehyde 4.14 (0.50 g, 0.96 mmol) was reacted according to General 
Procedure I to afford the crude material.  Recrystallisation from methanol gave the pure 
cyanohydrin as a white solid (0.43 g, 81%). 
NMR data reported for the diastereomeric mixture (1:1) 
1H NMR δ((CD3)2SO) 7.99 (1H, d, J = 8.7 Hz, NH), 7.90 (1H, d, J = 9.5 Hz, NH),   7.52 
(1H, d, J = 7.4 Hz, NH), 7.35 (10H, s, ArH (Cbz)), 7.31 (1H, d, J = 5.5 Hz, NH),  7.07 
(1H, d, J = 8.3 Hz, NH), 7.03-6.99 (4H, m, ArH (Tyr)), 6.96 (1H, d, J = 8.1 Hz, NH),   
6.76 (4H, d, J = 7.8 Hz, ArH (mtyr), 6.61 (1H, d, J = 6.9 Hz CHCHOH), 6.55 (1H, d, J = 
5.8 Hz CHCHOH), 5.08-4.99 (4H, m, CCH2O), 4.37-4.29 (4H, m, CHCH2Ph and 
OCH2CH2CH2CH2), 4.13-4.10 (1H, m, CHCH2CH(CH3)2),   4.08-4.01 (3H, m, 
CHCH2CH(CH3)2 and OCH2CH2CH2CH2), 3.98-3.94 (2H, m, OCH2CH2CH2CH2),  3.89-
3.85 (2H, m, CHCHOH), 2.85 (2H, dd, J = 5.2 and 13.1 Hz, CHCH2Ph), 2.64-2.58 (2H, m, 
CHCH2Ph), 1.76-1.67 (2H, m, OCH2CH2CH2CH2),  1.61-1.45 (4H, m, CHCH2CH(CH3)2 
and OCH2CH2CH2CH2), 1.37-1.12 (10H, m, CHCH2CH(CH3)2 and CHCH2CH(CH3)2  and 
OCH2CH2CH2CH2 and OCH2CH2CH2CH2 OCH2CH2CH2CH2), 0.84-0.75 (14H, m, 
CHCH2CH(CH3)2  and OCH2CH2CH2CH2); 
13C NMR δ((CD3)2SO) 171.19, 170.91, 169.41, 156.13, 155.76, 155.25, 137.10, 130.03, 
128.21, 127.65, 127.58, 119.86, 119.33, 115.39, 115.34, 115.30, 66.18, 66.14, 65.11, 
65.06, 63.40, 62.85, 56.04, 55.93, 50.54, 50.50, 49.95, 49.74, 43.46, 43.43, 43.34, 43.28, 
37.06, 30.02, 29.17, 28.13, 27.52, 27.18, 23.88, 23.63, 22.91, 22.77, 22.60, 21.68, 21.53; 
HRMS (ES) 551.2876 (MH+) C30H39N4O6 requires 551.2870; 
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νmax (KBr)  3319 (CH(OH)), 3064 (C(O)NH), 2922 (C(O)NH), 1882 (CH(OH)CN).  
 
 
Preparation of (7S-azidomethyl-10S-isobutyl-9,12-dixoxo-2-oxa-8,11-diazabicyclo-
[13.2.2]nonadeca-1(18),15(19),16-trien-13S-yl)carbamic acid benzyl ester (4.19) 
 
N
H
H
N
O
O
O
N
H
O
O
N3
 
 
To the macrocyclic alcohol 4.20 (0.19 g, 0.36 mmol, 1.0 equiv) in dichloromethane was 
added triethylamine (120 µL, 0.90 mmol, 2.5 equiv) and mesyl chloride (16 µL, 0.36 
mmol, 1.0 equiv).  The reaction mixture was stirred at rt overnight, then the solvent 
removed in vacuo.  The residue was dissolved in N,N-dimethylformamide and sodium 
azide (0.02 g, 0.36 mmol, 1.0 equiv) added and the reaction mixture stirred at rt for 4 h 
after which it was diluted with ethyl acetate.  The organic phase was washed with brine, 
dried over MgSO4 and solvent removed under reduced pressure to give the crude material.  
Recrystallisation from ethyl acetate/petroleum ether afforded the product as a white solid 
(0.12 g, 61%) 
mp > 250 °C 
1H NMR δ((CD3)2SO) 7.55 (1H, d, J = 9.1 Hz, NH), 7.52 (1H, d, J = 7.1 Hz, NH), 7.38-
7.35 (5H, m, ArH (Cbz)), 7.01 (2H, m, ArH (Tyr)), 6.93 (1H, d, J = 7.7 Hz, NH), 6.74 
(2H, m, ArH (Tyr)), 5.07 (2H, d, J = 12.6 Hz CCH2O), 4.99 (2H, d, J = 12.6 Hz CCH2O), 
4.59-4.57 (1H, m, CHCH2Ph), 4.34-4.29 (2H, m, OCH2CH2CH2CH2 and CHCH2N3), 
4.06-4.01 (2H, m, OCH2CH2CH2CH2 and CHCH2CH(CH3)2), 3.18-3.14 (1H, m, 
CHCH2Ph), 3.08-3.03 (1H, m, CHCH2Ph), 2.86 (1H, dd, J = 5.6 and 13.1 Hz, CHCH2N3), 
2.62-2.60 (1H, m, CHCH2N3), 1.77-1.68 (2H, m, CHCH2CH(CH3)2), 1.52-1.44 (2H, m, 
OCH2CH2CH2CH2), 1.33-1.14 (4H, m, OCH2CH2CH2CH2 and CHCH2CH(CH3)2), 0.87-
0.82 (1H, m, OCH2CH2CH2CH2), 0.80-0.77 (6H, m, CHCH2CH(CH3)2), 0.64-0.59 (1H, m, 
OCH2CH2CH2CH2);  
13C NMR δ((CD3)2SO) 170.92, 169.90, 156.54, 155.80, 137.46, 130.45, 128.72, 128.60, 
128.03, 115.03, 66.77, 65.65, 64.47, 56.62, 51.13, 49.60, 43.63, 37.38, 30.26, 28.28, 24.24, 
23.27, 23.12, 22.35 
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[α]D = -3.0 (c = 0.1 in (CH3)2SO); 
νmax (KBr)  2955 (C(O)NH), 2864 (C(O)NH), 2783 (C(O)NH), 2406 (CH2N3), 1701 
(OC(O)). 
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APPENDIX 
  
A1 Raw Assay Data and IC50 Calculation Example 
 
 
The data in Table A1 is that collected for one assay run of SJA6017.  Rows 1-3 correspond to the calcium blank; 4-6 EDTA blank; 7-
12 m-calpain; 13-15 SJA at 50 µM; 16-19 SJA at 10 µM; 20-22 SJA at 4 µM; 23-25 SJA at 2 µM; 26-28 SJA at 0.4 µM; 29-31 SJA at 
0.2 µM; 32-34 SJA at 0.1 µM; 35-37 SJA at 0.05 µM.  The columns labelled t = 1 to t = 10 show the amount of fluorescence (in 
fluorescence units) recorded at 1 min time intervals for a total of 10 min.  The column labelled t10-t1 shows the change in 
fluorescence that occurs over the time of the assay.  The numbers in the column labelled Adjusted are the values obtained by using 
Eqn A1 in the case of the inhibitor samples or Eqn A2 in the case of the uninhibited enzyme and represent the baseline corrected 
fluorescence. 
 
 
 t = 1 t = 3 t = 4 t = 5 t = 6 t = 7 t = 8 t = 9 t = 10 t10-t1 Averages Adjusted % inhib 
Ca blank 1326 1115 964 897 847 855 854 860 845 -481    
 1274 1040 939 927 874 894 889 892 883 -391    
 806 771 708 684 638 648 653 633 632 -174    
EDTA blank 689 675 666 659 645 645 625 631 628 -61    
 715 697 684 675 658 659 647 641 652 -63    
 682 672 664 641 636 633 623 620 619 -63 -205.5   
m-calpain 1009 1166 1289 1400 1458 1565 1650 1734 1796 787    
 967 1138 1260 1355 1421 1505 1587 1669 1746 779 
 
  
 952 1108 1246 1344 1438 1513 1627 1681 1747 795    
 946 1059 1184 1298 1367 1467 1539 1597 1684 738    
 926 1099 1214 1323 1381 1479 1581 1649 1720 794    
 909 1094 1212 1332 1409 1508 1575 1655 1721 812 784.16 989.66  
SJA 50.0 µM 461 456 451 439 425 423 422 427 413 -48    
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  475 465 454 437 429 429 428 437 423 -52    
 463 458 454 442 425 423 423 429 421 -42 -47.33 158.16 84 
SJA 10.0 µM 514 510 496 497 483 484 484 483 483 -31    
 485 498 487 483 458 471 473 469 465 -20    
 490 495 478 482 470 467 460 471 470 -20 -23.66 181.83 82 
SJA 2.00 µM 571 575 577 573 550 559 555 552 568 -3    
 569 579 567 564 559 554 558 553 547 -22    
 577 586 569 575 562 558 563 567 560 -17 -14.00 191.50 81 
SJA 0.40 µM 720 722 731 720 709 712 717 721 724 4    
 764 764 775 776 749 757 774 773 773 9    
 782 791 803 797 778 787 792 811 818 36 16.33 221.83 78 
SJA 0.20 µM 827 869 895 907 899 911 931 933 944 117    
 810 873 917 928 924 924 935 949 950 140    
 808 860 886 897 900 898 899 914 934 126 127.66 333.16 66 
SJA 0.10 µM 852 942 1007 1040 1048 1064 1084 1094 1106 254    
 843 930 998 1025 1019 1044 1062 1084 1108 265    
 835 955 1015 1030 1044 1072 1094 1111 1114 279 266.00 471.50 52 
SJA 0.05 µM 843 963 1036 1065 1088 1129 1160 1204 1231 388    
 837 950 1032 1092 1117 1167 1198 1230 1243 406    
 865 989 1086 1127 1151 1180 1226 1262 1280 415 403.00 608.50 39 
 
Table A1 Raw assay data and calculations 
 
 
 
The equations A1-A3 are used for determining the % inhibition, where FU represents the change in fluorescence units over 10 min: 
 
 
FUavg inhibitor = FUavg sample – FUavg blanks           Eqn A 
FUuninhibited = FUenzyme - FUavg blanks            Eqn A2 
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Where in this example the FUavg blanks corresponds to the calculated value of -205.5 and FUenzyme to the calculated value 784.16  
 
 
% Inhibition = {(FUuninhibited – FUinhibited)/FUuninhibited}×100         Eqn A3 
 
Where in this example the FUuninhibited is the calculated value of 989.66 and FUinhibited corresponds to the values calculated in the Adjusted 
column for each of the inhibitor samples assayed. 
 
 
The % inhibition values for the various dilutions of the inhibitor are graphed as the log of the concentration versus % inhibition as shown in 
Table A2.  IC50 values are calculated from the linear part of the graph using the equation generated from the trend line (y = 50, solving for x).  
The uncertainty of the IC50 values have been approximated to be within 10% error. 
 
conc (µM) Log(conc) % inhib 
50 1.69897 84 
10 1 82 
2 0.30103 81 
0.4 -0.39794 78 
0.2 -0.69897 66 
0.1 -1 52 
0.05 -1.30103 39 
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 y = 43.517x + 95.717
R2 = 0.9992
0
50
100
-1.5 -1 -0.5 0
Log of concentration 
%
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Table A2 Calculation of IC50 value 
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 A2 Percentage Inhibition at 50 µM  
 
 
The Table A.2 below outlines all compounds assayed using the assay protocols in Chapter Five.  Values given are the % inhibition for each 
compound at a concentration of 50 µM.  This was used as a screening process to determine which compounds would be assayed at lower 
concentrations (down to a concentration of 50 nM).  Any compounds exhibiting a % inhibition of the enzyme greater than 50% at 50 µM 
underwent this process and an IC50 value calculated in the manner illustrated in A1.      
 
% Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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 % Inhibition at 50 µM  
Compound m-calpain µ-calpain cathepsin B papain pepsin α-chymo- 
trypsin 
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Table A.2 Percentage Inhibitions for synthesised compounds at a concentration of 50 µM  
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